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Epidemiology
Esophageal adenocarcinoma is a highly aggressive disease from which more than 80% of 
patients die within 5 years after diagnosis. Worldwide almost 400,000 new patients are di-
agnosed annually. Herewith esophageal cancer ranks eighth on the list of most common 
cancers, and sixth on the list of cancer mortality causes 1. More than 90% of esophageal 
cancers are either squamous cell carcinomas or adenocarcinomas 2. Esophageal cancer in-
cidence has been rapidly increasing in Western Europe and the USA 3-5. This could be mainly 
ascribed to an increase in the rate of esophageal adenocarcinoma, which by now equals or 
even exceeds the rate of esophageal squamous cell carcinomas. Esophageal cancer inci-
dence in the Netherlands is 10.2/100,000 for men and 3.2/100,000 for women with around 
900 newly diagnosed patients annually 6. Adenocarcinomas of the gastric cardia and of the 
esophagus, commonly located in the distal esophagus, have several similarities. They show a 
parallel increase in incidence. Moreover, they show similarities in epidemiological and histo-
morphological features as well as in patterns of comorbidity 7-9. This thesis mainly deals with 
molecular biological aspects of adenocarcinomas of the distal esophagus and its precursor 
lesion, Barrett’s esophagus, but also includes work on adenocarcinomas of the gastric cardia. 
Adenocarcinomas from the distal third of the esophagus plus adenocarcinomas of the gastric 
cardia are in this thesis altogether mentioned by the description “gastro-esophageal junction 
(GEJ) adenocarcinomas”.
Etiology
Alcohol and/or tobacco use may confer risk for GEJ adenocarcinomas whereas they are estab-
lished risk factors for esophageal squamous cell carcinomas 10-14. 
Gastro Esophageal Reflux Disease (GERD) is described to be the most important etiologic fac-
tor since it can lead to the formation of Barrett’s esophagus 15,16. This precursor lesion forms 
the main established risk indicator for the development of carcinoma 7,15,17. Barrett’s esopha-
gus is characterized by columnar metaplasia with intestinal differentiation that has replaced 
the normally present stratified squamous epithelium in the lower third of the esophagus (also 
see ‘Pathology’). Patients with Barrett’s esophagus have a 30-125 times increased risk for de-
veloping esophageal adenocarcinoma, however only about 0.2-2% of patients with Barrett’s 
esophagus will eventually get a carcinoma 18. The true prevalence of Barrett’s esophagus in 
The Netherlands is difficult to establish since most patients do not undergo upper endoscopy. 
Weekly retrosternal pain however is present in around 10% of adults. When upper endoscopy 
is performed in these patients, around 12.5% of these have Barrett’s esophagus. Estimated 
prevalence in The Netherlands is therefore around 100,000 patients. 
Drugs that relax the lower esophageal sfincter and increase reflux, such as anticholinergic 
agents, aminophyllines and beta-blockers may contribute to the development of esophageal 
adenocarcinoma 19,20. 
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It has been postulated that Helicobacter Pylori infection (in particular strains that are positive 
for the CagA protein) may reduce the risk of GERD and therefore may provide protection 
against the development of adenocarcinoma 21-24. 
By increasing intraabdominal pressure and gastroesophageal reflux, obesitas may contribute 
to development of esophageal adenocarcinoma, however contradictory results are provided 
on this subject in the literature 19,25. 
Familial cases of esophageal adenocarcinoma are rare and Barrett’s esophagus and esopha-
geal adenocarcinoma have no known genetic cause to date. 
Clinical manifestations & Diagnosis
Dysphagia, retrosternal pain, odynophagia (pain on swallowing food and liquids), retroster-
nal pain, pain during food passage, weight loss and anaemia are the symptoms that lead 
patients with GEJ adenocarcinoma to seek medical attention. Physical examination is usually 
unremarkable. Lymphadenopathy, particularly in the left supraclavicular fossa (Virchow’s 
node), hepatomegaly and pleural effusion are indicators of metastatic disease. 
Physicians should consider testing high risk patients with GERD to rule out malignancy. Upper 
endoscopy is performed to obtain tissue samples of suspect areas of mucosa, aiming at early 
detection of high grade dysplasia and early adenocarcinoma (Figure 1.1). The histological 
identification of dysplasia in tissue biopsies is the best marker for cancer risk and is of major 
importance in determining the intensity of both surveillance and treatment 26. Patients with 
Barrett’s esophagus are usually subjected to intensive endoscopic surveillance with biopsy 
sampling to identify those with neoplastic progression. The surveillance program followed at 
the Erasmus MC is according the guidelines from the American College of Gastroenterology 
and the International Society for Diseases of the Esophagus. In patients with Barrett’s esopha-
gus without dysplasia, surveillance every 2 year is considered adequate. In patients with low 
grade dysplasia, yearly endoscopy is advised. If high grade dysplasia is found, the diagnosis 
should be confirmed by an experienced pathologist. If the diagnosis high grade dysplasia is 
confirmed, there is no agreement on the most appropriate management of these patients. 
Esophagectomy is recommended to eliminate the risk of cancer or to detect and treat an 
unsuspected cancer at an early stage. Concerns with this approach include the potential risks 
of surgery, especially in older patients, and the highly variable natural history of high grade 
dysplasia.
Pathology
Most esophageal adenocarcinomas appear to arise from dysplastic Barrett’s esophagus. Nor-
man Ruppert Barrett (1903-1979) was born in Adelaide, Australia, and devoted his carreer to 
thoracic surgery. He pulished in 1950 in the British Journal of Surgery on “Chronic peptic ulcer 
of the oesophagus and ‘oesophagitis’ ” supporting the view of previous observers that the af-
fected segment was actually the gastric cardia displaced by a congenitally short esophagus. 
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How this concept evolved to its current un-
derstanding and Barrett’s own conversion to 
the notion of esophageal mucosal metaplasia 
is told by Spechler and Goyal in Gastroente-
rology in 1996 27. 
Barrett’s esophagus is characterized by colum-
nar metaplasia with intestinal differentiation, 
as identified by Goblet cells, that has replaced 
the normally present stratified squamous 
epithelium in the lower third of the esophagus. 
Progression is considered to follow the ‘meta-
plasia-low grade dysplasia-high grade dyspla-
sia-carcinoma sequence’, characterized by ac-
cumulation of cell cycle abnormalities, genetic 
abnormalities and aneuploidy (Figure 1.2) 28-30. 
Most esophageal adenocarcinomas are lo-
cated in the lower third part of the esophagus 
which starts at the level of the trachea bifur-
cation and extends to the gastro-esophageal 
junction (‘the distal esophagus’). The gastro-
esophageal junction is characterized by the 
Z-line, which forms the transition zone from 
squamous cell epithelium to cylindrical epi-
thelium of the stomach. Carcinomas located at 
the gastro-esophageal junction are classified 
as gastric carcinomas according to the Union 
Internationale Contre Cancer (UICC)-TNM. With 
regard to epidemiology as well as histomorphology these tumors show similarities with distal 
esophageal adenocarcinomas 8. Moreover the therapeutic approach is identical. In the studies 
described in this thesis a carcinoma was considered to arise from the distal esophagus when 
premalignant Barrett’s mucosa was present and/or the epicenter of the mass was located in the 
tubular esophagus extending from the tracheal bifurcation to the gastro-esophageal junction 
including the intra-abdominal esophagus, according to the TNM classification (International 
Classification of Diseases for Oncology C15.5). The tumor was considered to be cardiac when 
the epicenter was immediately below the gastro-esophageal junction, extending approxi-
mately 2 cm downwards. The tumor was classified as a junction carcinoma if the epicenter was 
just at the GEJ, without predominance for distal esophagus or gastric cardia and if no Barrett’s 
mucosa was present (Figure 1.3). Tumors arising from the fundus or corpus of the stomach and 
infiltrating the gastric cardia or distal esophagus were classified as gastric carcinomas. 
Figure 1.1 Endoscopy images 
Adenocarcinoma
GERD
Barrett’s metaplasia 
High grade dysplasia
Figure 1.1 Endoscopy images. Also see color figures page 291.
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Figure 1.2 Histology of ‘metaplasia-low grade dysplasia-high grade dysplasia-carcinoma sequence’ 
Adenocarcinoma
Normal squamous epithelium
Barrett’s metaplasia
Low grade dysplasia
High grade dysplasia
Figure 1.2 Histology of ‘metaplasia-low grade dysplasia-high grade dysplasia-carcinoma sequence’. Also see color figures page 291.
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Staging
After diagnosing esophageal carcinoma, patients’ fitness for surgery needs to be established. 
Only in patients fit enough to undergo surgery, tumor staging is performed. Up to 50% of pa-
tients with esophageal cancer present with inoperable disease as a result of severe comorbidity 
or due to locally advanced or metastatic disease.
Endoscopic ultrasonography (EUS) identifies preoperative depth of tumor growth (T stadium) 
and involvement of lymph nodes (N stadium). Reliability of EUS in predicting T and N stadium 
is 84% and 77% respectively 31. Computer tomography scanning (CT, Figure 1.4) of thorax and 
abdomen as well as cervical ultrasonography are used to discover possible distant metasta-
ses (M stadium). Metastases comprise most often celiac lymph nodes, supraclavicular lymph 
nodes and liver metastases. Cytological confirmation of distant metastases can be obtained 
by percutaneous biopsies 32.
Figure 1.3 Resection specimen with GEJ adenocarcinoma. Also see color figures page 291.
Figure 1.4 CT scan with GEJ adenocarcinoma (arrow) 
Figure 1.4 CT scan with GEJ adenocarcinoma (arrow)
Linetta BW.indd   16 08-05-2006   17:57:04
General Introduction 17
AJCC-TNM (T-stage in Figure 1.5)
Stage 0 (pTisN0M0) tumor restricted to mucosa (pTis/carcinoma in situ/high grade dyspla-
sia) ; no regional lymph nodes (No); no distant metastasis (M0).
Stage I (pT1N0M0): tumor infiltrating in lamina propria or in submucosa (pT1); no regional 
lymph nodes (N0); no distant metastasis (M0).
Stage IIA (pT2-T3N0M0): tumor restricted to muscularis propria (pT2) or adventitia (pT3); no 
regional lymph node metastasis (N0); no distant metastasis (M0).
Stage IIB (pT1-T2N1M0): tumor restricted to mucosa or submucosa (pT1) or tumor infiltrating 
muscularis propria (pT2); regional lymph node metastasis (N1); no distant metasta-
sis (M0).
Stage III (pT3N1M0 or pT4NxM0): tumor restricted to adventitia (pT3) with regional lymph 
node metastasis (N1); or tumor invading neighbouring structures (pT4) with or 
without regional lymph node metastasis (Nx); no distant metastasis (M0). 
Stage IV Any T, Any N, distant metastasis M1a (i.e. metastasis in celiac lymph nodes in case of 
distal esophageal carcinomas) or M1b (other distant metastasis).
Treatment & prognosis
Surgical resection is the only curative treatment for GEJ adenocarcinoma. Survival rates 
mostly depend on pathological stage and are still poor despite recent achievements in surgi-
cal, anaesthesiologic and postoperative care 33. Surgical resection is currently the preferred 
treatment for fit patients with tumors that are considered resectable and without distant me-
tastases at preoperative workup (T1-3 N0-1 M0). Tumor depth restricted to the mucosa (Tis) 
is associated with a mean 5-year survival of 88%, whereas tumor restricted to adventitia (T3) 
is associated with a mean 5-year survival of 10-20% only. Tumor ingrowth in neighbouring 
structures (T4) and the presence of distant metastases are considered contra-indications for 
Figure 1.5 TNM classification 
Figure 1.5 TNM classification (T-stage). Also see color figures page 291.
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surgical resection. Recent advances in non-surgical palliative procedures, such as esophageal 
stenting and brachytherapy have been proven safe alternatives to secure passage of food 
and provide a comparable quality of life 34-36. 
Surgical treatment for esophageal cancer is still associated with a significant risk of morta-
lity and a high incidence of postoperative morbidity. In the 1980s, esophagectomy was the 
procedure with the highest mortality risk (29%) in general surgery at that time 37. Nowadays, 
the average reported mortality varies from 4% in specialized centres to more than 10% in low 
volume hospitals 38,39. 
Esophagectomy with removal of esophagus and gastric cardia including primary tumor as 
well as neighboring regional lymph nodes is performed with or without opening the thorax 
(transthoracic and transhiatal approach respectively). Extensive surgical resection is difficult 
due to proximity of trachea, main bronchi, pericardia, aorta and diaphragm. Moreover tu-
mor spread to lymph nodes occurs rather early in tumorigenesis due to the presence of a 
submucosal lymph plexus 40. Extended lymph node dissection can be obtained by opening 
abdomen and thorax (and neck) in order to obtain long term survival. On the other hand, per-
forming a less extensive, transhiatal, resection can decrease postoperative morbidity as well 
as mortality. In the literature a survival advantage has been described for distal esophageal 
adenocarcinoma patients when a thoracotomy with extensive lymph node dissection was 
performed as compared to patients that underwent regional lymph node dissection only by 
means of a transhiatal approach 41,42. In our clinic, a transhiatal approach is first choice for re-
section of GEJ adenocarcinomas since 1989 (Figure 1.6). A ‘blunt dissection’ of the esophagus 
under direct vision through the widened hiatus of the diaphragm is performed with en-bloc 
dissection of tumor and adjacent lymph nodes. A gastric tube is constructed to form the new 
esophagus. Esophago-gastrostomy is performed in the neck.
In general, microscopically irradical resections are performed in approximately 30% of pa-
tients 41,43,44. Several regimens of neoadjuvant therapy have been investigated in order to 
achieve tumor shrinkage in order to increase resectability rate and improve survival. Several 
randomised studies and reviews show that a possible benefit, if any, of neoadjuvant che-
motherapy is small and it is uncertain whether such a potential survival benefit outweighs 
the morbidity caused by such a treatment 43-51. Several studies show that preoperative ra-
diotherapy in combination with chemotherapy is recommended compared to surgery alone. 
Preoperative chemoradiotherapy might improve local control and therefore improve the 
prognosis of esophageal carcinomas. Currently, a randomized phase III trial is being con-
ducted in The Netherlands. 
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Figure 1.6 Schematic overview of surgical resection of GEJ adenocarcinoma. Photographs below the scheme 
show upper abdominal incision (A.), creation of the gastric tube (A. B. C.) to restore continuation of 
gastrointestinal tract after transhiatal en-bloc removal of esophagus and gastric cardia including tumor and 
adjacent lymph nodes (D.). Esophagogastrostomy will be performed in the neck (smaller incision left side of 
picture D.) 
A
C
B
D
Figure 1.6 Schematic overview of surgical resection of GEJ adenocarcinoma. Photographs below the scheme show upper abdominal incision (A.), 
and creation of the gastric tube (A. B. C.) to restore continuation of the gastrointestinal tract after transhiatal en-bloc removal of esophagus and 
gastric cardia including tumor and adjacent lymph nodes (D.). Esophagogastrostomy will be performed in the neck (smaller incision left side of 
picture D.). Also see color figures page 291.
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AIMS AND OUTLINE OF THIS THESIS 
Aims
Esophageal adenocarcinoma is a highly aggressive disease from which more than 80% of 
patients die within 5 years after diagnosis. Patients with Barrett’s esophagus have a 30 to 
125 times higher risk of developing esophageal adenocarcinoma as compared to the general 
population. Presently, histological detection of dysplasia is the best available marker for can-
cer risk. Intensive endoscopic surveillance, including tissue biopsies, is aiming at early detec-
tion of high grade dysplasia and early adenocarcinoma. Patients with high grade dysplasia or 
early adenocarcinoma have a survival rate of 80% after surgery, which stress the importance 
of early detection. To date it is not possible to predict which patients with Barrett’s esophagus 
will progress to invasive carcinoma. Stratification of Barrett’s esophagus patients that are at 
risk of esophageal adenocarcinoma and those not at risk, is therefore urgently needed. This 
would allow more aggressive or preventative treatment of the people at risk, but also release 
the vast majority of people who are not at risk from unnecessary endoscopic surveillance.
The genetic alterations underlying esophageal carcinogenesis remain poorly understood. 
Knowledge of molecular biology could be of additional value to the histological diagnosis 
of dysplasia in predicting neoplastic progression. The aim of this thesis was, first, to better 
understand the molecular mechanisms in GEJ adenocarcinomas and its neoplastic progres-
sion and, second, to identify genetic markers that, in the end, might distinguish Barrett’s epi-
thelia that will progress to esophageal adenocarcinoma from Barrett’s epithelia that will not 
progress to malignancy. Genetic alterations in Barrett’s esophagus and GEJ adenocarcinoma 
were correlated to clinicopathological characteristics and patient survival. Moreover, aspects 
on epidemiology and treatment were investigated. 
Outline
Chapter 2 provides a review of the literature on the molecular biology of esophageal adeno-
carcinoma. In general, genetic instability forms the hallmark of cancer development resul-
ting in the activation of proto-oncogenes and inactivation of tumor suppressor genes. In this 
thesis, mutation analyses (Single Stranded Conformation Polymorphism (SSCP) studies) and 
Loss of Heterozygosity (LOH) studies aiming to identify alterations in (candidate) proto-onco-
genes and tumor suppressor genes formed the main approach to study genetic alterations in 
GEJ adenocarcinomas. A schematic overview of the LOH analysis is provided in Figure 1.7. 
Part II concerns molecular biological studies within GEJ adenocarcinomas. The contribution 
of the Wnt signaling pathway, an oncogenic pathway with great importance in colorectal 
carcinomas amongst others, was studied in Chapter 3. This chapter presents immunohisto-
chemical data on diverse components of the Wnt signaling pathway in GEJ adenocarcinomas. 
Expression data were correlated to clinicopathological characteristics. In Chapter 4 mutation 
and LOH analysis of the AXIN1 locus was performed in primary GEJ adenocarcinomas and in 
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GEJ adenocarcinoma cell lines aiming to find an explanation for Wnt pathway activation in 
GEJ adenocarcinomas. 
Chapter 5 describes the identification of an overlapping region of LOH at the long arm of 
chromosome 14, possibly harboring a GEJ adenocarcinoma suppressor gene. The 7.1 mega 
base pairs minimal deletion was located at 14q31.1-32.11 and identified using primary GEJ 
adenocarcinomas, GEJ adenocarcinoma xenografts as well as GEJ adenocarcinoma cell lines.
In Chapter 6 an immunohistochemical study of neuroendocrine cells in GEJ adenocarcinoma 
and adjacent Barrett’s esophagus is described using chromogranin A antibody. Expression 
was correlated to TNM stage, tumor differentiation grade and survival. 
Part III of the thesis focuses on epidemiological aspects of GEJ adenocarcinomas. Comorbi-
dity patterns in esophageal adenocarcinomas were compared with patterns in cardia adeno-
carcinomas, esophageal squamous cell carcinomas and subcardia gastric carcinomas to gain 
more insight in variation of risk factor profiles in Chapter 7. Moreover, comorbidity patterns 
in these tumor types were, retrospectively, correlated to clinicopathological characteristics, 
Figure 1.7 Schematic overview of Loss of Heterozygosity (LOH) analysis. Amplified fragments of maternal and paternal DNA of chromosome 9 
are compared between normal and tumor DNA of a patient. Length of CA repeats within the fragments differs in the normal DNA, i.e. there is 
heterozygosity (maternal contains 20 CA repeats and paternal contains 15 CA repeats). In patients tumor DNA part of the short arm of paternal 
chromosome 9, containing the 15 CA repeat, is lost and therefore the heterozygosity is lost. This is visualized on a gel after radioactive labeling. 
Only the maternal 20 CA repeat is visualized in the tumor as compared to the normal DNA in which both fragments are shown and therefore this 
tumor shows LOH. Within LOH analysis, a separation of fragments takes place through difference in length, whereas Single Strand Conformation 
Polymorphism (SSCP) analysis separates fragments by a different conformation between normal and mutated DNA. Also see color figures page 291.
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treatment choice (either curative or palliative) and survival in Chapter 8. This was done in 
order to determine a possible role for comorbidity in prognosis and treatment choice. 
Part IV deals with aspects of surgery. Surgical resection of cancers of the esophagus and GEJ 
is associated with substantial morbidity and mortality. Local endoscopic techniques to de-
tect and to treat high grade dysplasia and early carcinoma have become more and more avai-
lable in recent years. A retrospective study described in Chapter 9 evaluated the outcome 
of transhiatal esophagectomy in 120 patients with early adenocarcinoma of the esophagus 
or gastro-esophageal junction. The question was addressed whether surgical resection is ne-
cessary in patients with early malignancies or whether local endoscopic techniques might be 
suffcient. In order to precisely classify this series of early cancers, the mucosa and submucosa 
were subdivided into six successive layers. Additionally the depth of tumor infiltration was 
correlated to lymphatic dissemination and recurrence free period. Chapter 10 describes the 
development and validation of a simple risk score combining clinical characteristics along 
with hospital volume to predict surgical mortality after esophagectomy which may be useful 
for risk adjustment in quality of care assessment.
Part V of this thesis aims to identify patients at high risk for developing GEJ adenocarcinoma. 
Patients with Barrett’s esophagus receive endoscopic surveillance to detect dysplasia and to 
diagnose carcinoma at an early and possibly treatable stage. The identification of genes that 
confer susceptibility for adenocarcinoma formation in Barrett’s esophagus would imply im-
proved manageability of Barrett’s patients. The CHEK2 gene, located on human chromosome 
22q12, encodes a cell cycle checkpoint kinase that is implicated in DNA damage responses. 
CHEK2*1100delC is a truncating germline variant that abrogates kinase activity and confers 
low-penetrance susceptibility to breast cancer. As CHEK2 and p53, having an important role 
in the development of esophageal adenocarcinoma, are participants of the same biological 
pathway, we aimed to establish whether CHEK2*1100delC confers susceptibility to esopha-
geal cancer in Chapter 11. 
In recent literature, single nucleotide polymorphisms, defined as germline variant sequences 
of DNA in the population that are non-pathogenic, have been described to confer susceptibi-
lity to development of various cancers. Chapter 12 describes the investigation of a possible 
prognostic role of different genetic polymorphisms in a large cohort of GEJ adenocarcinoma 
patients as compared to healthy persons. Moreover the distribution of polymorphism geno-
types was investigated in a large cohort of esophageal squamous cell carcinoma patients. 
Finally in Chapter 13, it was aimed to identify molecular markers that predict progression to 
malignancy in Barrett’s patients. First, the question was addressed whether GEJ adenocarci-
nomas are monoclonal or polyclonal proliferations. To this end, multiple biopsies per carci-
noma were selected from GEJ adenocarcinoma resection specimens. These were investigated 
for loss of heterozygosity (LOH) of chromosomal loci 17p (p53), 9p (p16), 5q (APC, MCC), 13q 
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(Rb) and 18q (DCC, DPC4/SMAD4), for p53 mutations (exon 5 to 8) and for mutations in the 
homopolymeric C-stretch (D310) within the mitochondrial DNA (mtDNA) displacement loop. 
Second, the usefulness of these aberrations as molecular progression markers was studied 
in the ‘metaplasia-low grade dysplasia-high grade dysplasia-carcinoma sequence’ in Barrett’s 
esophagus adjacent to GEJ adenocarcinoma. 
The studies described in this thesis are summarized in Part VI, Chapter 14. The Epilogue, 
Chapter 15, contains a general discussion. Moreover clinical applications as well as potential 
directions for future studies are addressed. 
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ABSTRACT 
Barrett’s esophagus is an acquired metaplastic change that occurs in the distal esophagus 
secondary to chronic gastroesophageal reflux. This premalignant condition forms the most 
important risk factor for developing esophageal adenocarcinoma, which is an extremely ag-
gressive tumor with a 5-year survival rate of less than 25%. Carcinomas that arise in the setting 
of Barrett’s esophagus are thought to develop as part of the metaplasia-dysplasia-carcinoma 
sequence. We aimed to review the current knowledge on the genomic alterations involved 
in the development of Barrett’s esophagus and its progression to dysplasia and/or cancer. 
Several changes in gene structure, gene expression and protein structure are associated with 
the progression of Barrett’s esophagus to adenocarcinoma. Accumulation of these changes 
seems to be essential, rather than the exact sequence of these changes. Multiple molecular 
pathways are involved and interact with each other. Alterations in tumor suppressor genes, 
amongst which p53 and p16, are early events in the metaplasia-dysplasia-adenocarcinoma 
sequence, followed by loss of cell cycle checkpoints. Ongoing genomic instability leads to 
cumulative genetic errors and thereby the generation of multiple clones of transformed cells. 
Within the multistep process of esophageal adenocarcinogenesis, to date no single molecular 
marker came forward able to predict who will and who will not develop cancer in the setting 
of Barrett’s esophagus. Instead, panels of markers need to be developed in the future allo-
wing to indicate disease progression. Identification of crucial molecular pathways involved in 
esophageal adenocarcinogenesis would ultimately improve therapy and facilitate develop-
ment of new treatment strategies.
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INTRODUCTION
Cancer of the esophagus represents the 9th leading cancer in the world and is associated 
with a five-year survival rate under 25%. Understanding of the molecular biology is a prere-
quisite to predict prognosis and to tailor treatment. The development of esophageal cancer 
is a multistep phenomenon involving genetic events that result in key abnormalities of cell 
cycle regulation, growth factor activity and intercellular adhesion mechanisms 1. This review 
focusses on esophageal adenocarcinoma, which is associated with an increasing incidence in 
the Western world as compared to squamous cell carcinomas. 
It is now generally accepted that esophageal adenocarcinomas develop from a premalignant 
lesion of the esophagus, referred to as Barrett’s esophagus. Barrett’s esophagus is an acquired 
condition in which the normal squamous cell epithelium of the esophagus is replaced by 
metaplastic columnar epithelium due to chronic gastroesophageal reflux disease. Barrett’s 
esophagus is associated with a predisposition to adenocarcinoma of the distal esophagus or 
the gastric cardia, i.e. an about 30-125 fold higher risk compared to the general population, 
with an estimated incidence of 1 in 180 patient-years 2-5. Although high grade dysplasia of 
Barrett’s esophagus is generally considered a precursor to invasive carcinoma, the endoscopic 
as well as histopathologic recognition of this lesion can be rather difficult. Problems concern 
amongst others, sampling errors, intra- and interobserver variation in diagnosis and grading 
of dysplasia, differentiation of high grade dysplasia and cancer, indetermination for dysplasia 
due to reactive or regenerative changes. Efforts are required to better understand the patho-
physiology of Barrett’s esophagus and its progression to cancer. Molecular genetic analysis 
and development of novel biomarkers might help to identify those patients at increased risk 
for malignant transformation. Biopsy samples of Barrett’s esophagus that histologically ap-
pear as low risk for neoplastic progression might in fact harbor genetic alterations that are 
indicative for a high risk profile. Molecular genetic knowledge might ultimately lead to more 
adequate cancer prevention and therapeutic interventions. In recent years a considerable 
amount of data has been accumulated regarding the molecular biological characterization 
of esophageal adenocarcinoma. 
Genetic alterations in human cancers
Cancer is a disease of the genome with accumulation of sequence alterations (mutations) 
in premalignant tissue, leading to evolution of cell clones with increasing genomic instabi-
lity and finally to cells with invasive and metastatic capabilities 6. Most mutations found in 
human malignancy are somatic and found only in the patient’s tumor tissue. It is generally 
accepted that some of these alterations are causally involved in the transition of a normal cell 
into a tumor cell 7. Additionally, epigenetic alterations like methylation of DNA sequences 
resulting in gene silencing can play a role in the cellular transformation, which is a multistep 
process of genetic and epigenetic alterations 8. These alterations render the cell independent 
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of regulated proliferative and cell death pathways and deliver the cells with proliferative, in-
vasive and metastasizing capacities. Evidence has been presented that at least 5 to 10 specific 
genetic alterations are necessary to generate the malignant phenotype and most tumors are 
characterized by genomic instability facilitating the accumulation of mutations 9. As a con-
sequence, a malignant tumor is generated composed of cells with an increased proliferative 
activity, a prolonged lifespan and with metastasizing capacity. The genomic instability occurs 
in two different forms: one characterized by chromosomal instability (aneuploidy) and the 
other characterized by microsatellite instability 10. The targets of the genomic instability, at 
the nucleotide or at the chromosomal level, comprise 4 classes of genes:
1. Proto-oncogenes. These are regulatory genes found in normal cells that perform a regu-
lated role in activation of cell proliferation or inhibition of apoptosis (regulated cell death). 
Upon activation (through point mutation, gene amplification, chromosomal translocation, 
insertion etcetera) these dominant genes turn into oncogenes with continuous stimula-
tion of cell proliferation or continuous inhibition of apoptosis. 
2. Tumor suppressor genes. Tumor suppressor genes are recessive genes, with in normal cells 
a role in inhibition of cell proliferation or stimulation of apoptosis. Both gene copies need 
to be inactivated for their tumor suppressive effect to be lost which can be caused by both 
genetic and epigenetic phenomena: mutation, deletion of (part of ) the gene and epige-
netic silencing through promoter methylation. 
3. Mismatch repair genes. These genes are in normal cells involved in repair of DNA sequence 
mistakes occurring primarily during DNA replication. Inactivation of both copies of these 
recessive genes results in defective DNA repair and as a consequence in a genome wide ac-
cumulation of mutations, also in proto-oncogenes and tumor suppressor genes. Because 
tandem repeat DNA sequences (microsatellites) are especially vulnerable for DNA replica-
tion mistakes, microsatellite instability is a hallmark of a defect in DNA repair 11. The genes 
PMS1, PMS2, MLH1, MSH2, MSH6 and the recently discovered MBD4 (MED1) are all associ-
ated with microsatellite instability 12,13. 
4. Mitotic checkpoint genes. These genes are involved in control mechanisms ensuring the 
proper separation of chromosomes during cell division. When the mitotic checkpoint is de-
fective, improper allocation of the chromosomes to the daughter cells takes place during 
mitosis. This results in chromosomal instability and an abnormal number of chromosomes 
per cell (aneuploidy) 14. To date nine human genes with a role in mitotic checkpoint control 
have been discovered14. Inactivation of mitotic checkpoint genes results in chromosomal 
instability and an abnormal chromosome number (aneuploidy) 14. Mutation analysis of the 
human mitotic checkpoint genes in aneuploid cancers revealed only few alterations and 
probably genes yet to be discovered are responsible for most of the checkpoint defects 
found in aneuploid cancers.
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The activation of proto-oncogenes and inactivation of tumor suppressor genes as the result 
of genetic instability form the key genetic foci contributing to tumor development. To date 
there are no proto-oncogenes nor tumor suppressor genes that are activated or inactivated 
in all cancers. Even comparable cancers from the same organ and cell type never share al-
terations in the same genes completely. However, comparable tumors might probably have 
alterations in the same molecular pathways but with different components affected 15. 
To date, evidence is accumulating that cancer cells originate from transformation of tissue 
stem cells. These transformed tissue stem cells are thought to function as cancer stem cells 
that maintain the generation of neoplastic clones in a tumor. The existence of cancer stem 
cells is established in leukemia more than a decade ago, and recently in breast and brain 
tumors 16-18. In all these tumors it is thought that the cancer is a reflection of the correspon-
ding normal tissue stem cells. However, Houghton et al. recently proposed a new concept 
in gastric carcinogenesis, i.e. that bone marrow-derived cells might represent a potential 
source of epithelial cancers 19. Working with mice infected by a Helicobacter strain, they 
found that these bone marrow-derived cells were able to home, repopulate the chronically 
inflamed gastric mucosa and contribute over time to metaplasia, dysplasia and cancer 19,20. 
This results supports the idea that chronic inflammation fosters cancer development. Even 
more remarkable, the results of Houghton et al. provide evidence that epithelial cancers can 
originate from bone marrow derived stem cells. A similar phenomenon could perhaps occur 
in different types of inflammation-linked cancers as well. To date there are no literature data 
on esophageal adenocarcinogenesis concerning involvement of bone marrow-derived stem 
cells. The value of these new findings and concepts in carcinogenesis awaits future experi-
mental confirmation. 
This review aims to summarize current knowledge on genomic aberrations in esophageal 
adenocarcinomas as from recent years. Described genomic abberations are categorized as 
follows: Proto-oncogenes, Tumor suppressor genes, Mismatch repair genes (microsatellite 
instability), Mitotic checkpoint genes (DNA content and chromosomal abnormalities), Cell 
proliferation and Apoptosis, Genes involved in controlling the cell cycle, and Cell-cell adhe-
sion genes. For comprehensive overviews published before, the authors refer to reviews by 
Jenkins et al. and Wijnhoven et al. 21,22. 
PROTO-ONCOGENES
Proto-oncogenes are cellular genes, which can be converted into oncogenes by activating 
mutations. These mutations are somatic events. 
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Growth factors and their receptors EGF, TGF-α and EGFR
The Epidermal Growth Factor (EGF) has a stimulatory effect on epithelial cell proliferation in 
the gastrointestinal tract. EGF and Transforming Growth Factor-α (TGF-α) belong to the fa-
mily of growth factors that binds to the epidermal growth factor receptor (EGFR or c-erbB1). 
EGFR directed therapies are already available for treatment of human tumors with epithelial 
origin. EGFR is located at chromosome 7p12-13, a frequently amplified region in esophageal 
adenocarcinomas which has been correlated with the occurrence of lymph node metastasis 
23,24. EGFR overexpression correlated with decreased postoperative survival of patients with 
locally advanced esophageal adenocarcinoma treated with preoperative chemoradiotherapy 
25. EGFR directed therapies such as the EGFR kinase inhibitor Gefitinib (Iressa) are already 
available for treatment of human tumors with epithelial origin with clinical responses in EFGR 
mutated non-small cell lung cancers 26-28. Barber et al. recently published about mutations in 
colorectal carcinomas 29. 
TGF-α binds to EGFR and stimulates cell division. Amplification of the TGF-α gene at chro-
mosome 2p13 has been found in the progression of esophageal adenocarcinoma 30. TGF-α 
protein expression was significantly associated with tumor progression and lymph node me-
tastasis 31. In Barrett’s tissue, TGF-α has been found to activate Vascular Endothelial Growth 
Factor (VEGF) which plays a role in the vascularization of adenocarcinomas 32. Expression of 
VEGF was indeed increased in Barrett’s adenocarcinomas 33.
c-erbB2
The c-erbB2 proto-oncogene (HER2/neu) is localized at chromosome 17q21 and shares signifi-
cant homology with EGFR. As a result of its potential role in the selection of therapy, HER2/neu 
has reached a near-standard-of-practice status in breast cancer. The humanized monoclonal an-
tibody Trastuzumab (Herceptin, Hoffmann-La Roche, Grenzach-Wyhlen, Germany) that inhibits 
the proliferation of c-erbB2 overexpressing tumor cells has become available commercially for 
the treatment of patients with breast cancer. C-erbB2 protein overexpression and/or amplifica-
tion of the c-erbB2 gene occurred in approximately 10-70% of esophageal adenocarcinomas 
30,34-41. Overexpression of c-erbB2 was not demonstrated in metaplastic or low grade dysplastic 
Barrett’s epithelium suggesting that it is a late event in the dysplasia-carcinoma sequence 35,42. 
Walch et al. showed that both c-erbB2 and Growth Factor Receptor-bound protein 7 (GRB7) 
alterations displayed concomitant elevated expression levels and increased copy numbers in 
high grade dysplasia and carcinoma 42. C-erbB2 overexpression in adenocarcinomas correlated 
significantly with tumor invasion, lymph node involvement, distant metastasis and status of re-
sidual tumor after resection 38,39. Furthermore, c-erbB2 amplification correlated with shortened 
patient survival and independently predicted poor outcome in patients with Barrett related 
adenocarcinoma 43. We found c-erbB2 amplification to be present in 5 out of 13 esophageal 
adenocarcinoma cell lines and in 18 out of 49 primary esophageal or gastric cardia adenocarci-
nomas (Dinjens et al., Van Dekken et al., unpublished results).
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FGF
The Fibroblast Growth Factors (FGFs) form an important proangiogenic factor with the capa-
bility to regulate growth and differentiation of various cell types. The expression of acidic and 
basic FGF (aFGF, bFGF) has also been studied in esophageal adenocarcinoma and Barrett’s 
metaplasia. bFGF expression levels were significantly increased in Barrett’s adenocarcinomas 
and dysplastic tissues as compared to normal esophageal mucosa and metaplasia 33.
TGF-β
Transforming Growth Factor (TGF-β), a potent mediator of cell growth, plays various roles 
in the process of malignant progression. TGF-β is a potent inhibitor of cell proliferation, an 
inducer of differentiation in epithelial cells of the intestine in vitro, and a suppressor of ge-
nomic instability 44. Cancer cells can become resistant to TGF-β cell growth inhibition. TGF-β 
induces diverse cellular changes trough heteromeric complexes of TGF-β receptor type I and 
II such that the loss of either receptor dramatically alters the cellular response 45. Loss of TGF-β 
receptor type II expression appeared to be associated with Barrett's esophagus and esopha-
geal adenocarcinomas 46,47. Pathways of TGF-β signaling involve SMAD proteins, of which the 
SMAD2 and SMAD4 protein were originally isolated as the MADR2 and DPC4 tumor suppres-
sor gene respectively, both located at chromosome 18q, a locus which frequently shows loss 
in esophageal adenocarcinomas. Mutational inactivation of TGF-β signaling pathways was 
investigated by Tanaka et al. and was found to be rare 48. The Runt domain transcription factor 
3 (RUNX 3) tumor suppressor gene was shown to inhibit cell proliferation and induce apopto-
sis by reinstating TGF-β responsiveness in an esophageal adenocarcinoma cell line 49.
Ras-family
Activation of the Ras oncogene is commonly found in gastrointestinal tract cancers. The 3 
Ras isoforms comprise H-Ras, K-Ras and N-Ras and are essential components in normal cell 
division and differentiation. Reports at point mutations in K-Ras in Barrett’s esophagus and 
in esophageal adenocarcinomas showed them to be rare 50-52. Another report described K-
Ras mutations in 0% of Barrett’s metaplasias, 0% of low grade dysplasias, 30% of high grade 
dysplasias and 40% of adenocarcinomas 53. Activation of the Ras proto-oncogenes seems to 
be of little importance in Barrett’s adenocarcinomas.
c-myc
The c-myc gene forms a transcription factor with a role in regulation of proliferation-associ-
ated genes crucial for cell cycle control. C-myc is located on chromosome 8q24 and activation 
may contribute to tumor progression by preventing cells from entering the G0-resting phase. 
Amplification was reported in none of metaplasias and low grade dysplasias, but in 25% of 
high grade dysplasias and 44% of adenocarcinomas 54. Studies suggested that c-myc is the 
target gene of the chromosome 8q high level amplifications found in esophageal adeno-
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carcinomas 55-58 (Figure 2.1). Tselepis et al. showed upregulation of c-myc protein in 50% of 
metaplasias and 90% of adenocarcinomas with a role for bile acids in an acid environment as 
potent inducers of this oncogene in vitro 59. 
src
The cellular oncogene c-src and its viral homologue v-src are cellular oncogenes, which en-
code a nonreceptor tyrosine kinase involved in a number of signal transduction pathways. Src 
may deregulate cell-adhesion by anchorage-dependent growth control, thereby maintaining 
cells in the proliferative state 60. Increased src activity was found in Barrett’s epithelium with a 
6 fold increase in esophageal adenocarcinomas 61. Moreover, Jankowski et al. found that 20% 
of a series of esophageal adenocarcinomas and Barrett’s esophagus expressed src 62. 
Prostaglandins
The rate-limiting step in the synthesis of prostaglandins is the conversion of arachidonic 
acid to prostaglandin. The enzyme that controls this crucial step is cyclooxygenase (COX), of 
which there are 2 isoforms, COX-1 and COX-2. COX-1 expression is predominantly constitutive 
whereas COX-2 expression is inducible by mediators of inflammation. The mechanisms by 
which COX-2 is thought to be involved in carcinogenesis include resisting apoptosis, increa-
sing cell proliferation, stimulating angiogenesis and modulating the invasive properties of 
cancer cells 63. COX-2 was shown to be functionally active in Barrett’s esophagus since treat-
Figure 2.1 Combined CGH data from Van Dekken et al. (20 gastric cardia adenocarcinomas) and from Riegman 
et al. (30 Barrett adenocarcinomas) 167,171. Boxes indicate regi ns of high-level amplification.  
Figure 2.1 Combined CGH data from Van Dekken et al. (20 gastric cardia adenocarcinomas) and from Riegman et al. (30 Barrett adenocarcinomas) 
167,171. Boxes indicate regions of high-level amplification. Also see color figures page 291.
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ment with COX-2 inhibitors hindered proliferation of Barrett cells in culture as well as adeno-
carcinoma cells 64,65. Proliferation was restored by prostaglandin treatment 64. Enhanced COX-
2 expression was detected in high amount in metaplasia (75-91%), low grade (83%) and high 
grade dysplasia (100%) and adenocarcinoma (97-100%) 66,67. Elevated COX-2 protein expres-
sion was significantly associated with reduced survival after esophagectomy for adenocarci-
noma 68. Moreover, COX-2 inhibition with the selective inhibitor rofecoxib showed a reduction 
of COX-2 expression, prostaglandin release and cell proliferation in Barrett’s patients, thereby 
forming a promising chemoprevention agent against dysplasia and carcinoma 69. Results of 
clinical studies to investigate the effect of COX-2 inhibitors as a novel treatment modality for 
patients with Barrett’s esophagus and adenocarcinoma have to be awaited. Since complex 
interactions seemed to exist between COX-2 and autocrine production of gastrin on Barrett’s 
adenocarcinogenesis, this needs to be considered when evaluating chemopreventive strate-
gies in Barrett’s adenocarcinoma 70.
BRAF
The Ras oncogene transmits extracellular growth signals trough the MAP kinase pathway, 
resulting in the activation of RAF kinase. The 3 isoforms of RAF comprise ARAF, BRAF and 
CRAF. Activating BRAF mutations were discovered in a variety of malignancies 71. BRAF muta-
tions are generally nonoverlapping with K-Ras, suggesting that only one mutational event in 
the pathway, comprising RAS, MAP kinase and BRAF, may be needed for tumorigenesis 72-74. 
Sommerer et al. detected activating BRAF mutations in 0% of low grade dysplasias, in 4% 
of high grade dysplasias and in 11% of adenocarcinomas 75. Interestingly, K-Ras mutations 
were detected in 11% and 21% of high grade dysplasias and adenocarcinomas respectively, 
all lesions with K-Ras mutations having an intact BRAF gene 75. The inhibition of the RAS-
MAP-RAF kinase pathway might be a new diagnostic or even therapeutic strategy in Barrett’s 
adenocarcinogenesis 76.
PIK3CA
Systematic cancer genome analysis has recently led to the discovery of somatic mutations 
in the PIK3CA gene, a member of the phosphatidylinositol 3-kinases (PI3Ks) 76. PIK3CA is a 
lipid kinase located at chromosome 3q26 that regulates signaling pathways important in cell 
proliferation, adhesion, cell survival and motility. Somatic PIK3CA mutations were detected 
in colon cancers, brain cancers, gastric, breast and lung cancers 77. Mutant PIK3CA is likely 
to function as an oncogene and therefore may prove useful for diagnostic and therapeutic 
purposes 77. No data exist on PIK3CA gene mutation analysis in esophageal adenocarcino-
mas, although amplification of PIK3CA was detected in 5.7% of 87 Barrett’s adenocarcinomas 
78. Interestingly PIK3CA amplification showed significant correlations with low tumor stage, 
absence of nodal involvement, small tumor size and lower T-status 78.
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HNF3α
The Hepatocyte Nuclear Factor 3α (HNF3α ) gene is located at 14q13 and forms a member 
of the forkhead gene family. HNF3α is involved in liver differentiation and regeneration, 
amongst others. Amplification of chromosome 14q13 with overexpression of the HNF3α in 
esophageal adenocarcinomas suggested a potential oncogenic role for this gene 79. 
TUMOR SUPPRESSOR GENES
In tumor suppressor genes both gene copies need to be inactivated for the tumor suppressive 
effect to be lost. One allele of these genes is frequently inactivated by Loss of Heterozygosity 
(LOH). The remaining copy is often inactivated by mutation or promotor methylation. To define 
chromosomal regions of deletion LOH-analysis is used, also referred to as Microsatellite Allelo-
typing or Allelic Imbalance analysis. Using the Comparative Genomic Hybridization (CGH) tech-
nique, genome wide detection of amplifications and losses can be performed. Frequent loss of 
one allele involving a chromosomal arm or locus suggests the presence, at or near that locus, 
of a tumor suppressor gene. Several groups have evaluated chromosomal regions for LOH in 
Barrett’s metaplasia, dysplasia and adenocarcinomas of the gastro-esophageal junction (Table 
2.1B). Most common areas of chromosomal loss with their target genes will be discussed. 
Chromosome 3p: FHIT, VHL and PPARγ 
Fragile sites are genomic regions that predispose for structural chromosome aberrations 
such as translocations or deletions. The Fragile Histidine Triad (FHIT) gene is localized on 
chromosome 3p14 and spans the common fragile site FRA3B. Even though its role in carcino-
genesis is still unclear, this gene is frequently inactivated by carcinogen-induced intragenic 
deletions in many types of cancers. Rare silent point mutations were found in esophageal ade-
nocarcinomas 80. A relationship between genomic deletions and the presence of abnormal 
FHIT transcripts (observed in 86% of Barrett’s esophagus and 93% of associated carcinomas) 
was found by Micheal et al. 81. Esophageal adenocarcinoma cell line experiments provided 
evidence for selection of loss of a functional FHIT gene by translocation events at the fra-
gile site harboring FHIT 82. Abnormal FHIT transcript were observed in 44% of 18 esophageal 
adenocarcinomas, genomic deletions were found in 44% also with overlap of both types of 
alterations in only 2 out of 18 patients 83. Since genomic deletions were observed in 80% 
of squamous cell carcinomas of the esophagus, the authors propose the FHIT gene to be 
a common target for carcinogens such as smoking and alcohol, known risk factors for the 
development of particularly esophageal squamous cell cancer 83. Array-based CGH showed 
DNA sequence copy number loss of FHIT in 28% of 18 Barrett’s carcinoma samples as part of 
approximately 50 genes identified 84. However, aberrant FHIT transcripts were also detected 
in normal, non-cancerous tissues of the gastrointestinal tract, questioning the role of FHIT as 
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a tumor suppressor 85. Its apparent involvement might simply reflect its location within an 
unstable region of the genome. 
Frequent loss is described at chromosome 3p25-26 encompassing two candidate tumor sup-
pressor genes: the Von Hippel-Lindau (VHL) gene and the peroxisome proliferator activated 
receptor-gamma (PPARγ) gene. Both genes are mutated in VHL disease and colon carcinomas, 
respectively 86,87. LOH analysis revealed 3p25-26 loss in 67% of 36 distal esophageal and gas-
tric cardia carcinomas whereas no mutations were detected 88. A high percentage of LOH at 
the 3p VHL locus was also shown by Dolan et al., Sanz-Ortega et al. and Raja et al. suggesting 
that other candidate tumor suppressor genes located at 3p might be involved in esophageal 
adenocarcinogenesis 89-91. Moreover, LOH at the VHL gene locus (and also at the APC, p16, 
DCC and MSH3 mismatch repair gene locus) could be detected in histologically normal tissue 
and in adjacent adenocarcinoma, being potential markers of early neoplastic progression 92.
Chromosome 5q: MCC and APC 
The Mutated in Colorectal Cancer (MCC) tumor suppressor gene is closely linked to the 
Adenomatosis Polyposis Coli (APC) tumor suppressor gene at chromosome 5q21. Bektas et 
al. performed LOH analysis in 36 patients with Barrett’s metaplasia and/or low grade dyspla-
sia and/or high grade dysplasia and adenocarcinoma 93. MCC allelic loss percentages were 
6%, 0%, 0% and 25% respectively 93. So far, no reports have been published on MCC mutation 
analysis in esophageal adenocarcinomas. Also in colorectal and gastric cancers, with high 
MCC LOH, mutation of the retained MCC allele is uncommon, suggesting that MCC does not 
function as a tumor suppressor gene in gastrointestinal malignancies. 
Performing LOH analysis we observed APC allelic loss in 16% of Barrett’s metaplasias, 23% of 
low grade dysplasias, 48% of high grade dysplasias and 50% of adenocarcinomas (Chapter 
13). Analogous to Zhuang et al. patterns of allelic loss of the APC gene in premalignant tis-
sue and in carcinomas were identical in all stages of neoplastic progression, suggesting the 
emergence of a clonal population of cells 94. A very low rate of APC mutations was described 
in esophageal cancers 95-97. Another putative tumor suppressor gene might therefore be the 
target of the frequent LOH on 5q and deletion of the APC locus may just be the result of large 
deletions on 5q and may therefore not be important in esophageal carcinogenesis 96. On the 
other hand, an alternative mechanism could be responsible for inactivation of the APC gene. 
In gastric cancer, methylation of the promotor region of the APC gene was strongly associ-
ated with silencing of its expression 98. Kawakami et al. observed hypermethylation of the 
promotor region of the APC gene in 92% of 52 Barrett’s adenocarcinomas and in 40% of 43 
patients with Barrett’s metaplasia 99. Interestingly, hypermethylated APC DNA was observed 
in the plasma in part of the patients and high levels significantly correlated with reduced 
patient survival 99. Monoallelic APC promotor methylation was found to be frequently altered 
in histologically normal-appearing gastric mucosa from patients with gastric or esophageal 
adenocarcinoma 100.
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Chromosome 9p: p16
Inactivation of the p16 tumor suppressor gene (also MTS1 or CDKN2A gene) at 9p21 is one of 
the most common genetic abnormalities in human cancers. P16 encodes a cell cycle regula-
tory protein that inhibits cyclin-dependent kinases 4 and 6, preventing the phosphorylation 
of the Rb protein and the release of a transcription factor. This blocks cell cycle progression 
in the G1-S phase. P16 becomes inactivated by a two-hit mechanism that can involve 9p21 
LOH, mutation, homozygous deletion or CpG island methylation (i.e. an epigenetic event). 
In esophageal adenocarcinomas frequent allelic loss at 9p21 has been described 89-91,95,101-105. 
Point mutations in exons 1 and 2 of the p16 gene were found to be rare in esophageal adeno-
carcinomas (ca. 5%) in contrast to squamous cell carcinomas 80,106-108. Barrett et al. reported 
a higher prevalence (23%) of p16 gene mutations in adenocarcinomas with LOH of 9p21 
109. However, in this study only aneuploid cell populations were investigated, which might 
not be representative for esophageal carcinomas in general and thus might explain the 
higher prevalence of p16 gene mutations. Gonzalez et al. reported homozygous deletions 
of the p16 gene in 3 of 12 (25%) esophageal adenocarcinomas 95. P16 promoter methylation 
(with or without p16 LOH) is a common mechanism of p16 inactivation during neoplastic 
progression in Barrett’s esophagus, and is already present in non-dysplastic premalignant 
Barrett’s epithelium 110-114. Wong et al. stated that p16 lesions are the earliest known somatic 
genetic/epigenetic abnormalities in Barrett’s esophagus occurring in more than 85% of cases 
at all histological grades of dysplasia 112. Cells with p16 aberrations, either hemizygous or 
nullizygous clones, undergo clonal expansion to involve large regions of the esophagus, 
creating a field in which other premalignant lesions can arise that can result in the formation 
of esophageal adenocarcinoma 112. P16 inactivation may therefore be a useful biomarker to 
stratify patients’ risk of progression of Barrett’s metaplasia to esophageal cancer 115,116. Suspiro 
et al. reported 9p LOH in 35% of 18 Barrett’s metaplasia patients without dysplasia or cancer 
(as well as 39% 17p LOH) regarding 9p and 17p LOH as useful markers for risk stratification 
within endoscopic surveillance programs 117. Other tumor suppressor genes on 9p being p15 
and p14ARF were rarely altered in esophageal adenocarcinomas 106,109,114.
Chromosome 13q: retinoblastoma 
The Retinoblastoma (Rb) gene encodes a cell cycle-associated protein important in regula-
ting the G1-S checkpoint of the cell cycle. Functional alterations play a key role in carcinoge-
nesis and cell proliferation. Rb allelic loss was found in none of the Barrett’s metaplasias, 7% 
of the low grade dysplasias, 8.3% of the high grade dysplasias and 18.5% of the carcinomas 
by Sarbia et al 118. There are no reports on mutation analysis of the Rb gene in esophageal 
adenocarcinomas. 
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Chromosome 17p: p53 
Loss or mutation of tumor suppressor gene p53 is probably the most common single ge-
netic change in cancer. This reflects the central importance of p53, which has several func-
tions in the cell. One is as a transcription factor. Tetramers of p53 bind DNA and can activate 
transcription of reporter genes situated downstream of a p53 binding site. However, p53 is 
believed to have a much broader role in the cell, which has been summarized as ‘the guar-
dian of the genome’. Normal cells with damaged DNA arrest at the G1-S cell cycle checkpoint 
until damage is repaired, cells that lack p53 or have a mutant form do not arrest and replica-
tion of damaged DNA presumably leads to random genetic changes, some of which are on-
cogenic, similar to cells with a defective mismatch repair system. In addition, cells that lack 
p53 or contain mutant p53 escape apoptosis. Molecular techniques can detect p53 gene 
alterations, such as single strand conformation polymorphism (SSCP) analysis, sequencing 
and LOH analysis. The prolonged half-life of the mutant p53 protein and the concomitant 
increased cellular p53 concentration makes visualization by immunohistochemistry pos-
sible. Deletion of one allele of p53 in combination with a functionally inactivating muta-
tion of the other p53 allele is among the most common combinations of genetic alterations 
documented in human cancer. P53 was the first such gene to be investigated in esopha-
geal adenocarcinomas 119-121. P53 LOH and mutations seem to be relatively early events in 
neoplastic progression in Barrett’s esophagus because it develops in diploid cells before 
aneuploidy and other LOH events involving 5p, 13p and 18q 105,115,122,123. LOH of the p53 locus 
has been found in 75-80% of esophageal adenocarcinomas as well as in 79% of high grade 
dysplasias, 42% of low grade dysplasias and 14% of Barrett’s metaplasias 102,124,125. P53 muta-
tions were found in 29-66% of Barrett’s metaplasias/low grade dysplasias and in 40-88% of 
high grade dysplasias/adenocarcinomas 126-130. In contrast, nuclear p53 protein overexpres-
sion was found often in absence of p53 mutations, therefore immunohistochemistry seems 
to be a poor indicator of p53 gene mutations and probably an alternative mechanism is 
responsible for p53 protein expression 126-131. 
17p LOH analysis performed on endoscopic biopsies identified patients with Barrett’s esopha-
gus at risk of neoplastic progression within surveillance programs, therefore it could supple-
ment histology in determining the frequency of endoscopy during surveillance 117,132. More-
over, since p53 mutations could be detected before development of high grade dysplasia 
or adenocarcinoma in Barrett’s esophagus patients in surveillance programs, it may also be 
useful in stratifying the risk for development of adenocarcinoma within Barrett’s esophagus 
133. Reid et al. found patients with p53 LOH in the flow cytometric-purified biopsy samples to 
be at increased risk for progression to adenocarcinoma, high grade dysplasia, increased 4N 
and aneuploidy 134. LOH at 17p13 (but also LOH at 3p21, 5q21 and 9p21) might have a role as 
potential biomarker for high chance of developing adenocarcinoma in patients with Barrett’s 
esophagus 90. Several groups have investigated clinical significance of p53 mutations. Patients 
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with p53 mutations and/or p53 protein overexpression in the tumor after surgical resection 
had significant reduced 5-year survival relative to patients with wild-type p53 135-137. 
In conclusion, there is overwhelming evidence that p53 gene alterations are early and fre-
quent events in esophageal adenocarcinomas and that this gene is associated with malig-
nant transformation of Barrett’s esophagus. Moreover, p53 alterations could be of value in 
the prevention as well as planning of treatment strategies in future studies. 
Chromosome 18q: SMAD4 (DPC4) and DCC 
LOH analysis revealed allelic loss of 18q in 63-70% of esophageal adenocarcinomas 89,91. Puta-
tive tumor suppressor genes in this region comprise the Deleted in Colorectal Cancer (DCC) 
and SMAD4 (Deleted in Pancreatic Cancer: DPC4) genes. Allelic loss of SMAD4 was described 
in 46% of 35 Barrett’s esophagus patients with premalignant epithelium and/or adenocarci-
noma 138. Mutational analysis of SMAD4 did not reveal inactivating alterations indicating that 
the targeted gene remains to be identified 138. 
MISCELLANEOUS TUMOR SUPPRESSOR GENES AND INACTIVATION 
Chromosome 7q
Frequent LOH has been described at 7q31 in numerous malignancies. Suppressor of Tumori-
genicity 7 (ST7) has been identified as a candidate tumor suppressor gene at this region. 
7q LOH was detected in 32% of 25 esophageal adenocarcinomas, but no mutations were 
detected in this region 139. Therefore ST7 is not the target gene at 7q in esophageal adeno-
carcinomas 139.
Chromosome 14q
LOH at 14q31-32.1 (harboring candidate gene Thyroid Stimulating Hormone Receptor TSHR) 
occurred in 46% of Barrett’s adenocarcinomas and gastric cardia adenocarcinomas 57. To date 
there is no clear indication as to what 14q tumor suppressor gene is the target for 14q loss. 
Methylation
The bi-allelic inactivation of tumor suppressor genes cannot always exclusively be explained 
by genetic alterations. LOH at for example the APC locus has been detected frequently with-
out mutations in the remaining allele in esophageal adenocarcinoma 94,105. Therefore other 
non-genetic events could contribute to gene inactivation in esophagal adenocarcinoma. 
Hypermethylation of CpG islands in the promotor region is such a non-genetic inactivation 
mechanism. Methylation of p16 is described to be the predominant mechanism for p16 inac-
tivation in esophageal adenocarcinogenesis as early as metaplasia 112-114,140,141. Methylation of 
APC is described in esophageal adenocarcinoma as well as Barrett’s metaplasia 99,141. Patients 
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whose tumors had more than 50% of a 7 gene-profile methylated had significantly poorer 
survival and earlier tumor recurrence 142. Moreover aberrant hypermethylation at many diffe-
rent loci within a panel of 20 genes suggested an overall deregulation of methylation control 
in Barrett adenocarcinogenesis 143. Interestingly, normal and metaplastic tissues from patients 
with evidence of associated dysplasia or cancer had a significantly higher incidence of hyper-
methylation than similar tissues from patients with no further progression of metaplasia 143.
MISMATCH REPAIR GENES: 
Microsatellite instability
The Mismatch Repair (MMR) system is one of the mechanisms by which rapid repair of da-
maged DNA can be achieved. This system primarily removes nucleotides mispaired by DNA 
polymerases, and insertion or deletion loops resulting from slippage during replication or 
recombination. MMR failure results in the accumulation of single nucleotide mutations and 
alterations in length of simple, repetitive microsatellite sequences throughout the genome. 
This is known as Microsatellite Instability (MSI). MMR deficiency has been shown to be an 
important defect in about 15% of sporadic and hereditary colorectal cancers, gastric, ova-
rian and endometrial cancers. In Hereditary Non-Polyposis Coli Colorectal Cancer (HNPCC) 
syndrome germline mutations in MMR genes (most frequently MLH1 and MSH2) are com-
monly found. Concerning colorectal cancer a panel of 5 microsatellites has been validated 
and is recommended to characterize cancers as ‘MSI-high’ (2-5 markers out of 5 markers show 
instability), ‘MSI-low’ (1 marker) or ‘MSS (stable)’. Such criteria lack for other human solid tu-
mors. Several groups published on MSI and MMR in esophageal carcinomas. These studies 
are summarized in Table 2.3.
Meltzer et al. suggested that the instability may develop as an early event in Barrett’s associ-
ated neoplastic progression since among 25 flow cytometry sorted adenocarcinomas insta-
bility occurred in 8 (32%) 144. Moreover in 4 of these 8 positive cases, the diploid component 
of the tumor showed instability 144. Several studies have confirmed the low prevalence of MSI, 
between 5-10%, in esophageal adenocarcinomas 89,103,107,125,145. Interestingly, Wu et al. found 
a trend towards an improved survival for esophageal adenocarcinomas demonstrating MSI, 
whereas others could not establish an association with survival or clinicopathologic features 
such as tumor grade, pathologic stage, perineural or vascular invasion, and also not with 
p53 alterations or mutations in the recently reported DNA repair gene MBD4 125,146,147. It is not 
yet known which mismatch repair genes are responsible for the MSI observed in Barrett’s 
adenocarcinoma. 
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MITOTIC CHECKPOINT GENES:
DNA content and chromosomal abnormalities
DNA content/aneuploidy
Due to defects in mitotic checkpoint genes cells can obtain an abnormal number of chro-
mosomes, defined as aneuploidy 148. To date nine human genes with a clear role in mitotic 
checkpoint control and prevention of aneuploidy have been discovered 14,149. Despite the fact 
that 95% of esophageal adenocarcinomas is aneuploid, the gene(s) involved in aneuploidy 
in these tumors are still unknown. Gene expression levels of the MAD2 and BUB1 mitotic 
spindle checkpoint genes were assessed in 37 Barrett’s patients by real time PCR, although no 
correlation with aneuploidy could be established 150. The APC tumor suppressor gene plays 
a role in chromosome segregation by binding to the microtubules that form the spindle 
apparatus 15,149,151. In Barrett’s epithelium and related adenocarcinomas frequent loss of the 
APC gene (5q21) as well as gene inactivation by hypermethylation has been described but 
few gene mutations (see Tumor Suppressor Genes paragraph). Whether loss of APC function 
plays a role in aneuploidy observed in Barrett and carcinoma remains to be demonstrated. 
Aneuploidy can be detected by measuring the DNA content of individual cells. With flow 
cytometry normal cells have a DNA content ranging from 2N (in G1 phase of cell cycle) to 4N 
(in G2/M phase of cell cycle). By using flow cytometry it has been shown that the evolution 
from normal esophagus to premalignant Barrett’s metaplasia was frequently associated with 
aneuploidy and increased G2/M fraction (4N) of the metaplastic cells 152-154. It has been sug-
gested that nuclear DNA ploidy analysis on flow cytometry might provide a more objective 
and reliable biomarker associated with progression from metaplasia to carcinoma than the 
histological diagnosis of high grade dysplasia 155,156. Indeed, prospective studies indicate that 
both aneuploidy and dysplasia may be prognostic factors for malignant transformation in 
Barrett’s epithelium 153,157,158: 70% of the patients with aneuploidy or increased G2/tetraploid 
fractions in biopsy specimens obtained during initial endoscopic evaluation developed high 
grade dysplasia or cancer, whereas none of the patients without flow cytometric abnormali-
ties on initial evaluation showed progression to invasive carcinoma or high-grade dysplasia 
153. A combination of histological dysplasia any grade and the measurement of DNA abnor-
malities might therefore help identify Barrett’s esophagus patients at risk for adenocarci-
noma 155,156. Rabinovitch et al. proposed that patients with negative, indefinite or low-grade 
dysplasia biopsy results in a surveillance program without increased 4N or aneuploidy may 
have subsequent surveillance deferred for up to 5 years 159. 
Specific Chromosomal abnormalities 
Detection of aneuploidy is based on the nuclear DNA content. No information is obtained 
about detailed chromosomal abnormalities in these cells. Techniques to investigate these 
chromosomal abnormalities comprise karyotyping, for which cells have to be cultured, In 
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Situ Hybridization (ISH), by which numerical aberrations can be detected as well as amplifica-
tion or loss of specific DNA loci, and LOH analysis, which investigates specific chromosomal 
regions for amplification or loss. The CGH technique allows genome wide screening for chro-
mosomal imbalances. 
The most consistent numerical chromosomal abnormalities found in cytogenetic studies 
of dysplastic Barrett’s mucosa and adenocarcinoma comprised loss of the Y-chromosome, 
namely in 31-93% of tumors, correlating with the development of carcinoma 160-162. Karyoty-
ping revealed frequent structural rearrangements in esophageal adenocarcinomas in the 1p, 
3q, 11p-13, and 22p regions 160,163. Using Fluorescence In Situ Hybridization (FISH), Doak et al. 
showed chromosome 4 and 8 hyperploidy to represent the earliest and most common altera-
tions identified using tissue from endoscopic cytology brushings (metaplasia 89% and 71%, 
low grade dysplasia 90% and 75%, high grade dysplasia 88% and 100%, carcinoma 100% 
and 100% respectively)164. CGH showed significant chromosome changes to be absent in low 
grade dysplastic lesions whereas a large amount of widespread instability was present in 
high dysplastic lesions (most often chromosome 4 amplification) and adenocarcinomas (with 
chromosome 8 amplified most frequently) 165. Furthermore, trisomies for chromosomes 5 and 
7 and translocations involving chromosome 3 and 6 in Barrett’s esophagus were described 
162. LOH studies and CGH studies reported in the literature showed frequent chromosomal 
losses in the metaplasia-dysplasia-adenocarcinoma sequence concerning amongst others 
chromosomes 4q, 5q, 7q, 9p, 13q, 17p and 18q and revealed over representation of chromo-
somes 6p, 7, 8q, 11, 12q, 14 and 20q 55,57,58,84,89-91,102,104,105,109,112,125,160,161,164,166-176, with a detailed 
summary of part of these studies in Tables 2.1A, 2.1B (losses) and Table 2.2 (gains and high 
level amplifications). Figure 2.1 shows combined CGH data from Van Dekken et al. (20 gas-
tric cardia adenocarcinomas) and from Riegman et al. (30 Barrett adenocarcinomas) 167,171. 
It remains to be determined whether any of these abnormalities are predictive markers of 
progression to malignancy. However, loss of 7q33-q35 was found to represent a significant 
distinction between low grade and high grade dysplasia whereas loss of 16q21-q22 and gain 
of 20q11.2-q13.1 were disclosed to significantly discriminate between high grade dysplasia 
and adenocarcinoma 167. Detection of DNA sequence copy number changes using array CGH 
revealed changes, mainly gains, of approximately 50 genes in Barrett’s adenocarcinoma, pro-
viding new candidate biomarkers in esophageal adenocarcinogenesis 84. 
CELL PROLIFERATION AND APOPTOSIS
In the light of molecular concepts about carcinogenesis it is important to realize that the ac-
cumulation of genetic alterations is only effective in combination with cell division. Dividing 
normal cell populations maintain the balance between cell proliferation and cell loss. If there 
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is increased proliferation, decreased apoptosis or both, uncontrolled growth occurs and this 
may result in tumor formation 177.
Cell proliferation
In order to assess the amount and distribution of cell proliferation in paraffin-embedded 
tissues monoclonal antibodies have been developed to detect cell cycle modulators. Se-
veral studies used a monoclonal Ki-67 (MIB-1) and PCNA antibody to study the proliferative 
properties in Barrett’s esophagus and adenocarcinomas. An increased number of prolifera-
ting cells and an expansion of the proliferative compartment was demonstrated in Barrett’s 
esophagus and adenocarcinoma 178-181. PCNA immunostaining was mainly seen in the basal 
cells of the neck/foveolar epithelial compartment of the glands in Barrett’s esophagus. How-
ever, in mucosa with high-grade dysplasia, the proliferative compartment extended upwards 
into the superficial layers of the glands 182-184. Ki-67 staining pattern also correlated with the 
histologic findings in Barrett’s esophagus: the number and localization of Ki-67 positive 
nuclei was significantly different between non, low and high grade dysplastic Barrett’s and 
adenocarcinoma 182,185-190. Interestingly, effective intra-esophageal acid suppression decreased 
cell proliferation and favored differentiation in Barrett’s epithelium, but had no effect on the 
grade of dysplasia 191. 
Apoptosis
Apoptosis, or programmed cell death, is one of the mechanisms responsible for cell loss. 
The net effect of cell division and apoptosis determines tissue growth. Apoptosis provides a 
protective mechanism by removing senescent, DNA-damaged, or diseased cells that could 
either interfere with normal function or lead to neoplastic proliferation. Apoptosis itself can 
be detected by use of immunohistochemical detection of DNA fragmentation as markers 
for apoptosis. An increase in apoptotic rate with increasing histologic severity in intestinal 
metaplasia/dysplasia and carcinoma was noted 178, whereas others found few apoptotic cells 
in Barrett’s high-grade dysplasia and adenocarcinoma 192,193. 
Fas and Fas Ligand
The Fas/APO-1 (CD95) gene encodes a transmembrane protein that is involved in apoptosis 
and is a member of the tumor necrosis factor receptor superfamily. Loss of its expression 
during carcinogenesis can result in the interruption of the apoptotic pathway. Hughes et al. 
found that expression of Fas on the cell surface by esophageal adenocarcinomas is reduced 
or absent whereas high levels of Fas mRNA were detected in these tumors 194. Furthermore, 
they demonstrated in an esophageal adenocarcinoma cancer cell line that wild-type Fas 
protein is retained in the cytoplasm. Apparently, retention of wild-type Fas protein within 
the cytoplasm may represent the mechanism by which malignant cells evade Fas-mediated 
apoptosis 194. Fas ligand binds to Fas, activating an apoptotic pathway. Younes et al. found that 
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Fas ligand was overexpressed in cases of Barrett’s metaplasia with dysplasia and esophageal 
adenocarcinomas but that Fas was usually undetectable or expressed at low levels 195,196. They 
propose that decreased Fas expression might protect Barrett’s metaplasia with dysplasia and 
carcinoma from self-destruction while allowing them to evade immune surveillance 195,196. 
Bcl-2 family (Bcl-2, Bcl-xl, Bax)
The Bcl-2 proto-oncogene at 18q21 encodes a protein that blocks apoptosis 197. Divergent 
results have been published in the literature concerning Bcl-2 expression. It was found to 
be increased in reflux esophagitis, non dysplastic Barrett’s and low grade dysplastic Barrett’s 
epithelium, but low or virtually absent in high grade dysplasia and carcinomas 182,187,193,198-200. 
Inhibition of apoptosis by overexpression of Bcl-2 protein occurs mainly early in the neo-
plastic progression. As malignancy appears, cells acquire other ways of avoiding apoptosis 
for instance by mutations in the p53 gene, since p53 dysfunction plays a major role in the 
progression from dysplasia to carcinoma in Barrett’s esophagus and appears unrelated to 
Bcl-2 expression 201. Van der Woude et al. proposed that the apoptotic balance in the trans-
formation of metaplasia to adenocarcinoma switches from a pro- to a antiapoptotic pheno-
type due to increased Bcl-xl and decreased Bax expression 200. Bcl-xl expression was shown 
to be elevated in the metaplasia-low grade-high grade dysplasia-adenocarcinoma sequence 
(27%, 60%, 71% and 59% respectively) 202. Loss of Bcl-2 expression in Barrett’s dysplasia and 
adenocarcinoma was associated with tumor progression as well as worse survival but not 
with response to neoadjuvant chemoradiation 203.
Mdm2
The p53 gene is an important tumor suppressor gene functioning both in cell cycle arrest and 
apoptosis. The human homologue of the murine double minute-2 gene (mdm2) at 12q15 is 
a known regulator of p53 activity. Its expression results in stabilization of the wild-type p53 
protein and loss of its tumor suppressor function. Soslow et al. showed mdm2 to be overex-
pressed in esophageal adenocarcinomas 128. Recently, a mdm2 promotor polymorphism was 
described that decreased p53 function in Li Fraumeni patients without a p53 mutation 204.
Survivin and other IAPs
Survivin forms an inhibitor of apoptosis protein (IAP) 205. It is expressed in the G2/M phase of 
the cell cycle and its interaction with the mitotic spindle apparatus has been reported to be 
essential for anti-apoptotic function 205. The expression of survivin has been shown to pre-
dict a poor prognosis in terms of survival and disease recurrence for patients with colorectal 
cancer, neuroblastoma and bladder cancer 206-209. Beardsmore et al. found survivin immuno-
staining in 95% of esophageal carcinomas (both squamous cell and adenocarcinomas) with 
a strong positive correlation between levels of survivin expression and the number of prolife-
rating cells in the malignant tissue 199. Although a predictive role for surviving in the response 
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to neoadjuvant chemoradiotherapy has been suggested in the literature, Beardsmore et al. 
were not able to show such a correlation in esophageal cancers 199. Expression of survivin and 
other IAPs (cIAP1, cIAP2, NAIP, and XIAP) was elevated in a series of esophageal squamous 
cell carcinomas 210.
Telomerase
The limited life span of normal somatic cells is characterized by telomere shortening. Cells 
that are not subject to replicative senescence such as germline cells, stem cells and cancer 
cells are able to maintain telomere length. Telomerase is a ribonucleoprotein enzyme com-
plex that is capable of restoring and maintaining telomere length by providing its own RNA 
template for the addition of telomeric sequences to chromosome ends. Telomerase activa-
tion is associated with increased expression of the telomere reverse transcriptase catalytic 
subunit (hTERT). Lord et al. measured mRNA expression levels of hTERT in Barrett’s meta-
plasia, dysplasia and adenocarcinoma and found a significant increase in upregulation in 
the metaplasia-dysplasia-adenocarcinoma sequence as compared to patients normal tissue 
211. Moreover, a significant difference was found in hTERT activation when normal tissues of 
cancer patients were compared to squamous cell epithelia of non-cancer patients211. Another 
study demonstrated that the vast majority of esophageal adenocarcinomas and high grade 
dysplasias contained high levels of telomerase RNA and that the greatest increase occurred 
during the transition from low to high grade dysplasia 212. 
Because of the tight link between cell proliferation and apoptosis in tumor growth the assess-
ment of both parameters in a neoplasm is suggested to be a sensitive marker for neoplastic 
progression 179.
Genes involved in controlling the cell cycle
Proliferation is crucial for tumor development. Cell cycle progression is the result of prolifera-
tion promoting factors: the Cyclin Dependent Kinases (CDKs) and the Proliferation Inhibiting 
components (CDK-inhibitors, CDKIs). Cyclins form a family of proteins that complex with 
CDKs. The CDKIs can be categorized in the Kip/Cip proteins (p21, p27, p57) and the INK4 pro-
teins (p15, p16, p18, p19). The development of dysplasia is characterized by a disregulation of 
cell cycling. In Barrett’s metaplasia progression of an increased fraction of S-phase and G2/M 
phase cells is described, suggesting that cells escape G1-G0 phase checkpoints 213. The Rb 
gene (mediating cell cycle progression), p16 gene (a CDKI) and p53 gene (inhibits cell cycle 
when DNA is damaged) have been described in the section ‘Tumor suppressor genes’.
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CYCLINS 
Cyclin D1 (11q13)
Disregulation of the cell cycle in the development of dysplasia is in part due to increased 
cyclin D1 expression and hypermethylation or mutation of p16 with mobilization of cells 
from G0 to G1 with subsequent accumulation in the G2 phase 1. Amplification of the cyclin 
D1 gene was observed in 16-26% of the esophageal adenocarcinomas, whereas increased 
nuclear expression of cyclin D1 was observed in 22-64% of the esophageal adenocarcinomas 
214-219. Within a prospective cohort of Barrett’s patients a statistically significantly increased 
risk of progression to adenocarcinoma was shown in patients with cyclin D1 positive biopsy 
specimens 220. The Rb protein is phosphorylated by cyclin D1 and thereby inactivated. The 
inactivated Rb facilitates transition of the cell from G1 into S-phase. Another group of CDKIs 
is the Cip/Kip family and includes p21, p27 and p57.
Cyclin B1 (5q12)
Cyclin B1 is synthesized in the early G2-phase and is believed to be involved in the control of 
G2-M-phase transition by promoting chromosome condensation, destruction of the nuclear 
membrane and assembly of the mitotic spindle. Overexpression of cyclin B1 is a frequent and 
early finding in the metaplasia - dysplasia - carcinoma sequence 221.
Cyclin E (19q12)
Cyclin E is involved in the process of cell entry into the S-phase of the cell cycle. Expression 
of the cyclin E protein was reported in dysplastic Barrett’s mucosa as well as in adenocarci-
nomas, and increased nuclear staining was associated with regeneration and proliferation 
of adjacent metaplastic epithelium of erosions or ulcerations in Barrett’s esophagus 222. 
Amplification of 19q12 with cyclin E as the best candidate gene was observed in 13.8% of 
esophageal adenocarcinomas 223. 
P21WAF1/CIP1 (6p21)
The wild type p53 tumor suppressor gene can induce the CDKI p21. Through inhibition of 
CDKs the G1-S phase of the cell cycle can be downregulated. P21 expression was elevated 
in low grade dysplasia, high grade dysplasia and in Barrett’s adenocarcinoma, but not in Bar-
rett’s metaplasia 224. Interestingly no correlation between p21 and p53 staining in esophageal 
adenocarcinomas was found, indicating a p53 independent mechanism for upregulation of 
p21 224,225. Elevated p21 expression was significantly associated with better prognosis 217.
P27Kip-1 (12p13)
P27 induces a block during G1 in the cell cycle. Loss of p27 expression is thought to be tumo-
rigenic and may lead to tumor progression. Most Barrett related adenocarcinomas are associ-
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ated with loss of p27 as well as altered cellular localization (cytoplasmic instead of nuclear) 
226. Loss of nuclear and/or cytoplasmic staining for p27 correlated with higher histological 
grade, depth of invasion, presence of lymph node metastasis and shorter survival 226. 
Cell-cell adhesion genes
Reduced cell-cell adhesion promotes growth of epithelial cells because contact inhibition of 
proliferation is lost. Moreover cell adhesion molecules are involved in the process of invasion 
and metastasis of cancers. 
E-cadherin-catenin complex
E-cadherin belongs to the family of calcium-dependent cell adhesion molecules and forms 
part of the adherens junction complex promoting tight adhesion of epithelial cells. Loss 
of E-cadherin occurs in several cancers and is associated with the development of invasive 
properties. E-cadherin expression was shown to be reduced in both Barrett’s esophagus and 
esophageal adenocarcinoma and in the latter this was correlated with a greater frequency 
of lymph node metastasis and decreased patient survival 227,228. Mutations of the E-cadherin 
gene were rare in adenocarcinomas 229. However, epigenetic silencing via aberrant methyla-
tion of the E-cadherin promotor seemed to be a common cause of inactivation in adenocar-
cinomas 230. 
β-Catenin is involved in cell-cell adhesion by its interaction with E-cadherin and with the 
cytoskeleton. A second function of β-catenin concerns cell-signaling. The β-catenin protein 
can translocate to the nucleus where it complexes with the transcription regulator proteins 
T-Cell factor 4/Lymphoid Enhancer-binding Factor 1 (TCF4/LEF1) to activate transcription 
of oncogenes including i.e. c-myc and cyclin D1. In general the APC gene product forms a 
complex with other proteins and targets β-catenin for degradation preventing β-catenin 
dependent transcription of oncogenes. However, activated Wnt signaling protects β-catenin 
from APC-mediated degradation and increases β-catenin-dependent transcription 231,232. 
Nuclear and cytoplasmic instead of membranous β-catenin localization has been described 
to occur frequently in esophageal adenocarcinomas, however mutations in β-catenin or APC 
appeared to be very rare 233-236.
CD44 protein family
The CD44 gene produces a variety of glycosylated cell surface proteins by alternative splicing 
of its at least 20 exons. CD44 is involved in cell-cell adhesion and cell-matrix interactions. 
Expression of CD44 in APC and TCF mutant mice was described to implicate its regulation 
by the Wnt pathway 237. Several reports focused on the expression of certain splice variants 
in esophageal adenocarcinoma. CD44V6 was detected by immunohistochemistry in 55% 
of Barrett’s metaplasias and 63% of adenocarcinomas 238. CD44V6 expression was related to 
an aggressive pathological feature in adenocarcinomas 239. With RT-PCR and southern blot 
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analysis CD44V5 en CD44V6 were found to be frequently and similarly expressed in both 
Barrett’s metaplasia and adenocarcinoma, thus not closely associated with development and 
progression of esophageal adenocarcinomas according to Menges et al. 240. 
Cathepsin B
The cysteine protease cathepsin B (CTSB) gene is localized at chromosome 8p22 and codes 
for a lysosomal enzyme that has been shown to be overexpressed or exhibit altered loca-
lization in cancers 241. Overexpression or altered localization of CTSB is thought to result in 
degradation of the basement membrane facilitating tumor invasion and metastasis. Characte-
rization of an amplicon at chromosome 8p22-23 revealed that CTSB was both amplified and 
overexpressed in esophageal adenocarcinomas. Gene amplification was observed in 13% of 
tumors, mRNA overexpression was observed in 25% of tumors and protein staining was de-
tected even in 75% of tumors, suggesting that CTSB overexpression could result from other 
mechanisms in addition to gene amplification 223. These data support an important role for 
CTSB gene amplification and CTSB protein overexpression in esophageal adenocarcinomas.
SUMMARY AND FUTURE PERSPECTIVES
Concerning Barrett’s metaplasia and its malignant potential there is still need for improved 
understanding of the molecular biology in order to develop a more scientific approach to 
cancer prevention in these patients. Since the annual incidence rate for developing esopha-
geal adenocarcinoma in Barrett’s esophagus is as low as 0.5-1%, a cancer preventive strategy 
needs to be cost effective and acceptable to a large number of patients at relatively low 
risk 76. Despite ongoing efforts to characterize the molecular changes leading to esophageal 
adenocarcinoma, no clinically applicable biomarkers for prediction of prognosis and/or res-
ponse to therapy came forward to date. Moreover, the proposed existence of intratumoral 
heterogeneity of genetic alterations has important implications for the development of such 
biomarkers. Using FISH analysis Walch et al. demonstrated intratumoral heterogeneity which 
they ascribe to a probable existence of many divergent neoplastic subpopulations 166. This 
highlights one of the main problems associated with surveillance of Barrett’s patients namely 
sampling error. LOH and gene amplification analysis at several gene loci of multiple tumor 
samples per patient elucidated marked intratumoral heterogeneity in Barrett’s adenocarci-
nomas 242. In studies of Galipeau et al., Prevo et al. and Barrett et al. the subject of clonal 
expansion of cells with certain alterations have been extensively studied 105,115,243. It seems 
likely that the acquisition of 9p LOH and 17p LOH predisposes to the evolution of aneuploid 
cell populations and other genetic abnormalities that culminate in the development of 
cancer 105,115,243. Maley et al. addressed the role of genetic instability and clonal expansion in 
Barrett’s metaplasia using prospective data 244. They measured the size of cell clones with p53 
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alterations, p16 alterations, aneuploidy and tetraploidy in serial endoscopy biopsy samples 
with a follow-up of 8 years 244. They demonstrated that not the single presence of p53 LOH, 
aneuploidy or tetraploidy predict progression to adenocarcinoma, but the size of clones with 
these lesions 244. Thus the combination of both genetic instability and clone size predicted 
progression to cancer in their prospective cohort study 244. 
In conclusion, the search for molecular markers to predict which Barrett’s patients are at high 
risk for neoplastic progression should be focused on early genetic events. Such early events 
concern loss of p16 and p53 with aneuploidy as a probable driving force. The value of various 
genetic alterations, amongst which p16 and p53, as molecular markers in GEJ adenocarcino-
genesis was investigated in chapter 13 of this thesis.
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ABSTRACT
We aimed to investigate the contribution and possible prognostic role of the Wnt signaling 
pathway in gastro-esophageal junction (GEJ) adenocarcinomas. An immunohistochemical 
study of the diverse components of the Wnt pathway was undertaken in 164 GEJ adenocar-
cinomas and in 5 human GEJ adenocarcinoma cell lines, in which we formerly demonstrated 
that nuclear β-catenin expression correlates with enhanced TCF-mediated transcription of 
a reporter gene. Expression of β-catenin, phospho-β-catenin Ser33/37/Thr41, phospho-β-
catenin Thr41/Ser45, dephosphorylated ‘active’ β-catenin, LEF1, TCF4, and the Wnt target 
genes CD44V6 and EphB2 was analysed in formalin-fixed, paraffin embedded tumor tissues 
and correlated to clinicopathological factors and survival. Thirty-five % of tumors expressed 
nuclear β-catenin in more than 10% of tumor cells, which correlated positively with elevated 
cytoplasmic (p=0.04) and reduced membranous (p=0.001) β-catenin as well as with elevated 
nuclear LEF1 expression (p=0.03). Membranous EphB2 as well as cytoplasmic EphB2 expres-
sion significantly correlated with better tumor differentiation grade (p=0.05 and p=0.04) and 
with better overall survival (p=0.04 and p=0.04 respectively), which was not substantiated 
in multivariable analysis. Activated Wnt signaling might probably be of less importance in 
GEJ adenocarcinomas than previously thought. However, expression of the Wnt target gene 
EphB2 correlated to prognosis of GEJ adenocarcinoma patients. 
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INTRODUCTION
Adenocarcinomas of the gastro-esophageal junction (GEJ) show a rapidly increasing inci-
dence in the western world since the last three decades 1,2. Little is known about the mo-
lecular mechanisms underlying the origin of these tumors. As in colorectal carcinomas the 
wingless-type (Wnt) pathway is suggested to play a key role in GEJ adenocarcinomas as well. 
Nuclear β-catenin expression, generally believed to indicate activated Wnt signaling, is re-
ported in up to 60% of GEJ adenocarcinomas 3-7. 
Wnt signaling has importance in a number of developmental processes in vertebrates and 
invertebrates, i.e. regulation of cell fate specification, proliferation and differentiation in vari-
ous tissues 8. Additionally, Wnt signaling is able to contribute to tumorigenesis by altering 
the state and activity of β-catenin 9, a protein that was first described in humans as a member 
of the cell membrane-bound adherens complex 10. Later β-Catenin was found to participate 
also in cell-signaling which involves translocation of the protein from the cytoplasm to the 
nucleus through activated Wnt signaling 11,12. β-Catenin levels are regulated by a protein 
complex containing the tumor suppressor gene product adenomatous polyposis coli (APC), 
serine/threonine protein kinase glycogen synthase kinase-3β (GSK3β) and Axin/conductin 
and by casein kinase Iα 13-19. Degradation of free cytosolic β-catenin is consecutively promo-
ted via phosphorylation of NH2-terminal β-catenin sequences at Ser45 (by casein kinase Iα) 
and subsequently at Thr41, Ser37 and Ser33 (by the GSK3β/APC/Axin complex) followed by 
ubiquination and proteasomal degradation 20. Upon Wnt signaling the degradation complex 
is inhibited. Non-phosphorylated β-catenin accumulates in the cytoplasm and translocates 
to the nucleus where it complexes with the transcription regulator proteins T-Cell factor 4/
Lymphoid Enhancer-binding Factor 1 (TCF4/LEF1) 14,21. TCF4/LEF1 proteins cooperate with 
β-catenin to activate transcription of target genes including i.e. c-myc, cyclin D1, immuno-
globulin transcription factor-2 (ITF-2), although many of the target genes remain unknown 
22-24. CD44V6 and ephrin receptors B2 and B3 (EphB2, EphB3) also function as potential TCF4/
LEF1 target genes 25,26. 
In carcinogenesis, β-catenin signaling, besides Wnt induced, can also be the result of in-
creased β-catenin levels caused by impaired β-catenin degradation due to lack of phospho-
rylation of β-catenin. In several tumor types mutations at phosphorylation sites in β-catenin 
or inactivating mutations in APC or Axin leading to inhibition of β-catenin phosphorylation 
and decreased degradation have been described 27-30. However, in GEJ adenocarcinomas very 
few inactivating mutations leading to β-catenin stabilisation have been identified in APC or 
Axin, neither β-catenin phosphorylation residue mutations were identified and therefore 
the mechanism of Wnt activation in these tumors remains unknown 4,31-33. Interestingly, Staal 
and colleagues showed Wnt signals to be transduced via N-terminally dephosphorylated β-
catenin using an antibody specific for β-catenin non-phosphorylated at residues Ser37 and 
Thr41 34,35. To obtain more insight in a possible role of Wnt activation in GEJ adenocarcinomas 
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we investigated by immunohistochemistry the expression of total-, phosphorylated- and 
non-phosphorylated β-catenin, the β-catenin signaling partners TCF4 and LEF1 and the Wnt 
target genes CD44V6 and EphB2 in a large series GEJ adenocarcinomas. The results were 
compared with clinicopathological data and survival.
MATERIALS AND METHODS
Patients and Tissue Samples
Routine formalin-fixed and paraffin-embedded tissues derived from 164 patients with an 
adenocarcinoma of the gastro-esophageal junction were retrieved from the files of the De-
partment of Pathology, Erasmus MC, Rotterdam, The Netherlands. All patients (141 men; 23 
women) had received transhiatal resection of the tumor with restoration of continuity of the 
gastrointestinal tract by a gastric tube with cervical anastomosis between 1987 and 2002. 
Patient’s mean age at the time of diagnosis was 64.7 year (range 44-84 years). Adenocari-
nomas arising from distal esophagus or gastric cardia, i.e. the gastro-esophageal junction, 
were included. Tumors arising from the fundus or corpus of the stomach and infiltrating the 
gastric cardia or distal esophagus were excluded. Histological diagnosis and staging were 
established following the TNM proposed by the International Union Against Cancer accor-
ding to standard criteria classification (TNM-stage I, n=15; TNM-stage II, n=41; TNM-stage III, 
n=86; TNM-stage IV, n=22). Every tumor was examined histologically for differentiation (well 
differentiated, n=9; moderately differentiated, n=73; poorly differentiated, n=82).
Antibodies and immunohistochemical staining
To detect the localization of β-catenin, phospho-β-catenin (Ser33/37/Thr41), phospho-β-
catenin (Thr41/Ser45), LEF1, TCF4, CD44V6 and EphB2, antibodies were used as described 
in Table 3.1. To detect dephosphorylated β-catenin, a monoclonal antibody active β-catenin, 
which recognises β-catenin when Ser37 and Thr41 are both non-phosphorylated, was used, 
as described by Van Noort et al., from here referred to as ‘active β-catenin’ 35. Four-μm thick 
paraffin sections were mounted on 3-aminopropyl-triethoxysilane (APES)-coated glass slides. 
Immunohistochemical staining was carried out by a standard avidin biotin immunoperoxi-
dase technique, using a commercially available kit (Labvision, Fremont, USA). Deparaffinized 
sections were treated with methanol containing 3% H2O2 for 20 minutes. After washing with 
phosphate-buffered saline (PBS), blocking serum was applied for 5 minutes. Then, primary 
antibodies were allowed to react as described in Table 3.1. After washing in PBS, biotin-conju-
gated secondary antibody was applied for 10 minutes followed by peroxidase-marked strep-
tavidin. After rinsing in PBS, peroxidase was visualized by diaminobenzidine hydrochloride 
(Fluka, Neu-Ulm, Germany) with 0.03% H2O2 solution for 10 minutes. The slides were then 
counterstained with Mayer’s Haematoxylin and dehydrated in alcohol before mounting. Ex-
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pression of antibodies was evaluated by highpower microscopic examination (400X) of the 
entire tissue section. As negative control we used normal mouse immunoglobulins and nor-
mal rabbit serum instead of the antibodies as described in Table 3.1. Normal gastric mucosas 
from the same resection specimens were used as internal positive controls.
Cell lines
As controls, sections of formalin fixed and paraffin embedded cultured cells were stained 
with β-catenin antibodies. In earlier experiments we performed a TCF/β-catenin reporter 
gene assay with pTOPGLOW and pFOPGLOW constructs 36. Esophageal adenocarcinoma cell 
lines JROECL19 and JROECL33 showed 350- and 18-fold increase in transcriptional activity 
of the pTOPGLOW reporter as compared to the negative control pFOPGLOW. Esophageal 
adenocarcinoma cell lines SKGT-4, TE-7 and OACP4C showed no enhanced transcription 
of the pTOPGLOW reporter 36. Sections of formalin fixed and paraffin embedded cultured 
cells were stained with β-catenin, phospho-β-catenin (Ser33/37/Thr41), phospho-β-catenin 
(Thr41/Ser45) and ‘active β-catenin’ antibodies. Moreover APC-mutant colon adenocarcinoma 
cell line SW480 with a 385-fold increase in transcriptional activity was immunohistochemi-
cally investigated. 
Quantitation of immunostaining
Nuclear, cytoplasmic and membranous staining of antibodies was determined separately 
for each specimen. Concerning cytoplasmic and membranous staining, sections were con-
sidered negative when immunoreactive cells were absent and positive when immunoreac-
tive cells, irrespective of the amount, were present. Nuclear expression levels of β-catenin, 
phospho-β-catenin (Thr41/Ser45), phospho-β-catenin (Ser33/37/Thr41), active β-catenin, 
LEF1, TCF4 and EphB2 were initially graded into 5 subgroups: (a) no detectable expression (0, 
negative); (b) expression detected in less than 10% of tumor cells (1+); expression detected 
in 10-30% of tumor cells (2+); expression detected in 30-80% of tumor cells (3+); expression 
detected in >80% of tumor cells (4+). Eventually, interpretation of staining score was defined 
as positive when >10% of tumor cells stained, and as negative when none or <10% of tumor 
cells stained.
Statistics
Significance testing for discrete variables was performed with the χ2-test or the Fisher’s exact 
test when appropriate. Reported P values are two-sided. P<0.05 was considered statistically 
significant. Follow-up was carried out until June 2003 for all patients. Survival rates were 
calculated according to the Kaplan-Meier method and differences in survival were assessed 
using the log rank test. Multivariate analysis using the Cox proportional hazards model was 
carried out to assess the independent prognostic significance of variables on overall sur-
vival. 
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RESULTS
Immunohistochemistry
Cell line JROECL19 (350-fold increase of transcriptional activity) expressed nuclear β-catenin, 
nuclear phospho-β-catenin (Thr41/Ser45) and nuclear active β-catenin, as did the APC mutant 
colon cancer cell line SW480 which served as a positive control (Table 3.2). Cell line JROECL33 
(18-fold increase of transcriptional activity) showed nuclear β-catenin expression (weak) 
and nuclear phospho-β-catenin (Thr41/Ser45) expression (Table 3.2). Cell line OACP4C (no 
enhanced transcriptional activity) showed absence of nuclear β-catenin, nuclear phospho-
β-catenin (Ser33/37/Thr41) and nuclear active β-catenin expression (Table 3.2). 
Table 3.2. ß-catenin expression in GEJ adenocarcinoma-derived cell lines JROECL19, JROECL33, OACP4, TE7, KGT4 and in APC mutant colorectal 
cancer cell line SW480. 
ß-catenin Phospho ß-catenin 
Ser33/37/Thr41
Phospho ß-catenin 
Thr41/Ser45a
Active ß-catenin
SW480
(APC mutation, 
signaling onb)
+ nucleus
+ cytoplasm
- nucleus + nucleus ++ nucleus
+ cytoplasm
JROECL19
(signaling onb)
+ nucleus
+ cytoplasm
+ membrane
- nucleus + nucleus +/- nucleus 
JROECL33
(signaling onb, 
although weak)
+/- nucleus 
+/- cytoplasm 
+/- membrane 
- nucleus + nucleus - nucleus
OACP4
(signaling offb)
- nucleus - nucleus No data - nucleus
TE7
(signaling offb)
No data No data No data - nucleus
+ membrane
SKGT4
(signaling offb)
No data No data No data - nucleus
+ membrane
a Strongly expressed in dividing cells (M-phase of cell cycle); b Shown by a TCF/ ß-catenin reporter gene assay performed with pTOPGLOW and p 
FOPGLOW constructs in a former study (Koppert et al. 36)
Typical immunostaining patterns for the antibodies used are shown in Figure 3.1. In ge-
neral, with all antibodies used we saw remarkable intratumor heterogeneity in staining. We 
noticed a very strong staining pattern of phospho-β-catenin (Thr41/Ser45) in mitotic cells 
(Figure 3.1G, H). 
Using scoring criteria for nuclear staining as described in Materials and Methods, expres-
sion data are reported in Table 3.3. Fifty-eight out of 164 tumors (35%) expressed nuclear 
β-catenin in >10% of tumor cells. Nuclear β-catenin correlated positively with elevated cyto-
plasmic (p=0.04) and reduced membranous (p=0.001) β-catenin. Moreover, nuclear β-catenin 
correlated positively with elevated nuclear LEF1 expression (p=0.03, data not shown). 
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Figure 3.1 
Figure 3.1. Immunohistochemistry of β-catenin in GEJ adenocarcinomas (Magnification x 200 (A., B., C., G.) and magnification x 400 (D., E., 
F., H.). A. Nuclear and cytoplasmic expression of β-catenin in the tumor cells. B. Nuclear active β-catenin staining in same GEJ tumor tissue as 
mentioned in A. C. Strong nuclear active β-catenin. D. Active β-catenin in membrane and cytoplasm of GEJ adenocarcinoma. E. EphB2 staining in 
cytoplasm of the tumor cells. F. Membranous EphB2 staining. G. Nuclear phospho β-catenin (Thr41/Ser45) with strong staining patterns in mitotic 
cells (insert H.). Also see color figures page 291.
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Table 3.3. Results staining, correlation with TNM-stage and histology grade.
Staining (%) TNM-stage P-value Histology grade P-value
I, II III, IV good, moderate poor
β-catenin 
 Nuclear
 
 Cytoplasmic 
 
 Nuclear and/or cytoplasm
 
 Membranous
<10%
>10%
-
+
-
+
-
+
 
106 (65)
48 (35)
102 (62)
62 (38)
72 (44)
92 (56)
31 (19)
133 (81)
38 
18 
36 
20 
24 
32 
8 
48 
68 
40 
66 
42 
48 
60 
23 
85 
0.5
0.7
0.8
0.3
55 
27 
56 
26 
40 
42 
15 
67 
51 
31 
46 
36 
32 
50 
16 
66 
0.5
0.1
0.2
0.8
Phβ-c 33/37/41
 Nuclear
 Cytoplasmic
<10%
>10%
-
+
132 (81)
31 (19)
143 (88)
20 (12)
47 
9 
49 
7 
85 
22 
94
13 
0.5
0.9
67 
15 
73 
9 
65 
16 
70 
11 
0.8
0.6
Phβ-c 41/45
 Nuclear
 
 Cytoplasmic 
 
 Membranous
 
<10%
>10%
-
+
-
+
38 (25)
114 (75)
50 (33)
102 (67)
146 (96)
6  (4)
13 
38 
16 
35 
47 
4 
25 
76 
34 
67 
99 
2 
0.9
0.8
0.08
19 
56 
24 
51 
72 
3 
19 
58 
26 
51 
74 
3 
0.9
0.8
0.9
Active β-catenin 
 Nuclear
 
 Cytoplasmic 
 
 Nuclear and/or cytoplasm
 
 Membranous
<10%
>10%
-
+
-
+
-
+
137 (84)
26 (16)
112 (69)
51 (31)
100 (61)
64 (39)
74 (45)
89 (55)
49 
7 
37 
19 
34 
22 
24 
32 
88 
19 
75 
32 
66 
42 
50 
57 
0.4
0.6
0.9
0.6
69 
12 
52 
29 
46 
36 
32
49 
68 
14 
60 
22 
54 
28 
42 
40 
0.7
0.2
0.2
0.1
LEF1
 Nuclear
 
 Cytoplasmic 
 
<10%
>10%
-
+
123 (77)
37 (23)
95 (59)
65 (41)
39 
15 
23 
31 
84 
22 
72 
34 
0.3
0.002
59 
20 
41 
38 
64 
17
54 
27 
0.5
0.06
TCF4
 Nuclear
 
 Cytoplasmic 
 
<10%
>10%
-
+
54 (34)
105 (66)
104 (65)
55 (35)
16
39 
31 
24 
38 
66 
73 
31 
0.3
0.08
30 
49 
54 
25 
24 
56 
50 
30 
0.3
0.4
CD44V6
 Membranous
 
-
+
30 (18)
133 (82)
11 
45 
19 
88 0.8
14 
68 
16 
65 0.7
EphB2
 Cytoplasmic 
 
 Membranous
 
-
+
-
+
56 (35)
103 (65)
120 (75)
39 (25)
14 
40 
39 
15 
42 
63 
81 
24 
0.08
0.5
22 
58 
55 
25 
34 
45 
65 
14 
0.04
0.05
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Correlations with clinicopathological parameters and multivariate analysis
Absence of cytoplasmic LEF1 expression significantly correlated with unfavorable TNM 
stage (p=0.002, Table 3.3). Cytoplasmic EphB2 as well as membranous EphB2 expression sig-
nificantly correlated with better tumor differentiation grade (p=0.04 and p=0.05 respectively, 
Table 3.3). 
Survival Analysis
In univariate analysis, significantly better survival was shown for patients with membranous 
EphB2 staining as compared to patients without membranous EphB2 staining (p=0.04, Table 
3.4, Figure 3.2). A significant better survival was also shown for patients with cytoplasmic 
EphB2 staining as compared to patients without cytoplasmic EphB2 staining (p=0.04, Table 
3.4). These significant outcomes were not substantiated in multivariable analysis, with ad-
justments for age, gender, TNM stage and differentiation grade (Table 3.4). When patients 
with EphB2 cytoplasmic and/or membranous expression were pooled, EphB2 expression 
reached a Hazard Ratio of 0.6 (95% Confidence Interval 0.4-1.0, data not shown). Only TNM 
stage turned out to be an independent predictor of overall survival in multivariable Cox’s 
proportional hazards analysis (p<0.001, Table 3.4). 
Figure 3.2 Membranous EphB2 Kaplan Meier survival curves in GEJ adenocarcinoma patients, p=0.04. �
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Figure 3.2. Overall survival of patients with membranous EphB2 staining (gray line n=39) versus patients with absence of membranous EphB2 
staining (black line n=120), P logrank = 0.04. Five-year overall survival percentages were 46% and 16% respectively.
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Table 3.4. Multivariable analysis of potential prognostic factors with overall survival in potentially curative resected GEJ adenocarcinomas. 
Multivariable analysis was performed using a Cox proportional hazards model.
Factor Univariate 5-yr 
overall survival (%)
P-value Hazard Ratio 95% Confidence Interval P-value
Agea 23 - 1.01 1.0-1.04 0.3
Gender (M, F)
 Mb 24 1 - -
 F 15 0.8 0.8 0.4-1.4 0.4
TNM-stage
 I, IIb 43 1 - -
 III, IV 11 <0.0001 2.7 1.6-4.5 <0.001
Differentiation grade
 Well/Moderateb 31 1 - -
 Poor 13 0.06 1.4 0.9-2.1 0.1
Cytoplasmic EphB2
 Negativeb 11 1 - -
 Positive 30 0.04 0.8 0.5-1.2 0.3
Membranous EphB2
 Negativeb 16 1 - -
 Positive 46 0.04 0.7 0.4-1.2 0.2
 a Age was included as a continous variable in the multivariable analysis. b Reference category.
DISCUSSION
Current models of Wnt signaling state that accumulation of nuclear β-catenin forms the key 
signaling event. In our series, 35% of GEJ adenocarcinomas (58/164) show nuclear β-catenin 
expression in >10% of tumor cells, being less than reported in literature 3-7. This percentage 
increased to 56% when nuclear and/or cytoplasmic β-catenin expression was taken into ac-
count. Staal and collegues postulate that not the accumulation of β-catenin per se but the 
lack of phosphorylation at both Ser37 and Thr41 of this increased β-catenin forms the key sig-
naling step 34. They showed that Wnt signals are transduced via N-terminally dephosphoryla-
ted β-catenin using an antibody specific for β-catenin non-phosphorylated at residues Ser37 
and Thr41 34,35. Only 16% of GEJ adenocarcinomas in our series express dephosphorylated 
β-catenin in >10% of tumor cells determined by the specific antibody for ‘active’ β-catenin 
which detects β-catenin when residues Ser37 and Thr41 are not phosphorylated both 35. This 
percentage went up to 39 when nuclear and/or cytoplasmic expression was taken into ac-
count. According to the findings of Staal et al., this would imply that GEJ adenocarcinomas 
occasionally show activated Wnt signaling and that the conventional ‘pan’ β-catenin antibody 
does not represent the ‘signal transducing’ form of β-catenin. 
By using esophageal adenocarcinoma cell lines with available TCF reporter assay data, we 
aimed to affirm this assumption in an earlier study 36. Nuclear β-catenin expression (as vi-
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sualized by the conventional ‘pan’ β-catenin antibody) correlated with high TCF transcrip-
tional activity (SW480, JROEC19, JROEC33). High TCF transcriptional activity in JROEC19 also 
correlated with nuclear ‘active’ β-catenin expression, though weak, as was the case in the 
control cell line SW480, known to have a homozygous inactivating APC mutation (Table 2). 
Also nuclear phospho-β-catenin (Thr41/Ser45) expression seemed to correlate with high TCF 
transcriptional activity in cell lines SW480, JROEC19, JROEC33. We hypothesize that casein 
kinase Iα still functions in these tumor cells, resulting in phosphorylation of β-catenin at 
position Ser45, but that these cells lack β-catenin phosphorylation by the GSK3β/APC/Axin 
complex, causing absence of phospho-β-catenin (Ser33/37/Thr41) expression. The immuno-
histochemical results in the colorectal cancer cell line SW480, with an inactive GSK3β/APC/
Axin complex, support this assumption. 
Notably, in 19 of 31 cases (61%) with nuclear phospho-β-catenin (Ser33/37/Thr41) none or 
less than 10% of tumor cells showed nuclear β-catenin, which could probably be due to an-
tibody affinities. We could not establish an improved survival in patients with nuclear phos-
pho-β-catenin (Ser33/37/Thr41), as reported in a large series of colorectal carcinoma patients 
37. Conversely, nuclear expression of phospho-β-catenin (Ser33/37/Thr41) in malignant mela-
nomas has been described to correlate with poor outcome, lending evidence for differential 
behaviours in different tumors 38. This could not be established in our series either. 
To date only APC and β-catenin exon 3 mutation analysis in GEJ adenocarcinomas have been 
performed and very few mutations were found 4,7,31-33. We investigated Axin1 mutations in 
all 10 exons in 17 GEJ adenocarcinomas with strong nuclear β-catenin expression and did 
not identify mutations 36. Mutations in other components therefore should be considered, 
as well as activation of the canonical Wnt pathway or deregulated expression of pathway 
components responsible for Wnt pathway activation in these tumors 39,40. A proper candidate 
for a mutation is β-transducing repeat-containing protein (β-TrCP), an F-box protein that is 
involved in β-catenin degradation. β-TrCP mutations are however rarely found in human tu-
mors which are wild type for β-catenin and APC. β-TrCP mutations only have been described 
in two prostate cancer samples, of which one had nuclear β-catenin expression 41. Despite 
the role of β-TrCP in β-catenin turnover, it is unlikely that β-TrCP might function as a tumor 
suppressor 42. Within hepatoblastomas, increased expression of Wnt-inducible genes such 
as Axin2, Dkk-1, NKD-1 and β-TrCP was seen to be a common event 43. These so called Wnt 
antagonists act as inhibitors of the Wnt pathway and their overexpression indicates Wnt 
pathway activation in hepatoblastomas, most likely because genetic alterations disrupt the 
multiprotein complex that controls β-catenin stability 43. Epigenetic silencing of the phos-
phorylation complex might be another possibility for Wnt pathway activation. Methylation 
of APC has been described by Clément and colleagues during the neoplastic progression of 
Barrett’s esophagus 44. Additionally, it is possible that the Alzheimer’s disease linked gene 
presenilin 1 (PS1) is deficient in these tumors. PS1 has been described as a negative regula-
tor of the Wnt pathway 45. Presinilin deficiency might reduce the pool of phospho-β-catenin 
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(Ser33/37/Thr41) available for ubiquitination by failing to target phospho-β-catenin (Ser45) 
for further phosphorylation and degradation 46. Interestingly, Kang et al. also report extensive 
nuclear localization of phospho-β-catenin (Ser45) in tumors with either PS1 deficiency or 
activating β-catenin mutations and propose that Ser45-phosphorylated β-catenin might be 
signaling competent 46. To our opinion rather the β-catenin mutation or PS1 deficiency than 
the presence of the phosphorylated protein seems responsible for Wnt-pathway activation 
in these tumors since phosphorylation means ubiquination and therefore degradation of 
β-catenin. In skin tumor tissues the absence of PS1 was associated with elevated nuclear 
β-catenin and upregulated β-catenin/LEF-dependent signaling 47. 
We noticed a very strong staining pattern of phospho-β-catenin (Thr41/Ser45) in mitotic cells 
(Figure 3.1G, H). Interestingly, a third function of β-catenin, besides participation in cell-cell 
adhesion and Wnt-stimulated transcriptional activation, was recently described by Kaplan et 
al. 48. They show evidence that β-catenin regulates the process of mitotic spindle formation 
by ensuring that components of the mitotic machinery are assembled in the correct place 
and at correct time for cell division to proceed efficiently 48. 
The EphB2 receptor has a role in cell positioning in the intestine and has been described as 
a target gene of the β-catenin/TCF4 complex 26,49. Moreover EphB2 is overexpressed in se-
veral human carcinomas, including tumors of the gastrointestinal tract, suggesting that this 
gene may indeed be involved in carcinogenesis 50,51. Loss of EphB2 expression was recently 
described to be a critical step in colorectal cancer progression, including the onset of tumor 
invasion, dedifferentiation and metastasis 52,53. Moreover EphB2 was identified as a prognos-
tic factor in colorectal cancer with shorter mean duration of survival when EphB2 expression 
was lost 54. Also in carcinomas of the small intestine and stomach EphB2 inactivation/down-
regulation may be relevant for tumor progression 55. Loss of EphB2 membranous expression 
was also associated with poorer survival as well as with poorer tumor differentiation grade in 
our series. Since it is generally believed that localization on the cell membrane is necessary 
for the function of the ephrin receptor/ephrin system, cytoplasmic presence or absence of 
EphB2 is less likely to confer significance in tumor progression 51,56. However, in our series 
cytoplasmic EphB2 staining was observed frequently, mostly apart from membranous EphB2 
staining. And loss of cytoplasmic EphB2 staining was significantly correlated with poorer tu-
mor differentiation grade as well as survival. Since membranous EphB2 is also expressed in 
the normal intestine, the observed better survival and tumor differentiation grade in patients 
with membranous expression could be the mere result of a proper functioning receptor in-
stead of an activated Wnt pathway 52.
Cell surface glycoprotein CD44 expression is part of a genetic program controlled by the β-
catenin/TCF4 signaling pathway and suggest a role for CD44 in the generation and turnover 
of epithelial cells 25. CD44V6, a variant isoform of CD44, is considered to be implicated in 
carcinogenesis 57-59. In Barrett’s related adenocarcinoma CD44V6 expression is described to 
be correlated with aggressive pathological features 60. In our series, 133 out of 163 tumors 
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had membranous CD44V6 expression, which was not correlated to either TNM-stage, tumor 
differentiation grade or patient survival. Membranous CD44V6 expression did not correlate 
with (any form, either phosphorylated or dephosphorylated) nuclear β-catenin expression. 
We therefore are not able to judge about a possible Wnt target gene function of CD44V6 in 
GEJ adenocarcinomas. 
In summary, Wnt pathway activation, as classically represented by nuclear β-catenin expres-
sion, was present in 35% of our large series of GEJ adenocarcinomas. Moreover, since Wnt 
pathway activation might be caused exclusively by β-catenin which is dephosphorylated at 
Ser37 and Thr41, this pathway might be even far less important in GEJ adenocarcinomas than 
previously thought. However, immunohistochemical analysis of diverse contributors and tar-
gets of the Wnt pathway in a large series of GEJ adenocarcinomas showed loss of expression 
of the Wnt target gene EphB2 to be significantly correlated with worse survival and poor 
tumor differentiation grade. 
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ABSTRACT
Up to 60% of gastro-esophageal junction (GEJ) adenocarcinomas show nuclear β-catenin 
expression, pointing to activated T-cell factor (TCF)/β-catenin driven gene transcription. We 
demonstrate in 5 human GEJ adenocarcinoma cell lines that nuclear β-catenin expression 
indeed correlates with enhanced TCF-mediated transcription of a reporter gene. In several 
tumor types, TCF/β-catenin activation is caused by mutations in either adenomatous poly-
posis coli (APC), β-catenin exon 3, AXIN1, AXIN2 or β-transducin repeat-containing protein 
(β-TrCP). In GEJ adenocarcinomas very few APC and β-catenin mutations have been found. 
Therefore the mechanism of Wnt pathway activation remains unclear. In the present study we 
did not find AXIN1 gene mutations in 17 GEJ tumors with nuclear β-catenin expression (with-
out β-catenin exon 3 mutations). Six intragenic single nucleotide polymorphisms (SNPs) were 
identified. One of these, the AXIN1 gene T1942C SNP has a frequency of 21% but is only very 
recently described despite numerous AXIN1 gene mutational studies. We provide evidence 
why this SNP was missed in single strand conformation polymorphism (SSCP) analyses. The 
AXIN1 gene G2063A variation was previously described as a gene mutation but we demon-
strate that this is a polymorphism. With these 6 SNPs loss of heterozygosity (LOH) was found 
in 11 of 15 (73%) informative tumors. To investigate a possible AXIN1 gene dosage effect in 
GEJ tumors expressing nuclear β-catenin, AXIN1 locus LOH was determined in 20 tumors ex-
pressing membranous and no nuclear β-catenin. LOH was found in 10 of 13 (77%) informative 
cases. AXIN1 protein immunohistochemistry revealed cytoplasmic expression in all tumors 
irrespective of the presence of AXIN1 locus LOH. These data indicate that nuclear β-catenin 
expression is indicative for activated Wnt signaling and that neither AXIN1 gene mutations 
nor AXIN1 locus LOH are involved in Wnt pathway activation in GEJ adenocarcinomas. 
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INTRODUCTION
The incidence of adenocarcinoma of the gastro-esophageal junction (GEJ), i.e. distal esopha-
gus and gastric cardia, is rising in the Western world 1-3. Patients with GEJ adenocarcinoma 
have a poor prognosis with 5-year survival rates of less than 25% 4. Despite the common 
occurrence of this malignancy, relatively little is known about the molecular mechanisms 
underlying the genesis and the progression of these tumors.
Numerous studies focussed on cell-cell adhesion in GEJ adenocarcinomas since defective 
cell-cell adhesion is an important feature in epithelial tumor initiation and progression 5-10. 
Aberrant expression of components of the E-cadherin-catenin complex, the prime mediator 
of epithelial cell-cell adhesion, has been found frequently in GEJ adenocarcinomas. In addi-
tion, E-cadherin-catenin complex aberrations appeared to have prognostic value in these 
tumors 11-16.
Recently, the E-cadherin-catenin complex component β-catenin has been demonstrated 
to play a dual role in the tumorigenic process 17-22. β-Catenin, originally described to func-
tion in epithelial cell-cell adhesion, is implicated also in the Wnt signaling cascade as a 
transcriptional activator. In the absence of Wnt signals β-catenin is located at the plasma 
membrane, linked to E-cadherin, and functions in cell-cell adhesion. Excess cytoplasmic 
β-catenin is sequestered in a protein complex comprised of adenomatous polyposis coli 
(APC), glycogen synthase kinase 3β (GSK-3β) and AXIN1 or AXIN2. In this complex β-catenin 
is phosphorylated by GSK-3β and then targeted by β-transducin repeat-containing protein 
(β-TrCP) to proteasomal degradation. Activated Wnt signaling inhibits the phosphorylation of 
β-catenin, thereby preventing its degradation. The impaired β-catenin degradation leads to 
an increase in cytoplasmic β-catenin and its translocation to the nucleus. Nuclear β-catenin 
forms heterodimers with members of the T-cell factor (TCF) family of transcription factors and 
activates genes containing TCF-binding sites 19,20.
It has been demonstrated that β-catenin/TCF activated gene transcription can induce neo-
plastic transformation 23-25 and the β-catenin/TCF target genes comprise the oncogenes c-myc 
26, cyclin D1 27 and ITF-2 23. Impaired degradation of β-catenin in tumors has been reported to 
be caused by inactivating mutations in APC, AXIN1, AXIN2 or β-TrCP or oncogenic mutations 
in β-catenin exon 3 5,19,20,28-33. These mutations are in most cases mutually exclusive 28,29,31,34-36 . 
Several studies have reported nuclear β-catenin expression in up to 60% of GEJ adenocar-
cinomas 11,12,15,16,37. This nuclear expression of β-catenin can be regarded as an indication for 
activated, oncogenic, β-catenin/TCF transcription. However, mutation analysis of APC and 
β-catenin in GEJ adenocarcinomas revealed mutations in only less than 7 and 3% of cases 
respectively 12,38-40. In accordance with these data, we recently did not find β-catenin exon 3 
mutations in a series of 69 GEJ adenocarcinomas 37. Inactivation of the AXIN1 gene has been 
demonstrated to induce β-catenin/TCF transcription and AXIN1 gene mutations have been 
described in hepatocellular carcinomas, hepatoblastomas, colorectal cancers, ovarian endo-
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metrioid adenocarcinomas and in sporadic medulloblastomas 29,31,33,41-47. In addition, reduced 
protein expression of AXIN1 has recently been reported to correlate with tumor progression 
in esophageal squamous cell carcinoma 48. These results prompted us to search for genomic 
aberrations in the AXIN1 gene in GEJ adenocarcinomas. From the previously investigated 
series of 69 GEJ adenocarcinomas, 17 tumors with prominent nuclear β-catenin expression 
were selected for mutation and loss of heterozygosity (LOH) analysis. The entire coding region 
including the exon-intron boundaries of the AXIN1 gene was analysed for genetic alterations 
by single strand conformation polymorphism (SSCP) analysis. The presence of 6 intragenic 
single nucleotide polymorphisms (SNPs) was used to detect LOH. These 6 SNPs were also 
used to perform AXIN1 gene LOH analysis in 20 tumors with strong membranous β-catenin 
expression. In addition, AXIN1 protein expression was investigated by immunohistochemis-
try in all 37 tumor samples.  
MATERIALS AND METHODS
TCF/β-catenin reporter gene assay
All cell lines, JROECL19, JROEL33, SKGT-4, TE-7, OACP4C and SW480 were cultured in RPMI 
1640 supplemented with 10% fetal calf serum and antibiotics. Transcriptional activation 
mediated by TCF/β-catenin protein complexes was determined by transient transfection 
of the cell lines with either the pTOPGLOW or pFOPGLOW reporter constructs as described 
previously 49. The pTOPGLOW and pFOPGLOW constructs contain a multimerized wildtype 
or mutant TCF binding motive, respectively, upstream of a luciferase gene. Cells were grown 
to 50-80% confluency in six-well plates and transfection was performed with 1μg of purified 
constructs each, using Fugene-6 (Boehringer, Mannheim, Germany). Transfection efficiencies 
were determined by cotransfection of a pRL-TK reporter construct (Promega, Madison, WI, 
USA) that contained the Renilla luciferase gene under control of the herpes simplex virus 
thymidine kinase promotor. Cells were harvested 24 h after transfection. Activity of both lu-
ciferases was measured sequentially in each sample using the Dual-Luciferase Reporter Assay 
System (Promega, Madison, WI, USA). TCF-mediated gene transcription was defined by the 
ratio of pTOPGLOW to pFOPGLOW luciferase activities. The luciferase activity of the internal 
control reporter was used to correct for differences in transfection efficiency.
Tumor and cell line DNA samples
In a previous study 69 GEJ adenocarcinoma samples, consisting of 54 primary tumors, 4 
lymph node metastases, 9 xenografts and 2 in vitro cell lines were investigated for β-catenin 
expression and β-catenin exon 3 mutations 37. From all cases tumor and normal DNA was 
isolated from frozen samples by standard proteinase K digestion and phenol/chloroform ex-
traction. After β-catenin immunohistochemistry on 5μm paraffin sections parts of the tumor 
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with intense nuclear reactivity were isolated by microdissection from consecutive unstained 
sections. From the microdissected fragments DNA was isolated with standard proteinase K 
digestion followed by phenol/chloroform extraction and ethanol precipitation. No β-catenin 
exon 3 aberrations were found in these samples. For the present study the DNA from 17 
tumors with strong nuclear β-catenin expression was used. Fifteen samples were originated 
from primary GEJ adenocarcinomas and 2 were from GEJ adenocarcinoma derived cell lines 
JROECL19 and JROECL33 50. In addition, the DNA’s from 20 tumors with strong membranous 
β-catenin expression were investigated for LOH with the 6 SNPs. These 20 samples comprised 
17 primary tumors and the established cell lines OACP4C, SKGT-4 and TE-7 51-53. Cell lines 
JROECL19 and 33 were obtained from the European Collection of Cell Cultures (ECACC, Wilt-
shire, United Kingdom), SKGT-4 and TE-7 were kind gifts from D. Schrump, NIH, Bethesda, USA 
and T. Kudo, Tohoku University, Sendai, Japan, respectively, OACP4C was established at our 
own institute. From cell lines JROECL19 and 33 patient’s normal tissue was kindly provided 
by Dr. S.J. Darnton, Birmingham Heartlands Hospital, Birmingham, UK. From cell line OACP4C 
patient’s normal tissue was obtained from our pathology archive and from cell lines SKGT-4 
and TE-7 patient’s normal tissue was not available. To determine SNP frequencies in the nor-
mal population we used DNA isolated from 161 healthy Caucasian blood donor volunteers.
Mutation analysis of the AXIN1 gene
The 17 pairs of tumor and normal DNA from tumors with nuclear β-catenin expression were 
screened for aberrations in the AXIN1 gene. The entire coding sequence, including the exon-
intron boundaries was investigated by PCR-SSCP using the previously described 23 sets of 
primers with slight modifications 54. All amplifications were performed in 15μL PCR contai-
ning 50-100ng DNA, 1.5mM MgCl2, 0.02mM dATP, 0.2 mM dGTP, dCTP and dTTP each, 0.8μCi 
of [32P]dATP (Amersham Biosciences, Buckinghamshire, UK), 20pmol of each primer and 0.3U 
AmpliTaq Gold polymerase (Perkin-Elmer Applied Biosystems, Foster City, CA, USA). AmpliTaq 
Gold polymerase was used because this enzyme is superior to other DNA polymerases with 
regard to amplification of DNA retrieved from routine formalin fixed and paraffin embed-
ded tissues. To the PCRs with primer sets 4, 10, 12, 13, 14, 15, 18, 21 and 23 DMSO (5%) was 
added to increase the amplification efficiency. The PCRs were performed for 35 cycles of 950C 
for 30 sec, 550C (primer sets 10 and 14 at 580C and 600C, respectively) for 45 sec and 720C 
for 1 min. The PCR products were diluted 1:4 with loading buffer (95% formamide, 10mM 
EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol), heated for 5 min, cooled on ice 
and electrophoresed in 6% polyacrylamide gels containing 10% glycerol at 7W overnight at 
room temperature, in 1x TBE running buffer. Gels were dried and exposed to X-ray films at 
–800C. Results were evaluated by visual inspection. With the used SSCP conditions the PCR 
products from primer sets 18, 19 and 21 resulted in simple banding patterns, inefficient for 
the detection of aberrations. To increase the DNA aberration detection efficiency these PCR 
products were electrophoresed without glycerol at 40C for 6 hours resulting in more complex 
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banding patterns. For each variant SSCP pattern identified by SSCP analysis, the genomic 
DNA samples were reamplified for bidirectional direct sequencing with the amplification 
primers. In 20 DNA samples from tumors with strong membranous β-catenin expression LOH 
was determined by SSCP analysis of 6 detected SNPs. These SNPs are at positions (according 
to GenBank accession no. AF009674) A94C, C874T, intron 4+17 G→A (nucleotide position 
identified from exon-intron boundary), G1396A, T1942C and G2063A. Amplification of these 
SNPs was performed with primer sets 1, 7, 11, 12 and 17, respectively.
β-catenin and AXIN1 immunohistochemistry
In all 37 tumor samples immunostaining for β-catenin and AXIN1 was performed on 5μm 
paraffin sections with a mouse anti-human β-catenin monoclonal antibody (Transduction 
Laboratories, Lexington, KY, USA; 1:200, 30 min, room temperature) 37 and a rabbit polyclonal 
anti-human AXIN1 antibody (Zymed Laboratories, San Francisco, CA, USA; 1:25, 30 min, room 
temperature), respectively. After deparaffinisation and treatment with methanol/H2O2, anti-
gen retrieval was performed in citrate buffer for 15 min prior to incubation with the β-catenin 
antibody. No antigen retrieval was necessary for the AXIN1 immunohistochemistry. Immuno-
reactivity was made visible by a standard avidin biotin immunoperoxidase technique, using 
a commercially available kit (Labvision, Fremont, CA, USA) and diaminobenzidine hydrochlo-
ride (Fluka, Neu-Ulm, Germany). As negative controls normal mouse immunoglobulins and 
normal rabbit serum were used.
RESULTS
TCF/β-catenin reporter gene assay 
The TCF/β-catenin reporter gene assay was performed with the pTOPGLOW and pFOPGLOW 
constructs. Cell lines JROECL19 and JROECL33, both with nuclear β-catenin expression 
(JROECL19, Figure 4.1c), showed 350- and 18-fold increase in transcriptional activity of the 
pTOPGLOW reporter as compared to the negative control pFOPGLOW (Figure 4.2). Cell lines 
SKGT-4, TE-7 and OACP4C, all with membranous β-catenin immunoreactivity (TE-7, Figure 
4.1d), showed no enhanced transcription of the pTOPGLOW reporter (Figure 4.2).
Mutation analysis of the AXIN1 gene
SSCP analysis of the AXIN1 gene in 17 tumor/normal DNA pairs from tumors with strong 
nuclear β-catenin expression (Figure 4.1a, 4.1c) revealed 6 different aberration patterns. All 
these aberrations were also present in the corresponding normal DNA. Sequencing of the 
aberrant samples identified 6 different SNPs. These were at positions (according to GenBank 
accession no. AF009674) A94C, C874T, intron 4+17 G→A, G1396A, T1942C and G2063A 
(Figure 4.3). 
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Figure 4.1 Immunohistochemistry of �-catenin in GEJ adenocarcinomas and cell lines. (�-catenin antibody, 
DAB and haematoxylin counterstain, magnification x 400). A. GEJ adenocarcinoma. Strong nuclear expression 
of �-catenin in the tumor cells. B. GEJ adenocarcinoma. Prominent membranous expression of �-catenin. C. Cell 
line JROECL19. Strong nuclear expression of �-catenin. D. Cell line TE-7. Membranous expression of �-
catenin.
Figure 4.1 Immunohistochemistry of β-catenin in GEJ adenocarcinomas and cell lines. (β-catenin antibody, DAB and haematoxylin counterstain, 
magnification x 400). A. GEJ adenocarcinoma. Strong nuclear expression of β-catenin in the tumor cells. B. GEJ adenocarcinoma. Prominent 
membranous expression of β-catenin. C. Cell line JROECL19. Strong nuclear expression of β-catenin. D. Cell line TE-7. Membranous expression of 
β-catenin. Also see color figures page 291.
Figure 4.2 TCF-mediated transcriptional activation in GEJ adenocarcinoma cell lines. Constitutive 
transcriptional activation was detected in cell line JROECL33 and JROECL19. APC mutant colorectal cancer 
cell line SW480 served as a positive control. TCF-mediated transcriptional activity was defined as the ratio of 
pTOPGLOW:pFOPGLOW luciferase activities, each corrected for pRL-TK luciferase activities and where no 
transactivation equals 1. 
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Figure 4.2 TCF-mediated transcriptional activation in GEJ adenocarcinoma cell lines. Constitutive transcriptional activation was detected in cell 
line JROECL33 and JROECL19. APC mutant colorectal cancer cell line SW480 served as a positive control. TCF-mediated transcriptional activity was 
defined as the ratio of pTOPGLOW:pFOPGLOW luciferase activities, each corrected for pRL-TK luciferase activities and where no transactivation 
equals 1.
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Figure 4.3 PCR-SSCP and sequencing analyses of the SNPs in tumors (T) and corresponding normal DNA (N), 
compared with DNA from individuals without SNPs (N1). Shown are informative cases with LOH. Black arrows 
point to allelic patterns. Red arrow heads point to deleted alleles in the tumor DNA. The sequencing 
chromatograms below each autoradiograph show the alterations (note the substituted nucleotide marked by an 
asterisk), which all represent SNPs. SNPs A94C and G1396A are annotated in the reverse complementary 
direction, whereas the SNPs C874, intron 4+17 G�A, T1942C and G2063A are annotated in forward direction. 
Figure 4.3 PCR-SSCP and sequencing analyses of the SNPs in tumors (T) and corresponding normal DNA (N), compared with DNA from individuals 
without SNPs (N1). Shown are informative cases with LOH. Black arrows point to allelic patterns. Red arrow heads point to deleted alleles in the 
tumor DNA. The sequencing chromatograms below each autoradiograph show the alterations (note the substituted nucleotide marked by an 
asterisk), which all represent SNPs. SNPs A94C and G1396A are annotated in the reverse complementary direction, whereas the SNPs C874, intron 
4+17 G→A, T1942C and G2063A are annotated in forward direction. Also see color figures page 291.
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Table 4.1 Patterns of allelic loss in GEJ adenocarcinomas with nuclear ß-catenin expression
Case A94C C874T Intron 4 + 17
G�A
G1396A T1942C G2063A
1 Loss HN Loss HN HN HN
2 HN No loss HN No loss Loss HN
3 HN HN HN HN HN HN
4 HP HN Loss HN HN HN
5 Loss HN HN HN HN HN
6 HN HP HN No loss HN HN
7 HN HP HN No loss HN HN
8 Loss HN Loss No loss No loss HN
9 HN Loss HN HN HN HN
10 No loss HN No loss No loss HN HN
11 HN HN HN HN HN Loss
12 HN HN HN HN HN HN
13 HN HN HN Loss Loss HN
14 HN HN HN Loss HN HN
15 HN Loss HN Loss HN HN
Frequency 6/34 (18%) 8/34 (24%) 4/34 (12%) 9/34 (26%) 4/34 (12%) 1/34 (3%)
Frequency NP ND ND ND ND 69/322 (21%) 9/322 (3%)
HN (Homozygous Normal) 
HP (Homozygous Polymorphism)
NP Normal Population
ND (No Data)
Fifteen of the 17 cases appeared to be heterozygous for at least one polymorphism and LOH 
was observed in 11 (73%) cases (Table 4.1). The polymorphisms were used to investigate LOH 
in 20 GEJ adenocarcinoma cases with strong membranous β-catenin expression (Figure 4.1b, 
4.1d). Also in this series all 6 polymorphisms were present and in 10 of 13 (77%) informative 
cases LOH was found (Table 4.2). 
The T1942C and G2063A SNPs were found to have population frequencies of 21% and 3%, 
respectively (Tables 4.1 and 4.2). The relatively frequent SNP T1942C was only described very 
recently in two independent studies 46,47 and remained undetected in 10 AXIN1 gene muta-
tion studies 29,31,43,44,48,54-58. In most of these studies, as in ours, SSCP analyses were used. To 
determine whether the SSCP conditions have influence on the detection of the T1942C SNP 
we amplified DNA samples with AmpliTaq Gold and with Promega Taq DNA polymerases 
(Promega, Madison, WI, USA) in both AmpliTaq Gold and Promega Taq buffers. The AmpliTaq 
Gold buffer consists of 15 mM Tris-HCl (pH 8.0), 50 mM KCl and 1.5 mM MgCl2 and the Pro-
mega buffer of 10 mM Tris-HCl (pH 9.0), 50 mM KCL, 1.5 mM MgCl2 and 0.1%Triton X-100. As 
demonstrated in Figure 4 the T1942C SNP is only clearly visible after amplification with the 
AmpliTaq buffer. 
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Table 4.2 Patterns of allelic loss in GEJ adenocarcinomas without nuclear ß-catenin expression
Case A94C C874T Intron 4 + 17
G→A
G1396A T1942C G2063A
1 No loss HP Loss HN Loss HN
2 HN Loss HN HN Loss HN
3 HN HN HN Loss Loss HN
4 HN HN HN HN Loss HN
5 HN HP HN HN Loss HN
6 HN HP HN Loss HN Loss
7 HN No loss HN HN HN HN
8 No loss HP No loss HN HN HN
9 HN HN HN HN HN HN
10 HN HN HN HN HN HN
11 Loss HP Loss HN HN HN
12 Loss Loss HN Loss Loss HN
13 HN HP HN HN HP HN
14 HN HN HN HN HN HN
15 HP HP HP HN HN HN
16 No loss HP No loss HN No loss HN
17 HN Loss HN HN HN HN
Frequency 7/40
(18%)
20/40
(50%)
6/40
(15%)
5/40
(13%)
9/40 
(23%)
2/40
(5%)
Frequency NP ND ND ND ND 69/322 (21%) 9/322 (3%)
HN (Homozygous Normal) 
HP (Homozygous Polymorphism)
NP Normal Population
ND (No Data)
β-catenin and AXIN1 immunohistochemistry
As mentioned before 37 GEJ adenocarcinoma samples were investigated, 17 with strong 
nuclear β-catenin expression and 20 cases with normal membranous reactivity (Figure 4.1). 
Eleven of the 15 (73%) informative cases with nuclear β-catenin expression and 10 of 13 (77%) 
informative cases with membranous β-catenin immunoreactivity showed loss of the AXIN1 
gene locus. In all tumor samples AXIN1 protein expression was confined to the cytoplasm of 
the tumor cells exclusively (Figure 4.5). No consistent differences in AXIN1 protein expression 
were observed between tumors with and without AXIN1 locus loss, irrespective of nuclear or 
membranous β-catenin expression (Figure 4.5). 
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Figure 4.4 T1942C PCR-SSCP. Three DNA samples, 1942T/T (homozygous normal); 1942C/C (homozygous 
polymorphic); 1942T/C (heterozygous), were amplified with AmpliTaq Gold polymerase and AmpliTaq Gold 
buffer (panel A), Promega Taq and Promega buffer (panel B), Promega Taq and AmpliTaq Gold buffer (panel 
C) and with AmpliTaq Gold and Promega buffer (no PCR products obtained). All samples were amplified and 
SSCP-electrophoresed in the same experiment. Arrows point to the polymorphic SSCP fragment. Note that the 
polymorphic fragments are clearly visible only after amplification in AmpliTaq Gold buffer (panels A and C). 
Figure 4.5 Immunohistochemistry of AXIN1 in GEJ adenocarcinomas. (AXIN1 antibody, DAB and 
haematoxylin counterstain, magnification x 200). A. and B. GEJ adenocarcinomas with nuclear �-catenin 
expression without (A.) and with (B.) AXIN1 locus LOH. C. and D. GEJ adenocarcinomas with membranous �-
catenin expression without (C.) and with (D.) AXIN1 locus LOH. Note the strong cytoplasmic AXIN1 expression 
in the tumor cells in all 4 cases. 
Figure 4.5 Immunohistochemistry of AXIN1 in GEJ adenocarcinomas. (AXIN1 antibody, DAB and haematoxylin counterstain, magnification x 200). 
A. and B. GEJ adenocarcinomas with nuclear β-catenin expression without (A.) and with (B.) AXIN1 locus LOH. C. and D. GEJ adenocarcinomas with 
membranous β-catenin expression without (C.) and with (D.) AXIN1 locus LOH. Note the strong cytoplasmic AXIN1 expression in the tumor cells 
in all 4 cases. Also see color figures page 291.
Figure 4.4 T1942C PCR-SSCP. Three DNA samples, 1942T/T (homozygous 
normal); 1942C/C (homozygous polymorphic); 1942T/C (heterozygous), 
were amplified with AmpliTaq Gold polymerase and AmpliTaq Gold 
buffer (panel A), Promega Taq and Promega buffer (panel B), Promega 
Taq and AmpliTaq Gold buffer (panel C) and with AmpliTaq Gold and 
Promega buffer (no PCR products obtained). All samples were amplified 
and SSCP-electrophoresed in the same experiment. Arrows point to the 
polymorphic SSCP fragment. Note that the polymorphic fragments are 
clearly visible only after amplification in AmpliTaq Gold buffer (panels 
A and C).
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DISCUSSION
Nuclear β-catenin expression has been reported in up to 60% of GEJ adenocarcinomas 
11,12,15,16,37. In the present study we used the nuclear expression of β-catenin in GEJ adeno-
carcinomas as indication for activated Wnt signaling. This presupposition is substantiated 
by our finding of highly enhanced TCF-mediated transcriptional activity in the cell lines 
JROECL19 and JROECL33, both with nuclear β-catenin expression. None of the 3 cell lines 
without nuclear but with membranous β-catenin expression had increased transcription of 
the TOPGLOW reporter. Activated Wnt signaling in tumors is caused by increased levels of 
β-catenin which can be the result of mutations in APC, β-catenin, AXIN1, AXIN2 or β-TrCP 
5,19,20,28-33. To date only APC and β-catenin mutation analysis in GEJ adenocarcinomas has 
been performed and only few mutations were found 12,37-40. Therefore, the mechanism of Wnt 
activation remains obscure in these tumors. These results prompted us to investigate GEJ 
adenocarcinoma samples with nuclear β-catenin expression for mutations in the AXIN1 gene. 
None of the tumors in the present study showed β-catenin exon 3 mutations 37. In 17 GEJ 
adenocarcinoma samples no AXIN1 gene mutations were found. We therefore conclude that 
Wnt activation in GEJ tumors is not caused by AXIN1 gene mutations.
Six previously described polymorphisms in the AXIN1 gene were detected. All the detected 
DNA variations were also found in patients’ constitutional DNAs indicating that they are truly 
polymorphisms and not somatic mutations. The G2063A SNP in exon 6 results in a substitu-
tion from glycine to serine. This polymorphism is described by Webster et al. 42 although these 
authors annotated the polymorphism to exon 7 and regarded it as a silent polymorphism. 
Furthermore, in a recent study by Taniguchi et al. 29 the G2063A polymorphism is found in 
one hepatocellular carcinoma and in one hepatoblastoma. Patients’ normal tissues were 
not investigated and because the SNP was not found in their 147 control individuals they 
regarded it as an AXIN1 mutation. We found a G2063A allele frequency of 4% and 3% in GEJ 
adenocarcinoma patients and healthy controls, respectively, indicating that this AXIN1 gene 
variant is a SNP and not a mutation. In addition, we found a silent T1942C SNP (ala-ala) in 
exon 6 with an allele frequency of 18% and 21% in GEJ adenocarcinoma patients and healthy 
controls, respectively. This frequent SNP was only recently described, with comparable allele 
frequencies, in 2 independent studies 46,47 and remained undetected in 10 AXIN1 gene muta-
tion investigations with in total 670 DNA samples 29,31,33,43,44,48,54,55,57,58. We demonstrate that 
detection of the T1942C SNP by SSCP analysis is influenced by the PCR buffer characteristics. 
This finding suggests that also other SSCP parameters (gel composition, running buffer, run-
ning temperature, etc.) can have influence on the SNP detection.
The AXIN1 gene polymorphisms were used to determine LOH. Fifteen of 17 cases with 
nuclear β-catenin expression appeared to be heterozygous for at least one polymorphism 
and from these in 11 (73%) clear LOH was observed. This frequent loss of the AXIN1 gene 
could point to a dosage effect where the presence of 50% of the AXIN1 protein is insufficient 
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for proper β-catenin degradation and subsequently leads to Wnt-activation. To gather more 
information about this possibility we investigated AXIN1 gene LOH with the detected SNPs 
in a series of 20 tumors from our previous study with strong, normal membranous β-catenin 
expression. These included 3 cell lines (OACP4C, SKGT-4 and TE-7) without enhanced TCF-
mediated transcriptional activity. In this series the T1942C and G2063A SNPs were detected 
in 4 and 2 samples, respectively. Thirteen cases were informative and in 10 (77%) clear LOH 
was observed. 
By AXIN1 immunohistochemistry no differences were observed between tumors with and 
without AXIN1 locus loss. It’s known that with the semiquantitative immunohistochemical 
method a twofold reduction in protein expression cannot be detected. In esophageal squa-
mous cell carcinoma reduced protein and RNA expression has recently been described by Na-
kajima et al. 48. These investigators suggest AXIN1 gene silencing by promotor methylation, in 
addition to allelic losses, as mechanism for AXIN1 downregulation. Our immunohistochemi-
cal results indicate that AXIN1 gene silencing does not occur in GEJ adenocarcinomas. 
All the above-mentioned results indicate that AXIN1 gene haplo-insufficiency is not sufficient 
for Wnt-activation. This is in accordance with studies that demonstrated bi-allelic inactiva-
tion of the AXIN1 gene in several tumor types 29,31,33,41, although heterozygous AXIN1 gene 
inactivation has also been described 42,45. Chromosome 16p loss has been reported in up to 
40% in GEJ adenocarcinomas 59 and the presence of a tumor suppressor gene on 16p13.3 has 
been suggested by Takamochi et al. 60. The frequent AXIN1 locus LOH in our study could point 
to a gene dosage effect independent of Wnt pathway activation. Furthermore, it cannot be 
excluded that an as yet to be defined tumor suppressor gene on 16p13.3 is the actual target 
for LOH in GEJ adenocarcinomas.
Since mutations in APC, β-catenin and AXIN1 do not play a major role in the frequent TCF/β-
catenin activation in GEJ adenocarcinomas other components should be considered. AXIN2 
gene mutations have been described in 11 colorectal cancers 32, one endometrioid ovarian 
adenocarcinoma 44 and two hepatocellular carcinomas 29. Twelve of these 14 tumor samples 
had nuclear β-catenin expression indicating activated Wnt signaling. The AXIN2 gene muta-
tions appear to be present exclusively in tumors with a microsatellite instable phenotype 
since all AXIN2 mutant colorectal carcinomas and the ovarian endometrioid adenocarcinoma 
were microsatellite instable 29,44. The AXIN2 gene is an improbable candidate for Wnt activa-
tion in GEJ adenocarcinomas because microsatellite instability has been described in only 
less than 6% in these tumors 37,61. Another candidate is β-TrCP, involved in β-catenin degra-
dation. Recently, β-TrCP mutations have been described in two prostate cancer samples, of 
which one had nuclear β-catenin expression 28.
Activated Wnt signaling can also be the result of activation of the canonical Wnt pathway 
by secreted Wnts or by expression of the Wnt receptors frizzled 62,63. In cell line cultures this 
would imply the presence of an autocrine Wnt/frizzled loop. Furthermore, tumor necrosis 
factor-α has recently been demonstrated to induce TCF/β-catenin mediated transcription in 
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a GEJ adenocarcinoma cell line 64. These findings indicate that next to mutational activation 
of the Wnt pathway, gene expression alterations should be considered also as driving force 
behind Wnt activation in GEJ adenocarcinomas.    
In summary, our results demonstrate that nuclear β-catenin expression in GEJ adenocarci-
noma cell lines correlates with TCF-mediated transcription activation and so with activated 
Wnt signaling. The frequent nuclear localization of β-catenin in GEJ adenocarcinomas cannot 
be attributed by AXIN1 gene mutations. The mechanism of Wnt activation in these tumors 
remains to be established. In addition, the role of the frequent LOH of the AXIN1 locus in GEJ 
adenocarcinomas deserves further investigation. 
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ABSTRACT 
A recent evaluation by comparative genomic hybridization (CGH) demonstrated chromosome 
14q31-32.1 to be frequently deleted in adenocarcinomas of the gastro-esophageal junction 
(GEJ). This suggests the presence of a tumor suppressor gene in the deleted region. In the 
present study we have performed a detailed loss of heterozygosity (LOH) analysis in 34 GEJ 
adenocarcinomas and one tumor-corresponding dysplastic Barrett’s epithelium sample with 
37 polymorphic microsatellite markers. Thirty-five markers are in the 14q24.3-32.33 region 
with a mean distance of 800 kilo base pairs. Fourteen of 34 tumor samples (41%) showed loss 
of 14q markers. We identified a minimal region of allelic loss of 7,105,440 base pairs between 
markers D14S1000 and D14S256 at cytogenetic location 14q31.1-32.11. Within this region 
markers D14S1035, D14S55, D14S1037, D14S1022, D14S1052, D14S974, D14S73, D14S1033, 
D14S67, D14S68 and D14S1058 showed loss in all informative tumors with 14q loss. The re-
gion between markers D14S1000 and D14S256 contains 7 known genes. The identification 
of this minimal deletion and the data base information on the genes present in this region 
facilitate the search for the candidate tumor suppressor gene(s). 
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INTRODUCTION
Adenocarcinomas arising from the lower esophagus or the gastric cardia are commonly re-
ferred to as adenocarcinoma of the gastro-esophageal junction (GEJ). As such, they can be 
regarded as a single entity 1,2. These tumors have shown a rapid increase in incidence over 
the past decades 1,3. The most important risk factor is gastro-esophageal reflux leading to 
the replacement of the normal stratified squamous epithelium by columnar epithelium. This 
condition is known as Barrett’s esophagus. The prognosis for patients with adenocarcinoma 
of the GEJ is poor. Five-year survival after surgery with curative intent is approximately 20-
25% 4,5. Little is known about the genetic alterations involved in the progression of Barrett’s 
epithelium towards dysplasia and invasive adenocarcinoma. 
Recently, we and others identified chromosomal aberrations in GEJ tumors by comparative 
genomic hybridisation (CGH) 6,8. Loss of chromosome 14q31-32.1 was detected in a signifi-
cant number of cases, suggesting the presence of a tumor suppressor gene in that region 
6. Deletion of part of chromosome 14 has also been reported in other malignancies such as 
colorectal carcinoma 9,12, adenocarcinoma of the stomach 13,14, gastrointestinal tract stromal 
cell tumors 15, ovarian 16, bladder 17, pancreaticobiliary 18, breast 19, head and neck 20,21, renal 
cell carcinoma 22,23, malignant mesothelioma 24, neuroblastoma 25, meningioma 26, esophageal 
squamous cell carcinoma 27 and oligodendroglial and astrocytic tumors 28. 
The goal of the present study was to define the common region of chromosome 14q31-32.1 
loss in GEJ adenocarcinoma in more detail by loss of heterozygosity (LOH) analysis using 37 
polymorphic microsatellite markers. From 34 patients 15 primary tumors, 15 xenografts from 
10 primary tumors and 5 lymph node metastases, and 4 in vitro GEJ adenocarcinoma cell 
lines were used. From one patient in addition to a cell line derived from the primary tumor, a 
cell line established from a lymph node metastasis was investigated. Furthermore, from one 
patient the primary tumor and the dysplastic epithelium adjacent to the tumor were investi-
gated. The xenografts and cell lines facilitate detection of homozygous deletions. 
MATERIALS AND METHODS
Patients
We analyzed 36 tissue samples from 34 patients. All patients were diagnosed with adeno-
carcinoma of the gastro-esophageal junction, i.e. distal esophagus or the gastric cardia, and 
underwent transhiatal resection of the esophagus and the proximal stomach with curative 
intent as described 2. 
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Tumor samples: frozen tumor tissue, xenografts and cell lines
The tissue samples were obtained from the resection specimens and used according to the 
Code of Proper Secondary Use of Human Tissue in the Netherlands established by the Dutch 
Federation of Medical Scientific Societies (http://www.fmwv.nl/gedragcodes/goedgebruik/
CodeProperSecondaryUseOfHumanTissue.pdf ). Immediately after surgery small pieces of 
tumor, dysplasia and adjacent normal mucosa were taken, snap frozen and stored in liquid 
nitrogen until further analysis. Specimens included 15 primary tumors (coded Ba) and one 
dysplastic epithelium sample (Ba10d) adjacent to an adenocarcinoma, 10 primary tumor 
nude mouse xenografts (with code P-X), 5 xenografts from lymph node metastases (with 
code M-X) and 5 in vitro cell lines 29,30 (Figure 5.1). All xenografts were used in the first or 
second passage. Two of the in vitro cell lines are derived from a primary tumor (P4C) and a 
lymph node metastasis (M4C) from the same patient. Two human cell lines JROECL19 and 
-33, established by Rockett et al 30 were obtained from the European Collection of Animal Cell 
Cultures (ECACC) and 3 cell lines (P4C, M4C and M5C) were established in our laboratory 29. 
Sixteen of the used tumors were previously investigated by CGH 6. Eight samples showed 14q 
loss in the CGH study and all these 8 demonstrated 14q LOH. Of the 8 tumors with no 14q loss 
in CGH, two demonstrated partial 14q LOH. The remaining 6 tumors without CGH 14q loss 
did also not show 14q LOH. In our investigated cases there is a generally good concordance 
between 14q CGH and LOH results, with LOH analysis somewhat more sensitive in detecting 
DNA loss, as expected. 
DNA extraction
DNA from cell lines was isolated according to standard procedures. Genomic DNA from xe-
nografts and tumor samples was isolated from consecutive 5 μm cryostat tissue sections by 
overnight proteinase K digestion at 55 ºC followed by phenol extraction and ethanol pre-
cipitation. DNA pellets were dissolved in TE (10 mM Tris/HCl pH 7.8; 1 mM EDTA). From the 
tumor and dysplastic tissue cryostat sections were microdissected to obtain tissue fragments 
containing at least 75% neoplastic cells. From all tumors and xenografts corresponding nor-
mal DNA was isolated from frozen normal lymph node, normal esophagus or normal stomach 
tissue. From cell lines JROECL19 and -33 corresponding normal DNA was isolated from forma-
lin fixed and paraffin embedded normal tissue (kind gift of Dr. S.J. Darnton). From the in vitro 
cell lines P4C/M4C and from the xenografts M53X1, P35X1, M30X1 and M55X1 corresponding 
primary tumor DNA was isolated after microdissection of cryostat sections. Normal mouse 
DNA, isolated from mouse liver, was used as negative control for the xenograft samples.
Microsatellite marker selection 
Thirty-seven polymorphic microsatellite markers with a high degree of heterozygosity were 
originally selected from the Généthon human genetic linkage map 31, from The Genome Da-
tabase (http://www.gdb.org) and from the published complete chromosome 14 sequence 
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Figure 5.1 Histology (H&E stained sections) of investigated tumors. A: adenocarcinoma of the gastric cardia with 14q LOH (Ba7). 
B: adenocarcinoma of the gastro-esophageal junction without 14q LOH (Ba1). C and D: primary tumor derived xenograft P35X1 (C) and 
corresponding primary tumor (D). Note comparable tumor histology. E and F: lymphnode metastasis derived xenograft M55X1 (E) 
and corresponding lymphnode metastasis (F). Note comparable tumor histology. G and H: esophageal adenocarcinoma (G, Ba10) 
and from the same patient dysplastic Barrett’s epithelium (H, Ba10d). Original magnifications x200. 
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(http://www.genoscope.cns.fr) 32. The exact position of the markers was retrieved from the 
UCSC database (http://genome.ucsc.edu/; freeze May 2004, Build 35) 33. Thirty-five markers 
are located in the region 14q24.1-32.33, spanning the region 14q31-32.1, and 2 markers are at 
14q11.2. All 37 markers are CA/TG dinucleotide repeats and their location is indicated by the 
position of the first nucleotide of the CA/TG repeat (C or T) in the chromosome 14 sequence 
(http://genome.ucsc.edu/; freeze May 2004, Build 35; Figure 5.2). In the 14q24.1-32.33 region 
the marker distance varies between 13.7 kb (kilo base pairs; markers D14S250 and D14S78; 
Figure 5.2) and 2,157 kb (markers D14S985 and D14S293; Figure 5.2). We used the primers 
from the database for marker amplification, except for marker CCC1 for which we used the 
primers: 5’-GGCAGTTAAGAAGACACAGC-3’ and 5’-GCCATAAGCCTGAAGATTGG-3’.
PCR amplification
PCR amplification was performed in a 15 μl reaction volume containing 0.1 μg of genomic 
DNA, 0.2 mM dCTP, 0.2 mM dGTP, 0.2 mM dTTP, 0.02 mM dATP and 0.8 μCi α-32P-dATP (Amer-
sham, Buckinghamshire, UK), 20 pmol of each primer, 0.4 U Taq polymerase (Promega, Madi-
son, WI, USA) and 2-4 mM MgCl2. Amplification proceeded during 35 cycles in a Biometra 
thermal cycler (Biometra, Göttingen, Germany) with the following parameters: denaturing at 
95ºC for 30 sec, annealing at either 50°C or 55°C for 45 sec and extension at 72ºC for 60 sec. 
Reactions concluded with a final extension at 72ºC for 10 min. 
Electrophoresis and interpretation of loss of heterozygosity (LOH)
Just prior to gel electrophoresis 5 μl of the PCR amplification products were diluted with 5 μl 
of loading buffer (95% formamide, 10 mM EDTA, 0.025% bromophenol blue, 0.025% xylene 
cyanol, pH 8.0). Then the PCR products were denatured at 95ºC for 5 min and loaded onto ad-
jacent lanes of a 6% denaturing polyacrylamide gel containing 42% ureum. Electrophoresis 
was performed at 65 W for 2 to 3 hrs, depending on the size of the amplified DNA fragment. 
Gels were dried and exposed to X-ray films.
The signals derived from tumor and corresponding normal DNA were compared by visual 
inspection, independently performed by at least three investigators (W.N.M.D., D.A.D., M.A., 
H.F.B.M. and B.P.L.W.). DNA samples with controversial results were reamplified and in a num-
ber of cases we isolated and amplified DNA from a seperate part of the tumor. A case was 
classified as informative and having undergone allelic loss (LOH), informative and no LOH, 
not informative, or as having undergone an allelic shift (microsatellite instability, MSI). 
RESULTS
From 34 patients 35 tumor samples and one dysplastic Barrett’s epithelium were analyzed 
for LOH using 37 polymorphic microsatellite markers. Thirty-five markers cover chromosome 
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Figure 2
Marker Chromosome Nucleotide P4
C
M4
C
Ba
7
Ba
19
M5
3X
1
Ba
32
P3
5X
1
Ba
23
Ba
27
M3
0X
1
Ba
10
Ba
10
d
M5
5X
1
Ba
18
Ba
15
Ba
34
14q position
D14S72 14q11.2  20,440,939  T ND
D14S283 14q11.2  21,757,345  T ND
D14S983 14q24.3  76,590,458  C ND
D14S74 14q24.3  77,728,139  T
D14S1008 14q31.1  78,971,691  C
D14S1000 14q31.1  81,175,635  T
D14S1035 14q31.2  82,615,934  T ND
D14S55 14q31.3  83,746,342  T
D14S1037 14q31.3  84,267,106  C
D14S1022 14q31.3  84,845,365  T ND
D14S1052 14q31.3  85,483,666  T ND
D14S974 14q31.3  85,699,861  T
D14S73 14q31.3  86,152,333  C
D14S1033 14q31.3  87,360,032  C ND
D14S67 14q31.3  87,457,793  T
D14S68 14q31.3  87,697,616  C
D14S1058 14q31.3  87,718,134  C ND
D14S256 14q32.11  88,281,215  T ND
D14S1005 14q32.11  88,447,872  T
CCC1 14q32.11  88,697,655  T
D14S995 14q32.12  90,747,226  T
D14S280 14q32.12  91,252,811  C
D14S1050 14q32.12  91,985,380  C
D14S977 14q32.12  92,239,077  T ND
D14S1142 14q32.13  93,907,156  C ND
D14S265 14q32.13  94,833,902  C
D14S65 14q32.2  96,691,265  T ND
D14S267 14q32.2  98,294,034  C ND
D14S250 14q32.2  99,528,043  T ND
D14S78 14q32.2  99,541,722  C
D14S1006 14q32.2 100,249,401 T ND
D14S985 14q32.2 100,366,436 C
D14S293 14q32.32 102,523,880 C ND
D14S1010 14q32.33 103,284,158 C
D14S260 14q32.33 103,460,544 C ND
D14S292 14q32.33 103,666,613 C ND
D14S1007 14q32.33 105,049,084 C ?
loss not informative
no loss ND no data
MRO
Figure 5.2 Chromosome 14 LOH results. All samples with loss of 14q markers are shown. P4C and M4C are in vitro cell lines from a primary 
tumor and a metastasis, respectively, from the same patient. P35X1 is a xenograft from a primary tumor and M30X1, M53X1 and M55X1 are 
xenografts from metastases. The Ba numbers are primary tumors and Ba10d is the dysplastic epithelium sample belonging to primary tumor 
Ba10. Nucleotide positions from the first nucleotide (C or T) of the CA or TG repeats are indicated by the position of the first nucleotide of the CA/TG 
repeat (C or T) in the chromosome 14 sequence (http://genome.ucsc.edu/; freeze May 2004, Build 35) 33. White squares: no loss; black squares: 
loss; striped squares: not informative; ND: no data. The solid bar indicates the minimal region of overlapping deletion (MRO). 
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Fig. 5.3 Autoradiograms from 6 representative tumors (M30X1, Ba10, M55X1, Ba18, Ba15 and 
Ba34) showing allelic band patterns from critical markers on 14q. Arrows indicate alleles; arrowheads 
point to deleted allele. N = normal DNA, X = xenograft DNA, T = tumor DNA and D = Barret’s 
dysplasia DNA. 
Figure 5.3 Autoradiograms from 6 representative 
tumors (M30X1, Ba10, M55X1, Ba18, Ba15 and Ba34) 
showing allelic band patterns from critical markers 
on 14q. Arrows indicate alleles; arrowheads point to 
deleted allele. N = normal DNA, X = xenograft DNA, T 
= tumor DNA and D = Barrett’s dysplasia DNA.
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region 14q24.3-14q32.33. The relevant results are summarized in Figure 5.2. We regard cell 
lines P4C and M4C as one sample since they are derived from the same patient and since they 
showed identical results. No LOH was found in 18 tumors and 2 tumors showed widespread 
MSI. LOH of 14q was observed in 14 of 34 tumors (41%). Eight tumors (P4C/M4C, Ba7, Ba19, 
M53X1, Ba32, P35X1, Ba23 and Ba27) showed loss of all informative markers for the entire 
region 14q11-qter. In 6 tumors both loss and retention of heterozygosity was seen at infor-
mative markers. These patterns were used for defining the minimal region of overlapping 
deletion (MRO). With all xenograft and cell line DNA samples PCR products were obtained 
with all markers. Seven markers amplified also normal mouse DNA, but with a significant size 
difference from human DNA. The corresponding primary tumors from cell lines P4C and M4C 
and from xenografts M53X1, P35X1, M30X1 and M55X1 were investigated with the boundary 
determining markers D14S72, D14S74, D14S1008, D14S1000, D14S1035, D14S267, D14S250 
and D14S292. The cell lines and xenografts and their corresponding primary tumors showed 
the same LOH pattern in all cases (Figure 5.3). 
We defined a region of loss which was proximally bounded by marker D14S1000 and distally 
by marker D14S256, the size being maximally 7,105,440 base pairs (determined from the 
position of the first base down stream of the reverse D14S1000 primer (81, 175, 728) and 
the last base up stream of the forward D14S256 primer (88, 281, 168) (base positions from 
the 14q sequence at http://genome.ucsc.edu/; freeze May 2004, Build 35). Informative LOH 
results are shown in Figure 5.3. Xenograft M55X1, with an interstitial deletion, was critical for 
defining the centromeric boundary, whereas tumor Ba34 defined the telomeric boundary. 
This region has been cytogenetically assigned to 14q31.1-32.11 and it was deleted in all tu-
mors that showed loss of 14q markers. Deletion of D14S1035, D14S55, D14S1037, D14S1022, 
D14S1052, D14S974, D14S73, D14S1033, D14S67, D14S68 and D14S1058 was found in all 
informative tumors with 14q loss. There was no correlation between LOH on 14q and the 
location of the tumor (esophagus or gastric cardia). GEJ tumors with 14q loss tended to have 
a higher tumor stage and more frequently distant metastases as compared to the tumors 
without 14q loss (χ2 test p = 0.13 and p = 0.076, respectively). 
DISCUSSION
In this study we confirmed our previous finding that allelic loss on chromosome 14q31-32.1 
occurs in more than 40% of all GEJ adenocarcinomas 6. This strongly suggests that this region 
contains one or more tumor suppressor genes involved in GEJ tumorigenesis. Furthermore, 
we identified the commonly deleted region of allelic loss. This is located at cytogenetic loca-
tion 14q31.1-32.11 between markers D14S1000 and marker D14S256, with a size of about 7.1 
Mb. In the 15 xenografts and 5 cell lines we did not detect homozygous deletions, since with 
all markers tested PCR products were obtained. Two cell lines (from one patient) and 4 xeno-
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grafts (1 from a primary tumor and 3 from metastases) showed 14q LOH. The corresponding 
primary tumors showed the same LOH patterns indicating that 14q LOH was not an ex vivo 
artefact. 
Genome-wide allelic loss analysis in colorectal carcinomas reported an overall mean LOH 
frequency of about 20% which is regarded as non specific, “background”, allelic loss 34,35. The 
finding of more than 40% 14q311-32.11 allelic loss in adenocarcinomas of the GEJ points 
to possible involvement of this region in the genesis of these tumors. Furthermore, loss of 
14q31-32 has been reported in several other carcinomas like colorectal adenocarcinoma 9-12, 
adenocarcinoma of the stomach 13,14, ovarian carcinoma 16, bladder carcinoma 17, pancreati-
cobiliary 18, breast 19 and head and neck carcinoma 20,21 and renal cell carcinoma 22,23. Loss of 
14q was reported to correlate with early age of onset, advanced stage, high grade and poor 
outcome of the disease 9,11,12,17,20-2. In our series we also found a trend that loss of 14q is more 
common in advanced stage tumors and in tumors with distant metastases. These findings 
indicate that inactivation of the putative 14q31-32 tumor suppressor gene is involved in di-
sease progression. Furthermore, in concordance with this is our finding of no 14q loss (with 
markers D14S1035, D14S1037, D14S1052, D14S67 and D14S1058) in 11 Barrett’s dysplasia 
samples, including 6 high grades (data not shown). However, the 14q loss found in tumor 
Ba10 was also detected in the tumor-adjacent dysplastic Barrett’s epithelium (Ba10d, Figures 
5.2 and 5.3). 
To our knowledge no clear candidate 14q31.1-32.11 tumor suppressor genes have been 
found to date. Seven known genes are present in the region between D14S1000 and D14S256 
(derived from: http://genome.ucsc.edu/; freeze May 2004, Build 35) 33. From centromeric to 
telomeric these are: fibronectin leucine rich transmembrane protein 2 (FLRT2), galactosylce-
ramidase (GALC), G-protein-coupled receptor 65 (GPR65) or T-cell death-associated protein 8 
(TDAG8), potassium channel subfamily K member 10 (KCNK10), spermatogenesis associated 
7 (SPATA7), protein tyrosine phosphatase non receptor type 21 (PTPN21) and echinoderm 
microtubule associated protein like 5 (EML5 or EMAP-2). From current literature data it can 
be deduced that 3 of the genes have potential as tumor suppressor genes. The function of 
FLRT2 has been suggested to be in cell adhesion 36 and as such this protein could have a 
tumor suppressor activity. However, recently evidence has been obtained that FLRT2 has po-
tential as an oncogene as the protein is involved in fibroblast growth factor (FGF) signaling 
37. GPR65/TDAG8 was originally described to function in activation-induced T-cell death 38. 
However, recently GPR65/TDAG8 has been found to have oncogenic capacity and the protein 
is over-expressed in several human cancers 39. PTPN21 is a tyrosine phosphatase and recently 
inactivating mutations in PTPN family members have been described in colorectal cancer 
although no mutations were found in PTPN21 40. From the other identified 14q31.1-32.11 
genes GALC, KCNK10, SPATA7 and EML5/EMAP-2 no tumor suppressor function is known to 
date. 
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The relevance of all the abovementioned genes in GEJ adenocarcinogenesis has to be deter-
mined. In addition, it cannot be excluded that the region between markers D14S1000 and 
D14S256 contains other tumor suppressor genes yet to be discovered. Despite our data, it 
is also possible that the 14q GEJ adenocarcinoma tumor suppressor gene(s) reside outside 
the detected MRO. And finally it should be recognized that even frequent loss of a certain 
chromosomal region can be a bystander phenomenon and not causally related to the tu-
morigenic process.  
In our previous CGH study we found that 14q loss occurred significantly more frequent in 
esophageal adenocarcinomas than in gastric cardia tumors 6. In the present study this rela-
tionship was not confirmed. Also in a larger CGH study (van Dekken, unpublished results) and 
in a microsatellite study no relation was found between the location of the tumor and loss 
of 14q 41. Besides phenotypical similarities, adenocarcinomas of the esophagus and gastric 
cardia apparently also have similar genotypes, as suggested by others 42,43. 
In conclusion, our study has contributed to unravelling the complex molecular alterations 
present in adenocarcinomas of the GEJ. We have comprehensively mapped the deletions 
of chromosome 14q that were previously demonstrated in this disease. The reliability of our 
findings has been greatly enhanced by the use of xenografts and in vitro cell cultures. We 
have determined an overlapping region of LOH, possibly harboring a GEJ adenocarcinoma 
suppressor gene. This result in combination with the available data base information on the 
genes present in this region can facilitate the identification of the candidate tumor suppres-
sor gene(s).
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ABSTRACT 
We estimated the prevalence and prognostic significance of neuroendocrine (NE) cells in a 
series of 208 resection specimens containing gastro-esophageal junction (GEJ) adenocarci-
nomas, with 56 specimens containing Barrett’s mucosa. Immunohistochemically, chromo-
granin A (CGA) was positive in 49% (102/208) of GEJ adenocarcinomas and in 68% (38/56) of 
Barrett’s mucosas. CGA in GEJ tumors correlated with pTNM stage. CGA in Barrett correlated 
with pTNM stage and tumor grade of the adjacent carcinoma. Patients with CGA in Barrett had 
better survival than patients without CGA in Barrett, with 5-year survival percentages of 56% 
and 9% respectively. In multivariate analysis, CGA in Barrett was an independent prognostic 
factor for survival after surgery. Therefore CGA in Barrett adjacent to GEJ adenocarcinoma 
might be helpful in the assessment of patient outcome.
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INTRODUCTION
Neuroendocrine (NE) cells are defined as argentaffin and argyrophil cells that produce 
peptides or amines. They belong to the Diffuse Neuroendocrine System (DNES) and were 
previously known as amino-precursor-uptake-decarboxylation (APUD) cells. The neuroendo-
crine system of the normal gastro-intestinal tract might regulate proliferation and growth 
of epithelial and mesenchymal cells and probably function in sensation of hunger during 
fasting and food-intake 1. Chromogranin A (CGA), a specific matrix component of endocrine 
granules, participates in vesicle aggregation, granulogenesis, and hormone secretion and 
serves as a precursor for bioactive peptides (prohormone function) in endocrine and NE cells 
2-4. CGA is stored in secretory granules of NE cells and is regarded as a general endocrine 
marker 5-7. The presence of NE cells in carcinomas of the gastrointestinal tract is well docu-
mented but their role remains speculative 8-21. In a number of immunohistochemical studies 
a prognostic relevance of NE cells in adenocarcinomas, mostly colorectal adenocarcinomas, 
has been reported, however, several other studies failed to demonstrate a relation between 
NE differentiation and biological behavior of colorectal adenocarcinomas 9-11,14-22. Reports on 
the prevalence and prognostic significance of NE cells in adenocarcinomas of the esophagus 
and its precursor lesion, the Barrett’s mucosa, have been scarce. Hamilton et al. did not find 
a significant correlation between the presence of chromogranin A (CGA) immunoreactive 
tumor cells and survival in patients with esophageal adenocarcinoma 23. We analyzed the 
presence of NE cells in 208 resection specimens with adenocarcinoma of the gastro-esopha-
geal junction (GEJ), i.e. gastric cardia or distal esophagus, and premalignant Barrett’s mucosa 
and correlated immunostaining with tumor characteristics and patient survival in order to 
evaluate the possible application of NE cells as prognostic marker. 
MATERIALS AND METHODS
Tissues and Patients 
Two hundred and eight patients (176 men; 32 women) with GEJ adenocarcinoma who under-
went transhiatal resection of the tumor with restoration of continuity of the gastrointestinal 
tract by a gastric tube with cervical anastomosis were included in this study. Patients were 
operated between April 1987 and April 2002 at the Department of Surgery, Erasmus MC, 
Rotterdam. A standard dissection of the perigastric, left gastric and coeliac nodes was per-
formed. Macroscopic tumor clearance was aimed at in all cases but no extended lymph node 
dissection was done. Seventeen patients received neoadjuvant chemotherapy and 2 patients 
received neoadjuvant chemoradiation. Patient’s mean age was 63.6 year (range 39-84 years) 
at the time of diagnosis. All patients were followed up until April 2003 or until death if earlier. 
All 208 pathology records were reviewed. Barrett’s mucosa was diagnosed by the GI-patholo-
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gist and was defined as the presence of intestinal type epithelium with Goblet cells in the tu-
bular esophagus 24. In 73 patients Barrett’s mucosa had been sampled prior to development 
of adenocarcinoma. Barrett’s mucosa adjacent to tumor could be obtained in 56 out of these 
73 resection specimens, whereas in 17 resection specimens the Barrett’s mucosa could not be 
detected in the resection specimen. Barrett’s mucosa showed no signs of dysplasia in 22, low 
grade dysplasia in 22 and high grade dysplasia in 12 resection specimens. A carcinoma was 
considered to arise from the distal esophagus when premalignant Barrett’s mucosa was pre-
sent and/or the epicenter of the mass was located in the tubular esophagus extending from 
the tracheal bifurcation to the gastro-esophageal junction including the intra-abdominal 
esophagus, according to the TNM classification (International Classification of Diseases for 
Oncology C15.5). The tumor was considered to be cardiac when the epicenter was immedi-
ately below the gastro-esophageal junction, extending approximately 2 cm downwards. The 
tumor was classified as a junction carcinoma when the epicenter was just at the GEJ, without 
predominance for distal esophagus or gastric cardia and no Barrett’s mucosa was present. 
Tumors arising from the fundus or corpus of the stomach and infiltrating the gastric cardia 
or distal esophagus were excluded. Of the adenocarcinomas in our patient group, 112 arose 
from the distal esophagus and 73 arose from the cardia. The exact location of 23 GEJ adeno-
carcinomas could not be specified as either distal esophagus or gastric cardia and these were 
classified as junction carcinomas. 
Immunohistochemical Analyses 
From formalin-fixed paraffin-embedded tissue blocks of the primary tumor 4 μm thick sec-
tions were mounted on 3-aminopropyl-triethoxysilane (APES)-coated glass slides. For immu-
nostaining a monoclonal antibody against CGA (Hybritech, San Diego, USA, at a dilution of 
1:1250) was used. Staining was carried out by a standard avidin biotin immunoperoxidase 
technique, using a commercially available kit (Labvision, Fremont, USA). Deparaffinized sec-
tions were treated with methanol containing 3% H2O2 for 20 minutes. After washing with 
phosphate-buffered saline (PBS), blocking serum was applied for 5 minutes. Then, primary 
CGA antibodies were allowed to react at room temperature for 1 hour. After washing in PBS, 
biotin-conjugated secondary antibody was applied for 10 minutes followed by peroxidase-
marked streptavidin. After rinsing in PBS, peroxidase was visualized by diaminobenzidine 
hydrochloride (Fluka, Neu-Ulm, Germany) with 0.03% H2O2 solution for 10 minutes. The slides 
were counterstained with Mayer’s Haematoxylin and dehydrated in alcohol before mounting. 
Expression of CGA was evaluated by high power microscopic examination (400 X) of the en-
tire tissue section. As negative controls normal mouse immunoglobulins and normal rabbit 
serum were applied on duplicate sections. Positive controls using normal colonic epithelium 
were also run with each batch, in addition to using non-involved normal gastric mucosa in 
the resection specimens, if present, as an internal positive control. Scoring of cytoplasmic 
CGA expression in adenocarcinomas was based on the percentage of positive cells: >20% of 
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cells with cytoplasmic staining (2+), 1-20% of cells with cytoplasmic staining (1+), no cells 
staining (0). 
Statistical Analysis
Correlations between CGA immunoreactivity and patient and tumor characteristics were as-
sessed by T-test and (a trend version of ) χ2 test. Survival rates were calculated according to 
the Kaplan-Meier method and differences in survival were assessed using the log rank test. 
P<0.05 was considered statistically significant. The Cox regression model was used to analyze 
the independent prognostic value of CGA expression after correction for possible confoun-
ding factors. 
RESULTS
CGA expression was detected in 102/208 (49%) adenocarcinomas of the GEJ (Table 6.1). The 
CGA positive cells mostly presented diffusely scattered throughout the tissue or multifocally 
located in small nests, with just eight tumors having >20% (2+) CGA positive cells (Figure 6.1). 
For statistical comparison we hence combined the groups with 1+ and 2+ staining. Negative 
controls did not show staining and positive controls were positive. In 56 of the 208 resection 
specimens Barrett’s mucosa adjacent to adenocarcinoma was detected. Positive staining for 
CGA was seen in 38/56 cases (68%). CGA immunoreactivity was absent in 18/38 (47%) tumors 
with CGA positive Barrett’s mucosa (Table 6.1). There was no correlation between CGA immu-
noreactivity in Barrett’s mucosas and CGA immunoreactivity in adenocarcinomas (P=0.57). 
In the patients with Barrett’s mucosa adjacent to tumor, there was no correlation between 
CGA immunoreactivity in the Barrett and presence or degree of dysplasia (P=0.97 and P=0.65 
respectively). 
Table 6.1 CGA Expression in Adenocarcinomas of the GEJ and Barrett’s Mucosa
Non-Barrett Barrett’s mucosa Total
CGA positive CGA negative
Adenocarcinomas 
CGA positive 74 20 8 102
  
CGA negative 78 18 10 106
Total 152 38 18 208
CGA positive staining in GEJ tumors correlated with a more favorable pTNM stage (P=0.04, 
Table 6.2). CGA positive staining in Barrett’s mucosas correlated with a more favorable pTNM 
stage and tumor grade (P=0.005 and P=0.024 respectively, Table 6.2). No difference in survival 
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Fig. 6.1 CGA immunoreactivity in normal gastric epithelium (A), CGA negative adenocarcinoma (B). Scatters 
of individual tumor cells show CGA staining (1+) within a well-differentiated adenocarcinoma (C).
Adenocarcinoma shows apparent cytoplasmic CGA staining in >20% (2+) of tumor cells (D). CGA negative 
Barrett’s epithelium adjacent to adenocarcinoma (E), CGA positive cells in Barrett’s epithelium most 
prominently located in the basal layer of the epithelium (F).
Fig. 6.1 CGA immunoreactivity in normal gastric epithelium (A), CGA negative adenocarcinoma (B). Scatters of individual tumor cells show CGA 
staining (1+) within a well-differentiated adenocarcinoma (C). Adenocarcinoma shows apparent cytoplasmic CGA staining in >20% (2+) of 
tumor cells (D). CGA negative Barrett’s epithelium adjacent to adenocarcinoma (E), CGA positive cells in Barrett’s epithelium most prominently 
located in the basal layer of the epithelium (F). Also see color figures page 291.
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Fig. 6.2 Cumulative survival of patients with (n=102) and without (n=106) CGA immunoreactivity in 
adenocarcinomas of the GEJ (P=.69). Broken line represents CGA positive tumors, uninterrupted line represents 
CGA negative tumors. 
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Fig. 6.2 Cumulative survival of patients with (n=102) and without (n=106) CGA immunoreactivity in adenocarcinomas of the GEJ (P=.69). 
Broken line represents CGA positive tumors, uninterrupted line represents CGA negative tumors.
Fig. 6.3 Cumulative survival of patients with (n=38) and without (n=18) CGA immunoreactivity in Barrett’s 
mucosa adjacent to adenocarcinoma (P=.0015). Broken line represents CGA positive Barrett’s mucosas, 
uninterrupted line represents CGA negative Barrett’s mucosas. 
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Fig. 6.3 Cumulative survival of patients with (n=38) and without (n=18) CGA immunoreactivity in Barrett’s mucosa adjacent to adenocarcinoma 
(P=.0015). Broken line represents CGA positive Barrett’s mucosas, uninterrupted line represents CGA negative Barrett’s mucosas.
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between patients with CGA positive and CGA negative adenocarcinomas was found (P=0.69, 
Figure 6.2). Five year survival percentages were 30% and 28% respectively. However, patients 
with CGA positive cells in Barrett’s mucosa adjacent to the tumor had a better survival than 
patients without CGA positive cells in Barrett’s mucosa (P=0.0015, Figure 6.3). Five year sur-
vival percentages were 56% and 9% for patients with and without CGA expression in Barrett 
respectively. Univariate analysis to identify prognostic variables in the total group showed 
pTNM stage, tumor grade and radicality of resection to be prognostic factors for survival 
(P=<0.001, P=0.012 and P=<0.001 respectively). In multivariate Cox regression analysis only 
pTNM-stage and radicality of resection turned out to be independent prognostic factors for 
survival in the total patient group (P=0.003 and P=0.006, Table 6.3A). However, in the group 
of patients with Barrett’s mucosa, univariate analysis showed age, radicality of resection and 
CGA immunoreactivity in the Barrett’s mucosa to be prognostic for survival (P=0.035, P=0.008 
and P=0.003 respectively, Table 6.3B), which was substantiated by multivariate analysis 
(P=0.03, P=0.037 and P=0.003 respectively, Table 6.3B).
Table 6.3. Results of the Cox Regression Analyses in (A.) 208 GEJ Adenocarcinomas and in (B.) 56 Barrett’s mucosas (adjacent to tumor), as part 
of the series of 208 GEJ adenocarcinomas
A.
Confounding Variable Univariate RRa (CIb) P value Multivariate-Adjusted RRc (CI) P value
Age 1.01 (1.0-1.03) 0.15 1.02 (1.0-1.04) 0.11
Gender 
(M, F)
0.94 (0.59-1.52) 0.81 0.75 (0.45-1.25) 0.27
pTNM-stage I - <0.001 - 0.003
      II 3.76 (1.16-12.22) - 2.88 (0.88-9.48) -
      III 8.43 (2.63-27.04) - 5.35 (1.63-17.56) -
      IV 8.08 (2.38-27.40) - 5.22 (1.50-18.20) -
Tumor grade well     - 0.012 - 0.118
      moderate 6.84 (0.94-49.51) - 4.95 (0.68-36.04) -
      Poor 9.98 (1.38-71.98) - 6.24 (0.85-45.68) -
Radicality of resection 
(R0 vs R1, R2)
2.43 (1.69-3.49) <0.001 1.73 (1.17-2.57) 0.006
CGA tumor 
(positive vs negative)
1.09 (0.77-1.55) 0.63 1.12 (0.78-1.61) 0.56
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B.
Confounding Variable Univariate RRa (CIb) P value Multivariate-Adjusted RRc (CI) P value
Age 1.04 (1.0-1.08) 0.035 1.04 (1.0-1.10) 0.030
pTNM-stage
(I, II vs III, IV)
1.92 (0.91-4.03) 0.086 0.63 (0.22-1.83) 0.395
Tumor grade
(well, moderate vs poor)
1.33 (0.65-2.71) 0.435 0.93 (0.35-2.45) 0.883
Radicality of resection 
(R0 vs R1, R2)
2.63 (1.28-5.40) 0.008 2.91 (1.07-7.95) 0.037
CGA Barrett mucosa 
(positive vs negative)
3.12 (1.48-6.58) 0.003 4.21 (1.61-11.0) 0.003
a Relative Risk; b 95% Confidence Interval. c In multivariate analysis correction was carried out for the confounding variables age, gender, pTNM-
stage, tumor grade, radicality of resection and CGA immunoreactivity in the tumors (A.), age, pTNM-stage, tumor grade, radicality resection and 
CGA immunoreactivity in Barrett’s mucosa (B.), variables are mentioned in the column ‘Confounding Variables’.
DISCUSSION
Our study, which showed that the presence of NE cells in GEJ tumors did not correlate with 
5-year survival rate, is in concordance with the results reported by Hamilton et al. They inves-
tigated the expression of CGA in 52 patients with adenocarcinomas of the esophagus and did 
not find a correlation with survival 23. We also confirm their findings of CGA positive Barrett’s 
mucosas with adjacent CGA negative tumors (namely in 38% of their tumors and in 47% 
of our tumors). Obviously neuroendocrine differentiation common disappears in invasive 
adenocarcinomas. We likewise observed NE cells more often in Barrett’s mucosa without dys-
plasia or with low grade dysplasia than in high grade dysplastic Barrett’s mucosas, although 
this difference lacked statistical significance. Hamilton et al. found expression of CGA in 62% 
(21/34) of the Barrett’s mucosas, as compared to our finding of 68% (38/56). In our study 
patients with CGA positive Barrett’s mucosa had a better survival rate than patients with CGA 
negative Barrett’s mucosa. Our study differs from the study of Hamilton et al. in several ways. 
The monoclonal CGA antibody we used differs from the antibody used by Hamilton et al. Our 
study encompasses 208 patients versus 52 patients in the study of Hamilton et al. Finally, their 
population contained 37 of 52 patients who underwent preoperative therapy, compared to 
19 of our 208 patients, and this might influence CGA staining. However, when the 19 pa-
tients that received preoperative therapy were left out from the analyses, our results did not 
change. Moreover, Shia et al. suggested that the increased endocrine differentiation shown in 
rectal adenocarcinomas treated by chemo(radio)therapy could be related to therapy induced 
cytotoxity which is in contrast with the lower percentage of CGA positive patients although 
higher percentage of pretreated patients in the study of Hamilton et al. as compared to our 
study 25. Since adenocarcinomas of the distal esophagus and the gastric cardia are regarded 
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as one clinical entity by some authors 26,27, we investigated the expression of NE markers in 
adenocarcinomas of the GEJ whereas in the study of Hamilton et al. only esophageal adeno-
carcinomas were included. Because the prevalence of NE differentiation in our series was 
about the same in esophageal and cardia adenocarcinomas, the different results cannot be 
ascribed to the fact that in our study cardia adenocarcinomas were included. 
Several studies concerning colorectal carcinomas showed that the presence of CGA positive 
cells does not influence prognosis 14-19, whereas other studies indicate that CGA expression 
in tumor cells might distinguish a subgroup of colorectal carcinomas with poorer prognosis 
10-12,21. Swatek and Chibowski reported that endocrine cells were significantly more frequent 
in less advanced and better differentiated colorectal carcinomas, using immunostaining for 
CGA 13. Two other studies showed a significantly better survival in patients with NE expression 
in pancreatic cancer and non small cell lung cancer 28,29. 
In the current study we demonstrated that CGA expression in Barrett’s mucosa adjacent to 
the tumor is an independent predictor of improved survival after surgery for GEJ adenocar-
cinomas. To our knowledge this is the first example that in the concurrent presence of a pre-
malignant lesion and a carcinoma a characteristic of the premalignant lesion has prognostic 
significance. An explanation for this finding remains obscure. The presence of NE cells in 
Barrett’s epithelium has been described by several authors 30-34, suggesting that it arises from 
a multipotent gastrointestinal stem cell probably responsible for the risk of adenocarcinoma 
31,34. Smith and Haggitt have described 4 explanations for the presence of NE cells in non-
carcinoid adenocarcinomas of the gastrointestinal tract 14: 1) entrapment of normal NE cells 
within the malignant tumor; 2) benign proliferation of NE cells within a malignant population 
of intestinal cells; 3) malignant transformation of 2 distinct stem cell lines (1 neuroendocrine 
and 1 endodermal); and 4) malignant transformation of 1 stem cell line capable of both en-
dodermal and neuroendocrine differentiation. The last hypothesis has found support from 
several studies 20,35, including that by De Bruïne et al., who demonstrated mucin and CGA 
expression in the colorectal cell line H716 36. 
Since NE cells comprise an integral part of the intestinal epithelium, the presence of NE cells 
in Barrett’s mucosa can be the mere result of the intestinal type differentiation. However, 
additional factors in NE differentiation can be involved. Duodeno-gastro-esophageal reflux 
is known to be a risk factor for the development of Barrett’s mucosa. Reflux disease is often 
treated by acid-suppressive therapy. Sanduleanu et al. found that serum CGA increases dur-
ing profound gastric acid inhibition 37. Furthermore, Helicobacter pylori infection was associ-
ated with higher serum CGA levels 37. It should therefore be addressed that both long-term 
acid-suppressive therapy and Helicobacter pylori status might play a role in CGA expression 
in Barrett’s mucosa and adenocarcinomas of the GEJ. Unfortunately, we were not able to ob-
tain reliable information on previous acid-suppressive therapy or Helicobacter pylori status 
in our patient population. 
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Colombo et al. investigated the effect of CGA on neoplastic growth and morphogenesis by 
use of mouse models 38. They found slower progression of mouse mammary adenocarcinoma 
after transfection of CGA cDNA and suggested that CGA may contribute to regulate tumor 
growth in a negative manner. Given the fact that distal esophageal adenocarcinomas often 
develop from a precursor lesion, i.e. Barrett’s mucosa, being present for years already prior to 
tumor formation, we were able to investigate the significance of CGA on tumor growth in 56 
patients with Barrett available adjacent to tumor 39. CGA expression in these Barrett’s muco-
sas indeed correlated with less advanced pTNM stage and tumor grade of adjacent tumors 
as compared to Barrett related carcinomas without CGA in the precursor lesion. Furthermore, 
CGA expression in the Barrett’s mucosa came forward as an independent predictor of sur-
vival in Cox regression analysis. Future experiments focussing on transfection of CGA cDNA 
in Barrett’s metaplasia cell lines could possibly gain more insight in the role of CGA in GEJ 
adenocarcinoma development. 
In summary, the current study demonstrates NE differentiation in Barrett’s epithelium to be 
correlated with survival in patients with Barrett’s associated adenocarcinomas of the GEJ. 
CGA immunoreactivity in Barrett’s mucosa adjacent to tumor is an independent prognostic 
factor for better survival after surgery. It appears from these data, obtained in a large patient 
group, that CGA expression in Barrett’s mucosa might be helpful in the prognostic assess-
ment of patient outcome.
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ABSTRACT 
We investigated the distribution of serious comorbidity in patients with newly diagnosed 
esophageal and gastric cancer between 1993 and 2001. Our special interest was comparing 
distal esophageal and gastric cardia adenocarcinoma patients since a common origin of 
these tumors has been suggested. Data on comorbidity (previous cancers, Chronic Obstruc-
tive Pulmonary Diseases (COPD), cardiovascular and cerebrovascular diseases, hypertension, 
ulcerative digestive tract diseases, liver diseases and diabetes) were derived from a popula-
tion-based database in the Netherlands to compare risk factor profiles for 479 esophageal 
squamous cell carcinomas, 339 distal esophageal adenocarcinomas, 570 cardia adenocarci-
nomas and 1965 subcardia cancers. Comparable age and gender distribution was shown in 
distal esophageal and cardia adenocarcinoma patients. After adjustment for age and gender, 
only the prevalence of previous cancers differed between adenocarcinomas of distal esopha-
gus and cardia (more frequent in distal esophageal adenocarcinoma patients, odds ratio 
(OR)=1.84, p=0.01). Ulcerative and liver diseases were more prevalent in esophageal squa-
mous cell carcinoma patients as compared to distal esophageal adenocarcinoma patients 
(OR=1.90, p=0.02; OR=8.82, p=0.04 respectively), whereas diabetes was more prevalent in 
the latter (OR=0.56, p=0.03). Cardia adenocarcinoma patients significantly more often had 
hypertension as compared to subcardia cancer patients (OR=1.53, p=0.001), whereas the lat-
ter more often suffered from previous cancers and ulcerative diseases (OR=0.54, p=0.0009; 
OR=0.25, p< 0.0001 respectively). In terms of comorbidity at diagnosis cardia adenocarci-
noma patients resemble distal esophageal adenocarcinoma rather than gastric subcardia 
carcinoma patients with likewise equal age and gender distribution. 
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INTRODUCTION
Consistent with countries in Western Europe and the USA, the incidence of distal esopha-
geal as well as gastric cardia, i.e. gastro-esophageal junction (GEJ), adenocarcinomas in the 
Netherlands has been increasing during the last decades, especially in males 1-5. Causal fac-
tors underlying the upward trend in incidence in GEJ adenocarcinomas are not elucidated 
yet. In contrast, the incidence of squamous cell carcinoma of the esophagus has been stable 
or decreasing in males. Subcardia gastric cancer incidence has decreased since before the 
Second World War in industrialised countries, but remained the world’s second leading cause 
of cancer mortality 6. 
Although clear differences exist in risk factor profiles and epidemiological features between 
adenocarcinomas of the distal esophagus and cardia 7-11, similarities in epidemiological and 
histomorphological features as well as parallel, rising incidence rates have been shown by 
others 12-14. Gastro-esophageal reflux disease is a known risk factor for distal esophageal 
adenocarcinomas, for which Barrett’s esophagus, a columnar cell metaplasia of the native 
squamous cell epithelium, is a risk indicator 8,14,15. A subgroup of cardia carcinomas may de-
velop within short segments of intestinal metaplasia at the GEJ 14,16 although a causal role of 
gastro-esophageal reflux has been difficult to establish. Additionally, alcohol and/or tobacco 
use may confer risk for esophageal and for cardia adenocarcinomas 17-20 and they are also 
established risk factors for esophageal squamous cell carcinomas 18,21. 
Esophageal squamous cell carcinomas and distal esophageal adenocarcinomas show marked 
differences in pathogenesis, tumor biology and patient characteristics 18,22. 
Helicobacter Pylori infection plays an important role in the pathogenesis of not only per-
sistent gastritis, but also of peptic ulcers and gastric subcardia carcinomas 23. Diet rich in 
salted, smoked or poorly preserved food is another well-known risk factor for gastric cancer 
23. Gastric subcardia carcinomas are clearly distinct from cardia adenocarcinomas concerning 
epidemiology 13,19,24.
To gain more insight in variation of risk factor profiles of esophageal and gastric cancer, 
we investigated the prevalence of prognostically relevant comorbidity in newly diagnosed 
esophageal and gastric cancer patients in the South of the Netherlands.
METHODS
Study population
Data were derived from the population based Eindhoven Cancer Registry, which covers ap-
proximately 2 million inhabitants in the Southeast of the Netherlands 5. They are served by 16 
community hospitals and two large radiotherapy institutes that collaborate with the Cancer 
Registry within the framework of the Comprehensive Cancer Centre South, IKZ. Upon notifi-
Linetta BW.indd   139 08-05-2006   17:59:17
140
C
ha
pt
er
 7
cation by one of six pathological laboratories and the hospital medical records departments, 
registration clerks actively collect information (diagnosis, tumor stage, treatment, comorbi-
dity) from the medical records. The Eindhoven Cancer Registry, at the request of clinicians, has 
been collecting data on clinically relevant comorbidity for new cancer patients since 1993 25, 
according to a slightly adapted version of the list of Charlson et al. 26, Table 7.1. Information on 
comorbidity was extracted from previous admissions, letters of referral from and discharge to 
general practitioners, the medical history, current medication, and preoperative assessment. 
Cardiovascular, cerebrovascular and other vascular diseases were also included after a circu-
latory event or vascular surgery. Digestive tract diseases mainly consisted of major surgery 
for ulcerative diseases in the upper digestive tract. Previous cancers did not include basal cell 
skin cancer and cervix carcinoma in situ. 
Table 7.1 Classification of comorbidity, according to an adapted list of Charlson et al. 26
Comorbidity
Previous malignancies (except basal cell skin carcinoma and cervix carcinoma in situ)
Chronic Obstructive Pulmonary Diseases 
Cardiovascular diseases: 
  Myocardial infarction
  Heart failure
  Angina pectoris
  Intermittent claudication 
  Abdominal aneurysm
  Cardiomyopathy
  Valve prothesis (aorta or mitralis)
Cerebrovascular diseases:
  Cerebrovascular accident
  Hemiplegia
Hypertension 
Digestive tract diseases:
  Ulcerative disease (only registered since 1997)
  Patients who underwent major surgery for ulcerative disease (Billroth I or II)
  Chronic inflammatory diseases (M. Crohn, Colitis Ulcerosa except polyposis coli)
Liver disease (cirrhosis, hepatitis)
Diabetes Mellitus
Other:
  Urinary tract diseases 
  Connective tissue diseases 
  Dementia
  Chronic infections
Selection of tumors
All primary tumors of the esophagus (N=952) and stomach (N=2581) that were newly di-
agnosed between 1 January 1993 and 31 December 2001 were included in our analysis. 
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Endoscopic, radiological, surgical and pathological data (if available) were taken into con-
sideration for subsite assignment. Cancer of the esophagus was categorised into four groups 
based on the last ICD-O-3 digit: upper (codes C15.0 and C15.3), middle (C15.4), distal (C15.5) 
esophagus and other (overlapping and not otherwise specified (NOS); C15.8/9). Cancer of the 
stomach was classified: cardia (C16.0), midstomach (fundus, body or curvatures; C16.3/4/5/6 
and C16.8), antrum/pylorus (C16.1/2) and other (unspecified; C16.9). Tumors were considered 
to be cardiac when the epicentre was at the gastric cardia, defined as the area at and immedi-
ately below the gastro-esophageal junction, extending approximately 2cm downwards. Tu-
mors centred on the gastro-esophageal junction were considered to be of esophageal origin 
when Barrett’s epithelium was present and as cardiac when Barrett’s epithelium was absent, 
according to the advice of the International Union Against Cancer (UICC) 27. Tumors arising 
from the fundus or corpus of the stomach and infiltrating the gastric cardia or distal esopha-
gus were considered to be subcardiac. Esophageal tumors were classified as squamous cell 
carcinoma (codes 8050-8052 and 8047), adenocarcinoma (codes 8480-8490, 8140-8473 and 
8500-8550) and all other morphology including unspecified cases and cases without histo-
logical confirmation (NOS). Gastric carcinomas were classified as adenocarcinomas, carcino-
mas with other morphology and NOS. Esophageal carcinomas were subdivided in squamous 
cell carcinomas, adenocarcinomas of the distal esophagus and other carcinomas. Gastric 
carcinomas were subdivided in cardia adenocarcinomas and subcardia carcinomas. 
Statistical analysis
Multivariate (logistic regression) analyses, adjusted for gender and age (<55, 55-69, 70-84, 
≥85 years) were performed for risk estimation of comorbidity in the different tumor groups. 
Odds ratios (OR) and 90% confidence intervals (90% CI) were computed. 
RESULTS 
Between 1993 and 2001, 952 esophageal cancer patients and 2581 gastric cancer patients 
were diagnosed. General characteristics are shown in Table 7.2. The age and gender distribu-
tion of patients with adenocarcinomas of the distal esophagus resembled that of patients 
with gastric cardia adenocarcinomas. In general, cardiovascular diseases, hypertension and 
previous malignancies were the most common associated concomitant diseases. Five pa-
tients with digestive diseases suffered from Crohn’s disease. Below 70 years of age, 51% of 
males and 57% of females did not suffer from any serious comorbid condition, whereas this 
was true for only 29% and 42%, respectively, in the group over 70 years of age. 
Table 3 shows the distribution of the various comorbidities according to subsite, gender and 
age. A rank order according to subsite is depicted in Figure 7.1. 
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Table 7.2 Distribution of subsites and subtypes of esophageal and gastric carcinomas diagnosed from 1993 to 2001, according to gender and 
age .
Squamous cell 
carcinomas 
esophagus
Adeno-
carcinomas 
distal 
esophagus
Other esopha-
geal carcino-
masa
Adeno-
carcinomas 
gastric cardia
Subcardia 
gastric 
carcinomas
Other 
gastric 
carcinomasb
Total
Total cases 
(%)
479
(13.6)
339
(9.6)
134
(3.8)
570
(16.1)
1965
(55.6)
46
(1.3)
3533
(100)
gender 
 M
 F
 M/F ratio
307
172
1.8
264
75
3.5
78
56
1.4
434
136
3.2
1199
766
1.6
28
18
1.5
2310
1223
1.9
age (yrs)
 mean 
 range
64.2
27-97
65.8
26-95
70.1
41-94
 
65.8
30-91
70.0
25-100
67.6
35-93
68.1
25-100
a Tumors with other morphology than squamous cell (n=82) and adenocarcinomas of the upper 1/3 and middle 1/3 of the esophagus (n=52).
b Tumors of the gastric cardia with other than adenocarcinoma morphoplogy. 
Esophageal squamous cell carcinoma patients most often presented with cardiovascular 
comorbidity (mainly in males over 70 years of age) and previous cancers, which mainly 
comprised skin cancer (16 patients), head and neck cancer (13 patients), or lung cancer (13 
patients). Furthermore, hypertension (mainly elderly females), COPD (mainly in males) and 
ulcerative diseases (mainly in males) were also more common. Most obvious male prepon-
derance was shown for COPD, cardiovascular and ulcerative diseases. 
Distal esophageal adenocarcinoma patients most often presented with cardiovascular co-
morbidity (mainly in older males), hypertension (in older females and males), diabetes (main-
ly in older females and males), previous cancers, mainly comprising skin, prostate and breast 
cancer (11, 8, 5 patients) and COPD (mainly in older males). Evident male preponderance was 
shown for previous cancers, COPD, cardiovascular and ulcerative diseases.
Cardia adenocarcinoma patients presented with hypertension (mainly older females), car-
diovascular disease (mainly in older males), diabetes (mainly in older females), COPD (mainly 
older males) and previous malignancies, mainly comprising colorectal cancer (9 patients), 
skin (6 patients), prostate (5 patients) and breast cancer (5 patients). Male preponderance 
was shown for COPD and cardiovascular diseases, whereas female preponderance was shown 
for hypertension and diabetes.
Gastric subcardia carcinoma patients presented with cardiovascular comorbidity (mainly 
older males), hypertension (mainly older females), ulcerative diseases (mainly older males), 
previous malignancies consisting of skin (55 patients), colorectal cancer (39 patients), pros-
tate (33 patients) and breast cancer (31 patients) and diabetes (mainly older females). Obvi-
ous male preponderance in both cardia adenocarcinoma and subcardia cancer patients con-
cerned COPD and cardiovascular comorbidity, whereas female preponderance was shown for 
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hypertension and diabetes.
Patients with ‘other esophageal carcinomas’ consisted of 52 patients with adenocarcinomas 
in the upper or middle 1/3 of the esophagus and of 82 patients with ‘mixed type epithe-
lial carcinomas’ or ‘epithelial carcinomas, not otherwise specified’, mainly due to advanced 
disease at diagnosis with, consequently, abandoned resection. Patients with ‘other esopha-
geal carcinomas’ did not clearly resemble either squamous cell carcinoma or distal esophageal 
adenocarcinoma patients concerning comorbidity (results not shown) and were excluded for 
further analysis. Also cardia carcinomas with other morphology than adenocarcinomas were 
excluded for further analysis. 
In age and gender adjusted multivariate analysis, only previous cancers were more prevalent 
among patients with distal esophageal adenocarcinoma patients than among cardia adeno-
carcinoma patients (OR=1.84, 90% CI 1.22-1.75, Table 7.4a). 
Esophageal squamous cell cancer patients exhibited a lower male/female ratio and had a 
younger mean age in comparison with distal esophageal adenocarcinoma patients (Table 
7.2). Ulcerative diseases and liver diseases were more prevalent among patients with esopha-
geal squamous cell carcinomas than among patients with distant esophageal adenocarcino-
mas (OR=1.90, 90% CI 1.18-3.03; OR=8.82 90% CI 1.57-49.7 respectively, Table 7.4b), whereas 
patients with distal esophageal adenocarcinoma were more often diagnosed with diabetes 
(OR=0.56, 90% CI 0.36-0.87, Table 7.4b). 
Cardia adenocarcinoma patients exhibited a higher male/female ratio and had a younger 
mean age in comparison with subcardia cancer patients (Table 7.2). Previous cancers and 
ulcerative diseases were less common among patients with cardia adenocarcinomas than 
among those with gastric subcardia tumors (OR=0.54, 90% CI 0.40 -0.73; OR=0.25, 90% CI 
0.17-0.36, Table 7.4c), contrasting hypertension (OR=1.53, 90% CI 1.23-1.89, Table 7.4c). 
The prevalence of patients who suffered from both COPD and cardiovascular comorbidity, 
as an indicator of tobacco use, was equally distributed between esophageal squamous cell 
cancer patients and distal esophageal adenocarcinoma patients, between distal esophageal 
adenocarcinoma and cardia adenocarcinoma patients, and between cardia adenocarcinoma 
and gastric subcardia patients in multivariate analysis. 
DISCUSSION
We performed a population-based study of comorbidity prevalence in order to assess risk 
factor profiles of esophageal and gastric cancer. Patients with distal esophageal adenocarci-
noma and gastric cardia adenocarcinoma had the same age and gender distribution as well 
as almost comparable comorbidity patterns. A common origin of these tumors is therefore 
likely 12-14, contrasting reports that described distal esophageal adenocarcinomas and gastric 
cardia carcinomas as separate entities 10,11. Only previous cancers were more prevalent in dis-
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tal esophageal adenocarcinoma patients as compared to cardia adenocarcinoma patients. 
These previous malignancies mainly comprised skin cancer, prostate cancer and breast can-
cer in both patients groups and colorectal cancer in cardia adenocarcinoma patients. Two 
previous studies have analysed a possible common aetiology of colorectal and esophageal 
cancer and showed conflicting results 28,29. We could not establish a common aetiology be-
tween specific previous cancers and esophageal or gastric cardia cancer, since they form a 
mixed subset with consequently small patient numbers.
Adenocarcinomas of the distal esophagus versus adenocarcinomas of the gastric cardia
Ulcerative diseases were comparable prevalent in subjects with adenocarcinoma of the 
distal esophagus and subjects with gastric cardia adenocarcinoma. Lagergren et al. found a 
probable causal relationship between gastro-esophageal reflux and esophageal adenocarci-
noma, and a relatively weak relation with adenocarcinoma of the gastric cardia 8. Neverthe-
less, digestive tract diseases were even more strongly related to esophageal squamous cell 
carcinomas than to distal esophageal adenocarcinomas in our patient cohort, whatever the 
mechanism for this. 
Case-control studies report discrepant findings about nicotine and alcohol consumption 
as risk factors for the development of esophageal and cardia adenocarcinomas 17-20. COPD, 
largely resulting from nicotine abuse, may confer risk to esophageal or gastric cardia adeno-
carcinoma 30,31 through its contribution to gastro-esophageal reflux by an increased thora-
coabdominal pressure gradient during COPD exacerbation, high hiatal hernia prevalence and 
altered crural diaphragm function 31-33. Furthermore, asthma medication can worsen or cause 
reflux by relaxing the lower esophageal sphincter. However, in our study COPD prevalence 
did not differ between distal esophageal and cardia adenocarcinoma patients. 
For registration and hence comparison of GEJ adenocarcinomas careful designation of can-
cer subsite is of vital importance. The necessity to distinctly determine gastro-esophageal 
junction tumor subsite led, as a consequence, to the introduction of a separate code for 
cardia cancer in the Netherlands as early as with the 8th revision of the ICD system (1978). 
However, since no separate code for gastro-esophageal junction tumors exists, the decision 
whether a tumor originates from the distal esophagus or the true gastric cardia is difficult. In 
concordance with Wayman et al. we feel that recognition of cancers at the gastro-esophageal 
junction as distinct from other esophageal and gastric subsites might improve the use of 
cancer registration data 34. 
Esophageal squamous cell carcinomas versus adenocarcinomas of the distal esophagus
In our study, esophageal squamous cell carcinoma patients exhibited a lower male/female 
ratio and were younger than distal esophageal adenocarcinoma patients. The prevalence 
of the various comorbid conditions between these 2 patient groups differed somewhat 
less than expected, if one takes into account the marked contrasts in pathogenesis, tumor 
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biology, and patient characteristics 18,22. The presence of concomitant ulcerative diseases 
provided an increased risk for esophageal squamous cell cancer patients as compared to 
distal esophageal adenocarcinoma patients. Patients aged 70-84 years mainly accounted for 
this difference (results not shown). Also liver diseases were more prevalent in squamous cell 
carcinoma patients, albeit small patient numbers. Impaired hepatic function in squamous 
cell cancer patients may result from increased alcohol consumption, which is known to be 
an important aetiological factor for squamous cell cancer of the esophagus 18,21. In a preop-
erative risk analysis esophageal squamous cell cancer patients had considerably impaired 
liver function as well as impaired pulmonary function as compared to esophageal adeno-
carcinoma patients 35. Pulmonary comorbidity largely results from nicotine abuse, which 
is another important risk factor for squamous cell cancer 18,21. In our study COPD and also 
cardiovascular comorbidity prevalence did not differ between squamous cell carcinoma and 
distal esophageal adenocarcinoma patients. The higher prevalence of lung as well as head 
and neck cancer in esophageal squamous cell cancer patients nevertheless affirmed the 
role of alcohol and nicotine abuse in these patients. Diabetes was more prevalent in distal 
esophageal adenocarcinoma patients as compared to esophageal squamous cell carcinoma 
patients, for which the reason is not understood. One could speculate that this higher diabe-
tes prevalence might be related to a higher obesity prevalence, which is described to be a risk 
factor for distal esophageal (and cardia) adenocarcinomas 18,36.
Adenocarcinomas of the gastric cardia versus subcardia carcinomas 
In previous studies, risk factors as well as epidemiological features from cardia cancers have 
been reported to differ from subcardia cancers, which is also reflected in largely different co-
morbidity patterns in our data 13,19,24. Cardia adenocarcinoma patients presented more often 
with hypertension as compared to subcardia cancer patients, especially in the age group of 
70-84 years (results not shown). This is consistent with Zhang et al., who compared risk factors 
between esophageal plus cardia adenocarcinoma patients and distal stomach adenocarci-
noma patients, speculating on a common cause 19. Obesity, possibly related to hypertension, 
has emerged as a major risk factor for gastro-esophageal reflux disease 37 and (subsequent) 
esophageal and gastric cardia adenocarcinomas, by increasing intra-abdominal pressure 
7,18,36. The mounting evidence that obesity is associated with increased (distal esophageal as 
well as) cardia adenocarcinoma risk is supported by our finding of a higher hypertension 
prevalence in cardia adenocarcinoma as compared to subcardia adenocarcinoma patients. 
Data on body weight were unfortunately not available in our study. Moreover, nicotine and 
alcohol consumption might contribute to the development of both hypertension as to the 
development of (esophageal and) cardia cancer. Case-control studies report discrepant fin-
dings about nicotine and alcohol consumption as a risk factor for the development of car-
dia adenocarcinomas 18-20. Previous ulcerative diseases occurred more frequently in gastric 
subcardia cancer patients as compared to cardia cancer patients, mainly in the age group of 
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55-84 years (results not shown). The higher frequency of previous ulcerative diseases in sub-
cardia cancer patients might be explained by the probable carcinogenic potential of (gastric) 
ulcers and Helicobacter Pylori infections as possible underlying cause of ulcer development. 
Unfortunately, information on Helicobacter Pylori infection status in the patients was not 
available. Neither ulcer origin, whether duodenal or gastric, was recorded. In our data previ-
ous malignancies, mainly comprising skin cancers, colorectal cancers, prostate and breast 
cancers, were more common in gastric subcardia cancer as compared to cardia adenocarci-
noma patients. Patients in the age of 55-69 years mainly accounted for this difference (results 
not shown). The mechanism how these previous malignancies could confer risk for subcardia 
cancer is unclear. Moreover, as these previous malignancies form a mixed subset, it is difficult 
to speculate on a probable common origin of these cancers. As mentioned earlier, 2 previous 
studies have analysed a possible association between colorectal cancer and esophageal, but 
not gastric carcinomas 28,29. 
In conclusion, only the prevalence of previous malignancies differed between distal esopha-
geal adenocarcinoma and cardia adenocarcinoma patients, with predominance in the first 
mentioned. Esophageal squamous cell cancer patients had more ulcerative as well as liver 
diseases in comparison with distal esophageal adenocarcinoma patients, whereas diabetes 
was more common in the latter patients. Cardia adenocarcinoma patients were apparently 
different from gastric subcardia cancer patients concerning age and gender distribution 
as well as concerning previous malignancies, hypertension and ulcerative diseases. Hence, 
cardia adenocarcinoma patients resembled distal esophageal adenocarcinoma patients 
considerably more than subcardia carcinoma patients concerning comorbidity, with likewise 
equal age and gender distribution. 
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ABSTRACT
We analysed the influence of comorbidity on treatment choice and survival in patients with 
newly diagnosed esophageal and gastric cancer between 1995 and 2002. Data on comorbi-
dity (previous cancers, Chronic Obstructive Pulmonary Diseases (COPD), cardiovascular and 
cerebrovascular diseases, hypertension, ulcerative digestive tract diseases, liver diseases 
and diabetes) were derived from the population-based Eindhoven Cancer Registry for 
430 esophageal squamous cell carcinomas, 392 distal esophageal adenocarcinomas, 494 
cardia adenocarcinomas and 1708 subcardia cancers. Surgical resection with or without 
(neo)adjuvant therapy was applied in 76% of TNM stage I-III patients: in 49% of esophageal 
squamous cell carcinoma patients, 75% of distal esophageal adenocarcinoma, 83% of cardia 
adenocarcinoma and 83% of subcardia carcinoma patients. Surgery was less often applied 
in patients aged 70 years or older and in patients with ≥ 2 comorbidities at diagnosis. After 
adjustment for age, gender, tumor differentiation grade, TNM stage (I vs. II-III), tumor type, 
socio-economic status and type of hospital (non-teaching vs. teaching), the presence of ≥ 
2 comorbidities independently lessened the chance of receiving surgery (p=0.006, OR 0.6) 
and formed a negative prognostic factor in multivariable survival analysis (p=0.02, HR 1.2). 
Since there was an adjustment for TNM stage and applied therapy (surgical resection or 
palliation) within multivariable survival analysis, the dismal prognosis for patients with ≥ 2 
comorbidities at cancer diagnosis is likely to be a direct effect of the poor condition of the 
patient. Further refinement in perioperative care seems especially important in patients with 
≥ 2 comorbidities. The exact role of comorbidity in therapy decision making and prognosis 
has to be addressed in prospective studies. 
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INTRODUCTION 
Patients with esophageal or gastric carcinoma are often diagnosed at an advanced state due 
to late presentation of symptoms 1. Surgery forms the only treatment with curative intent and 
is currently the preferred treatment if the tumor is considered to be resectable without evi-
dence of distant metastases. Moreover, a patient needs to be fit enough to undergo surgery. 
Five-year overall survival after surgery is approximately 25% in esophageal and gastric cardia 
carcinoma patients and 30% in gastric carcinoma patients 2,3. Unfortunately, around 40% of 
patients present with locally advanced or metastatic disease and receive palliative instead of 
curative therapy 3,4. 
In the Netherlands, annually around 900 patients are newly diagnosed with esophageal 
cancer and 2050 with gastric cancer 5. Patient’s age and fitness might influence treatment 
outcome and, moreover, prior treatment decision making especially if comorbidity concer-
ning vital organs is present. 
The aim of this study was to analyse the influence of age and comorbidity on treatment 
choice in patients with esophageal or gastric cancer using the population-based database of 
the Eindhoven Cancer Registry. Moreover we analysed the influence of age and comorbidity 
on survival. 
PATIENTS AND METHODS
All patients newly diagnosed with esophageal or gastric cancer between 1st of January 1995 
and 31st of December 2002 in the registration area of the population-based Eindhoven Can-
cer Registry were included. This registry covers approximately 2.4 million inhabitants in the 
Southeast of the Netherlands 6. There are no university hospitals in the registry area. Infor-
mation on diagnosis, staging, treatment and comorbidity was extracted from the medical 
records by trained registrars 7. Comorbidity was recorded, according to a slightly adapted 
version of the list of Charlson et al., Table 8.1 8. 
Only patients aged 40 years or older were included (872 patients with esophageal cancer and 
2345 patients with gastric cancer). 
Endoscopic, radiological, surgical and pathological data (if available) were taken into consi-
deration for subsite assignment 9. Cancer of the esophagus was categorized into four groups 
based on the last ICD-O-3 digit: upper (codes C15.0 and C15.3), middle (C15.4), distal (C15.5) 
esophagus and other (overlapping and not otherwise specified (NOS); C15.8/9). Cancer 
of the stomach was classified as: cardia (C16.0), midstomach (fundus, body or curvatures; 
C16.3/4/5/6 and C16.8), antrum/pylorus (C16.1/2) and other (unspecified; C16.9). Tumors 
were considered to be cardiac when the epicenter was at the gastric cardia, defined as the 
area at and immediately below the gastro-esophageal junction, extending approximately 2 
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cm downwards. Tumors centered on the gastro-esophageal junction were considered to be 
of esophageal origin when Barrett’s epithelium was present and as cardiac when Barrett’s 
epithelium was absent, according to the advice of the International Union Against Cancer 
(UICC) 10. Tumors arising from the fundus or corpus of the stomach and infiltrating the gastric 
cardia or distal esophagus were considered to be subcardiac. Esophageal carcinomas were 
subdivided in squamous cell carcinomas (N=430), adenocarcinomas of the distal esophagus 
(N=392) and other carcinomas (N=50). Gastric carcinomas were subdivided in cardia adeno-
carcinomas (N=494), subcardia carcinomas (N=1708) and other carcinomas (N=143). Both 
esophageal and gastric ‘other carcinomas’ were left out for further analysis (N=193). Primary 
treatment of esophageal and gastric cancer patients was classified as surgery alone; surgery 
in combination with chemotherapy, radiotherapy, or in combination with chemotherapy and 
radiotherapy; chemotherapy alone; radiotherapy alone; chemotherapy in combination with 
radiotherapy; palliative therapy (i.e. flexible wallstent placement mostly); other therapy; and 
unknown therapy. Using the database, no discrimination could be made between neoadju-
vant or adjuvant treatment within the group of surgically treated patients. For analysis, surgi-
cally treated patients (with or without (neo)adjuvant therapy) were regarded as treated with 
curative intent (potentially curative treatment) and were compared to patients that did not 
Table 8.1. Classification of comorbidity, according to an adapted version of the list of Charlson et al. 8.
Comorbidity
Previous malignancies (except basal cell skin carcinoma and cervix carcinoma in situ)
Chronic Obstructive Pulmonary Diseases 
Cardiovascular diseases: 
  Myocardial infarction
  Heart failure
  Angina pectoris
  Intermittent claudication 
  Abdominal aneurysm
  Cardiomyopathy
  Valve prothesis (aorta or mitralis)
Cerebrovascular diseases:
  Cerebrovascular accident
  Hemiplegia
Hypertension 
Digestive tract diseases:
  Ulcerative disease (only registered since 1997)
  Patients who underwent major surgery for ulcerative disease (Billroth I or II)
  Chronic inflammatory diseases (M. Crohn, Colitis Ulcerosa except polyposis coli)
Liver disease (cirrhosis, hepatitis)
Diabetes Mellitus
Other:
  Urinary tract diseases 
  Connective tissue diseases 
  Dementia
  Chronic infections
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receive therapy or received other therapy than surgery (palliative treatment). Importantly, 
in our retrospective study, surgery in patients with TNM stage IV or unknown stage could 
well have been palliative instead of potentially curative. To overcome this problem, patients 
with TNM stage IV or unknown were excluded from the analyses regarding application of 
potentially curative treatment.
TNM stage was calculated using pathological TNM data or, in case of unresected patients, 
using clinical TNM data. 
Socio-economic status (SES) of the patients was defined at neighbourhood level (based on 
postal code of residence area, 17 households on average) combining mean household in-
come (in 1998) and mean value of the house/apartment (in 2000), derived from individual 
fiscal data made available at an aggregated level. Postal codes were assigned to 3 SES catego-
ries: low (1st-3rd decile), intermediate (4th-7th decile), and high (8th-10th decile). Postal codes of 
institutions, such as nursing homes, were assigned to a separate category and left out of the 
analysis (198 patients, mentioned as unknown in Table 8.2). Another 39 patients had missing 
SES data and were left out of the analysis. 
Type of hospital was defined as non-teaching hospital or teaching hospital. 
For each tumor type the applied treatment was analysed, according to number of comorbid 
conditions and age (<70, 70+ years). Differences between groups were determined using the 
chi-square test. Logistic regression was applied to determine the independent effects of age, 
gender, tumor type, tumor differentiation grade, TNM-stage, SES, type of hospital and number 
of comorbid conditions on the application of curative treatment. Survival time was defined 
as the time from diagnosis until death (any cause). Vital status of all patients on January 1st, 
2005 was assessed through merging with the database of the Central Bureau for Genealogy, 
that collects data on all deceased Dutch citizens via the civil municipal registries. In this way, 
information on patients who moved outside the registry area was also obtained. Crude sur-
vival rates were calculated according to age, gender, tumor type, tumor differentiation grade, 
TNM-stage, SES, applied treatment, type of hospital and comorbidity. In a multivariable Cox’s 
proportional hazard regression analysis, independent hazard ratios (HR) were estimated for the 
variables mentioned, with either number of comorbid conditions, type of comorbid conditions 
or combinations of comorbidities (separate models). Patients with TNM stage IV or unknown 
were excluded from the analysis (N=1707). In order to analyse whether ‘applied treatment’ in-
fluenced differences in survival within age categories or within comorbidity categories, the 
model was first run without this variable. The SAS computer package (version 8.2) was used for 
all statistical analyses (SAS Institute Inc., Cary, North Carolina, USA, 1999). 
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Table 8.2. Distribution of gender, age, comorbidity, TNM-stage and tumor differentiation grade according to subsites and subtypes of esophageal and 
gastric carcinomas diagnosed from 1995 to 2002. 
Squamous cell 
carcinomas 
Adenocarcinomas distal 
esophagus
Adenocarcinomas gastric 
cardia
Subcardia gastric 
carcinomas
Total cases (%) 430 (14) 392 (13) 494 (16) 1708 (57)
Age (yrs)
 median 
 range
65
40-97
67
40-95
66
40-91
71
40-100 
Gender M
 F
 M/F ratio
275
155
1.8
317
75
4.2
375
119
3.2
1040
668
1.6
Concomitant disease (% within type)a
 No comorbidity 152 (35) 138 (35) 202 (40) 522 (30)
 Previous cancers 59 (14) 48 (12) 32 (6) 236 (14)
 COPD 56 (13) 56 (14) 53 (11) 174 (10)
 Cardiovascular 77 (18) 80 (20) 104 (20) 404 (24)
 Cerebrovascular 19 (4) 15 (4) 21 (4) 92 (5)
 Hypertension 69 (16) 67 (17) 94 (19) 300 (18)
 Ulcerative 
 digestive diseases
36 (8) 30 (8) 26 (5) 265 (16)
 Liver diseases 10 (2) 1 (0.3) 3 (0.6) 7 (0.4)
 Diabetes 
 Unknown
25 (6)
40 (9)
44 (11)
29 (7)
46 (9)
40 (8)
189 (11)
160 (9)
Number of comorbidities
 0 152 (35) 138 (35) 202 (40) 522 (30)
 1 126 (29) 121 (31) 132 (26) 527 (30)
 ≥2
 Unknown
111 (26)
40 (9)
104 (26)
29 (7)
126 (25)
40 (8)
522 (30)
160 (9)
TNM-stage
 I   23 (5)   23 (6) 54 (11) 325 (19)
 II 67 (16) 58 (15) 75 (15) 267 (16)
 III 89 (21) 60 (15) 76 (15) 200 (12)
 IV
 Unknown 
99 (23)
152 (35)
131 (33)
120 (31)
171(35)
118 (24)
540 (32)
376 (22)
Differentiation grade
 Well 27 (6) 22 (6) 23 (5) 55 (3)
 Moderate 180(42) 113 (29) 161 (33) 412 (24)
 Poor
 Unknown
140 (33)
83 (19)
165 (42)
92 (23)
240 (49)
70 (14)
940 (55)
301 (18)
Social Economic Status
 Low 136 (32) 101 (26) 135 (27) 568 (33)
 Intermediate 148 (34) 150(38) 200 (40) 590 (35)
 High 110 (26) 111 (28) 131 (27) 384 (22)
 Unknown 33 (8) 30 (8) 28 (5) 146 (10)
Therapy
 Surgeryb 97 (23) 116 (30) 185 (37) 885 (52)
 No surgeryc 327 (76) 271 (69) 301 (61) 799 (47)
 Unknown 6 (1) 5 (1) 8 (2) 24 (1)
Hospital
 Non-teaching 305 (71) 281 (72) 375 (76) 1266 (74)
 Teaching 125 (29) 111 (128) 119 (24) 442 (26)
a More concomitant diseases per patient possible. b Surgery with or without neoadjuvant or adjuvant therapy; c palliative therapy included 
chemotherapy and or radiotherapy, stent placement or no therapy.
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RESULTS
General characteristics of the patients are shown in Table 8.2. Median age was 69 years (range 
40-100 years). The most common comorbid conditions were cardiovascular (22%), hyperten-
sion (18%), upper digestive tract ulcerative diseases (12%) and COPD (11%). Comorbidity was 
absent in 41% of patients <70 years of age and in 24% of patients 70+ years of age. Potentially 
curative treatment (i.e. surgery with or without (neo)adjuvant therapy) within patients stage 
I-III was offered to 76% of patients: 49% of squamous cell carcinoma patients, 75% of distal 
esophageal adenocarcinoma patients, 83% of cardia adenocarcinoma patients and 83% of 
subcardia gastric carcinoma patients. Surgery was applied less often in patients aged 70+ as 
compared to patients aged <70 concerning squamous cell and distal esophageal adenocarci-
noma patients (Table 8.3). Within distal esophageal adenocarcinoma patients aged 70+ years 
the application of surgery was significantly decreased with increasing number of comorbidi-
ties (Table 8.3). 
Surgical therapy was applied to 5% of squamous cell carcinoma patients, 4% of distal esopha-
geal adenocarcinoma patients, 6% of cardia adenocarcinoma patients and 16% of subcardia 
gastric carcinoma patients with TNM stage IV tumors, which can explained by the possible 
application of palliative instead of curative surgery (bypass to ensure food passage) or to the 
fact that pathological TNM data instead of clinical data were analysed (‘upstaging’). Upstag-
ing was however seen in only 48 patients out of the total group. In logistic regression analysis 
with adjustment for age, gender, tumor type, tumor differentiation grade, TNM stage, SES and 
type of hospital the presence of 2 or more comorbid conditions was significantly associated 
with a lower probability of receiving curative treatment (p=0.006, OR 0.6, Table 8.4). When the 
different types of comorbid conditions (i.e. previous cancer, COPD, cardiovascular disease, 
cerebrovascular disease, hypertension, ulcerative disease, liver disease, diabetes) were en-
tered into the multivariable models (instead of the number of comorbid conditions; a sepa-
rate model for each condition), no specific comorbid condition came forward that conferred 
a lower chance for receiving curative treatment. Concerning combinations of comorbidity, 
three most common combinations were analysed in separate multivariate models (hyperten-
sion and diabetes n=19, cardiovascular and hypertension n=42, cardiovascular and COPD 
n=19). The combination hypertension and diabetes conferred a lower chance for receiving 
curative treatment (p=0.049, HR 0.3, data not shown). The combination cardiovascular and 
hypertension as well as cardiovascular and COPD did not show an effect. Apart from comor-
bidity also age, TNM-stage, tumor differentiation grade and tumor type were independently 
correlated with administration of curative treatment with lowest chance for squamous cell 
carcinoma patients and increasing chances for distal oesophageal adenocarcinoma, cardia 
adenocarcinoma and subcardia cancer patients (as compared to squamous cell carcinoma 
patients, Table 8.4).
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One-month, 6-month, 1-year and 5-year survival rates are denoted for separate patient 
groups (Table 8.5). In multivariable Cox proportional-hazard analysis within TNM stage I-III 
patients, the presence of ≥ 2 comorbidities came forward as an independent prognostic fac-
tor for overall survival (Table 8.5). When the different types of comorbid conditions (i.e. previ-
ous cancer, COPD, cardiovascular disease, cerebrovascular disease, hypertension, ulcerative 
disease, liver disease, diabetes) were entered into the multivariable model instead of the 
number of comorbid conditions (a separate model for each condition), no specific condition 
came forward to confer an independent prognostic role. Three most common combinations 
of comorbidities were analysed in separate multivariable models but did not come forward 
Table 8.3. Application of surgical therapy according to tumor type, age group and number of comorbidities among patients with stage I, II or III 
esophageal or gastric carcinoma.
Application of surgerya <70 years (%)b 70+ years (%)b p-valuec
Squamous cell carcinomas esophagus
Number of comorbidities
0 36 (30) 4 (15) 0.096
1 23 (32) 5 (9) 0.003
≥2 14 (24) 5 (9) 0.04
p-valuec 0.6 0.8
Adenocarcinomas distal esophagus
Number of comorbidities
0 37 (39) 8 (20) 0.02
1 30 (45) 15 (27) 0.03
≥2 13 (33) 3 (5) 0.0002
p-valuec 0.4 0.005
Adenocarcinomas gastric cardia
Number of comorbidities
0 56 (88) 15 (79) 0.4
1 34 (83) 13 (76) 0.6
≥2 18 (75) 21 (72) 0.8
p-valuec 0.4 0.9
Subcardia gastric carcinomas
Number of comorbidities
0 126 (93) 86 (91) 0.7
1 110 (91) 111 (89) 0.6
≥2 81 (91) 140 (87) 0.3
p-valuec 0.9 0.5
a Surgery with or without neoadjuvant or adjuvant therapy. b Number of patients surgically treated out of total number of patients with specific 
number of comorbidities in specific age group; patients within categories ‘unknown’ in either group were excluded from analysis. c Linear-by-linear 
association. 
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to confer an independent prognostic role. When the model was run without ‘applied therapy’ 
as an independent variable, the presence of ≥ 2 comorbidities conferred an even stronger 
independent significant effect on overall survival (p=0.005, HR 1.3, data not shown). Apart 
from TNM-stage and tumor differentiation grade, also age 70+ and tumor type subcardia 
carcinoma came forward as independent prognostic factors (p=0.04, HR 1.2; p=0.003, HR 0.7 
respectively, data not shown). 
Table 8.4. Chance for administration of surgical treatment among patients with stage I, II or III esophageal or gastric carcinoma; logistic 
regression model including all listed variables. 
Surgerya
OR (95% CI)b p-value
Age
 <70 years 1.0 -
 70+ years 0.7 (0.5-0.98) 0.04 
Gender
 Malec 1.0 -
 Female 0.9 (0.6-1.3) 0.5
Tumor type
 Squamous cell ca esophagus c 1.0 -
 Distal esophageal adenoca 2.6 (1.5-4.6) 0.0006
 Cardia adenocarcinoma 3.8 (2.2-6.4) <0.0001
 Subcardia carcinoma 7.4 (4.6-11.8) <0.0001 
TNM-stage
 Ic 1.0
 II, III 0.3 (0.2-0.4) <0.0001
Tumor differentiation grade
 Well/moderatec 1.0 -
 Poor 1.3 (0.9-1.9) 0.2
 Unknown 0.3 (0.2-0.5) <0.0001
No. of comorbid conditions
 0c 1.0 -
 1 0.9 (0.6-1.3) 0.5
 ≥2 0.6 (0.4-0.8) 0.006
Social Economic Status
 Lowc 1.0 -
 Intermediate 0.8 (0.5-1.2) 0.3
 High 0.8 (0.5-1.2) 0.3
Hospital
 Non-teachingc 1.0 -
 Teaching 1.5 (0.99-2.2) 0.06
a Surgery with or without neoadjuvant or adjuvant therapy (whereas non-surgical therapy included: chemotherapy and or radiotherapy, stent 
placement or no therapy). b Odds Ratio with 95% Confidence Interval. c Reference category. 
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DISCUSSION
A surgical resection is currently the preferred treatment for esophageal and gastric cancer if 
the tumor is considered to be resectable without evidence of distant metastases (TNM stage 
I-III). Moreover a patient needs to be fit enough to undergo surgery. Intuitively, presence of 
comorbidities as well as increasing age might be associated with worse outcome of esopha-
gectomy as well as gastrectomy. Curative therapy might be applied less often because of a 
subjective perception about life expectancy and ability to tolerate treatment. In this retro-
spective series from the area of the Eindhoven Cancer Registry 76% of patients with TNM 
stage I-III carcinomas received surgery. Within logistic regression analysis restricted to TNM 
stage I-III patients, age 70+ years as compared to age ≤ 70 significantly lowered the chance 
for application of curative treatment. Also the presence of ≥ 2 comorbidities clearly altered 
the chance for receiving curative therapy in multivariable analysis. 
In retrospect, intuitions on possible worse outcome after surgery in elderly patients and in 
patients suffering from comorbidity seemed to be followed indeed. Only 49% of TNM stage 
I-III squamous cell carcinoma patients received surgery. Percentages for distal esophageal 
adenocarcinoma, cardia adenocarcinoma and subcardia carcinoma patients were 75%, 83% 
and 83% respectively. The question is whether this is good clinical practice, i.e. whether a 
higher percentage of patients should have received surgery instead of palliation. To answer 
this question, one might wonder whether decreased prognosis in palliatively treated patients 
is due to comorbidity or due to less aggressive treatment. In multivariable Cox proportional-
hazard analysis restricted to TNM stage I-III patients, the presence of ≥ 2 comorbidities came 
forward as an independent prognostic factor. Since there was an adjustment for stage and 
applied therapy the dismal prognosis of patients with ≥ 2 comorbidities is likely an effect of 
the poor condition of the patient. Given the increasing age of the population and parallel 
increasing comorbidity and given the rising incidence of distal esophageal as well as cardia 
adenocarcinoma, weighing of risk becomes more and more important in clinical decision-
making. Application of a tailor made therapy approach might be indicated to augment the 
patient’s prognosis. 
In the literature, a composite scoring system has been described with data on cardiovascular, 
pulmonary, hepatic and renal function as well as alcohol drinking habits and willingness to 
undergo major surgery 11,12. Strict application of this scoring system led to a marked reduc-
tion of postoperative mortality after esophagectomy 11,13. Data on comorbidity might add to 
data on detailed organ function in preoperative ‘fitness’ assessment. 
Within a retrospective study in a tertiary medical center, comorbidity, as defined by the 
Charlson comorbidity index score, was univariately associated with increased mortality after 
esophagectomy, which effect disappeared in multivariable analysis 14. In two recently per-
formed studies concerning gastric cancer surgery in elderly patients, comorbidity not only 
was an independent prognostic factor for survival (Charlson index) but also formed a fre-
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quent cause of death during follow-up 15,16. Studies from the surgical literature on outcomes 
from colorectal carcinoma and from primary non-small cell lung cancer suggested that co-
morbidity, more than age, was a significant predictor for mortality 17,18. 
Our data showed that the presence of ≥ 2 comorbidities had not only an effect on treatment 
choice, but also had an independent prognostic effect on overall survival. No specific type 
of comorbidity came forward (i.e. previous cancers, COPD, cardiovascular or cerebrovascular 
diseases, hypertension, ulcerative digestive tract diseases, liver diseases or diabetes) to con-
fer a significant independent effect. Although patients with the combination of hyperten-
sion and diabetes at diagnosis had a independently lower chance for receiving surgery, this 
combination was not associated with worse survival in Cox proportional hazard analyses. 
Two other investigated combinations of comorbidity (cardiovascular and hypertension, 
cardiovascular and COPD) also did not confer significancy concerning survival. Noteworthy, 
patient numbers were very small. Multiple comorbidities in gastric cancer patients aged 80+ 
years involved much higher operative mortality in a retrospective study from Italy, however 
the presence of postoperative complications nor the number of comorbidities significantly 
influenced 5-year survival rate of curatively resected patients 19. 
Concerning age, previous single-institution retrospective studies demonstrated that esopha-
gectomy can be performed as safely in elderly patients as in younger patients with compa-
rable long term survival 16,20-23. Also surgery for gastric carcinoma has been reported to be 
relatively safe in patients aged 70+ years with survival that is comparable to younger patients 
24. In our multivariable survival analysis age 70+ years showed a trend to worse survival al-
though not significant. 
Limitations of our study exist in its retrospective nature. Some desirable information was 
not available, for instance data on performance status, scheme of (neo)adjuvant therapy and 
details about applied surgical technique. The Charlson’s list was used to score prognostic 
comorbidity, without subdivision according to severity, because this was too complex for 
the registrars 25. Misclassification of comorbidity is limited, because the comorbid diseases 
are recorded routinely by trained registry personnel and data are collected directly from the 
medical records of the patients, which is considered to be the most reliable source for co-
morbidity 26. 
The fact that only 49% of squamous cell carcinoma patients received surgery as compared 
to 75% of distal esophageal adenocarcinomas, 83% of cardia carcinoma patients and 83% 
of subcardia carcinoma patients is reflected in univariable survival analysis with large diffe-
rences in survival between tumor types. Within the multivariable analysis tumor type was 
not shown to be an independent prognostic factor which is in accordance with studies 
comparing squamous cell and adenocarcinomas of the esophagus 27,28. This observation 
is in contrast with studies that show a markedly better prognosis for resected esophageal 
adenocarcinoma as compared to squamous cell carcinoma 29,30. In the studies mentioned no 
adjustment was however applied for comorbidity.
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We found a limited effect of socioeconomic status on choice of treatment or on overall sur-
vival in our population-based database, which did not change when a division was made 
between patients aged >70 and 70+ years. This is in contrast with Trivers and coworkers who 
found low income to be associated with shorter survival in esophageal and gastric cancer 
patients with exception of subcardia cancers 31. The impact of socioeconomic status is most 
pronounced for cancers with relatively good survival, probably reflecting variations in access 
to quality health care 32,33. 
In summary, this population-based study confirmed that surgery was applied less often in 
esophageal and gastric cancer patients (TNM stage I-III) than would be expected based on 
their TNM stage. This was most pronounced for esophageal squamous cell carcinoma pa-
tients and, to less extent, for distal esophageal adenocarcinoma patients. In retrospect, age 
70+ years as well as presence of ≥ 2 comorbidities independently influenced chances for 
receiving surgery. No specific type of comorbidity came forward to confer this effect, unless 
the combination of hypertension and diabetes which independently lowered the chance for 
receiving surgery although patient numbers were small. The presence of ≥ 2 comorbidities 
was independently associated with worse survival, after adjustment for therapy. The balance 
between outcome of surgery on the one hand and the risk of withholding higher-risk patients 
any prospect of cure by not performing surgery on the other hand is a difficult dilemma for 
upper gastrointestinal surgeons. Further refinement in perioperative care seems especially 
important in patients with ≥ 2 comorbidities. The exact role of comorbidity in therapy deci-
sion making and prognosis has to be addressed in future prospective studies. 
ACKNOWLEDGMENTS
We thank the registration team of the Eindhoven Cancer Registry for their dedicated data 
collection.
Linetta BW.indd   165 08-05-2006   17:59:34
166
C
ha
pt
er
 8
REFERENCES
1.  Hundahl SA, Menck HR, Mansour EG, Winchester DP: The National Cancer Data Base report on 
gastric carcinoma. Cancer 80:2333-41, 1997
2.  Wijnhoven BP, Siersema PD, Hop WC, van Dekken H, Tilanus HW: Adenocarcinomas of the dis-
tal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumor Study 
Group. Br J Surg 86:529-35, 1999
3.  Dickson JL, Cunningham D: Systemic treatment of gastric cancer. Eur J Gastroenterol Hepatol 
16:255-63, 2004
4.  Enzinger PC, Mayer RJ: Esophageal cancer. N Engl J Med 349:2241-52, 2003
5.  Visser O, Siesling SS, Dijck van JAAM (eds.). Incidence of cancer in the Netherlands 1999/2000. 
Netherlands Cancer Registry, 2003.
6.  Janssen-Heijnen MLG, Louwman WJ, van de Poll-Franse LV, Coebergh JWW (eds.). Results of 50 
years cancer registry in the South of the Netherlands: 1955-2004 (in Dutch). Eindhoven: Eind-
hoven Cancer Registry, 2005. 
7.  Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Maas HA, Coebergh JW: Prognos-
tic impact of increasing age and co-morbidity in cancer patients: a population-based approach. 
Crit Rev Oncol Hematol 55:231-40, 2005
8.  Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comor-
bidity in longitudinal studies: development and validation. J Chronic Dis 40:373-83, 1987
9.  Koppert LB, Janssen-Heijnen ML, Louwman MW, Lemmens VE, Wijnhoven BP, Tilanus HW, Coe-
bergh JW: Comparison of comorbidity prevalence in oesophageal and gastric carcinoma patients: 
a population-based study. Eur J Gastroenterol Hepatol 16:681-688, 2004
10.  Wittekind C HD, Hutter RVP, Sobin LH. TNM Supplement. A Commentary on Uniform Use, 2nd ed. 
2001.
11. Bartels H, Stein HJ, Siewert JR: Preoperative risk analysis and postoperative mortality of 
oesophagectomy for resectable oesophageal cancer. Br J Surg 85:840-4, 1998
12. Bartels H, Stein HJ, Siewert JR: Risk analysis in esophageal surgery. Recent Results Cancer Res 
155:89-96, 2000
13. Stein HJ, Brucher BL, Sendler A, Siewert JR: Esophageal cancer: patient evaluation and pre-treat-
ment staging. Surg Oncol 10:103-11, 2001
14. Atkins BZ, Shah AS, Hutcheson KA, Mangum JH, Pappas TN, Harpole DH, Jr., D’Amico TA: Reducing 
hospital morbidity and mortality following esophagectomy. Ann Thorac Surg 78:1170-6; discus-
sion 1170-6, 2004
15. Gasparini G, Inelmen EM, Enzi G, Santoro C, Sergi G, Cardin F, Terranova O: Clinical and prognostic 
aspects of gastric carcinoma in the elderly. J Gastrointest Surg 10:395-401, 2006
16. Kinugasa S, Tachibana M, Yoshimura H, Dhar DK, Shibakita M, Ohno S, Kubota H, Masunaga R, 
Nagasue N: Esophageal resection in elderly esophageal carcinoma patients: improvement in 
postoperative complications. Ann Thorac Surg 71:414-8, 2001
17. Birim O, Maat AP, Kappetein AP, van Meerbeeck JP, Damhuis RA, Bogers AJ: Validation of the 
Charlson comorbidity index in patients with operated primary non-small cell lung cancer. Eur J 
Cardiothorac Surg 23:30-4, 2003
18. Lemmens VE, Janssen-Heijnen ML, Verheij CD, Houterman S, Repelaer van Driel OJ, Coebergh JW: 
Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal 
cancer. Br J Surg 92:615-23, 2005
19. Roviello F, Marrelli D, De Stefano A, Messano A, Pinto E, Carli A: Complications after surgery for 
gastric cancer in patients aged 80 years and over. Jpn J Clin Oncol 28:116-22, 1998
20. Poon RT, Law SY, Chu KM, Branicki FJ, Wong J: Esophagectomy for carcinoma of the esophagus in 
the elderly: results of current surgical management. Ann Surg 227:357-64, 1998
21. Ellis FH, Jr., Williamson WA, Heatley GJ: Cancer of the esophagus and cardia: does age influence 
treatment selection and surgical outcomes? J Am Coll Surg 187:345-51, 1998
22. Jougon JB, Ballester M, Duffy J, Dubrez J, Delaisement C, Velly JF, Couraud L: Esophagectomy for 
cancer in the patient aged 70 years and older. Ann Thorac Surg 63:1423-7, 1997
23. Sabel MS, Smith JL, Nava HR, Mollen K, Douglass HO, Gibbs JF: Esophageal resection for carci-
noma in patients older than 70 years. Ann Surg Oncol 9:210-4, 2002
Linetta BW.indd   166 08-05-2006   17:59:35
Epidemiology 167
24. Schwarz RE, Karpeh MS, Brennan MF: Factors predicting hospitalization after operative treatment 
for gastric carcinoma in patients older than 70 years. J Am Coll Surg 184:9-15, 1997
25. Louwman WJ, Janssen-Heijnen ML, Houterman S, Voogd AC, van der Sangen MJ, Nieuwenhuijzen 
GA, Coebergh JW: Less extensive treatment and inferior prognosis for breast cancer patient with 
comorbidity: a population-based study. Eur J Cancer 41:779-85, 2005
26. Kieszak SM, Flanders WD, Kosinski AS, Shipp CC, Karp H: A comparison of the Charlson comor-
bidity index derived from medical record data and administrative billing data. J Clin Epidemiol 
52:137-42, 1999
27. Lerut T, De Leyn P, Coosemans W, Van Raemdonck D, Scheys I, LeSaffre E: Surgical strategies in 
esophageal carcinoma with emphasis on radical lymphadenectomy. Ann Surg 216:583-90, 1992
28. Lieberman MD, Shriver CD, Bleckner S, Burt M: Carcinoma of the esophagus. Prognostic signifi-
cance of histologic type. J Thorac Cardiovasc Surg 109:130-8; discussion 139, 1995
29. Stein HJ, Siewert JR: Improved prognosis of resected esophageal cancer. World J Surg 28:520-5, 
2004
30. Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U: Histologic tumor type is an inde-
pendent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive 
resections at a single center in the Western world. Ann Surg 234:360-7; discussion 368-9, 2001
31. Trivers KF, De Roos AJ, Gammon MD, Vaughan TL, Risch HA, Olshan AF, Schoenberg JB, Mayne 
ST, Dubrow R, Stanford JL, Abrahamson P, Rotterdam H, West AB, Fraumeni JF, Chow WH: Demo-
graphic and lifestyle predictors of survival in patients with esophageal or gastric cancers. Clin 
Gastroenterol Hepatol 3:225-30, 2005
32. Kogevinas M, Porta M: Socioeconomic differences in cancer survival: a review of the evidence. 
IARC Sci Publ:177-206, 1997
33. Auvinen A, Karjalainen S: Possible explanations for social class differences in cancer patient sur-
vival. IARC Sci Publ:377-97, 1997
Linetta BW.indd   167 08-05-2006   17:59:35
Part IV
Linetta BW.indd   168 08-05-2006   17:59:36
Th
erap
y
Part IV
Linetta BW.indd   169 08-05-2006   17:59:40
Chapter 9
Linetta BW.indd   170 08-05-2006   17:59:42
Outcome of surgical treatment 
for early adenocarcinoma of the 
esophagus or gastro-esophageal 
junction
Virchows Archives, 2005 May;446(5):497-504
Marinke Westerterp
Linetta B Koppert
Christianne J Buskens
Hugo W Tilanus
Fiebo JW ten Kate
Jacques JHGM Bergman
Peter D Siersema
Herman van Dekken
Jan JB van Lanschot
Chapter 9
Linetta BW.indd   171 08-05-2006   17:59:49
172
C
ha
pt
er
 9
ABSTRACT 
To contribute to therapeutic decision making we retrospectively analysed the outcome of 
transhiatal esophagectomy in 120 patients with pathologically proven high grade dysplasia 
(HGD; n=13) or T1-adenocarcinoma (n=107) of the distal esophagus or gastro-esophageal 
junction (GEJ). Adenocarcinoma of the esophagus or GEJ has a poor prognosis. Early lesions 
(i.e. HGD or T1-carcinoma) are pre-eminently the tumors which are potentially curable. Local 
endoscopic therapies are promising treatment options for superficial lesions, however for 
deeper lesions surgical resection is considered to be the treatment of choice. Tumors were 
subdivided into six different depths of invasion (‘T1-mucosal’ m1- m3, ‘T1-submucosal’ sm1-
sm3), and the frequency of lymphatic dissemination and time to locoregional and/or distant 
recurrence were analysed. Only one of the 79 T1m1-3/sm1 tumors (1%) showed lymph node 
metastases as compared to 18 out of 41 T1sm2-3 tumors (44%). There was a significant dif-
ference in recurrence free period between T1m1-m3/sm1 versus T1sm2-sm3 tumor patients 
(p log rank < 0.0001), with 5-year recurrence free percentages of 97% and 57%, respectively. 
In multivariate analysis including age, gender, tumor differentiation grade and depth of inva-
sion, only depth of invasion (T1sm2-3 versus T1m1-m3/sm1) was an independent prognostic 
factor for recurrence free period (hazard rate=7.5, 95% CI 2.0-27.7). These data indicate that 
T1m1-m3/sm1 adenocarcinomas of esophagus or GEJ show a very low risk of lymphatic dis-
semination and are therefore eligible for local endoscopic therapy. After transhiatal surgi-
cal resection almost half of the patients with T1sm2-sm3 lesions develop recurrent disease 
within 5 years, and therefore need additional therapy to improve survival. 
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INTRODUCTION
The incidence of adenocarcinomas of the esophagus or gastro-esophageal junction is rising 
1-3. As a result of the increased awareness of the malignant potential of Barrett’s esophagus, 
the more generally applied endoscopic surveillance programmes, and the availability of 
more accurate endoscopic techniques (e.g. methylene blue staining, high resolution endos-
copy, fluorescence endoscopy, optical coherence tomography and narrow band imaging),4,5 
high grade dysplasia (HGD) and early esophageal adenocarcinoma are being diagnosed with 
increasing frequency in the Western world 6-8 . Early carcinoma is defined as a tumor limited to 
the mucosa or submucosa irrespective of the presence of lymph node metastases 9. 
Many institutions favor radical esophagectomy with lymphadenectomy as standard therapy 
for esophageal carcinoma. As this procedure is associated with substantial morbidity and 
mortality,10 the question rises if this extensive resection is also necessary in patients with early 
malignancies of the esophagus 11,12 . Presently, various techniques have been applied for the 
treatment of early esophageal carcinoma, i.e. local endoscopic, organ-preserving treatment 
modalities (e.g. endoscopic mucosal resection (EMR) or photodynamic therapy (PDT)),13-15 
limited surgical resection (e.g. Merendino operation or vagal-sparing esophagectomy)16,17 
and radical esophagectomy with or without systematic lymphadenectomy (transthoracic or 
transhiatal).
In this study we retrospectively evaluated the outcome of transhiatal esophagectomy in 120 
patients with early adenocarcinoma of the esophagus or gastro-esophageal junction. In order 
to precisely subclassify this series of early cancers we subdivided the mucosa and submucosa 
into six successive layers (m1, m2, m3, sm1, sm2, sm3), as previously has been described for 
early squamous cell carcinoma of the esophagus by the Japanese Society for Esophageal 
Diseases (1999) 18. Subsequently, we analysed whether a possible correlation between the 
depth of tumor infiltration on the one hand, and lymphatic dissemination and recurrence 
free period on the other hand, was present. 
MATERIALS AND METHODS
Patient materials
Data from all patients operated for carcinoma of the esophagus or gastro-esophageal junc-
tion (GEJ) in the Erasmus University Medical Center in Rotterdam and the Academic Medi-
cal Center at the University of Amsterdam, The Netherlands, are continuously collected in 
prospective databases since 1980 and 1993, respectively. A cancer was termed esophageal 
adenocarcinoma, if the centre was clearly situated in the distal esophagus with or without 
specialised Barrett’s epithelium. Also cancers at the GEJ in the presence of Barrett’s epithe-
lium were considered esophageal adenocarcinoma. A tumor was designated GEJ adenocar-
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cinoma, if the centre was located at the junction in the absence of Barrett’s mucosa, or if 
the centre of the tumor was seen in the proximal stomach. Between January 1980 and July 
2002, 702 patients underwent subtotal esophageal resection with proximal gastrectomy for 
HGD or adenocarcinoma in Rotterdam; between January 1993 and July 2002, 398 patients 
underwent this same procedure in Amsterdam. All patients with a pathologically proven 
HGD (n=13) or pT1 invasive adenocarcinoma (n=107), who underwent a transhiatal resec-
tion, were included in the present study. All 13 HGD lesions were situated in Barrett’s mucosa. 
The 107 pT1 carcinomas included 94 early cancers of the distal esophagus, 13 were classi-
fied as GEJ adenocarcinomas. None of the patients received (neo)adjuvant chemo- and/or 
radiotherapy.
Histopathologic assessment
The resection specimens of all included patients were reviewed by two experienced pa-
thologists (FJWtK, HvD) to determine size and location of the primary tumor, the number of 
resected and involved lymph nodes, and the radicality of resection. All tumors were graded, 
staging was performed according to the 2002 UICC TNM classification 9. The depth of tumor 
invasion was measured and subclassified based on the criteria proposed by the Japanese 
Society for Esophageal Diseases 18. High-grade dysplasia (carcinoma in situ) arising in a Bar-
rett segment was defined by the lack of obvious invasion through the basement membrane 
(HGD, m1). Intramucosal carcinoma was defined as tumor cells extending beyond the base-
ment membrane into the lamina propria (m2), or as carcinomas with deepest invasion into 
the muscularis mucosae (m3). In the presence of a double muscularis mucosae (i.e. a super-
ficial and a deep one in Barrett’s mucosa), we considered the deep one as the pre-existing 
muscularis mucosae and the superficial one as newly formed 19. Consequently, a carcinoma 
invading into the superficial, i.e. newly formed, muscularis mucosae was defined as m2 and 
invasion into the deeper (pre-existing) muscularis mucosae was defined as m3. Carcinomas 
infiltrating into the submucosa without invasion of the muscularis propria were further sub-
classified as invasion limited to the upper third (sm1), intermediate third (sm2), or lower third 
part of the submucosal layer (sm3). 
Follow-up
Patients were followed until death or until April 2003 with a median follow-up time of 44 
months (range, 1 day to 13.6 years). They were seen on a regular basis for 5 years in the outpa-
tient clinic (at 3- to 4-month intervals for the first 2 years and at 6-month intervals thereafter). 
For the present study, patients and/or their family practitioners were contacted by telephone 
to assess their current status when the patient had been discharged after 5 years. No patients 
were lost to follow-up.
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Statistical analysis
All statistical analyses were performed using the Statistical Software Package version 11.5 
(SPSS INC., Chicago, IL, USA). Recurrence free periods were calculated according to the Kap-
lan-Meier method and differences in recurrence free period were assessed using the log-rank 
test. P-values of <0.05 were considered statistically significant. The Cox regression model was 
used to analyse the independent prognostic value of different variables.
RESULTS
Pathological findings in the esophagectomy specimens
Of the 1100 patients operated upon for HGD or adenocarcinoma in both institutions, 120 pa-
tients were found to have an early lesion and underwent a transhiatal resection. There were 
103 men (85%) and 17 women (15%), with a median age of 65.4 years (range 31-83 years). 
Hundred and seven patients had an early lesion of the distal esophagus (94 adenocarcino-
mas, 13 HGD’s), in all but 2 cases associated with specialised intestinal metaplasia (Barrett’s 
epithelium). Thirteen patients had a GEJ carcinoma (including 9 gastric cardia adenocarci-
nomas). All the 13 HGD cases were associated with Barrett’s mucosa. Of the 107 invasive 
adenocarcinomas 26 were classified as well differentiated, 58 as moderately differentiated, 
whereas the remaining 23 tumors showed a poor differentiation grade.
Thirteen patients (11%) had a T1m1 tumor without clear invasion into the deeper layers 
(HGD, carcinoma in situ, Table 9.1). In 18 patients invasion was limited to the lamina propria 
(T1m2, 15%), 23 patients had the deepest tumor infiltration into the (deeper, pre-existent) 
muscularis mucosae (T1m3, 19%). In 25 patients the tumor extended into the upper third 
of the submucosal layer (T1sm1, 21%), 23 of the patients had a cancer infiltrating into the 
intermediate one-third (T1sm2, 19%), and in 18 patients the carcinoma infiltrated into the 
lower third part of the submucosal layer (T1sm3, 15%). Examples of each T1-substage are 
depicted in Figure 9.1. Of the 79 patients with T1m1-m3 or sm1 cancers, only one patient 
(T1m3) showed lymph node metastasis (1%), whereas 18 out of 41 patients with T1sm2-sm3 
tumors (44%) had lymph node metastases (Table 9.1). The 19 cases with lymph node involve-
ment included 18 distal esophageal adenocarcinomas and 1 GEJ cancer. The mean number of 
resected lymph nodes was 8.6 (range 1-40). The ratio of infiltrated to removed lymph nodes 
in these 19 pN+ cases was 0.21, the mean number of resected nodes was 10.0 (range 3-20). In 
16 patients only regional lymph node metastases were present (paraesophageal, paracardial 
and/or along the lesser curvature), in 3 patients lymph nodes at the origin of the left gastric 
artery contained metastatic tumor (M1a).
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Table 9.1 Histopathological features in 120 transhiatal esophagectomy specimens with high grade dysplasia (m1) or early invasive 
adenocarcinoma of the esophagus or gastro-esophageal junction.
T1m1 T1m2 T1m3 T1sm1 T1sm2 T1sm3 Total
Tumor characteristics (n=13) (n=18) (n=23) (n=25) (n=23) (n=18) (n=120)
Lymph node involvement
Negative 13 18 22 25 17 6 101
Positive 0 0 1 0 6 12 19
Locoregional recurrence
Absent 13 17 23 25 19 14 111
Present 0 1 0 0 4 4 9
Distant recurrence
Absent 13 18 22 24 19 13 109
Present 0 0 1 1 4 5 11
Mortality
No 13 12 18 21 12 7 83
Yes 0 6 5 4 11 11 37
Figure 9.1.  Hematoxylin-eosin stained histological sections of examples of the six different subgroups 
for depth of tumor invasion. A] T1m1,  HGD; note the newly formed Barrett-associated muscularis 
mucosae (arrow) in relation to the pre-existent muscularis mucosae. B] T1m2, a mucinous, well 
differentiated, intra-mucosal adenocarcinoma. C] T1m3,  adenocarcinoma reaches into the (pre-
existent) muscularis mucosae. D] T1sm1, a small group of tumor cells is present in the superficial 
submucosa (arrow). E] T1sm2, carcinoma can be seen in the middle part of the submucosa, surrounded 
by vessels and esophageal salivary glands. F] T1sm3, a poorly differentiated adenocarcinoma infiltrates 
the deep submucosa. A-C, 4X objective,  D-F, 2X objective. Abbreviations: HGD, high grade 
dysplasia; MP, muscularis propria; MM, muscularis mucosae; SM, submucosa; T, tumor. 
Figure 9.1. Hematoxylin-eosin stained histological sections 
of examples of the six different subgroups for depth of tumor 
invasion. A. T1m1, HGD; note the newly formed Barrett-
associated muscularis mucosae (arrow) in relation to the 
pre-existent muscularis mucosae. B. T1m2, a mucinous, well 
differentiated, intra-mucosal adenocarcinoma. C. T1m3, 
adenocarcinoma reaches into the (pre-existent) muscularis 
mucosae. D. T1sm1, a small group of tumor cells is present in 
the superficial submucosa (arrow). E. T1sm2, carcinoma can be 
seen in the middle part of the submucosa, surrounded by vessels 
and esophageal salivary glands. F. T1sm3, a poorly differentiated 
adenocarcinoma infiltrates the deep submucosa. A-C, 4X 
objective, D-F, 2X objective. Abbreviations: HGD, high grade 
dysplasia; MP, muscularis propria; MM, muscularis mucosae; SM, 
submucosa; T, tumor.
Linetta BW.indd   176 08-05-2006   17:59:51
Therapy 177
Outcome after surgical resection
In all patients microscopically complete resection (R0) of the tumor was achieved. Five pa-
tients died in the hospital (mortality = 4%). Overall, the 120 patients with early lesions had 
a 5-year disease free survival of 68%. During follow-up 37 patients died. The proportions of 
patients without recurrence, per subgroup of depth of tumor invasion, are shown in Figure 
9.2. Recurrence free period of patients with T1sm1 tumors did not differ from that of patients 
with T1m1, nor from that of patients with T1m2, or from that of patients with T1m3 tumors. 
However, recurrence free period did significantly differ from that of patients with T1sm2 and 
T1sm3 tumors (Figure 9.2). We, therefore, redefined depth of invasion into two subclasses, i.e. 
group I (T1m1, T1m2, T1m3 and T1sm1) and group II (T1sm2 and T1sm3), and subsequently 
compared recurrence free periods in both groups. A significant difference in recurrence 
free period was found between group I and group II (p logrank < 0.0001, Figure 9.3), with 
Figure 9.2.  Proportion of patients without recurrence for depth of tumor invasion subgroups T1m1, 
T1m2, T1m3, T1sm1, T1sm2 and T1sm3. Patients with T1sm1 did not differ from patients with T1m1, 
T1m2 or T1m3 (p logrank=0.5, 0.6 and 0.9, respectively), but differed from patients with T1sm2 or 
T1sm3 (p logrank=0.02 and 0.002, respectively). Tick marks represent censored patients, i.e. end of 
follow-up. 
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Figure 9.2. Proportion of patients without recurrence for depth of tumor invasion subgroups T1m1, T1m2, T1m3, T1sm1, T1sm2 and T1sm3. 
Patients with T1sm1 did not differ from patients with T1m1, T1m2 or T1m3 (p logrank=0.5, 0.6 and 0.9, respectively), but differed from patients 
with T1sm2 or T1sm3 (p logrank=0.02 and 0.002, respectively). Tick marks represent censored patients, i.e. end of follow-up.
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Figure 9.3. Proportion of patients without recurrence, T1m1, T1m2, T1m3, T1sm1 (group I, broken 
line, n=79) versus T1sm2 or T1sm3 (group II, uninterrupted line, n=41). A clear difference can be seen 
between the two groups (p logrank < 0.0001). Five-year recurrence free percentages for group I and 
group II were 97% (95% CI 93%-100%) and 57% (95% CI 40%-74%), respectively. Tick marks 
represent censored patients, i.e. end of follow-up. 
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Figure 9.3. Proportion of patients without recurrence, T1m1, T1m2, T1m3, T1sm1 (group I, broken line, n=79) versus T1sm2 or T1sm3 (group II, 
uninterrupted line, n=41). A clear difference can be seen between the two groups (p logrank < 0.0001). Five-year recurrence free percentages 
for group I and group II were 97% (95% CI 93%-100%) and 57% (95% CI 40%-74%), respectively. Tick marks represent censored patients, i.e. 
end of follow-up.
Table 9.2 Results of the Cox regression analysis, concerning recurrence free period, in the total group of 120 early carcinomas.
Prognostic factors Univariate 5 yrs recurrence 
free survival %
p-value Multivariatea
HRb (CI)c
p-value
Aged 1.0 (0.9-1.1) 0.9
Gender 
Me
F
 81
 100 .3
1.0
0.5 (0.06-3.8) 0.5
Tumor grade 
Well/Moderatee  
Poor
 87
 59 .001
1.0
2.0 (0.7-5.2) 0.2
Depth of tumor invasion
T1m1, T1m2, T1m3, T1sm1e
T1sm2, T1sm3
 97
 57 < .0001
1.0
7.5 (2.0-27.7) 0.002
a In multivariable analysis correction was carried out for the prognostic variables age, gender, tumor differentiation grade and depth of tumor 
invasio ; variables are mentioned in the column ‘Prognostic f ctors’. b Hazard Rate. c CI: 95% Confidence Interv l. d In the multivariable analysis, 
age is included as a continuous variable. e Reference category.
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5- year recurrence free percentages of 97% (95% CI 93%-100%) and 57% (95% CI 40%-74%), 
respectively. Importantly, when patients with HGD were left out of analysis, the difference 
in recurrence free period remained significant between T1m2, T1m3, T1sm1 (group I minus 
T1m1) and T1sm2, T1sm3 (group II) patients (p logrank < 0.0001), with 5-year recurrence free 
percentages of 96% (95% CI 92%-100%) and 57% (95% CI 40%-74%), respectively. Univariate 
Cox regression analysis to identify prognostic variables in the total group showed tumor dif-
ferentiation grade and depth of tumor invasion to be prognostic factors for recurrence free 
period (p = 0.001 and p < 0.0001, respectively; Table 9.2). In multivariate analysis only depth 
of tumor invasion was an independent prognostic factor (HR 7.5, 95% CI=2.0-27.7, p=0.002). 
Alternatively, when recurrence free survival instead of recurrence free period was analysed, 
the significant difference between group I (T1m1, T1m2, T1m3, T1sm1) and group II (T1sm2, 
T1sm3) remained intact (p logrank=0.0001) with 5-year recurrence free survival percentages 
of 83 % (95% CI 65%-92%) and 42% (95% CI 25%-59%), respectively. Again, when patients 
with HGD were left out of this analysis a significant difference in recurrence free survival re-
mained (p logrank=0.0008) with 5-year recurrence free survival percentages of 80% (95% CI 
68%-91%) and 42% (95% CI 25%-59%), respectively.
Table 9.3 Tumor recurrence; of the 18 patients, some patients had recurrence at more than one site.
Recurrence Number of patients
Locoregional 7
Distant 8
Bone 2
Pleural 3
Peritoneal 1
Liver 3
Truncal region 1
Both locoregional and distant
Truncal region
Bone
Supraclav lymph node
3
1
1
1
During the follow-up period 18 patients developed tumor recurrence (Table 9.3). The mean 
interval between operation and recurrence was 16 months (range 4-85 months). Seven pa-
tients died because of locoregional tumor recurrence without evidence of distant disease, 
eight patients developed only distant recurrence (of whom one patient was still alive at the 
end of follow-up), and three patients died because of both locoregional and distant recur-
rence. One patient died because of a second primary carcinoma in the lung (Table 9.4). Twelve 
out of eighteen patients, who died of locoregional recurrence and/or distant metastases, al-
ready had lymph node metastases at the time of resection. Recurrence free period differed 
significantly between patients with N0 (n=101) and N+ (n=19) tumors (p logrank < 0.0001, 
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Figure 9.4) with 5-year recurrence free percentages of 94% (95% CI 89%-99%) and 33% (95% 
CI 12%-55%), respectively.
Table 9.4 Distribution of patients at the end of follow-up.
Distribution Number of patients
In-hospital mortality 5
Intercurrent death without disease 14
Death with locoregional recurrence only 7
Death with locoregional and distant recurrence 3
Death with distant recurrence only 7
Death due to second primary cancer 1
Alive with distant recurrence 1
Alive without evidence of disease 82
TOTAL 120
Figure 9.4.  Proportion of patients without recurrence, N0 (broken line, n=101) versus N+ 
(uninterrupted line, n=19). Patients with positive lymph nodes display a strikingly higher frequency of 
recurrence (p logrank < 0.0001). Five-year recurrence free percentages for N0 and N+ patients were 
94% (95% CI 89%-99%) and 33% (95% CI 12%-55%), respectively. Tick marks represent censored 
patients, i.e. end of follow-up. 
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Figure 9.4. Proportion of patients without recurrence, N0 (broken line, n=101) versus N+ (uninterrupted line, n=19). Patients with positive 
lymph nodes display a strikingly higher frequency of recurrence (p logrank < 0.0001). Five-year recurrence free percentages for N0 and N+ 
patients were 94% (95% CI 89%-99%) and 33% (95% CI 12%-55%), respectively. Tick marks represent censored patients, i.e. end of follow-up.
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DISCUSSION
We have created a detailed map of T1-substages of early Barrett’s and GEJ cancers in relation 
to lymphatic dissemination and tumor recurrence. A favorable outcome was characterised 
by vertical tumor growth into, but not deeper than the upper layer of the submucosa. In 
contrast, cancers proliferating into the middle and deeper layers of the submucosa showed 
an unfavorable outcome with a high rate of recurrence after surgical resection. In our study 
the overall 5-year disease free survival was 68%, which is comparable to the sparse literature 
on this subject 20-23 . In the literature 5-year overall survival rates of 100% have been reported 
for T1 tumors limited to the mucosa, and rates declining to 63-100% for T1 tumors invading 
into the submucosa. 
The group of T1m1-m3/sm1 tumors had lymph node metastases in only 1% as compared to 
44% in the group of T1sm2-sm3 carcinomas. The very low frequency of lymphatic dissemina-
tion in the first group could not be attributed to the inclusion of 13 HGDs, as the recurrence 
free period did not alter by excluding them from analysis. In a previous study of our group 
the correlation between vertical cancer growth, angio-lymphatic permeation and the pre-
sence of lymph node metastasis has already been investigated. However, this concerns only 
a subset of the present cohort that was operated on with various procedures. 
The histopathological examination of endoscopically removed T1 adenocarcinomas in 
Barrett’s esophagus can be difficult due to the presence of a double muscularis mucosae 19. 
In Barrett’s esophagus the mucosa consists of columnar epithelium, a superficial lamina pro-
pria, a superficial (newly formed) muscularis mucosae, a deep (pre-existent) lamina propria 
and a deep (pre-existent) muscularis mucosae. Precise classification of T1m2, T1m3 or T1sm1 
cancer can be hampered, if there is doubt concerning the presence of the deep muscularis 
mucosae in the endomucosal resection specimen. Another, likely more important issue, is 
the correct classification of superficial tumor invasion of the submucosa in EMR specimens, 
because the deep (pre-existent) muscularis mucosae is not always a continuous structure 24. 
However, our data indicate that this probably has no therapeutic consequences, since there 
is no difference in prognosis between T1m3 and T1sm1.
The 5-year recurrence free percentage of the patients with early tumors with lymph node in-
vasion after transhiatal resection is disappointing (33%) and comparable to the prognosis of 
tumors with a more advanced T-stage and lymph node invasion 25. The potential, particularly 
of the T1sm2-sm3 tumors, for both lymphatic and hematogenous dissemination already in 
an early stage is an indication of their aggressiveness. This might justify a more radical treat-
ment, i.e. transthoracic esophagectomy with extended lymphadenectomy of the posterior 
mediastinum, upper abdomen and perhaps even the neck 26. Moreover, the unordered pat-
tern of lymphatic dissemination in esophageal cancer, resulting in the frequent presence of 
tumor cells at a relatively large distance from the primary lesion, 27 is once more a reason for 
extensive procedures. Extended resection is believed to reduce the rate of locoregional re-
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currence, thereby increasing the quality of life and prolonging the recurrence free period and 
perhaps even survival. However, a more extensive resection for patients with early carcino-
mas could only be legitimated if it leads to a higher chance for cure. The possible advantages 
should be weighed against the increased risk of postoperative morbidity and mortality, since 
these patients are exposed to the higher risk of surgical complications 28. 
To improve long term outcome, many institutes apply neoadjuvant chemoradiotherapy for 
advanced esophageal carcinoma, especially after the recent publication of favorable long 
term results of a randomized MRC-trial comparing neoadjuvant chemotherapy followed by 
surgery versus surgery alone 29. However, the poor prognosis of submucosal T1 tumors, and 
the high frequency of lymphatic dissemination indicate that these patients could also benefit 
from neoadjuvant chemoradiotherapy.
In conclusion, based on these results we suggest that the combined group of mucosal (T1m1-
m3) and superficial submucosal (T1sm1) adenocarcinomas are eligible for local endoscopic 
treatment, since they carry only a 1% risk of lymphatic dissemination in combination with 
a 5-year recurrence free period of 97%. For the T1sm2-sm3 adenocarcinoma group, which 
showed lymph node metastases in 44% and a recurrence free period of 57%, surgical re-
section should be the treatment of choice. The substantial locoregional recurrence with or 
without distant dissemination after limited transhiatal resection is an argument in favor of 
more extensive surgery, and/or neoadjuvant chemoradiation.
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ABSTRACT
Surgery has curative potential in a proportion of patients with esophageal cancer, but is asso-
ciated with considerable peri-operative risks. We aimed to develop and validate a simple risk 
score for surgical mortality that could be applied to administrative data. We analyzed 3592 
esophagectomy patient from 4 cohorts. We applied logistic regression analysis to predict 
mortality occurring within 30 days after esophagectomy for 1327 esophageal cancer patients 
over 65 years of age, diagnosed between 1991 and 1996 in the linked Surveillance, Epidemi-
ology, and End Results (SEER) - Medicare database. A simple score chart for preoperative risk 
assessment of surgical mortality was developed and validated on 3 other cohorts, including 
714 SEER-Medicare patients diagnosed between 1997 and 1999, 349 patients from a popula-
tion-based registry in the Netherlands diagnosed between 1993 and 2001, and 1202 patients 
from a referral hospital in the Netherlands diagnosed between 1980 and 2002. Surgical mor-
tality in the 4 cohorts was 11% (147/1327), 10% (74/714), 7% (25/349) and 4% (45/1202) res-
pectively. Predictive patient characteristics included age, comorbidity (cardiac, pulmonary, 
renal, hepatic, and diabetes), preoperative radiotherapy or combined chemoradiotherapy, 
and a relatively low hospital volume. At validation, the simple score showed good agreement 
of predicted risks with observed mortality rates (calibration), but low discrimination (area 
under the ROC curve 0.58 to 0.66). A simple risk score combining clinical characteristics along 
with hospital volume to predict surgical mortality after esophagectomy from administrative 
data may form a basis for risk adjustment in quality of care assessment. 
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INTRODUCTION
Surgical resection offers a chance of long-term survival in patients with esophageal cancer 
1. However, even after careful staging, survival remains disappointing with less than 25% of 
patients surviving at 5 years after esophagectomy 2. Better results may be achieved with the 
concomitant use of preoperative (neoadjuvant) chemotherapy and radiotherapy, although 
the benefits may be small 3-5. The surgical risk in the short-term and the potential loss in qua-
lity of life have to be weighed against the long-term benefit, such as a longer survival 6 7. 
Accurate prediction of surgical mortality is important not only for appropriate selection of 
candidates for esophagectomy 8, but also for evaluation of quality of care and policy de-
cisions. Risk-adjustment is particularly necessary when comparing surgical mortality rates 
between institutions 9-11. It is well known that the short-term surgical risk of esophagectomy 
varies by clinical characteristics, such as age 12 and presence of concomitant diseases (comor-
bidity) 8, 13. Further, esophagectomy is among the procedures where physician and hospital 
characteristics, especially volume, have been found to be strongly related to the surgical 
outcome 14-18. Hence, patients at higher risk may most appropriately undergo surgery at high 
volume centers 18-20.
Patient characteristics have been combined in multivariable prediction models for short-term 
mortality after esophagectomy. However, these models were often based on selected patient 
groups in specialized centers 8, 21, thus limiting the generalizability of the results. Furthermore, 
validation on new patients was often not performed, or showed unsatisfactory results 22. The 
aim of the present study was to develop a simple and robust prediction model for surgical 
mortality in esophageal cancer patients. We first analyzed several previously identified pre-
dictive characteristics in a large population-based cohort, then developed a simple risk score, 
and finally validated this score in 3 other cohorts.
METHODS
We analyzed 4 cohorts: two population-based series of 1327 and 714 patients from the linked 
Surveillance, Epidemiology, and End Results (SEER) - Medicare database 23, another popula-
tion-based series of 349 patients from the Netherlands (‘Eindhoven’) 24, and 1202 patients 
from a referral hospital in the Netherlands (‘Rotterdam’) 25, 26. The larger SEER–Medicare co-
hort served as the model development set and the other three as validation sets.
Patients: SEER-Medicare
The SEER database is made up of 11 tumor registries covering approximately 14% of the Uni-
ted States population. It has been linked to the Centers for Medicare and Medicaid services 
Medicare database through the end of 2001. We identified 2 sets of patients diagnosed with 
Linetta BW.indd   187 08-05-2006   18:00:02
188
C
ha
pt
er
 1
0
pathologically confirmed esophageal cancer. The first set (‘SEER 91-96’) included patients 
diagnosed between January 1, 1991 and December 31, 1996. It was used for development 
of the prediction model. The second set included patients diagnosed between January 1, 
1997 and December 31, 1999 (‘SEER 97-99’), for validation of the developed model. The selec-
tion criteria and definitions of variables were identical in both sets. We excluded patients for 
whom the date of death differed by more than three months between the SEER and Medicare 
database, patients who were diagnosed from death certificate or autopsy, and patients for 
whom the month of diagnosis was not available. We also excluded patients who were only 
eligible for Medicare on the basis of end-stage renal failure or disability; therefore, all patients 
were 65 years or older. 
We considered combinations of surgery, radiation, and chemotherapy 27. Surgery was identi-
fied from the Medicare database using the International Classification of Diseases, 9th revi-
sion (ICD-9 codes 42.0 to 43.99) 28. Information on radiation use was based on SEER records 
and Medicare data 29. Information on chemotherapy was based on Medicare data only 30.
Comorbidity was determined based on Medicare claims between 13 months and 1 month 
before diagnosis 31. Missing values were assigned to patients without Medicare data from 
this time window if no comorbidity was registered. Missing values were statistically imputed 
to allow for analysis of the available information from other predictors 32. Exclusion of these 
patients in a sensitivity analysis did not affect results (data not shown). ICD-9 codes of both 
inpatient and outpatient bills were analyzed 33, 34. Comorbidities were grouped as cardio-
vascular (previous myocardial infarction, heart failure, peripheral arterial disease, cerebro-
vascular disease), diabetes (with or without complications), pulmonary (COPD), renal (mild 
to severe), and hepatic (mild to severe) 8, 35. We created a simple comorbidity score based 
on the presence of cardiac, pulmonary, renal, or hepatic comorbidity, or diabetes. For simpli-
city, each comorbidity was counted as one point, based on similar regression coefficients 36. 
Patients were classified as having surgery performed in a teaching hospital versus not in a 
teaching hospital. Further hospital characteristics included the hospital volume, based on 
the sum of esophagectomies per hospital using the unique hospital provider number in the 
Medicare data 37. Low, intermediate and high volumes were defined by tertile of patients. 
Patients: Eindhoven
As a second validation cohort, we considered 349 patients who underwent surgical resection 
for a primary tumor of the esophagus, diagnosed between January 1, 1993 and December 
31, 2001 in the Southeast of the Netherlands 24. The Eindhoven Cancer Registry covers ap-
proximately 2 million inhabitants who are served by 16 community hospitals and two large 
radiotherapy institutes (16% of the Netherlands). Upon notification by one of six pathological 
laboratories and the hospital medical records departments, registration clerks actively collect 
information on diagnosis, tumor stage, treatment, and comorbidities from the medical re-
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cords. The Eindhoven Cancer Registry has been collecting detailed data on clinically relevant 
comorbidity for new cancer patients since 1993 35.
Patients: Rotterdam
As a third validation cohort, we considered 1202 patients who underwent surgical resection 
for a primary tumor of the esophagus at the University Hospital Rotterdam, between January 
1, 1980 and December 31, 2002. This hospital serves as a referral center for the Southwest of 
the Netherlands. A database system is maintained with detailed information on diagnosis, 
tumor stage, treatment, and comorbidity 25, 26. Information on hepatic and renal disease was 
not available for these patients.
Statistical analysis
Descriptive statistics were used for univariate analyses, with cells with fewer than 5 patients 
in the SEER cohorts indicated as ‘<5’. We applied logistic regression analysis to relate patient 
and treatment characteristics to mortality within 30 days after surgery. Mortality was con-
sidered irrespective of the cause. Odds ratios (ORs) were calculated with 95% confidence 
intervals (95%CI). Potential predictive characteristics were chosen from the clinical literature 
and expert opinion 38. The performance of the model was assessed with respect to calibra-
tion and discrimination 39. Calibration refers to the agreement between observed outcomes 
and predicted probabilities and is the most important quality when trying to predict the 
expected mortality rate for a group of patients. Calibration was assessed graphically, and 
tested with the Hosmer-Lemeshow goodness of fit test 40. Discrimination refers to the ability 
to distinguish patients who will die from those who will survive. Discrimination was quanti-
fied by the Area Under the Receiver Operating Characteristic Curve (AUC), which is identical 
to the concordance (c) statistic 39. An AUC of 0.5 indicates no discriminative ability at all, i.e. 
a coin flip, while an AUC of 1 indicates perfect discrimination, i.e. a test with 100% sensitivity 
and 100% specificity. Prediction models with an AUC exceeding 0.8 have often been labeled 
as good to excellent, those with AUC between 0.7 and 0.8 as moderate, and those with AUC 
between 0.6 and 0.7 as providing low discrimination. 
Multivariable models were internally and externally validated. Internal validation was per-
formed with a standard bootstrap procedure 38, 39. Bootstrap samples were drawn with re-
placement, of the same size as the original sample. Predictions from each bootstrap model 
were evaluated in the original sample. The difference in performance in the bootstrap sample 
and in the original sample quantifies the optimism that may be expected when the multi-
variable model is applied to new, but similar, patients. A score chart was derived from the 
multivariable regression coefficients. For simple application, the coefficients were multiplied 
by two and rounded. 
For external validation, we constructed logistic regression models for each cohort, containing 
the same predictors as the multivariable model based on SEER 1991-96. We studied whether 
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the predictors had similar effects. Subsequently, we derived a combined model based on all 
patient data, with stratification for study.
RESULTS
The SEER-Medicare patients were on average 73 and 74 years of age (Table 10.1). The patients 
in the Eindhoven and Rotterdam series were approximately 10 years younger on average 
(64 and 62 years respectively), since these series included patients of all ages, not just over 
65 or older. The majority of patients was male. Comorbidity was found in around 20% of the 
SEER-Medicare patients (19% and 23%, respectively, especially pulmonary (9% and 9%), car-
diovascular (9% and 9%), and diabetes (8% and 10%)). Pulmonary and cardiovascular comor-
bidities were more often registered for the Rotterdam patients (15% and 16% respectively), 
while cardiovascular comorbidity was more common in the Eindhoven patients (18%). Most 
patients had adenocarcinoma, and pathologically confirmed locoregional disease. Neoadju-
vant treatment was given in around 20% of the SEER-Medicare patients, 7% of the Eindhoven 
patients and 38% of the Rotterdam patients. Most SEER-Medicare patients were treated in 
teaching hospitals, though the annual volumes of esophagectomies were relatively small. 
This information was not reliably available for the Eindhoven patients. The Rotterdam center 
is a referral hospital with over 50 esophagectomies per year.
Of the 1317 and 714 SEER-Medicare patients undergoing surgery, 147 (11%) and 74 (10%) 
died within 30 days after surgery, respectively. Mortality was lower among the Eindhoven 
and Rotterdam patients (7% and 4% respectively).
Univariate analyses
In univariate analysis of the 1317 SEER 91-96 patients, characteristics that were statistically 
significantly associated with mortality included age and comorbidity (pulmonary, diabetes) 
(Table 10.2). Neoadjuvant treatment with radiotherapy was associated with a substantially 
higher surgical mortality risk (23%), as was neoadjuvant chemoradiotherapy (16%). In con-
trast, neoadjuvant chemotherapy alone was associated with a somewhat lower risk of mor-
tality (6%). For robust further analyses we combined the patients without any neoadjuvant 
treatment with those with neoadjuvant chemotherapy. Finally, higher hospital volume was 
clearly associated with lower surgical mortality (p-value for trend 0.003).
Similar relationships were observed in the other 3 cohorts, with higher mortality among 
older patients, those with comorbidity, and those who had neoadjuvant radiotherapy or 
chemoradiotherapy (Table 10.2).
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Table 10.1 Characteristics of patients with esophageal cancer undergoing cancer-directed surgery in 4 cohorts.
Characteristic SEER 91-96
n=1327
SEER 97-99
n=714
Eindhoven
n=349
Rotterdam
n=1202
Demographics N  % N  % N  % N  %
Age (years)
 <55
 55-64.9
 65-74.9
 75-84.9
 85+
-
-
853  64%
409  31%
65  5%
-
-
457  64%
218  31%
39  5%
74  21%
104  30%
112  32%
54  15%
5  1%
294  24%
389  32%
406  34%
110  9%
3  0%
Male gender 1002 76% 523  73% 251  72% 909  76%
Comorbidities
Pulmonary disease  
Cardiovascular disease
Diabetes
Hepatic disease
Renal disease
95/909 9%
95/1002 9%
84/998 8%
2/987 0%
5/987 1%
58/668 9%
62/667 9%
70/667 10%
2/665 0%
6/665 1%
31  9%
64  18%
28  8%
2  1%
0  0%
185  15%
195  16%
69  6%
-
-
Comorbidity count
 0
 1
 2+
1073 81%
210  16%
44  4%
553  77%
127  18%
34  5%
239  68%
95  27%
15  4%
839  70%
283  24%
80  7%
Cancer characteristics
Histology
 Adenocarcinoma
 Squamous cell 
 Mixed and other
700  53%
538  41%
89  7%
423  59%
255 36%
36 5%
258  74%
85  24%
6  2%
737  61%
429  36%
33  3%
Pathological stage
 Local/In situ
 Regional
 Distant
 Unknown 
468  35%
484  36%
152  11%
223  17%
270  38%
289  40%
87  12%
68  10%
139  40%
195  56%
12  3%
3  1%
592  49%
461  38%
138  11%
11  1%
Neoadjuvant treatment
No neoadjuvant treatment
Preoperative radiotherapy
Preoperative chemotherapy
Preoperative chemoradiotherapy
1069 81%
80  6%
49  4%
129  10%
568  80%
21  3%
13  2%
112  16%
326  93%
11  3%
0  0%
12  3%
751  62%
253  21%
167  14%
31  3%
Hospital characteristics
Teaching hospital 768  58% 443  62% - 1202 100%
Volume of hospital 
 <=1 esophagectomy /yr
 1.1–2.5 / yr
 >= 2.6 /yr
477  36%
358  27%
492  37%
198  28%
169  24%
347  49%
-
-
-
1202 100%
Outcome
30-day mortality 147  11% 74  10% 25  7% 45  4%
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Multivariable analyses
Neoadjuvant treatment remained associated with an increased risk of surgical mortality in 
multivariable logistic regression analysis of the 1317 SEER 91-96 patients, with adjusted ORs 
of 2.5 and 1.9 for radiotherapy and chemoradiotherapy respectively (Table 10.3). Comorbi-
Table 10.2 Relationships between patient characteristics and 30-day mortality after cancer- directed surgery for esophageal cancer in 4 
cohorts (univariate analyses). Mortality is shown by absolute numbers and as a percentage of patients with a characteristic. 
Characteristic SEER 91-96
147/1327 11%
SEER 97-99
74/714 11%
Eindhoven
25/349 7%
Rotterdam
45/1202 4%
Demographics N % N % N % N %
Age (years)
 <55
 55-64.9
 65-74.9
 75-84.9
 85+
-
-
84 10%
49 12%
14 22%
-
-
39 9%
31 14%
4 10%
6 8%
6 6%
9 8%
4 7%
4 1%
16 4%
20 5%
5 5%
Male gender 108 11% 59 11% 16 6% 37 4%
Comorbidities
Pulmonary disease
Cardiovascular disease
Diabetes
Hepatic disease
Renal disease
21 22%
14 15%
16 19%
-
-
3 5%
12 19%
14 20%
-
-
4 13%
3 5%
4 14%
-
-
12 6%
10 5%
5 7%
-
-
Comorbidity count
 0
 1
 2+
107 10%
28 13%
12 27%
50 9%
18 14%
6 18%
14 6%
10 11%
1 -
24 3%
16 6%
5 6%
Cancer characteristics
Histology
 Adenocarcinoma
 Squamous cell 
 Mixed and other
75 11%
66 12%
6 7%
36 9%
33 13%
5 14%
20 8%
4 5%
1 -
23 3%
22 5%
40 4%
Neoadjuvant treatment
No neoadjuvant treatment
Preoperative radiotherapy
Preoperative chemotherapy
Preoperative chemoradiotherapy
106 10%
18 23%
3 6%
20 16%
54 10%
4 19%
1 8%
15 13%
23 7%
1 -
- -
1 -
22 3%
18 7%
3 2%
2 6%
Hospital characteristics
Teaching hospital 73 10% 50 11% - -
Volume of hospital 
 <=1 esophagectomy /yr
 1.1–2.5 / yr
 >= 2.6 /yr
66 14%
42 12%
39 8%
27 14%
30 18%
17 5%
- -
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dity and age were also highly predictive, with an OR of 1.6 per comorbid condition, and an OR 
1.6 per decade of age. Higher volume hospitals exhibited close to half the mortality of lower 
volume hospitals (OR 0.59). 
The effects of age, comorbidity, and neoadjuvant therapy were very similar for the 714 SEER 
97-99 patients. For the Eindhoven patients, comorbidity was associated with a higher morta-
lity (OR 1.5 per condition), while age had no effect (OR close to 1). For the Rotterdam patients, 
predictive effects of age, comorbidity and neoadjuvant therapy were largely similar to those 
for the SEER-Medicare patients. When we combined all 4 cohorts (n=3592), the predictive 
effects were similar to those observed in the SEER 91-96 patients that were initially used for 
model development. For hospital volume, we found that mortality in ‘high volume’ centers 
was about half that in ‘low volume’ centers. For a ‘very high’ volume center such as Rotterdam 
the mortality was only a third of that in ‘low volume’ centers (Table 10.3).
Table 10.3 Multivariable logistic regression analyses in 4 cohorts. The combined data set contained 3592 patients, of whom 291 had died by 30 
days.
Characteristic SEER 91-96 SEER 97-99 Eindhoven Rotterdam Combined
Age per decade 1.6 [1.2-2.0] 1.5 [1.0-2.2] 0.94 [0.6-1.4] 1.4 [1.0-2.0] 1.4 [1.2-1.7]
Comorbidity count 1.6 [1.2-2.1] 1.3 [.91-1.9] 1.5 [0.8-2.9] 1.5 [1.0-2.3] 1.5 [1.2-1.8]
Neoadjuvant therapy
 No neoadjuvant treatment
 Radiotherapy
 Chemoradiotherapy
1
2.5 [1.4-4.4]
1.9 [1.1-3.3]
1
2.5 [0.78-8.1]
1.4 [0.74-2.7]
- 1
3.1 [1.7-5.9]
2.9 [0.7-13]
1
2.6 [1.8-3.8]
1.8 [1.3-2.7]
Volume of hospital 
 <=1 /yr
 1.1–2.5 / yr
>= 2.6 /yr
 ± 50/yr
1
0.80 [0.52-1.2]
0.59 [0.39-0.90]
1
1.5 [0.82-2.6]
0.36 [0.19-0.69]
- -
1
0.88 [0.65-1.2]
0.49 [0.35-0.70]
0.30 [0.20-0.46]*
Performance
Apparent ROC area
Score chart ROC area
0.66 [0.61-0.70]
0.65 [0.61-0.69]
0.70 [0.64-0.76]
0.66 [0.60-0.72]
0.56 [0.45-0.68]
0.58 [0.46-0.70]
0.66 [0.58-0.75]
0.66 [0.57-0.74]
0.70 [0.67-0.73]
0.70 [0.67-0.73]
* Estimate for Rotterdam, a very high volume referral center
Model performance and risk score
The multivariable model based on the 1317 SEER 91-96 patients showed low discrimination 
(AUC 0.66). Internal validation of this model indicated a slight decrease in discriminative abi-
lity (AUC 0.65). The multivariable model performed similarly in the 714 SEER 97-99 patients 
(AUC 0.70) and Rotterdam patients (AUC 0.66), but poor in the Eindhoven patients (AUC 
0.56). 
A simple chart assigned 1 point per 15 years of age, 1 point per comorbidity, 1 point for neo-
adjuvant chemoradiotherapy, and 1.5 points for radiotherapy (Table 10.4). Hospital volume 
was scored as 0, –0.5, –1.5 and –2 for low, intermediate, high and very high volume respec-
tively, based on the multivariable effects from Table 10.3. A summary score corresponds to 
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Figure 10.1 Estimated surgical mortality in relation to the sum score that can be obtained from Table 
10. 4. The 95% confidence intervals are based on analysis of 4 cohorts, containing 3592 patients 
undergoing surgery for esophageal cancer. Dot size is proportional to number of patients. 
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Figure 10.1 Estimated surgical mortality in relation to the sum score that can be obtained from Table 10. 4. The 95% confidence intervals are based 
on analysis of 4 cohorts, containing 3592 patients undergoing surgery for esophageal cancer. Dot size is proportional to number of patients.
Table 10.4 Score chart to estimate 30-day mortality after cancer-directed surgery for esophageal cancer.
Characteristic Value Score
Age (years) 50
65
80
-1
0
1
Comorbidity Pulmonary
Cardiovascular
Diabetes
Hepatic
Renal
1
1
1
1
1
Neoadjuvant therapy Radiotherapy
Chemoradiotherapy
1.5
1
Hospital volume Low (<1/ yr)
Intermediate (1.1-2.5/ yr) 
High (>2.6/yr)
Very high (±50/yr)
0
-0.5
-1.5
-2
Sum score (add scores)
Intermediate scores for age can be approximated by linear interpolation, e.g. age 72 corresponds to a score of +0.5.
The formula to calculate the predicted probability of surgical mortality is 
P(mort) = 1 / [1+exp(2.41 – 0.32 * score)].
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Figure 10.2 Calibration of predictions of 30-day mortality in 4 
cohorts. Predictions are derived from the simple score as shown in 
Table 10.4 and Figure 10.1. Results are shown for the combined data 
set (A, n=3592), SEER 91-96 (B, n=1327), SEER 97-99 (C, n=714), 
Eindhoven (E, n=349), and Rotterdam (D, n=1202).
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a predicted probability of 30-day mortality (Figure 10.1). For example, a 65-year-old patient, 
who has pulmonary and cardiovascular comorbidity, has not received neoadjuvant treat-
ment, and undergoes surgery in a low volume hospital has a score of 0 + 2 + 0 + 0 = 2 points. 
This score corresponds to a predicted mortality of 17% [95%CI 14 – 21%]. If this patient were 
to be treated in a very high volume hospital (score –2, sum score=0), the predicted mortality 
would be 7% [5.7 – 8.5%]. The performance of the risk score was similar to the original model 
for each cohort (Table 10.3).
In Figure 10.2 we show the calibration of the predictions corresponding the risk scores. Pre-
dictions were above 19% for only 5% of the patients, consistent with the low discrimination. 
Calibration was excellent for all patients combined (Fig 10.2 A), and for the 2 series of SEER 
patients (Fig 10.2 B-C). Calibration was modest for Eindhoven and reasonable for Rotterdam 
(Figures 10.2 D-E). 
DISCUSSION
Surgical mortality after esophagectomy is an important quality of care measure, but is only 
predictable to a certain extent with a limited set of patient, treatment and hospital characte-
ristics. Using data from 3 different settings we found, as expected, that age and comorbidity 
were strongly related to outcome. Also, preoperative radiotherapy and chemoradiotherapy 
were clearly associated with 30-day mortality, as was a lower hospital volume. The discrimi-
native ability of a simple risk score that combined these characteristics was however low.
Age predicts surgical risk for a wide range of procedures. For esophagectomy, one major 
study found that 30-day mortality increased from 10.7% for patients between 65 and 69 years 
of age to over 20% for those over 80 years 12. We confirmed this trend in our data, especially 
in the SEER-Medicare cohorts, where we observed a relative increase in mortality of 40% 
per decade in adjusted analysis. The presence of comorbidity is known to affect outcome in 
many cancers. A number of scoring systems have been developed to measure it, including 
the Charlson score 41 and the ACE-27 13. We used a simple count of comorbid cardiovascular, 
pulmonary, renal, hepatic conditions, and diabetes, and found that each point was on ave-
rage associated with a 50% increase in surgical risk (OR 1.5). Comorbidity scoring was claims-
based in the SEER-Medicare data, and chart-based in the other 2 cohorts. Despite these and 
other differences in definitions, the comorbidity-mortality relationship was similar across the 
4 study cohorts, in line with findings in a previous study 42.
Preoperative unimodality radiotherapy was clearly associated with higher surgical mortality. 
This treatment strategy has largely been abandoned in recent years 43, so a more relevant 
finding is that neoadjuvant chemoradiotherapy nearly doubled mortality compared to no 
neoadjuvant treatment or neoadjuvant chemotherapy alone. It is possible that these results 
may be somewhat confounded by selection of patients with more advanced tumors for 
Linetta BW.indd   196 08-05-2006   18:00:18
Therapy 197
neoadjuvant treatment. However, our findings are consistent with recent meta-analyses of 
randomized trials, showing that neoadjuvant chemoradiotherapy was associated with a 1.72 
fold higher surgical mortality (95%CI 0.96 – 3.1, p = 0.07) 3, while neoadjuvant chemotherapy 
alone was not (OR 1.08 [95%CI 0.45 – 2.6]; p=0.87) 44. This implies that part of the benefit of 
neoadjuvant chemoradiotherapy (e.g. on small metastases which would not be resected by 
surgery) may be offset by higher surgical mortality. This issue requires further detailed evalu-
ation in randomized trials. Our results suggest that measures to reduce surgical risk should 
especially be considered for patients with neoadjuvant chemoradiotherapy.
Reported surgical risks vary widely in the literature. Much of this variation can be explained 
by differences in hospital volume 14-19, 45, 46. Hospital volume remained important after adjust-
ment for case-mix, which is generally an important methodological consideration in such 
analyses of observational data 9-11. Many authors suggest that a policy of concentrating care 
in high-volume centers should be considered especially for esophagectomy, where outcome 
varies substantially between low-volume and high-volume providers 20, 47. As illustrated, a pa-
tient could have a 17% or 7% predicted mortality risk depending on surgery in a low volume 
or in a high volume center. 
Our study has some limitations. Our 4 cohorts were of considerable size, but the Eindhoven 
and Rotterdam series had only few events, which makes firm conclusions on external validity 
difficult 48. We included all patients undergoing esophagectomy. Around 10% had pathologi-
cally distant disease, and we cannot exclude that a few patients had clinically known distant 
disease before surgery. The inclusion of these patients may have led us to overestimate risk 
for patients with true locoregional disease. On the other hand, we considered 30-day mortal-
ity, and in-hospital mortality can be substantially higher. We further note that the model was 
mainly based on patients over 65 years of age; validity may be best for this patient category. 
Next, the exact limits to define low, medium and high volume centers are hard to determine. 
We used rather low annual volumes (<1, 1-2.5, >=2.6 per year), based on tertiles of patients, 
while higher limits may be better defendable. Finally, we did not have information on physio-
logic variables such as performance status or ASA score which have been used in clinical 
models 45, 49. Our risk model hence had only a low discriminative ability, and can therefore 
only be a relatively rough, though evidence-based, basis for the surgical risk of individual 
patients. Our score is easy to calculate from existing, readily available data, however, and so 
could well serve for case-mix adjustment when comparing surgical mortality rates between 
institutions.
In conclusion, we found substantial mortality after esophagectomy, which was related to 
patient, neoadjuvant therapy, and hospital characteristics. We developed and externally vali-
dated a simple risk score, which provides an admittedly rough estimate of surgical mortality 
with which to compare actual outcomes. Further validation and extension of this score is 
mandatory.
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ABSTRACT 
In response to DNA damage, the cell cycle checkpoint kinase 2 (CHEK2) may phosphorylate 
p53, Cdc25A and Cdc25C, and regulate BRCA1 function, leading to cell cycle arrest and DNA 
repair. The truncating germline mutation CHEK2*1100delC abrogates kinase activity and 
confers low-penetrance susceptibility to breast cancer. We found CHEK2*1100delC in 0.5% of 
190 esophageal squamous cell carcinomas and in 1.5% of 196 esophageal adenocarcinomas. 
In addition we observed the mutation in 3.0% of 99 Barrett’s metaplasias and 1.5% of 66 
dysplastic Barrett’s epithelia, both known precursor lesions of esophageal adenocarcinoma. 
Since CHEK2*1100delC mutation frequencies did not significantly differ among esophageal 
squamous cell carcinomas, adenocarcinomas and (dysplastic) Barrett’s epithelia as compared 
to healthy individuals, we conclude that the CHEK2*1100delC mutation has no major contri-
bution in esophageal carcinogenesis. 
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INTRODUCTION
Esophageal carcinoma is the ninth most common tumor type worldwide. Despite surgical 
intervention, 5-year overall survival is less then 20%, mainly due to the fact that patients 
often present with an advanced tumor stage. Alcohol and tobacco use are established risk 
factors for the development of esophageal squamous cell carcinomas 1. The presence of 
Barrett’s esophagus is the main risk factor for adenocarcinoma formation, being 30-125 times 
higher in patients with Barrett’s esophagus as compared to the general population. Barrett’s 
esophagus is defined as a columnar cell metaplasia of the native distal esophageal squamous 
cell epithelium 2, accompanied by the presence of Goblet cells, as a result of chronic gastro-
esophageal reflux. Barrett’s metaplasia can progress to low and high grade dysplasia and 
ultimately to invasive and metastasising adenocarcinoma. Patients with Barrett’s esopha-
gus receive endoscopic surveillance to detect dysplasia and to diagnose carcinoma at an 
early and possibly treatable stage. The identification of genes that confer susceptibility for 
adenocarcinoma formation in Barrett’s esophagus would imply improved manageability of 
patients with Barrett’s esophagus. Familial cases of esophageal cancer are however rare, and 
susceptibility genes for esophageal cancer are thus unlikely to be found by linkage analysis. 
Consequently, screening of candidate susceptibility genes may be a more feasible approach 
for esophageal cancer. 
CHEK2 (also known as CHK2) is the mammalian homologue of Saccharomyces cerevisiae 
Rad53 and Schizosaccharomyces pombe Cds1 genes 3,4. The CHEK2 gene, located on hu-
man chromosome 22q12, encodes a cell cycle checkpoint kinase that is implicated in DNA 
damage responses. Phosphorylation of the p53, Cdc25A and Cdc25C protein results in ar-
rests in various phases of the cell cycle 5,6. In addition, CHEK2 has been implicated in the 
regulation of DNA repair by the BRCA1 protein 5,6. CHEK2*1100delC is a truncating germline 
variant of CHEK2 that abrogates kinase activity 7,8 and has initially been reported in families 
suffering from the Li-Fraumeni syndrome without p53 mutations 9. In familial gastric cancers, 
which are known to cluster in Li-Fraumeni families, germline CHEK2 mutations were absent 
10. In sporadic (osteo)sarcomas, lung cancers, breast cancers, ovarian cancers, colon cancers 
and hematopoietic neoplasms, CHEK2 was found to be rarely mutated 9,11-17. From recent pu-
blications it appeared that the germline CHEK2*1100delC mutation in fact confers low-pene-
trance susceptibility to breast cancer 18,19. An increased frequency of CHEK2*1100delC was 
found among breast carcinoma families without BRCA1 or BRCA2 mutations, associated with 
an approximately twofold increase of breast cancer risk in female carriers 18. 
The p53 protein is one of the downstream targets of CHEK2 kinase. Mutations of the p53 gene 
result in a variety of disturbances in growth control involving DNA replication, DNA repair 
and apoptosis. Like in breast carcinoma, mutations of the p53 gene appear to play an im-
portant role in the development of esophageal squamous cell carcinoma, dysplastic Barrett’s 
epithelium and the progression to esophageal adenocarcinoma 20-22. Ample studies have re-
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ported mutations in p53 in esophageal carcinomas, with mutation frequencies varying from 
40-90% 23-26. As CHEK2 and p53 are thought to be participants of the same biological pathway 
we aimed to establish whether CHEK2*1100delC confers susceptibility to esophageal cancer 
by determining the frequency of the mutation among an unselected series of esophageal 
cancers and precursor lesions. 
MATERIALS AND METHODS
Tissue specimens and controls
We investigated a cohort of 190 esophageal squamous cell cancer patients, 196 esophageal 
adenocarcinoma patients, 99 patients with Barrett’s metaplasia and 66 patients with dys-
plastic Barrett’s epithelium. Tissue samples were obtained from resection specimens (car-
cinomas) or endoscopic biopsies (Barrett’s metaplasia and dysplasia), all derived from diffe-
rent patients. We microscopically confirmed that the endoscopic biopsy specimens did not 
exhibit any tumor cell invasion. Tissue fragments were digested from routine formalin-fixed, 
paraffin-embedded tissue blocks, without deparaffinization, in 180μL of 50mM/L Tris/HCl 
(pH=8.0), and 20μL of Proteinase K (20mg/μL) was added. After overnight incubation at 56°C, 
the lysates were boiled for ten minutes and subsequently centrifuged. Two series of Dutch 
control individuals consisted of (A) 184 spouses of individuals heterozygous with respect to 
cystic fibrosis from the Southwest Netherlands, and (B) 460 individuals at ages 55 and older 
ascertained through the Erasmus Rotterdam Health and the Elderly Study (ERGO) 18. 
Allele-specific oligonucleotide hybridisation assay
CHEK2 exon 10 was amplified using forward CHEK2 primer (5’-CAACATTATTCCCTTTTG-
TACTG-3’) and reverse CHEK2 primer (5’-GTTCCACATAAGGTTCTCATG-3’). DNA samples (1µL) 
were subjected to PCR analysis in a total volume of 50 µL containing 1x Promega buffer, 1.5 
mM MgCl2-solution, 4 µM dGTP, dTTP, dCTP and dATP, 3U Taq DNA polymerase (Promega, 
Madison, USA), and 0.2µg of forward and reverse CHEK2 primer. PCR amplification consisted 
of 35 cycles (95°C for 30 sec, 55°C for 45 sec and 72°C for 45 sec) followed by a final exten-
sion at 72°C for 10 minutes. We detected the CHEK2*1100delC mutation by application of 
diluted PCR products to nylon filters and hybridisation under high stringency of [32P]-labelled 
oligonucleotides complementary to CHEK2*1100delC and the wild-type sequence (5’-TTAG-
ATTATGATTTTGGG-3’ and 5’-TTAGATTACTGATTTTGG-3’ respectively). 
Polymorphic marker analysis
DNA was radioactively amplified essentially as described above, using forward primer (5’-
TAAGGTGGGAGGTTCACTTG-3’) and reverse primer (5’-ACCCATCCTCCTGCCTTAG-3’) for the 
D22S275 locus. PCR products were separated on a 6% polyacrylamide denaturing gel. After 
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electrophoresis, gels were dried on blotting paper and exposed to X-ray films. Films were 
evaluated by visual inspection.
Immunohistochemistry
From formalin-fixed paraffin-embedded tissue blocks, 4-μm thick sections were mounted 
on 3-aminopropyl-triethoxysilane (APES)-coated glass slides. The sections were incubated 
with a mouse monoclonal antibody DCS 270.1 against the human CHEK2 protein (Novocas-
tra Laboratories, Newcastle, UK; at a dilution of 1:50). Immunoreactivity was visualised by 
a standard avidin biotin immunoperoxidase technique, using a commercially available kit 
(Labvision, Fremont, USA)27,28. 
Statistics
Differences of the CHEK2*1100delC mutation frequency between patients and controls were 
expressed in terms of odds ratios (OR) and 95% confidence intervals (95% CI), and tested with 
the χ2-test.
RESULTS AND DISCUSSION
We analysed tumor and biopsy samples obtained from 551 Dutch patients by a CHEK2*1100delC 
allele-specific oligonucleotide hybridisation assay. CHEK2*1100delC mutations were detected 
in 0.5% of 190 squamous cell carcinomas, 1.5% of 196 adenocarcinomas, 3.0% of 99 Barrett’s 
metaplasias and in 1.5% of 66 dysplasias (Table 11.1). Chi-square analysis revealed no sig-
nificant differences between patient groups and the CHEK2*1100delC mutation frequency of 
1.4% among 644 control individuals (p=.94) and the Odds Ratio of the total patient group 
compared to the controls was 1.04 (95%CI 0.35-3.06, Table 11.1). These results suggest that 
CHEK2*1100delC does not substantially contribute to the development of esophageal carci-
noma. CHEK2*1100delC could still confer a three-fold risk, which is greater than the estimated 
two-fold risk associated with breast cancer and CHEK2*1100delC thus may still be a low-pene-
trance susceptibility gene to esophageal cancer. Given the low frequency of the mutation, 
however, even the maximal possible three-fold risk conferred by CHEK2*1100delC would only 
marginally contribute to the overall incidence of esophageal cancer.
Examples of the hybridisation assay are shown in Figure 11.1. Median ages of patient groups 
at diagnosis were 59.6, range 14-86 years (Barrett’s metaplasias), 60.3, range 32-84 years (dys-
plasias), 63.9, range 36-84 years (adenocarcinomas) and 60.9, range 31-79 years (squamous 
cell carcinomas). Ages at diagnosis of CHEK2*1100delC mutation carriers were 48, 73 and 77 
years (Barrett’s metaplasias), 59 years (dysplasia), 44, 50 and 63 years (adenocarcinomas) and 
73 years (squamous cell carcinoma), which was not different from non-carriers and again not 
supporting a major role of CHEK2*1100delC in esophageal cancer predisposition. 
Linetta BW.indd   207 08-05-2006   18:00:33
208
C
ha
pt
er
 1
1
All mutations were confirmed and proven to be germline-derived by investigating patients’ 
normal tissue. Only paraffin embedded samples of tumor negative lymph nodes were avai-
lable, precluding confirmation of mutations by sequencing of long range PCR products 29. The 
CHEK2*1100delC germline mutation has however been found to be linked to one specific al-
lele of the D22S275 polymorphic marker, that is located in intron 4 of CHEK2, which is present 
in 13% of the Dutch population 18. All eight mutation-positive cases were demonstrated to 
carry the D22S275 allele linked to the CHEK2 mutation, which supports the detected muta-
tions (Figure 11.2). Comparison of allele patterns in mutated tumors with their normal tis-
sues revealed LOH in only one of the three informative carcinomas (T1 without LOH in Figure 
11.2B, T4 with LOH in Figure 11.2C). LOH was also observed in three out of 14 informative 
non-mutated tumor samples. Limited data are however available on LOH of CHEK2 in tumors 
and the possible tumor suppressing role of CHEK2 therefore awaits further studies.
Table 11. 1 CHEK2*1100delC mutation frequencies.
CHEK2*1100delC mutation 
number tested carriers percentage OR (95%CI)a P-valuea
Controls
Netherlands (A)b 184 3 1.6
Netherlands (B-ERGO)b 460 6 1.3
Total 644 9 1.4
Barrett’s metaplasias 99 3 3.0 2.20 (0.38-9.04) .23
Dysplasias 66 1 1.5 1.09 (0.02-8.05) .93
Adenocarcinomas 196 3 1.5 1.10 (0.19-4.45) .89
Squamous cell carcinomas 190 1 0.5 0.37 (0.01-2.73) .33
Total 551 8 1.5 1.04 (0.35-3.06) .94
aOR: Odds Ratio, 95%CI: 95% Confidence Interval, and P-values are determined by χ2-test, as compared to frequency in controls. bCHEK2*1100delC 
frequency in Dutch control cohorts A and B by Meijers-Heijboer et al., 2002.
Figure 11.1 Allele-specific oligonucleotide hybridisation assay of 94 adenocarcinomas. Blot A, 
hybridisation with wild-type oligonucleotide. Blot B, hybridisation with mutant oligonucleotide. 
Adenocarcinoma samples T1, T2 and T3 are positive for the CHEK2*1100delC mutation, sample ‘+C’ 
represents a control indivi ual with CHEK2*1100delC, a d sampl  ‘-C’ re resents a control i dividual 
negative for CHEK2*1100delC.
Figure 11.1 Allele-specific oligonucleotide hybridisation assay of 94 adenocarcinomas. Blot A, hybridisation with wild-type oligonucleotide. Blot 
B, hybridisation with mutant oligonucleotide. Adenocarcinoma samples T1, T2 and T3 are positive for the CHEK2*1100delC mutation, sample ‘+C’ 
represents a control individual with CHEK2*1100delC, and sample ‘-C’ represents a control individual negative for CHEK2*1100delC.
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Immunohistochemistry using monoclonal antibody DCS 270.1 on a series of mutated and 
non-mutated tumor tissues showed clear nuclear staining in all cases (Figure 11.3). Since the 
DCS 270.1 epitope lies within the N-terminus of CHEK2, staining of both wild type and mutant 
protein may be expected. We observed no differences in CHEK2 protein levels, i.e. no lower 
intensity nor a lower percentage of CHEK2-positive cells, between CHEK2*1100delC mutated 
and non-mutated cancers. This was also true for the single mutated tumor with LOH (T4 in 
Figure 11.3F), suggesting that a theoretical two-fold reduction in CHEK2 protein level can not 
be detected by the applied immunohistochemistry method. This appears to contrast results of 
Vahteristo et al. who reported loss of expression in three of the four CHEK2*1100delC tumors 
and reduction of CHEK2 protein expression in the fourth, using the same antibody 19. Compari-
son of the two studies is however difficult, as they did not indicate the precise level of reduction 
in protein expression 19. Since only few CHEK2*1100delC tumors have currently been reported, 
both the data of Vahteristo et al. and the present data should be interpreted with caution. 
In summary, our study of a large and unselected series of Barrett’s metaplasias and dyspla-
sias, esophageal adenocarcinomas and squamous cell carcinomas suggests that the germline 
CHEK2*1100delC mutation has no major contribution in esophageal carcinogenesis. 
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Figure 11.2 D22S275 polymorphic marker analysis in samples with CHEK2*1100delC. A, the allele 
(arrow), known to be present in all carriers of CHEK2*1100delC (18), is present in all samples with the 
CHEK2*1100delC mutation (T1-T3 mutated adenocarcinoma samples, T4 mutated squamous cell 
carcinoma, D1 mutated dysplastic tissue, M1-M3 mutated metaplastic tissue), ‘+C’ represents a control 
individual with CHEK2*1100delC. B, C, LOH patterns from 2 mutated tumors (T1 adenocarcinoma 
and T4 squamous cell carcinoma) compared with corresponding normal tissues (N1 and N4) are 
shown. Arrowhead points to the deleted allele in T4.  
Figure 11.2 D22S275 polymorphic marker analysis in samples with CHEK2*1100delC. A, the allele (arrow), known to be present in all carriers of 
CHEK2*1100delC18, is present in all samples with the CHEK2*1100delC mutation (T1-T3 mutated adenocarcinoma samples, T4 mutated squamous 
cell carcinoma, D1 mutated dysplastic tissue, M1-M3 mutated metaplastic tissue), ‘+C’ represents a control individual with CHEK2*1100delC. B, 
C, LOH patterns from 2 mutated tumors (T1 adenocarcinoma and T4 squamous cell carcinoma) compared with corresponding normal tissues (N1 
and N4) are shown. Arrowhead points to the deleted allele in T4. 
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Figure 11.3 CHEK2 protein expression. Non-mutated squamous cell carcinoma in A, non-mutated 
adenocarcinoma in B. Remaining samples are from the 4 mutated tumors: adenocarcinomas T1, T2 and 
T3 shown in C, D, E, squamous cell carcinoma T4 shown in F. Magnification 100 x B, E 50 x A, C, D, 
F. Note: the strong nuclear CHEK2 immunoreactivity in the tumor cells. 
Figure 11.3 CHEK2 protein expression. Non-mutated squamous cell carcinoma in A, non-mutated adenocarcinoma in B. Remaining samples are 
from the 4 mutated tumors: adenocarcinomas T1, T2 and T3 shown in C, D, E, squamous cell carcinoma T4 shown in F. Magnification 100 x B, E 50 
x A, C, D, F. Note: the strong nuclear CHEK2 immunoreactivity in the tumor cells. Also see color figures page 291.
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ABSTRACT
Research has begun to identify common genetic variants, so called Single Nucleotide Poly-
morphisms (SNPs), that confer susceptibility to cancer. The aim of the present study was to 
analyse the relationship between SNPs and the susceptibility for cancer of the esophagus 
and gastro-esophageal junction (GEJ). SNPs were selected from the literature upon associa-
tion with cancer predisposition in various other types of cancer. SNPs were genotyped in DNA 
from 254 GEJ adenocarcinomas and 189 esophageal squamous cell carcinomas obtained from 
resection specimens and in a control group of 235 healthy blood donors. The SNPs in p53 
(exon 4 G72C and intron 6), Her-2/neu (exon 17 A655G), Cyclin D1 (exon 4 A870G) and STK15 
(exon 5 T31A) were genotyped by PCR-restriction fragment length polymorphism (PCR-RFLP) 
analysis. SNPs in p53 intron 3 (16 bp duplication), TGF β receptor 1*6A and E-cadherin (-347 
G/GA) were visualized on agarose gels or denaturing gels. SNPs in E-cadherin (-160 C/A), TGF 
β (-509 G/A), p16 (exon 3 C540G), p73 (exon 2 G4C14-A4T14) and PPAR γ (exon 7 C34G) were 
analysed with the Taqman allelic discrimination assay. Significant differences between cases 
and controls were validated in separate validation cohorts of 326 GEJ adenocarcinomas and 
209 squamous cell carcinomas. Subjects with the p16 exon 3 C/C genotype were at 1.5-fold 
reduced risk for squamous cell carcinoma as compared to those with C/G and G/G geno-
types. Genotype frequencies were 51% (CC), 46% (CG) and 3% (GG) as compared to 75% , 23% 
and 2% GG in controls (p<0.001). Subjects with the Cyclin D1 exon 4 A/A genotype were at 
1.3-fold reduced risk for squamous cell carcinoma as compared to the other genotypes. P73 
exon 2 GC/GC genotype conferred a 1.2-fold increased risk for adenocarcinoma whereas the 
AT/AT genotype conferred a 1.99-fold increased risk for squamous cell carcinoma. These data 
suggest that the p16 exon 3 C/C wildtype genotype and the Cyclin D1 exon 4 A/A variant 
genotype might be protective for the development of squamous cell carcinoma. The p73 
exon 2 SNP may be a genetic susceptibility factor for the onset of esophageal squamous cell 
carcinoma (AT/AT) and GEJ adenocarcinoma (GC/GC). 
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INTRODUCTION
Under current therapy modalities esophageal cancer remains a disease with poor prognosis. 
Alcohol and tobacco use are established risk factors for the development of esophageal squa-
mous cell carcinomas 1. Gastro-esophageal reflux disease (GERD) with formation of Barrett’s 
esophagus is a well established risk factor for adenocarcinomas of the distal esophagus and 
the gastric cardia, the gastro-esophageal junction (GEJ) 2,3. Despite these etiological conditions 
only a small group of patients suffering from predisposing disease or environmental exposure 
will ever develop cancer. It seems likely that progress with this cancer will be made only with 
early detection, prevention and a clearer understanding of its aetiology and tumor biology. 
The number of known genetic mutations that are associated with cancer susceptibility is 
growing at an exponential rate 4. With completion of the Human Genome project physicians 
are provided with an arsenal of genetic information that will hopefully lead to better under-
standing and treatment of approximately 4000 genetic diseases. An important example is 
the discovery of single nucleotide polymorphisms (SNPs) that occur about once every 1000 
bases along the 3-billion base human genome. Individual variations in cancer risk have been 
associated with specific variant alleles of different genes, SNPs, that are present in a signifi-
cant proportion of the normal population. The aetiology of specific cancers might therefore 
be associated with a set of SNPs, many of which could adversely interact with environmental 
factors. SNPs are thought to serve as genetic markers for identifying disease genes by linkage 
studies in families. Familial cases of esophageal cancer are however rare, and susceptibility 
genes for esophageal cancer are thus unlikely to be found by linkage analysis. Consequently, 
screening of candidate susceptibility genes may be a more feasible approach. Genes directly 
involved in tumor mutagenesis form the most interesting candidate susceptibility genes, 
i.e. tumor suppressor and proto-oncogenes. In this study SNPs with known susceptibility 
in several types of cancer were analysed in esophageal squamous cell carcinomas and GEJ 
adenocarcinomas. Selected SNPs concerned the tumor suppressor or proto-oncogenes p53 
5-21, p16 22-24, Cyclin D1 25-39, p73 16,40-50, Transforming Growth Factor β (TGF β) receptor 1 51-54, 
TGF β 55,56, E-cadherin 33,57-62, Peroxisome Proliferator-Activator Receptor-γ (PPAR-γ) 63-67, Serine/
Threonine protein Kinase 15 (STK15) 68-71 and Her-2/neu 72-74 (Table 12.1).
MATERIALS AND METHODS 
Study subjects 
Cases included 254 GEJ adenocarcinoma patients and 189 esophageal squamous cell carci-
noma patients who underwent esophagectomy at the Erasmus Medical Center (Rotterdam). 
Tissue was obtained from resection specimens. Validation cohorts of 326 adenocarcinomas 
and 209 squamous cell carcinomas were obtained from the archives of the Academic Medical 
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Table 12.1. Selection of SNPs from the literature. 
Gene function Associated tumortypes Literature references
P53 exon 4 G72C Tumor suppressor Esophageal squamous cell carcinomas Lee et al. 9
Esophageal cancer Lee et al. 10
Gastric cancer Perez-Perez et al. 14
Lung cancer Kawajiri et al. 8
Jin et al. 7
Wu et al. 20
Biros et al. 6
Birgander et al. 5
Liu et al. 11
Schabath et al. 16
Breast cancer Själander et al. 18
Weston et al. 19
Hepatocellular carcinoma Zhu et al. 83
Oral squamous cell cancer Hsieh et al. 84
Colorecal cancer Själander et al. 17
Liver cancer Yu et al. 21
P53 intron 3 Tumor suppressor Lung cancer Wu et al. 20
Biros et al. 6
Birgander et al. 5
Schabath et al. 16
Ovarian cancer Runnebaum et al. 15
Colorecal cancer Själander et al. 17
Gemignani et al. 85
Breast cancer Weston et al. 19
P53 intron 6 Tumor suppressor Lung cancer Wu et al. 20
Biros et al. 6
Birgander et al. 5
Schabath et al. 16
Ovarian Mavridou et al. 12
Breast, colon cancer Peller et al. 13
Colorecal cancer Själander et al. 17
Breast cancer Weston et al. 19
P16 exon 3 C540G Tumor suppressor Melanomas Kumar et al. 22
Sauroja et al. 24
Sakano et al. 23
Cyclin D1 exon 4 A870G Proto-oncogene Colorectal cancer Le Marchand et al. 27
McKay et al 30
Porter et al. 33
Colorectal adenomas Lewis et al. 28
Lung cancer Qiuling et al. 34
Bladder cancer Ito et al. 26
Wang et al. 36
Esophageal squamous cell carcinoma 
and cardia carcinoma
Zhang et al. 38
Esophageal adenocarcinoma Casson et al. 25
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Head and neck squamous cell 
carcinoma
Matthias et al. 29
Zheng et al. 39
Nishimoto et al. 32
Monteiro et al. 31
Renal cell carcinoma Yu et al. 37
Prostate cancer Wang et al. 35
P73 exon 2 G4C14-A4T14 Tumor suppressor/ Esophageal carcinoma Ryan et al. 50
Proto-oncogene Esophageal squamous cell carcinoma Cai et al. 40
Uterine cervix cancer Craveiro et al. 41
Niwa et al. 47
Endometrial cancer Niwa et al. 48
Lung cancer Mai et al. 46
Li et al. 45
Schabath et al. 16
Hu et al. 42
Head and neck squamous cell 
carcinoma
Li et al. 44
Colorectal cancer Pfeifer et al. 49
Breast cancer Huang et al. 43
TGF β receptor 1 Tumor suppressor/ 
Proto-oncogene
Breast, ovarian, colorectal cancer
Hematologic malignancies
Kaklamani et al. 53
Breast and ovarian cancer Baxter et al. 51
Breast, colon, bladder cancer Pasche et al. 54
Uterine cervix cancer Chen et al. 52
TGF β promotor –509 G/A Tumor suppressor/ 
Proto-oncogene
Breast cancer
Prostate cancer
Shu et al. 56
Ewart-Toland et al. 55
E-cadherin promotor 
-347 G/GA
Tumor suppressor
(putative)
Colorectal cancer Shin et al. 59
E-cadherin promotor 
-160 C/A
Tumor suppressor
(putative)
Gastric carcinoma Wu et al. 61
Humar et al. 57
Colorectal cancer Porter et al. 33
Bladder cancer Zhang et al. 62
Prostate cancer Jonsson et al. 58
Verhage et al. 60
PPAR γ exon 7 C34G Proto-oncogene Colorectal cancer Landi et al. 65
Koh et al. 64
Colorectal adenomas Gong et al. 63
Bladder cancer Leibovici et al. 66
Renal cell carcinoma Smith et al. 67
STK15 exon 5 T31A Proto-oncogene Esophageal squamous cell carcinoma Miao et al. 71
Esophageal cancer Kimura et al. 70
Breast cancer Cox et al. 68
Dai et al. 69
Her-2/neu exon 17 
A655G
Proto-oncogene Breast cancer Xie et al. 74
Cox et al. 72
Gastric cancer Kuraoka et al. 73
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Centers (Amsterdam, Maastricht) and non-academic hospitals Medisch Centrum Rijnmond 
Zuid (Rotterdam), Reinier de Graaf Gasthuis (Delft) and analysed when significant differences 
were found between cases (Rotterdam) and controls. All control cohorts consisted of Dutch 
healthy blood donors. To compare frequencies of the 3 investigated p53 polymorphisms con-
trol cohort 1 was analysed (N=166). For the TGF β receptor 1 polymorphism a control cohort 
was used described in the literature (control cohort 2, N=183) 75. For the other investigated 
polymorphisms control cohort 3 was used (N=235). A fourth control cohort was used when 
the genotype distribution was not in agreement with Hardy-Weinberg equilibrium (N=360). 
SNP genotyping 
Genomic DNA was extracted from frozen or paraffin-embedded formalin fixed normal (not 
tumor) tissues (patients) or from whole blood samples (controls). PCR-primer sequences are 
shown in Table 12.2. Used technique per SNP, flanking sequences, genotype and dbSNP ID rs 
number are mentioned in Table 12.3. For SNPs in E-cadherin promotor -347, p53 (exon 4 G72C, 
intron 3 and intron 6), Her-2/Neu (exon 17 A655G), Cyclin D1 (exon 4 A870G) and STK15 (exon 
5 T31A) PCR conditions were standardised at 35 cycles of 95oC for 30 sec, 55oC for 45 sec, 72oC 
for 45 sec and 72oC for 10 min. Amplified PCR products using p53 intron 3 primers were visua-
lized on 1.5% agarose gels. E-cadherin (promotor -347 G/GA) SNP was visualized on denatu-
ring polyacrylamide gels (acrylamide/bisacrylamide 19:1). PCR-Restriction Fragment Length 
Polymorphism (PCR-RFLP) analysis was performed for determining genotypes of p53 (exon 4 
and intron 6), Her-2/neu (exon 17 A655G), Cyclin D1 (exon 4 A870G), and STK15 (exon 5 T31A). 
Ten units of restriction enzym (BstU, MspI, APOI or BsmAI) were added to PCR products with 
16 hours of incubation at 60oC (BstU), 37oC (MspI), 50oC (APOI) or 55oC (BsmAI) with a final 
inactivation at 80oC for 20 min. Digested products were visualized on 3% agarose gels.
Table 12.2. PCR-primer sequences.
SNP Forward Reverse
p53 exon 4 5’...ACCCAGGTCCAGATGAAGC…3’ 5’...GATGACAGGGGCCAGGAG…3’
p53 intron 3 5’...AACGTTCTGGTAAGGACAAG…3’ 5’...GAAAAGAGCAGTCAGAGGAC…3’
p53 intron 6 5’...GGGGTTAAGGGTGGTTGTC…3’ 5’...CCCATTTACTTTGCACATCTC…3’
p16 exon 3 5’...CCCCGATTGAAAGAACCAGAGA…3’ 5’...AGGACCTTCGGTGACTGATGAT…3’
Cyclin D1 exon 4 5’...CGCAGTGCAAGGCCTGAAC…3’ 5’...CAAGGCTGCCTGGGACATC…3’
p73 exon 2 5’...TCAGGTGTCATTCCTTCCTTCCT…3’ 5’...GGTGGACTGGGCCATCTTC…3’
TGF- β R1 exon 1 5’...CGTCGCCCCCGGGAGCAGCGCCGC…3’ 5’...CCACAGGCGGTGGCGGCGGGACCATG…3’
TGF-β -509 5’...GGAGAAGAGGGTCTGTCAACATG…3’ 5’...GGAGAGCAATTCTTACAGGTGTCT…3’
E-cadherin -347 5’...GGCCAGAGGACCGCTTGAG…3’ 5’...GTTTGTTCGTTTTGGAGA…3’
E-cadherin -160 5’...CCACCTAGACCCTAGCAACTC…3’ 5’...AGGGCGGAGCTGACG…3’
PPARγ exon 1 5’...GTTATGGGTGAAACTCTGGGAGATT…3’  5’...GCAGACAGTGTATCAGTGAAGGAAT…3’
STK15 exon 5 5’...TCCATTCTAGGCTACAGCTC…3’ 5’...AAGAATTTGAAGGACACAAGAC…3’
Her2/neu exon 17 5’...AGCCCTCTGACGTCCATC…3’ 5’...CTGCAGCAGTCTCCGCATC…3’
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Table 12.3. Wildtype and SNP sequences, dbSNP ID number, used technique. 
Polymorphism Genotype SNP ID rs 
numbera
Wild type/polymorph sequence Used technique
p53 exon 4 G/C 1042522 5’...TCCCC(G/C)CGTGCC…3’ RFLP (BstUI)
p53 intron 3 -/+ 16bp - 5’…(1n/2n)CCAGGTCCCAGCCCT…3’ PCR
p53 intron 6 G/A 1800372 5’...CCCTCCG(G/A)GTGAG…3’ RFLP (MspI)
p16 exon 3 C/G 11515 5’…GTTTCC(C/G)GAGGTT…3’ Taqman
Cyclin D1 exon 4 A/G 11557584 5’…CAAGGG(A/G)AGATTG…3’ RFLP (MspI)
p73 exon 2 GC/AT 5031052 5’…CAGAGC(G/A)AGCTGC…3’ Taqman
TGF- β R1 exon 1 9A/6A 11466445 5’…GCGGCGGCG(GCGGCGGCG)GCGGCGGCG…3’ PCR
TGF- β –509 C/T 1800469 5’…CCATCC(C/T)TCAGGT…3’ Taqman
E-cadherin –347 G/GA 5030625 5’…AGTGAG(G/GA)CCCCAT…3’ Denaturing gel
E-cadherin –160 C/A 16260 5’…ACGCG(G/T)TGACC…3’ Taqman
PPARγ exon 1 C/G 1801282 5’…ATTGAC(C/G)CAGAAA…3’ Taqman
STK15 exon 5 A/T 2273535 5’…AAGGAA(A/G)TTGCTG…3’ RFLP (APOI)
Her-2/neu exon 17 A/G 11655866 5’…GGATGC(A/G)TCTGTG…3’ RFLP (BsmAI))
a dbSNP http://www.ncbi.nlm.nih.gov/SNP
A touchdown PCR was performed for the TGF β receptor 1*6A (deletion of three alanines (6A) 
from a nine-alanine stretch (9A)) SNP for 27 cycles of 95oC for 30 sec, 68oC (-0,5oC per cycle) for 
30 sec, 72oC for 30 sec, 10 cycles of 95oC for 30 sec, 55oC for 30 sec, 72oC for 30 sec and 72oC 
for 10 min. Amplified products were analysed on 3% agarose gels.
E-cadherin (promotor -160 C/A), TGF β (promotor -509 G/A), p16 (exon 3 C540G), p73 (exon 2 
G4C14-A4T14) and PPAR γ (exon 7 C34G) were genotyped in 5-ng genomic DNA with the Taq-
man allelic discrimination assay (Applied Biosystems, Foster City, Calif ). PCR conditions were 
standardised at 95oC for 10 min, 40 cycli of 92oC for 15 sec and 60oC for 1 min. Reactions were 
performed with the Taqman Prism 7900HT 384 wells format. Primer sequences are reported 
in Table 12.2, probe sequences corresponded to wildtype or SNP sequence mentioned in 
Table 12.3. Examples of Taqman allelic discrimination analysis and PCR-RFLP analysis are 
shown in Figures 12.1 and 12.2.
Statistics 
The χ2 test was used to compare genotype frequencies between cases and controls and 
to compute deviations from Hardy-Weinberg equilibrium. The association between the 
variant genotypes and risk of esophageal and GEJ cancer was estimated by computing 
odds ratios (ORs) and their 95% confidence interval (CIs). Statistical significance was set at 
p<0.05. All analyses were 2-sided and conducted using SPSS software (version 11.0; SPSS, 
Inc., Chicago, IL). 
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RESULTS
Mean age ± standard deviation (cases) and gender (cases and controls) are shown in Table 
12.4. The distributions of genotype frequencies of the 13 investigated SNPs between the 
cases and controls are summarized in Table 12.5. Only informative samples were mentioned. 
For the p16 exon 3 C540G SNP in squamous cell carcinomas the frequencies of CC, CG and GG 
genotypes were 51%, 46% and 3% respectively which were significantly different from the 
frequencies in controls (75%, 23% and 2%, p<0.001, Table 12.5). After significant results in the 
cases in the first cohort, results were validated using a validation cohort with substantiation 
Figure 12.1. Taqman allelic discrimination assay concerning p73 exon 2 G4C14-A4T14 of 
191 GEJ adenocarcinomas (A.) and 232 controls (B.). Distribution of homozygous normal 
(blue dots), heterozygous (green dots) and homozygous polymorphism (red dots).  
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Figure 12.2. Example of PCR-RFLP analysis concerning Cyclin D1 exon 4 A870G. The 
polymorphic allele contains a restriction site resulting in two bands, 92 basepairs and 33 
basepairs respectively (arrows). The normal allele, without a restriction site has a length of 
125 basepairs. Examples shown are heterozygous (lane 1), homozygous normal (lane 2) and 
homozygous polymorphic (lane 3). 
Polymorph allele Polymorph allele
B.A.  oocarcinomasadeadeadAdenocarcinomas 
125 bp
 92  bp
 33  bp
Figure 12.2. Example of PCR-RFLP analysis concerning Cyclin D1 exon 4 
A870G. The polymorphic allele contains a restriction site resulting in two 
bands, 92 basepairs and 33 basepairs respectively (arrows). The normal 
allele, without a restriction site has a length of 125 basepairs. Examples 
shown are heterozygous (lane 1), homozygous normal (lane 2) and 
homozygous polymorphic (lane 3).
Figure 12.1. Taqman allelic discrimination assay concerning p73 exon 2 G4C14-A4T14 of 191 GEJ adenocarcinomas (A.) and 232 controls (B.). 
Distribution of homozygous normal (blue dots), heterozygous (green dots) and homozygous polymorphism (red dots). Also see color figures page 
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Figure 12.2. Example of PCR-RFLP analysis concerning Cyclin D1 exon 4 A870G. The 
polymorphic allele contains a restriction site resulting in two bands, 92 basepairs and 33 
basepairs respectively (arrows). The normal allele, without a restriction site has a length of 
125 basepairs. Examples shown are heterozygous (lane 1), homozygous normal (lane 2) and 
homozygous polymorphic (lane 3). 
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of significancy. Pooled results are depicted in Table 12.5. The odds ratio (OR) for development 
of squamous cell carcinoma in C/C homozygotes compared to the other genotypes was 0.68 
(95% CI 0.60-0.77), corresponding to a 1.5-fold reduced risk in these individuals and there-
fore a protective effect of the C/C homozygote genotype. The OR in C/G heterozygotes as 
compared to the other genotypes was 1.99 (95% CI 1.53-2.59), corresponding to a 1.99-fold 
increased risk. 
For the Cyclin D1 exon 4 A870G SNP in squamous cell carcinomas the frequencies of A/A, 
A/G and G/G genotypes were 18%, 52% and 30% respectively which were different from the 
frequencies in controls (23%, 52% and 25%, p=0.048, Table 12.5). The OR for development of 
squamous cell carcinoma in G/G homozygotes compared to the other genotypes was 1.21 
(95% CI 0.99-1.49, p=0.07), corresponding to a 1.21-fold increased risk in these individuals or 
a 1.3-fold reduced risk for A/A homozygotes (OR 0.75 (95% CI 0.58-0.98, p=0.03). Examples of 
Cyclin D1 exon 4 A870G PCR-RFLP analysis are shown in Figure 12.2.
SNPs in the same chromosomal region are not inherited randomly, but as combinations of 
alleles which form haploblocks. The p73 exon 2 G4C14-A4T14 SNP is such an example. For 
this SNP in adenocarcinomas and squamous cell carcinomas frequencies of GC/GC, GC/AT, 
AT/AT genotypes were 70% and 65% respectively, 25% and 24% respectively and 5% and 10% 
respectively as compared to 57%, 37% and 5% in healthy blood donors which significantly 
differed (p=0.003 and p=0.003, Table 12.5). The OR for development of adenocarcinoma in 
GC/GC homozygotes compared to the other genotypes was 1.21 (95% CI 1.07-1.37). The OR 
for development of squamous cell carcinoma in AT/AT homozygotes compared to the other 
genotypes was 1.99 (95% CI 1.03-3.84). 
Table 12.4. Characteristics of patients and controls.
Cohort Age, years (mean ± SDa) Gender (M:F)
Adenocarcinomas
N= 254 63.1 ± 10.2 223:31
Squamous cell carcinomas
N=189 60.9 ± 9.5 121:68
Adenocarcinomas (validation cohort)
N=326 64.3 ± 9.7 275:51
Squamous cell carcinomas (validation cohort)
N=209 61.3 ± 9.6 115:94
Control cohort 1
N=166 -b 83:83
Control cohort 275
N=183 -b -b
Control cohort 3
N=235 -b 145:82
Control cohort 4
N=360 -b -b
aStandard deviation; bUnknown
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Table 12.5. Distribution of SNP genotypes in GEJ adenocarcinomas and esophageal squamous cell carcinomas as compared to controls.
N= Homozygous
Normal
Heterozygous Homozygous
Polymorphism
P-valuea
P53 exon 4 G72C
AC 165 89 (54) 60 (36) 16 (10) 0.7
SCC 180 103 (57) 62 (34) 15 (8) 0.5
Controls 166 85 (51) 67 (40) 14 (8)
P53 intron 3 
AC 158 121 (77) 32 (20) 5 (3) 0.6
SCC 184 140 (76) 39 (21) 5 (3) 0.8
Controls 166 124 (75) 39 (23) 3 (2)
P53 intron 6
AC 159 120 (75) 37 (23) 2 (1) 0.7
SCC 177 143 (81) 32 (18) 2 (1) 0.4
Controls 166 125 (75) 37 (22) 4 (2)
p16 exon 3 C540G 
AC 473 338 (71) 126 (27) 9 (2) 0.6
SCC 337 171 (51) 155 (46) 11 (3) <0.001
Controls 229 171 (75) 53 (23) 5 (2)
Cyclin D1 exon 4 A870G
AC 552 141 (26) 253 (46) 158 (29) 0.1
SCC 392 69 (18) 205 (52) 118 (30) 0.048
Controls 587 137 (23) 304 (52) 146 (25)
P73 exon 2 G4C14-A4T14 
AC 471 330 (70) 117 (25) 24 (5) 0.003
SCC 262 171 (65) 64 (24) 27 (10) 0.003
Controls 232 134 (57) 86 (37) 12 (5)
TGF β receptor 1
AC 73 61 (84) 10 (14) 2 (3) 0.7
SCC 185 150 (81) 34 (18) 1 (0.5) 0.6
Controls 183 148 (81) 32 (17) 3 (2)
TGF β promotor –509 G/A
AC 178 98 (55) 73 (41) 7 (4) 0.3
SCC - - - - -
Controls 229 118 (52) 94 (41) 17 (7)
E-cadherin promotor -347 G/GA
AC 246 192 (78) 51 (21) 3 (1) 0.3
SCC 146 106 (73) 39 (27) 1 (1) 0.98
Controls 228 165 (72) 61 (27) 2 (1)
E-cadherin promotor -160 C/A
AC 519 277 (53) 200 (39) 42 (8) 0.8
SCC 322 142 (44) 155 (48) 25 (8) 0.2
Controls 231 118 (51) 93 (40) 20 (9)
PPAR γ exon 7 C34G
AC 109 79 (72) 27 (25) 3 (3) 0.7
SCC - - - - -
Controls 222 153 (69) 64 (29) 5 (2)
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The distribution of none of the other genotypes was associated with risk of esophageal squa-
mous cell carcinoma or adenocarcinoma. Examples of the p73 exon 2 G4C14-A4T14 Taqman 
allelic discrimination assay in GEJ adenocarcinomas and controls is shown in Figure 12.1.
All genotype frequencies of controls were in Hardy-Weinberg equilibrium (p>0.05), except for 
Cyclin D1 exon 4 A870G and Her-2/neu exon 17 A655G (control cohort 1, p=0.01 and p=0.005 
respectively). There could have been an influence from control selection. To overcome this 
problem a second control cohort was used, which was in agreement with the Hardy-Wein-
berg equilibrium (p=0.6 and p=0.8 respectively). When the two control cohorts were pooled 
it was in Hardy-Weinberg equilibrium (Table 12.5, p=0.4 and p=0.1 respectively). All genotype 
frequencies of the cases were in Hardy-Weinberg equilibrium except for the p16 exon 3 poly-
morphism (squamous cell carcinomas, p<0.001) and the p73 (squamous cell carcinomas and 
adenocarcinomas, p=0.002 and p<0.001 respectively), which gave significant results when 
distribution of genotypes were compared between cases and controls (Table 12.5). 
DISCUSSION
The current study analysed the possible influence of common genetic variants, Single Nucle-
otide Polymorphisms (SNPs), for risk of esophageal squamous cell carcinoma and GEJ adeno-
carcinoma. Most SNPs are ‘silent’, i.e. do not alter the function or expression of a gene. The 
term ‘mutation’ is reserved for rare variants with a particularly high penetrance, usually asso-
ciated with a detrimental phenotype, such as Hereditary Breast and Ovarian Cancer (BRCA1, 
BRCA2), Hereditary Non-Polyposis Colorectal cancer (MSH2, MSH6, MLH2, PMS1, PMS2) and 
Familial Adenomatous Polyposis (APC) amongst others. As classically thought, changes in 
either tumor suppressor or oncogenes sort 100% effect, in an on/off way. SNPs are associated 
with low penetrance and variable effects on wildtype activity. Interestingly, all SNPs with a 
significant effect on esophageal cancer susceptibility in this study (p16 exon 3 C540G, Cyclin 
D1 exon 4 A870G, p73 exon 2 G4C14-A4T14) did not lead to an amino acid sequence change. 
SNPs are, however, thought to be able to sort their effect by influence on splicing, by link-
age with other SNPs (on the same or on a different gene) with functional effects or by mere 
coincidence. Even intronic SNPs, within non-coding regions of the corresponding genes, are 
STK15 exon 5 T31A
AC 251 147 (59) 93 (37) 11 (4) 0.6
SCC 183 103 (56) 70 (38) 10 (5) 0.6
Controls 227 123 (54) 95 (42) 9 (4)
Her-2/neu exon 17 A655G
AC 251 141 (56) 96 (38) 14 (6) 0.8
SCC 346 208 (60) 123 (36) 15 (4) 0.6
Controls 581 330 (57) 225 (39) 26 (4)
aP-value as compared to controls by χ2 test. AC: Adenocarcinoma. SCC: Squamous cell carcinoma.
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described to confer functional relevance without a proven explanation. It becomes increa-
singly apparent that cancer susceptibility might be related to polymorphic variations in the 
DNA sequence 76. 
In the current study, healthy blood donors were chosen as controls. Although it is not clear if 
blood donors exactly mirror the genotypes of a population, e.g. due to ethnic asymmetries, 
blood donors are generally accepted as controls for SNP studies for practicability reasons 77. 
However, as blood donors tend to be younger than cancer patients, no perfect match be-
tween patients and controls was gained in our study. 
A 1.5-fold reduced risk was shown for squamous cell carcinoma subjects with the p16 exon 
3 C540G C/C genotype as compared to those with C/G and G/G genotypes. This suggests a 
protective role for the C/C genotype in the development of squamous cell carcinoma. P16 
regulates function in G1 cell cycle arrest and is therefore important in carcinogenesis. P16 
exon 3 C540G SNP does not lead to an amino acid sequence change but has, however, been 
associated with tumor susceptibility in a number of studies 22-24. The SNP has been associated 
with low expression of p53 24. In our series not the variant G/G genotype but the heterozy-
gous C/G genotype was increased prevalent in squamous cell carcinoma cases, with an OR 
1.99 (95% CI 1.53-2.59), corresponding to a 1.99-fold increased risk for squamous cell carci-
nomas as compared to the other genotypes. We were not able to test for linkage disequi-
librium, described for melanomas in the literature, since we did not analyse the described 
p16 intronic SNP 24. Analogous to Geddert and colleagues, who did not find an association 
of p16 exon 3 C540G SNP with esophageal adenocarcinomas, cardia adenocarcinomas and 
subcardia adenocarcinomas, we could also not find an association between this SNP and GEJ 
adenocarcinomas in our series 78. 
Subjects with the Cyclin D1 exon 4 G/G genotype were at 1.21-fold increased risk for squa-
mous cell carcinoma as compared to the other genotypes. The control cohort used (control 
cohort 3) was not in agreement with the Hardy-Weinberg equilibrium (HWE) and therefore 
was supplemented with a second control cohort (n=581 in total, HWE p=0.4). Cyclin D1 is 
a key protein for the regulation of cell cycle G1-S-transition. The Cyclin D1 exon 4 A870G 
SNP does not lead to an amino acid sequence change but it creates an alternative splice 
site in its mRNA, encoding a protein with an altered C-terminal domain. It has been sug-
gested that DNA damage in cells with the A allele bypasses the G(1)/S checkpoint of the cell 
cycle more easily than damage in cells without the A allele. Several studies have suggested a 
significant association between the Cyclin D1 genotype and onset or progression of various 
cancers 25-39. Interestingly, this SNP is in the literature contradictory reported as A>G and G>A. 
Within the dbSNP (http://www.ncbi.nlm.nih.gov/SNP) this SNP is reported as A870G, which 
was followed in our study. Concerning squamous cell carcinomas of head and neck and of 
esophagus, having comparable risk factors, significant associations between the A/A geno-
type and cancer risk were described, which is not in agreement with our data which show a 
protective role of the A/A genotype instead of susceptibility for esophageal squamous cell 
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carcinoma 38,39. In these studies there was an adjustment for smoking habits within multivari-
able analyses. Unfortunately, since our study was not designed as a prospective case-control 
study, data on life style riskfactors were not available for cases or for controls. Interestingly, in 
a recently performed study the A/A genotype was shown to confer increased risk for GERD, 
Barrett’s esophagus and esophageal adenocarcinoma 25. In a northern Chinese population 
the A/A genotype conferred an increased risk for gastric cardia adenocarcinoma 38. In our 
study, distribution of Cyclin D1 genotypes within 253 GEJ adenocarcinomas as compared to 
587 controls did significantly differ (A/A 29% vs. 23%, p=0.01), but when a validation cohort 
existing of 299 adenocarcinomas was analysed, this significancy disappeared (22% vs. 23%, 
p=0.7; total group 26% vs. 23% p=0.1). Cyclin D1 exon 4 A870G therefore did not function as 
a genetic susceptibility factor in GEJ adenocarcinomas in our study.
P73 is a gene that is structurally similar to the p53 tumor suppressor gene and can inhibit 
cell growth and induce apoptosis. Two common SNPs in position 4 (G/A) and 14 (C/T) in the 
uncoding region of exon 2 of the p73 gene are in complete linkage disequilibrium with one 
another and form a haplotype block. The AT allele is described to possibly affect p73 func-
tion by altering the efficiency of translation initiation 79. P73 exon 2 G4C14-A4T14 has been 
associated with several cancer types 16,40-50. In our current study, p73 exon 2 GC/GC genotype 
conferred a 1.2-fold increased risk for adenocarcinoma whereas the AT/AT variant genotype 
conferred a 1.99-fold increased risk for squamous cell carcinoma. Analysing esophageal squa-
mous cell and adenocarinomas (n=25 and n=59), Ryan et al. reported less prevalent AT/AT in 
the total group of patients as compared to controls (1.2% vs. 4%, p<0.02) 50. When squamous 
cell carcinomas and adenocarcinomas were separately analysed genotype frequencies were 
48% and 50.8% (GC/GC), 48% and 49.1% (GC/AT) and 4% and 0% (AT/AT) respectively 50. In our 
study, using large patient numbers, genotype frequencies were 65% and 70% (GC/GC), 24% 
and 25% (GC/AT) and 10% and 5% (AT/AT) in squamous cell and adenocarcinomas respec-
tively. AT/AT was increased prevalent in squamous cell carcinomas as compared to controls, 
in contrast to the Ryan-study. GC/GC was increased prevalent in GEJ adenocarcinomas. Since 
esophageal squamous cell and adenocarcinomas concern different tumortypes, harbouring 
different genetic alterations, we analysed them separately, with different outcomes concer-
ning p73 (amongst others). Different results in the Ryan-study and our study might perhaps 
be explained by different ethnic background, although the control group used by Ryan et al. 
is a Caucasian one (homogeneous Irish) as are the control groups used in our study. Ethnicity 
is known to be an important confounding factor in epidemiologic studies involving genetic 
polymorphisms 80. Interestingly, in the study performed by Ryan et al., LOH of p73 was shown 
in 37.8% of 37 heterozygote tumor tissues being exclusive loss of the AT allele, suggesting a 
specific functional role for the AT allele 50. They speculate that the p73 AT allele might modu-
late the inflammatory response to GERD and its subsequent evolution of Barrett’s esophagus, 
dysplasia and cancer because it may lead to difference in p73 function, perhaps due to splice 
variant expression 50. We did not perform LOH analysis in our cases, which might be very 
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interesting. It could well be that this allele is lost in tumors of part of the patients harbouring 
the allele in their normal DNA. Since it could also be that the p73 SNP is in linkage disequili-
brium with other functional polymorphisms, thereby altering the function of p73 or invol-
ving adjacent susceptibility loci, it would also be interesting to study multigenetic effects of 
variant alleles, for example from p53 exon 4, introns 3 and 6, and p73.
Over the past decades, there has been an increasing incidence of GEJ adenocarcinomas in de-
veloped countries. GEJ adenocarcinoma now exceeds the incidence of esophageal squamous 
cell carcinoma. GERD and Barrett’s esophagus, the precursorlesion of GEJ adenocarcinoma, 
are highly prevalent in the population. Only a fraction of individuals show progression to 
adenocarcinoma. Endoscopic surveillance of Barrett’s esophagus patients is a widely accep-
ted and utilized strategy to detect early carcinoma, which is potentially curable. Most Barrett’s 
patients however never develop carcinoma. It is likely that interactions between molecular 
and lifestyle risk factors confer individual susceptibility for neoplastic progression. SNPs may 
modify the effect of environmental exposures and therefore susceptibility for cancer 81. As 
published previously for breast cancer, microarray technique allowing for the simultaneous 
detection of a high number of mutations and SNPs might provide prognostic information in 
addition to established clinical parameters 82. Analysis of SNPs can be performed convenient-
ly from a simple blood test. This might be of help to define subsets of Barrett’s esophagus 
patients or patients suffering from GERD, who are at increased risk for adenocarcinoma and 
therefore to further stratify surveillance. There is no known precursor lesion of squamous 
cell carcinoma, although chronic irritation and inflammation of the esophagus in response 
to environmental factors such as alcohol or nicotine is thought to play a role in the develop-
ment of cancer. Also in these patients at risk SNPs analysis might be helpful in the future. 
Our data confirm that SNPs confer risk for esophageal squamous cell carcinoma (p16 exon 2 
C540G, Cyclin D1 exon 4 A870G and p73 exon 2 G4C14-A4T14) and for GEJ adenocarcinoma 
(p73 exon 2 G4C14-A4T14). Currently a large cohort of Barrett’s esophagus patients, who did 
not develop cancer yet, is being analysed for p73 exon 2 G4C14-A4T14 genotype frequencies 
as well as for the other SNPs described in this study to reveal whether SNPs could be helpful 
to stratify surveillance. 
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ABSTRACT 
Barrett’s metaplasia (MET) or intestinal differentiation in columnar lined esophagus can 
progress to low grade dysplasia (LGD), high grade dysplasia (HGD) and ultimately to inva-
sive carcinoma (CA). Since the genetic abnormalities involved in this multistep process are 
still poorly understood, we aimed to identify molecular markers that predict progression 
to malignancy in Barrett’s patients. We investigated first whether gastro-esophageal (GEJ) 
adenocarcinomas are monoclonal or polyclonal proliferations. To this end, multiple biopsies 
per carcinoma were selected from 14 GEJ adenocarcinoma resection specimens. These were 
investigated for loss of heterozygosity (LOH) of chromosomal loci 17p (p53), 9p (p16), 5q 
(APC, MCC), 13q (Rb) and 18q (DCC, DPC4/SMAD4), for p53 mutations (exon 5 to 8) and for 
mutations in the homopolymeric C-stretch (D310) within the mitochondrial DNA (mtDNA) 
displacement loop. We then investigated the usefulness of these aberrations as molecular 
progression markers in the MET-LGD-HGD-CA sequence in Barrett’s esophagus from 31 GEJ 
resection specimens. Results of the genetic analyses were compared to the histology of the 
specimens. Identical 17p LOH patterns in multiple biopsies from one tumor were seen in 10 
out of 11 informative tumors and, especially, identical intratumor p53 mutations in all nine 
tumors with a p53 mutation indicated monoclonality of GEJ adenocarcinomas. LOH of 9p was 
detected in 76% of MET, p53 aberrations appeared in around 60% of LGD, 13q LOH and 18q 
(DCC and DPC4) LOH appeared in around 45% of LGD adjacent to carcinoma. Consistent LOH 
and mutation patterns, i.e. loss of the same allele or identical mutations, were found in the 
majority of cases within the MET-LGD-HGD-CA sequence. A combination of the investigated 
markers, especially p53 mutations, 17p LOH, 9p LOH, 13q LOH and 18q LOH may be used in 
conjunction with the histopathological diagnosis for detection of neoplastic progression in 
Barrett’s esophagus. 
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INTRODUCTION
Chronic gastro-esophageal reflux disease leads to Barrett’s esophagus (BE) in around 10% of 
the patients suffering from this common disease. BE is characterized by columnar metaplasia 
with intestinal differentiation that has replaced the normally present stratified squamous epi-
thelium in the lower third of the esophagus. BE harbors the risk of progression to dysplasia 
and adenocarcinoma, with 0.2-2% of patients with Barrett’s metaplasia eventually developing 
a carcinoma 1. Progression is considered to follow the ‘metaplasia (MET)-low grade dysplasia 
(LGD)-high grade dysplasia (HGD)-carcinoma (CA) sequence’, characterized by accumulation 
of cell cycle abnormalities, genetic abnormalities and aneuploidy 2-4. Patients with BE are 
mostly subjected to intensive endoscopic surveillance with biopsy sampling to identify those 
with neoplastic progression. The histological identification of dysplasia in tissue biopsies is 
of major importance in determining the intensity of both surveillance and treatment 5. The 
histological diagnosis of the grade of dysplasia, however, is characterized by problems con-
cerning biopsy sampling error and intra- and interobserver variation 6. 
Preferably, BE patients at high risk for neoplastic progression should be identified before 
histologic presence of dysplasia. From the literature it is known that aneuploidy as well as 
genetic abnormalities could be predictors of neoplastic progression, demonstrating a clinical 
application of early tumor markers in BE surveillance programs 7,8. From this perspective, it is 
important to know whether GEJ cancer develops via a process of monoclonal or polyclonal 
expansion. Monoclonal development would enhance the reliability of molecular markers, 
since the genetic aberrant clone that represents a possible developing tumor could then be 
harvested from the premalignant Barrett’s epithelium. If we assume that progression from 
premalignant Barrett’s epithelium to carcinoma is a monoclonal process, we expect intratu-
mor homogeneity of early genetic alterations. 
In the current study we investigated whether GEJ adenocarcinomas are monoclonal or poly-
clonal proliferations. Furthermore we investigated the value of several candidate molecular 
markers as predictors of neoplastic progression from Barrett’s metaplasia to adenocarcinoma. 
We hypothesized that genetic alterations may occur before phenotypic changes in Barrett’s 
epithelium take place. The most promising candidate markers are genetic alterations that are 
known to occur early in GEJ carcinogenesis as shown by Loss of Heterozygosity (LOH) studies 
and Comparative Genomic Hybridization (CGH) studies reported in the literature 2,9-28. In ad-
dition, mitochondrial DNA (mtDNA) mutation analyses were performed of a homopolymeric 
C stretch (D310), a mutational hotspot in the mitochondrial genome. MtDNA mutations have 
been suggested to be indicators of clonal expansion and as such can be considered as can-
cer biomarkers 29,30. The molecular aberrations detected were evaluated for their use as early 
tumor markers in 31 GEJ resection specimens containing several combinations of MET-LGD-
HGD and adenocarcinoma. 
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MATERIALS AND METHODS
Patients and specimens
Resection specimens of patients with GEJ adenocarcinomas were obtained from 35 patients 
(33 male, 2 female, mean age at the time of cancer diagnosis 65.4 ± 8.4 years, age range 50-80 
years) treated between July 1999 and April 2002 at the Erasmus MC, Rotterdam. All patients 
underwent a transhiatal resection of the tumor with restoration of the continuity of the gas-
trointestinal tract by a gastric tube with cervical anastomosis. In thirty-one patients Barrett’s 
epithelium was present. In one patient high grade dysplastic Barrett’s epithelium without 
invasive carcinoma was present. In 4 patients no Barrett’s epithelium was found. Thirty-one 
tumors were located at the distal esophagus, 2 were located at the GEJ and 2 carcinomas 
were located at the gastric cardia.
Tissue samples and DNA isolation 
Tissue biopsies were derived from premalignant and malignant tissue from the 35 GEJ 
adenocarcinoma resection specimens who were all embedded in paraffin. From 14 GEJ ade-
nocarcinomas multiple, macroscopically separated, tumor biopsies were collected (Figure 
13.1). From 31 GEJ resection specimens, 10 of which were also used for the analysis of mul-
tiple tumor samples, both premaligant and malignant tissue was present and collected (11 
cases MET-LGD-HGD-CA, 6 cases LGD-HGD-CA, 4 cases HGD-CA, 3 cases MET-LGD-CA, 2 cases 
MET-HGD-CA, 3 cases MET-CA, 1 case LGD-CA, 1 case MET-LGD-HGD). Five-μm thick sections 
of the paraffine embedded tissue biopsies were mounted on uncoated glass-slides. After 
deparaffinisation, the sections were stained with eosine and Mayer’s haematoxylin solution, 
analysed by an experienced GI-pathologist (HvD) and finally areas of interest were isolated 
by Laser Capture Microdissection (LCM, Figure 13.2). In all 35 cases tumor-negative lymph 
nodes were used as normal non-cancerous tissue. Microdissected tissues and multiple sec-
tions of normal tissue were incubated in 50μl of lysis buffer (10 mmol/L Tris-HCl, 1mmol/L 
EDTA and 1% Tween 20 pH 8.0) plus 1μl proteinase K (20μg/ml) for at least 48 hours. Every 
24 hours, 1 μl of proteinase K was added to the samples. Thereafter samples were heated for 
10 minutes at 95 °C to inactivate proteinase K. 
PCR amplification 
DNA was amplified by a radioactive 15μl Polymerase Chain Reaction (PCR). The PCR mix per 
sample consisted of 10μl distilled H2O, 1.5μl goldbuffer, 1.5μl 25 mM MgCl2-solution, 0.3μl 
10mM dGTP, dTTP, dCTP, 0.3μl 1mM dATP, 0.9 Units (5U/μl x 0.18μl) Amplitaq polymerase 
(Perkin-Elmer, Wellesley, MA, USA), 30 ng (0.1μg/μl x 0.3μl) of forward and reverse primer, 
0.075μl αP32-dATP and 1μl DNA sample. Before amplification, the PCR-mix was heated at 95°C 
for 5 minutes to activate the Amplitaq polymerase. The temperatures for amplification were 
95°C for 30 seconds, 55°C for 45 seconds and 72°C for 45 seconds. These steps were repeated 
Linetta BW.indd   236 08-05-2006   18:01:00
Identifi cation of high-risk patients 237
Figure 13.1 Collection of macroscopically separated tumor biopsies from a distal esophageal 
adenocarcinoma.
Figure 13.1 Collection of macroscopically separated tumor 
biopsies from a distal esophageal adenocarcinoma.
Figure 13.2 Laser Capture Microdissection was performed to obtain DNA from metaplasic, dysplastic 
and carcinoma tissue. With this technique DNA of target tissue (metaplasia, upper left) can be obtained 
without admixture of normal cells, which are left behind in the tissue slide (upper right). DNA is 
subsequently isolated from microdissected cells (lower picture). 
Figure 13.2 Laser Capture Microdissection was performed to obtain DNA 
from metaplasic, dysplastic and carcinoma tissue. With this technique 
DNA of target tissue (metaplasia, upper left) can be obtained without 
admixture of normal cells, which are left behind in the tissue slide (upper 
right). DNA is subsequently isolated from microdissected cells (lower 
picture).
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for 35 cycles followed by a final extension at 72°C for 10 minutes.
LOH and Single Strand Conformation Polymorphism (SSCP) analysis 
For LOH analysis, highly polymorphic dinucleotide repeat markers were amplified. The 
markers used were located at chromosomal regions known to be frequently deleted in GEJ 
adenocarcinomas 2,9-28. The chromosome loci selected harbor the tumor suppressor genes 
p53 (17p), p16 (9p), Adenomatous Polyposis Coli (APC, 5q), Mutated in Colorectal Cancer 
(MCC, 5q), Retinoblastoma (Rb, 13q), Deleted in Colorectal Cancer (DCC, 18q), and Deleted 
in Pancreatic Cancer (DPC4/SMAD4, 18q). Exons 5 to 8 of the p53 gene were investigated 
by SSCP analysis. Each exon was amplified in 2 overlapping fragments. In addition, dele-
tion/insertion mutations in the mitochondrial D310 fragment were investigated according to 
the revised human mitochondrial DNA Cambridge sequence 31. For the mtDNA experiments 
DNA samples from the mtDNA-less 143B206 ρ° cells and parental 143B206 cells were used as 
negative and positive controls (cell lines were kind gifts of Dr. G.P. Comi, Milan, Italy, and Dr. 
D.M. Turnbull, Newcastle upon Tyne, United Kingdom). All primers used are listed in Table 1. 
PCR products (15μl) were diluted with 14μl loading buffer (95% formamide, 10 mM EDTA pH 
8, 0.05% bromophenol blue and 0.05% xylene cyanol) and denaturated at 95°C for 5 minutes. 
Solutions were chilled on ice and, per sample, 4μl was loaded on a 15% polyacrylamide gel 
(acrylamide to bisacrylamide 19:1) for LOH analysis, or on an 8% polyacrylamide gel (acryl-
amide to bisacrylamide 49:1) containing 10% of glycerol for SSCP analysis. Electrophoresis 
was performed at 65W at room temperature for 1.5-2 hours for LOH analysis, and at 8W 
overnight at room temperature for SSCP analysis. The gels were vacuum dried at 80°C and 
exposed to X-ray films. For LOH as well as for SSCP analyses, tumor DNA was always compared 
with normal DNA from the same patient. 
Table 13.1. LOH microsatellite markers, p53 exon 5-8 and D310 mtDNA PCR Primer information. 
Chromosome Marker Primer sequences Productsize (bp) Heterozygosity
17p (p53) TP53CA F AGG GAT ACT ATT CAG CCC GAG GTG < 130 ?
R ACT GCC ACT CCT TGC CCC ATT C
17p (p53) D17S786 F TAC AGG GAT AGG TAG CCG AG 135-157 0.77
R GGA TTT GGG CTC TTT TGT AA
p53 exon 5/1 F CCT GAC TTT CAA CTC TTG CTC 158 Not applicable
R ACT GCT TGT AGA TGG CCA TG
p53 exon 5/2 F CAG CTG TGG GTT GAT TCC AC 176 Not applicable
R CTG GGG ACC CTG GGC AAC
p53 exon 6/1 F AGG CCT CTG ATT CCT CAC TG 127 Not applicable
R GCA CCA CCA CAC TAT GTC GA
p53 exon 6/2 F CTC CTC AGC ATC TTA TCC GA 159 Not applicable
R CCA CTG ACA ACC ACC CTT
p53 exon 7/1 F AGG CGC ACT GGC CTC ATC TT 141 Not applicable
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R TCC AGT GTG ATG ATG GTG AGG
p53 exon 7/2 F CAT GTG TAA CAG TTC CTG CAT G 135 Not applicable
R GCG GCA AGC AGA GGC TGG
p53 exon 8/1 F CCT TAC TGC CTC TTG CTT CTC 130 Not applicable
R CTT GCG GAG ATT CTC TTC CTC
p53 exon 8/2 F TTG TGC CTG TCC TGG GAG AG 127 Not applicable
R CTC CAC CGC TTC TTG TCC T
9p (p16) D9S1748 F GTG TGC TTG AAA TAC ACC TTT C 110 0.87
R AGT GAG TCC CGA ATA TCC TG
9p (p16) D9S942 F TCC TGC GGA AAC CAT TAT AAC 100 0.78
R CAA GAT TCC AAA CAG TAA ACA G
9p (p16) D9SREP1 F ATG AGA AGA TAC TTA TTC CCA G 110 0.78
R ACA AGA GTG AAA CTC CAT CTC
9p (p16) D9S1870 F GGG GTT TTC ATT CTA GAA CAG 130 0.67
R ATA TGT GGG AAA GTG GGT ATG
9p (p16) D9S269 F GAA ACT ATA ATC TCA AAG GAT G 130 0.64
R TGT GAC TAA ATC TGG CCA ATG
9p (p16) D9S274 F CTT CAC GGG TCA ATC CAT TTC 115 0.78
R GCA ATT TCT TCC TTC AGC ATT G
9p (p16) D9S304 F GAT GAT AGA TGA TTG ATA GAT TG 110 0.83
R GTA TAT GTG CCC ACA CAC ATC
5q (APC) D5S346 F ACT CAC TCT AGT GAT AAA TCG GG 110 0.82
R AGC AGA TAA GAC AGT ATT ACT AGT T
5q (APC) D5S82 F TCA CCT ACC TGC CCC AAT TG 110 0.76
R AAT TAT ACA TGC ACA CAC ATA TC
5q (MCC) D5S659 F TGT ATT TTA ATG GTC TGG TTG C 134 0.81
R TCA ACT TTC ATG GTA CCC TTC
5q (MCC) D5S2001 F ATA TTT TTC CAG AGT CTT CAT TC 130 88
R GTC TCT GGG GAG GAG TAA G
13q (Rb) D13S118 F GTC TAT CTC TGT CTC TTT ATT TC 95 0.72
R TAT ATA ACT TGT GTG AGC ACA G
13q (Rb) D13S1307 F CCT CAC TGA TAA ATG GGC TG 95 0.71
R CTC ATC TAC TCC TTC AAA CAG
18q (DCC) D18S484 F TTT AGA AAC CCT AAA ATG TGA AG 120 0.72
R GAT TTC TGT GAC ATA TTC CTT G
18q (DCC) D18S35 F GCT AGA TTT TTA CTT CTC TGA C 110 0.70
R CCT GGT TGT ACA TGC CTG AC
18q (DPC4) D18S474 F CAC CCA CTA GAT GTC AGT AG 120 0.80
R GCC TTG GAC TGG CTA ATG AG
18q (DPC4) D18S1110 F GAA ACC AAT GTG ACA GTT CTT TG 75 0.75
R AAA CTC AGA GTG AAA ACA G
Mitochondrial D310 F TTG AAT GTC TGC ACA GCC AC 112 Not applicable
R GGG GTT TGG CAG AGA TGT G
F=Forward primer, R=Reverse primer
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Sequencing 
P53 mutations indicated by SSCP analysis were identified by direct sequencing (Figure 13.4). 
PCR products were used for cycle sequencing using a Dye Terminator Cycle Sequencing 
Ready Reaction and analysed on an ABI Prism 3100 genetic analyser according to the instruc-
tions of the manufacturer (PE Biosystems, Foster City, CA). 
Statistics
The mean number of molecular aberrations was compared between the total groups of MET 
and LGD, between total groups of LGD and HGD, between total groups of HGD and carci-
noma and between MET/LGD and HGD/carcinoma using the independent samples T-test. 
The number of molecular aberrations was calculated as the sum of p53 mutation, LOH at 7 
investigated loci (wit maximum count of 7) and D310 mutation.
Figure 13.3 PCR-LOH 17p (p53, marker 
TP53CA), PCR-SSCP p53 (exon 7), PCR-LOH 9p 
(p16, marker D9S1748) and PCR-SSCP MtDNA 
(marker D310) analyses of GEJ adenocarcinoma 
with MET-LGD-HGD and 9 carcinoma samples 
(see also Table 13.2, Table 13.3 patient 12). 
Black arrows at the left side point to allelic 
patterns. The upper picture demonstrates loss 
of the lower allele (arrow heads) in LGD, HGD 
and in all carcinoma (Ca) samples as compared 
to corresponding Normal DNA (N). The second 
picture demonstrates an identical p53 mutation 
in MET (M), LGD (L), HGD (H) and all Ca samples 
(arrow head points to mutation pattern). The 
third picture demonstrates loss of the lower 
allele in L, Ca6 and Ca7 (arrow heads) and loss of 
the upper allele in H (arrow head) as compared 
to N. The fourth picture demonstrates a MtDNA 
mutation in L (arrow head). 
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RESULTS
Clonal analysis
A mean number of six biopsies (range 2-10) was taken from different areas within the tumor. 
LOH (17p, 9p, 5q, 13q and 18q), p53 exon 5 to 8 and D310 mutation analyses were thus inves-
tigated in a total number of 78 samples from 14 tumors. The LOH and mutation data of 1 of 
the 14 tumors are shown in Table 13.2 and Figure 13.3. 
In 9 out of 14 tumors, p53 mutation analysis showed complete intratumor homogeneity, i.e. 
all biopsies from one tumor harbored an identical p53 mutation. In 5 out of 14 tumors no p53 
mutation could be detected in all tumor biopsies (Table 13.3). With regard to the intratumor 
clonality of 17p LOH (p53), 11 patients had an informative LOH pattern for at least one of the 
microsatellite markers and 10 of the tumors demonstrated LOH with intratumor homogene-
ity (Table 13.3). In the remaining informative tumor, no p53 locus LOH was detected in all 
tumor biopsies. Thirteen tumors showed LOH of the p16 locus with 9 tumors demonstrating 
intratumor homogeneity and 4 tumors heterogeneity of 9p LOH (Table 13.3). Of the 14 infor-
mative tumors for the 5q (APC) locus, 10 showed LOH, with 6 tumors intratumor homogene-
Figure 13.4 PCR-SSCP and sequencing analyses of three p53 mutations in High grade dysplasia (H), 
Carcinoma (C) and corresponding normal DNA (N). Black arrows point to allelic patterns. Red arrow 
heads point to mutated alleles. The sequencing chromatograms below each autoradiograp  show the 
alterations (note the substituted nucleotide marked by an asterisk), which all represent p53 mutations.  
Figure 13.4 PCR-SSCP and sequencing 
analyses of three p53 mutations in High 
grade dysplasia (H), Carcinoma (C) and 
corresponding normal DNA (N). Black 
arrows point to allelic patterns. Red 
arrow heads point to mutated alleles. 
The sequencing chromatograms 
below each autoradiograph show 
the alterations (note the substituted 
nucleotide marked by an asterisk), 
which all represent p53 mutations. 
Also see color figures page 291.
Linetta BW.indd   241 08-05-2006   18:01:07
242
C
ha
pt
er
 1
3
ity (14/10/6, Table 13.3). For the 5q (MCC) locus these Figures were 14/10/5, for 13q 13/8/3, 
for 18q (DCC) 11/9/4, and for the 18q (DPC4/SMAD4) locus 13/11/4 (Table 13.3). Intratumor 
consistent LOH patterns were detected in all 14 tumors for at least one microsatellite marker. 
In 6 tumors mtDNA D310 mutations were found. In 3 of these tumors there was intratumor 
homogeneity with regard to the D310 mutations and in 3 tumors with D310 mutation he-
terogeneity was observed (Table 13.3). 
Table 13.2 LOH and mutation data in GEJ adenocarcinoma with MET-LGD-HGD and 9 carcinoma samples (see also Table 13.2 patient 12 and 
Figure 13.3).
No
rm
al
M
ET
LG
D
HG
D
Ca
1
Ca
2
Ca
3
Ca
4
Ca
5
Ca
6
Ca
7
Ca
8
Ca
9
p53, D17S786 ni ni ni ni ni ni ni ni ni ni ni ni ni
P53, TP53CA   L L L L L L L L L L L 
P53, exon 5              
p53, exon 6              
p53, exon 7              
p53, exon 8              
p16, D9S1748   L U      L L   
p16, D9S942 ni ni ni ni ni ni ni ni ni ni ni ni ni
p16, REP 1    L          
p16, D9S1870 ni ni ni ni ni ni ni ni ni ni ni ni ni
p16, D9S269 ni ni ni ni ni ni ni ni ni ni ni ni ni
p16, D9S274              
p16, D9S304 ni ni ni ni ni ni ni ni ni ni ni ni ni
APC, D5S346              
APC, D5S82              
MCC, D5S659              
MCC, D5S2001              
Rb, D13S118   U U     U U    
Rb, D13S1307              
DCC, D18S484 ni ni ni ni ni ni ni ni ni ni ni ni ni
DCC, D18S35    U  U U   U U   
SMAD 4, D18S474 ni ni ni ni ni ni ni ni ni ni ni ni ni
SMAD 4, D18S1110 ni ni ni ni ni ni ni ni ni ni ni ni ni
D310              
Normal = normal tissue; MET = Metaplasia; LGD = Low grade dysplasia; HGD = High grade dysplasia; Ca = carcinoma; ni= not informative.
 =LOH;  =mutation;  = no LOH/ no mutation; U=Upper allele; L=Lower allele.
Molecular analysis in MET-LGD-HGD-CA
Table 13.4 summarizes the LOH analysis and mutation data for the 31 patients with GEJ 
adenocarcinoma and adjacent premalignant lesions. In 25 of the 31 investigated cases one 
or more p53 mutation was found, in 21 cases in the CA sample. Examples of PCR-SSCP and 
sequencing analyses are shown in Figure 13.4. In 11 resection specimens from which MET, 
LGD, HGD and CA were microdissected, we found 9 p53 mutations. In one case the same p53 
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mutation was present in MET, LGD, HGD and CA, and in 6 cases an identical p53 mutation 
was found in LGD, HGD and CA with no mutation in the MET samples. In 2 cases the same 
mutation was found only in the HGD and CA samples, with no mutation in MET and LGD. 
In addition, in 6 cases from which we had only LGD, HGD and CA 2 cases had an identical 
mutation in the LGD, HGD and CA samples, 2 cases had no p53 mutation, one case had a p53 
mutation only in the LGD and one case only in the HGD sample. 
In 19 of 21 MET samples, at least one molecular aberration was found (p53 mutation, LOH of 
one of 7 investigated loci, D310 mutation). In 13 of these cases at least one aberration in the 
MET was also found in all of the more advanced stages.
As shown in Table 13.4, p53 mutations were found in 10% (MET), 59% (LGD), 68% (HGD) and 
71% (CA). P53 allelic loss increased from 0% (MET), to 67% (LGD), to 76% (HGD) and to 93% 
(CA). P16 allelic loss increased from 76% (MET), to 91% (LGD), 91% (HGD) and 91% (CA). For 
APC and MCC allelic loss percentages were: 16% and 29% (MET), 23% and 32% (LGD), 48% 
and 59% (HGD) and 50% and 51% (CA) respectively. Rb allelic loss was detected in 26% (MET), 
45% (LGD), 50% (HGD) and 52% (CA). Finally, DCC and DPC4/SMAD4 allelic loss increased 
with 5% and 26% (MET), 48% and 43% (LGD), 45% and 62% (HGD) to 63% and 65% (CA) 
respectively. 
Table 13.4 Results of LOH and mutation analysis in 31 patients within Metaplasia-Dysplasia-Carcinoma sequence.
Metaplasia Low grade dysplasia High grade dysplasia Carcinoma 
p53 LOHa (%) 0/20 (0) 12/18 (67) 13/17 (76) 28/30 (93)
p53 mutation (%) 2/21 (10) 13/22 (59) 15/22 (68) 25/35 (71)
p16 LOHa (%) 16/21 (76) 20/22 (91) 20/22 (91) 33/35 (91)
APC LOHa (%) 3/19 (16) 5/22 (23) 10/21 (48) 16/32 (50)
MCC LOHa (%) 6/21 (29) 7/22 (32) 13/22 (59) 18/35 (51)
Rb LOHa (%) 5/19 (26) 9/20 (45) 10/20 (50) 17/33 (52)
DCC LOHa (%) 1/20 (5) 10/21 (48) 9/20 (45) 19/30 (63)
DPC4 LOHa (%) 5/19 (26) 9/21 (43) 13/21 (62) 22/34 (65)
MtDNA mutation (%) 4/18 (22) 6/22 (27) 6/19 (32) 11/30 (37)
a Number of patients with LOH out of total number of informative patients. 
Of 30 cases from which we obtained D310 mutation data, 12 cases had one or more D310 in-
sertion/deletion mutation. Four of 18 MET, 6 of 22 LGD, 6 of 19 HGD and 11 of 30 CA samples 
had D310 mutations. In 3 of the 4 MET samples with the D310 mutation, the same mutation 
was also found in the more advanced histological stages. In 5 cases with a D310 mutation in 
LGD, and without a MET sample or with a MET sample without D310 mutation, 3 mutations 
were also found in more advanced lesions from the same cases. 
Within MET, a mean number of 1.95 ± 1.28 molecular aberrations (p53 mutation, LOH of one 
of 7 investigated loci, D310 mutation) was found. Within LGD a mean number of 4.0 ± 1.54, 
within HGD 4.91 ± 1.69 and within CA a mean number of 5.03 ± 1.74 molecular aberrations 
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was found. This number differed significantly between MET and LGD (p<0.001). No significant 
differences in mean number of molecular aberrations were found when LGD and HGD were 
compared or when HGD and CA were compared (p=0.07 and p=0.8 respectively). The mean 
number of molecular aberrations was significantly lower in the combined group MET and 
LGD (3.0 ± 1.74) as compared to the combined group HGD and CA (5.0 ± 1.71, p<0.001). 
DISCUSSION
Currently the histological diagnosis of dysplasia is still the gold standard for the risk strati-
fication for malignant progression in patients with BE. In recent years, many studies have 
reported that (combinations of ) molecular markers could be of additional value in predicting 
neoplastic progression. In this respect, a monoclonal development of adenocarcinoma in BE 
would be a prerequisite to find molecular markers that predict progression. Monoclonality in 
human cancers has been reported for several cancers, amongst which endometrial cancer, 
head and neck cancer, and bladder cancer 32-34. To investigate whether GEJ adenocarcinomas 
are monoclonal or polyclonal proliferations, we performed p53 exon 5 to 8 mutation analy-
ses, LOH analyses of 7 loci with 19 microsatellite markers and mtDNA D310 mutation analyses 
on a total of 78 samples from 14 GEJ adenocarcinomas. Nine of 14 GEJ adenocarcinomas 
showed identical p53 mutations in multiple carcinoma biopsies within each tumor, whereas 
the other 5 carcinomas had no p53 mutation in their carcinoma biopsies. All 5 carcinomas 
without p53 mutations demonstrated however homogeneity for p53 locus LOH and/or p16 
locus LOH. From 13 tumors with LOH at the p16 locus, 9 showed intratumor homogeneity 
and 4 intratumor heterogeneity. Three of these latter 4 had homogeneous p53 mutations in 
all tumor biopsies per case. The fourth tumor without p53 mutation demonstrated homoge-
neous p53 locus LOH. These results strongly indicate that GEJ adenocarcinomas are mono-
clonal in origin and that p53 and p16 genomic aberrations are early events in GEJ adenocar-
cinogenesis, as has been proposed by other investigators 2,3,9,11,14,21,25,26,35-37. The patterns of 
allelic loss of MCC, Rb, DCC and DPC4/SMAD4 showed higher percentages of heterogeneity 
in different carcinoma samples (Table 13.2A and 13.3), and might therefore be later events in 
GEJ adenocarcinogenesis. Miyazono et al. investigated mtDNA D310 mutations in 20 Barrett’s 
adenocarcinomas and adjacent Barrett’s epithelium 30. They found two D310 c-track muta-
tions (10%), both one nucleotide deletions, in only two carcinoma samples 30. We found D310 
c-track mutations in six of 14 (43%) GEJ adenocarcinomas. Three tumors with D310 mutations 
showed intratumor homogeneity and three heterogeneity. This indicates that D310 c-track 
mutations have limited value as clonality marker in GEJ adenocarcinomas. 
Our finding that GEJ adenocarcinomas are monoclonal in origin is in agreement with several 
other studies. Nowell et al. proposed that tumors may be monoclonal in origin and share, 
common, early genetic abnormalities predisposing to the evolution of clones with accumu-
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lated, different, late genetic abnormalities 38,39. Several studies on GEJ adenocarcinomas with 
or without metaplastic areas and studies on high grade dysplasia without carcinoma show 
evidence for a monoclonal origin of these lesions by use of comparative genomic hybridisa-
tion (CGH), LOH analysis, mutation analysis, X-chromosome inactivation analysis as well as 
methylation analysis 27,40-46.
Supported by this evidence for monoclonality of GEJ adenocarcinomas, molecular tumor 
markers can potentially be found which identify BE patients at increased or decreased risk 
for neoplastic progression. Due to good accessibility of the distal esophagus, tissue biopsies 
and thus DNA from Barrett’s epithelium can readily become available for molecular investiga-
tion. DNA in our study was derived from routine formalin fixed and paraffin embedded tissue 
specimens after LCM. We were able to perform genetic analyses on isolated epithelium from 
MET, LGD, HGD and CA with minimal contamination of stromal cells (Figure 13.2). 
Next to the molecular clonality analyses in 14 GEJ adenocarcinomas molecular aberrations 
were determined in 31 cases of different combinations of the MET-LGD-HGD-CA sequence. 
LOH as well as p53 mutations were found in premalignant lesions already. 9p LOH was found 
in 76% of MET. Within LGD 9p LOH and p53 alterations comprised 91% and about 60%, res-
pectively. LOH of 13q, 18q (DCC) and 18q (DPC4/SMAD4) was also found in LGD in about 45% 
of cases. We found consistent LOH and p53 mutation patterns, i.e. loss of the same allele or 
identical mutations, in the majority of cases within the MET-LGD-HGD-CA sequence. This in 
accordance with Zhuang et al. who found identical allelic loss patterns of the APC gene in 
metaplasia, dysplasia and adjacent carcinoma as well as the same X-chromosome inactiva-
tion patterns in female cases 41. In that study, metaplasia distant from dysplasia, however, 
did not show identical LOH patterns as compared to dysplasia and carcinoma 41. Wu et al. 
report the same allelic losses of 17p, 18q and 5q in Barrett’s metaplasia and carcinoma in 
59%, 62% and 27%, respectively 11. After flow cytometric cell sorting, the same p53 mutations 
were found in both carcinoma and surrounding HGD in their study as well as in diploid and 
aneuploid cell populations in another study 11,27. Walch et al. used CGH analysis and found a 
high concordance between specific aberration patterns in the MET-LGD-HGD-CA sequence 
within several samples 9. Gleeson et al. showed dysplastic Barrett’s epithelium and adjacent 
carcinoma to have the same pattern of novel microsatellite alleles at a number of loci in three 
cases 14. In a CGH study by Riegman et al. about one-third of the aberrations present in the 
dysplasias was also found in the adjacent carcinomas 2. Identical 18q (DCC), 5q (APC) and 17p 
(p53) LOH was detected in premalignant and malignant tissues in 4 of 17 patients by Dolan 
et al. 13. In contrast to our findings and that of others, Raja et al. found that the genotype of 
dysplastic Barrett crypts did not necessarily mirror that of the adjacent adenocarcinoma 36. 
Finally, Galipeau et al. reported different 9p and 17p LOH patterns in patients with HGD using 
purified cell fractions by flow cytometry 35. Flow cytometric cell sorting selects cells with 
aberrant DNA content, whereas in our study cells were selected by histology. 
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Our results and literature data demonstrate that part of the DNA aberrations present in the GEJ 
adenocarcinomas are also present in the tumor adjacent precursor lesions. These molecular 
results provide evidence that in the investigated GEJ adenocarcinoma resection specimens 
the precursor lesions progressed to malignancy. This implies that molecular aberrations pre-
sent in premalignant lesions potentially can predict disease progression. In the current study 
all resection specimens contained next to premalignant lesions, HGD or adenocarcinoma, 
indicating that progression had occurred. In the literature few studies have reported on LOH 
or p53 mutations in premalignant Barrett’s epithelium without simultaneous, or in follow up, 
HGD or cancer. Also in these studies on premalignant Barrett’s epithelia without evidence 
of progression the number of molecular aberrations increases with increasing histological 
grade 21,25,26,37,47. 
Interestingly, in a few cases the premalignant lesions and the adjacent CA samples did show 
both LOH of a specific locus, though with different allelic loss (i.e. upper allele could be lost 
in MET whereas lower allele was lost in LGD, HGD and/or CA (Figure 13.3). However, consis-
tent patterns of LOH or absence of LOH in all premalignant lesions and carcinoma were de-
monstrated in 84% of p53 LOH informative patients (16/19), in 75% of p53 mutation patients 
(12/16), in 63% of p16 LOH informative patients (17/27), in 61% and 62% of APC and MCC 
LOH informative patients (14/23 and 16/26), in 68% of Rb LOH informative patients (17/25) 
and in 57% and 62% of DCC and DPC4 LOH informative patients (12/21 and 13/21). In the 
cases with slightly different locus LOH patterns clonal expansion may have occurred from 
a different cell population than the sampled precursor lesion, as suggested by Gleeson et 
al. 14. Hypothetically, Barrett’s epithelium may comprise multiple genetically different clones 
while one of these clones progresses, representing the genetic alterations of the tumor. Such 
a development is known in polyclonal colorectal adenoma and the eventually monoclonal 
adenocarcinoma 48. In our study we provided evidence for a monoclonal origin of Barrett’s 
adenocarcinoma, thus minimizing ‘genetic sampling error’. 
In summary, the MET-LGD-HGD-CA sequence is complex from a molecular point of view. 
We presented molecular evidence that GEJ adenocarcinomas are monoclonal in orgin. Most 
likely, a monoclonal tumor harbors clonal diversity concerning later genetic events. Sup-
ported by evidence for monoclonality by this current study, we think that tumor markers 
potentially can be applied in conjunction with histopathology to identify Barrett patients 
at risk for neoplastic progression. Since the mean number of molecular aberrations (p53 
mutation, LOH of one of 7 investigated loci, D310 mutation) significantly differed between 
MET/LGD as compared to HGD/CA these aberrations potentially can be used as diagnostic 
markers in tissue biopsies showing indefinite for dysplasia. Importantly, we have to test this 
hypothesis in a cohort of non-progressive versus progressive BE patients. To date, 17p LOH 
and DNA content as measured by flow cytometry represent markers which might be prospec-
tively predictive of progression, although routine clinical use is not recommended yet 7,8,49. 
In general, a ‘multimarker’ approach seems more promising than a ‘single marker’ approach. 
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Fearon and Vogelstein proposed ‘accumulation of changes, rather than order, to be most 
important in (colorectal) tumor progression’ 50. The development of a ‘combined histological 
and molecular staging system’ seems to be a realistic aim to classify patients into various risk 
groups very early on in the development of malignancy, allowing a tailor-made program for 
follow-up, screening and therapeutic interventions 51. The burden of proof lies in prospective 
future studies. An eventual management strategy could be proposed restricting endoscopic 
surveillance for neoplastic progression of BE to BE patients with more than a certain number 
of genetic aberrations in a panel of markers 52. We suggest that a combination of the investi-
gated markers, especially p53 mutations, 17p LOH, 9p LOH, 13q LOH and 18q LOH might be 
part of the panel of markers, in conjunction with histopathological diagnosis. 
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SUMMARY
Adenocarcinoma of the distal esophagus or gastric cardia, the gastro-esophageal junction, 
is an aggressive disease with an extremely poor prognosis as reflected by a 5-year survival 
rate of less than 25% after surgery. Most of these cancers are detected at an advanced stage 
when they cannot be cured surgically. Barrett’s esophagus is the only known precursor to 
adenocarcinoma. Barrett’s esophagus is an acquired metaplastic change that occurs in the 
distal esophagus secondary to chronic gastro-esophageal reflux. The progression towards 
adenocarcinoma is believed to follow the ‘metaplasia-low grade dysplasia-high grade dys-
plasia-carcinoma sequence’. This neoplastic progression involves an accumulation of genetic 
and cell cycle abnormalities. Actual knowledge on these genetic pathways remains limited, 
especially in relation to clinicopathologic characteristics. The interest of the studies described 
in this thesis was to analyze genetic alterations within GEJ adenocarcinomas and Barrett’s 
esophagus in order to develop molecular markers that in the end could predict which Barrett’s 
patients are at high risk for adenocarcinoma formation and which patients are not. Genetic 
alterations were related to tumor and patient characteristics as well as to patient outcome. 
Moreover epidemiological and treatment aspects were highlighted. 
The current literature on the molecular biology of esophageal adenocarcinoma was reviewed 
in Chapter 2. Findings on proto-oncogenes, tumor suppressor genes, mismatch repair genes 
and mitotic checkpoint genes, as the targets of genomic instability, were summarized. From 
Chapter 2 it was concluded that within the multistep process of esophageal adenocarcino-
genesis, no single molecular marker came forward yet able to predict who will and who will 
not develop cancer in the setting of Barrett’s esophagus. Instead, combinations of markers 
will perhaps lead to a further differentiation in the prediction of neoplastic risk. 
Part II concerns molecular biological studies in GEJ adenocarcinomas. The contribution of 
the Wnt signaling pathway in GEJ adenocarcinomas was studied in Chapter 3 and 4. As in 
colorectal carcinomas the Wnt pathway is suggested to play a key role in GEJ adenocarcino-
mas. Nuclear β-catenin expression is generally believed to indicate activated Wnt signaling. 
In chapter 4 it was demonstrated that nuclear β-catenin expression in GEJ adenocarcinoma 
cell lines indeed correlated with T-cell factor 4 (TCF4)-mediated transcription activation and 
therefore with activated Wnt signaling. In several tumor types, TCF/β-catenin activation is 
caused by mutations in either Adenomatous Polyposis Coli (APC), β-catenin exon 3, AXIN1, 
AXIN2 or β-Transducin repeat-Containing Protein (β-TrCP). In GEJ adenocarcinomas very few 
APC and β-catenin mutations have been described in the literature. As described in chapter 
4 we did not find AXIN1 gene mutations in 17 GEJ tumors with nuclear β-catenin expression 
(without β-catenin exon 3 mutations). Therefore the mechanism of Wnt pathway activation 
in GEJ adenocarcinomas still remains unclear. To elucidate a possible prognostic role of the 
diverse components of the Wnt pathway, an immunohistochemical study was undertaken 
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in 164 GEJ adenocarcinomas and in 5 human GEJ adenocarcinoma cell lines (chapter 3). Ex-
pression of β-catenin, phospho-β-catenin Ser33/37/Thr41, phospho-β-catenin Thr41/Ser45, 
dephosphorylated ‘active’ β-catenin, Lymphoid Enhancer-binding Factor 1 (LEF1), TCF4, and 
the Wnt target genes CD44V6 and Ephrin receptor B2 (EphB2) was analysed in formalin-fixed, 
paraffin embedded tumor tissues. Thirty-five % of tumors expressed nuclear β-catenin in 
more than 10% of tumor cells, which indicated that activated Wnt signaling might probably 
be of less importance in GEJ adenocarcinomas than previously thought. However, loss of 
expression of the Wnt target gene EphB2 in the membrane or the cytoplasm correlated 
with worse tumor differentiation grade (p=0.05 and p=0.04) and with worse overall survival 
(p=0.04 and p=0.04 respectively). 
Within the search for genetic alterations that play a role in GEJ adenocarcinogenesis, recent 
work demonstrated chromosome 14q31-32.1 to be frequently deleted in GEJ adenocarcino-
mas, suggesting the presence of a tumor suppressor gene in the deleted region. In Chapter 
5 a detailed Loss of Heterozygosity (LOH) analysis was performed in 34 GEJ adenocarcinomas 
and one tumor-corresponding dysplastic Barrett’s epithelium sample with 37 polymorphic 
microsatellite markers. Fourteen of 34 tumor samples (41%) showed loss of 14q markers. 
A minimal region of allelic loss of 7,105,440 base pairs was identified between markers 
D14S1000 and D14S256 at cytogenetic location 14q31.1-32.11 containing 7 known genes. 
The identification of this minimal deletion and the data base information on the genes pre-
sent in this region facilitate the search for the candidate GEJ adenocarcinoma suppressor 
gene(s). 
In Chapter 6 the prevalence and prognostic significance of neuroendocrine (NE) cells was 
estimated in a series of 208 GEJ adenocarcinomas and 56 Barrett’s mucosas adjacent to 
carcinoma, using immunohistochemistry with chromogranin A (CGA) antibodies. CGA was 
positive in 49% (102/208) of GEJ adenocarcinomas and in 68% (38/56) of Barrett’s mucosas. 
In multivariate analysis, CGA in Barrett adjacent to carcinoma was an independent prognostic 
factor for better survival after surgery. To our knowledge this is the first example that in the 
concurrent presence of a premalignant lesion and a carcinoma a characteristic of the prema-
lignant lesion has prognostic significance. An explanation for this finding remains obscure. 
Although, its finding might be helpful in the prognostic assessment of patient outcome.
In Part III of the thesis epidemiological aspects of GEJ adenocarcinomas as well as gastric 
carcinomas are discussed. Similarities in epidemiological and histomorphological features 
haven been described between patients with adenocarcinomas of the distal esophagus and 
patients with adenocarcinomas of the gastric cardia as well as parallel, rising incidence rates. 
This formed the assumption for pooling adenocarcinomas of the GEJ within the studies des-
cribed in this thesis. In Chapter 7 it was questionized whether distal esophageal adenocar-
cinoma patients and gastric cardia carcinoma patients were comparable concerning comor-
bidity. Data on comorbidity at diagnosis (previous cancers, Chronic Obstructive Pulmonary 
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Diseases (COPD), cardiovascular and cerebrovascular diseases, hypertension, ulcerative di-
gestive tract diseases, liver diseases and diabetes) were derived from a population-based da-
tabase in the Netherlands (Eindhoven Cancer Registry/IKZ) to compare comorbidity profiles 
for 479 esophageal squamous cell carcinomas, 339 distal esophageal adenocarcinomas, 570 
cardia adenocarcinomas and 1965 subcardia cancers. In terms of comorbidity at diagnosis, 
cardia adenocarcinoma patients resembled distal esophageal adenocarcinoma patients with 
likewise equal age and gender distribution. 
Additionally, the influence of comorbidity on treatment choice (either curative (surgery) 
or palliative) and its prognostic value was analyzed within 430 esophageal squamous cell 
carcinomas, 392 distal esophageal adenocarcinomas, 494 cardia adenocarcinomas and 1708 
subcardia cancers in a retrospective study described in Chapter 8. It was concluded from 
multivariable analyses with adjustment for TNM stage and applied therapy that esophageal 
and gastric carcinoma patients with ≥2 comorbidities had a lower chance of receiving surgery 
as well as worse overall survival. The dismal prognosis for patients with ≥ 2 comorbidities at 
cancer diagnosis was likely to be a direct effect of the poor condition of the patient stressing 
importance of further refinement in perioperative care.
Part IV of the thesis describes several aspects of surgery. Since surgical resection of cancers 
of the GEJ is associated with substantial morbidity and mortality, one might wonder if this is 
also necessary in patients with early malignancies, i.e. high grade dysplasias, and intramuco-
sal or submucosal (T1) tumors. Local endoscopic techniques seem to offer a safe alternative 
to surgery in these patients. A retrospective study described in Chapter 9 evaluated the out-
come of transhiatal esophagectomy in 120 patients with early GEJ adenocarcinoma (13 high 
grade dysplasias and 107 T1 tumors). Tumors were subdivided into six different depths of 
invasion (‘T1-mucosal’ m1- m3, ‘T1-submucosal’ sm1-sm3). T1m1-m3/sm1 GEJ adenocarcino-
mas showed a very low risk of lymphatic dissemination and are therefore eligible for local en-
doscopic therapy. In contrast, almost half of the patients with T1sm2-sm3 lesions developed 
recurrent disease within 5 years, and therefore need aggressive therapy to improve survival. 
With less than 25% of patients surviving at 5 years after surgical resection, the risk in the 
short-term and the potential loss in quality of life have to be weighed against the long-term 
benefit. It is well known that the short-term surgical risk varies by clinical characteristics, such 
as age and comorbidity. In Chapter 10 3592 esophagectomy patients from 4 cohorts were 
analyzed to develop and validate a risk score able to predict mortality occurring within 30 
days after esophagectomy. The risk score combines age, comorbidity (cardiac, pulmonary, 
renal, hepatic, and diabetes), preoperative radiotherapy or combined chemoradiotherapy 
along with hospital volume. 
In Part V of the thesis it was aimed to identify Barrett’s patients at high risk for developing 
GEJ adenocarcinoma using molecular biology. The identification of genetic alterations that 
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confer susceptibility for adenocarcinoma formation in Barrett’s esophagus would imply 
improved manageability of patients with Barrett’s esophagus. CHEK2 was investigated as a 
candidate susceptibility gene within a cohort of adenocarcinomas and (dysplastic) Barrett’s 
epithelia as well as in esophageal squamous cell carcinomas in Chapter 11. CHEK2*1100delC 
is a truncating germline variant of CHEK2 that abrogates kinase activity and confers low-pene-
trance susceptibility to breast cancer. CHEK2*1100delC was found in 1.5% of 196 esophageal 
adenocarcinomas, 3.0% of 99 Barrett’s metaplasias, 1.5% of 66 dysplastic Barrett’s epithelia 
and in 0.5% of 190 esophageal squamous cell carcinomas. Since these CHEK2*1100delC 
mutation frequencies did not significantly differ as compared to healthy individuals it was 
concluded that the mutation has no major contribution in esophageal carcinogenesis. There-
fore CHEK2*1100delC is not suitable for risk prediction of neoplastic progression in Barrett’s 
patients. 
Individual variations in cancer risk have been associated with specific variant alleles of dif-
ferent genes, Single Nucleotide Polymorphisms (SNPs). SNPs are present in a significant 
proportion of the normal population. Chapter 12 investigated the distribution of various 
SNPs in GEJ adenocarcinoma and esophageal squamous cell carcinoma patients. Frequen-
cies were compared between patients (cases) and healthy blood donors (controls), in order 
to investigate a possible significance for cancer susceptibility. Selected SNPs concerned the 
tumor suppressor or proto-oncogenes p53, p16, Cyclin D1, p73, Transforming Growth Factor 
β (TGF β) receptor 1, TGF β, E-cadherin, Peroxisome Proliferator-Activator Receptor-γ (PPAR-
γ), Serine/Threonine protein Kinase 15 (STK15) and Her-2/neu. The value of several candi-
date molecular markers as predictors of neoplastic progression in Barrett’s metaplasia was 
investigated in Chapter 13. Application of such markers in the future would be favoured 
by a monoclonal growth pattern from the Barrett’s esophagus towards adenocarcinoma. A 
monoclonal growth pattern would enhance the reliability of molecular markers, since the 
genetic aberrant clone that represents a possible developing tumor could then be harvested 
from the premalignant Barrett’s epithelium. Multiple biopsies per carcinoma were selected 
from 14 GEJ adenocarcinoma resection specimens and obtained by Laser Capture Microdis-
section (LCM). LCM allows isolation of target cells without admixture of normal cells. DNA was 
investigated for LOH of several chromosomal loci (17p (p53), 9p (p16), 5q (APC, Mutated in 
Colorectal Cancer (MCC)), 13q (Retinoblastoma (Rb)) and 18q (Deleted in Colorectal Cancer 
(DCC), Deleted in Pancreatic Cancer (DPC4/SMAD4)), for p53 mutations (exon 5 to 8) and for 
mutations in the homopolymeric C-stretch (D310) within the mitochondrial DNA (mtDNA) 
displacement loop. In 9 out of 14 tumors, p53 mutation analysis showed complete intratumor 
homogeneity, i.e. all biopsies from one tumor harbored an identical p53 mutation and there-
fore evidence for a monoclonal origin of GEJ adenocarcinomas was provided. Next to the 
clonality analyses, the mentioned molecular aberrations were determined in 31 cases of dif-
ferent combinations of the ‘metasplasia-low grade dysplasia-high grade dysplasia-carcinoma 
sequence’, again isolated by LCM. Part of the DNA aberrations present in the GEJ adenocarci-
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nomas was also present in the tumor adjacent precursor lesions and therefore could be able 
to predict adenocarcinoma formation. A combination of the investigated markers, especially 
p53 mutations, 17p LOH, 9p LOH, 13q LOH and 18q LOH might be part of a future panel of 
molecular markers, in conjunction with histopathological diagnosis.
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SAMENVATTING
Klierbuisvormende tumoren (adenocarcinomen) van het onderste gedeelte van de slok-
darm of van het bovenste gedeelte van de maag, de slokdarm-maag overgang (SMO), zijn 
agressieve tumoren met een zeer slechte prognose. De 5-jaarsoverleving bedraagt <25% na 
chirurgie. De meeste van deze tumoren worden pas in een vergevorderd stadium gediag-
nostiseerd als er geen mogelijkheden meer zijn om te opereren. Het enige bekende voorlo-
perstadium van deze tumoren vormt de zogenaamde Barrett slokdarm. Dit is een verworven 
weefselverandering (metaplasie) in het onderste gedeelte van de slokdarm die ontstaat na 
langdurige expositie aan zure reflux (‘zuurbranden’). Eventuele progressie naar kanker vindt 
plaats volgens de ‘Barrett metaplasie-laaggradige dysplasie-hooggradige dysplasie-carci-
noom sequentie’. Deze maligne ontaarding gaat gepaard met een opeenstapeling van gene-
tische afwijkingen en disregulatie van de celcyclus. Gedetailleerde kennis over deze cascade 
van moleculair genetische gebeurtenissen is beperkt en met name kennis over het verband 
tussen genetische afwijkingen en patiënt- en tumorkenmerken ontbreekt. De studies in dit 
proefschrift hadden tot doel moleculair genetische afwijkingen in SMO adenocarcinomen en 
Barrett slokdarm te analyseren om zodoende moleculaire markers te vinden. In de toekomst 
zouden moleculaire markers wellicht behulpzaam kunnen zijn in het voorspellen welke Bar-
rett patiënten een hoog risico lopen op het krijgen van kanker en welke Barrett patiënten niet. 
De gevonden genetische afwijkingen werden gecorreleerd aan patiënt- en tumorkenmerken 
en overleving. Tevens werden epidemiologische aspecten en aspecten van de behandeling 
van SMO adenocarcinomen belicht.
In een review in Hoofdstuk 2 werd de bestaande literatuur over de moleculaire biologie van 
slokdarm adenocarcinomen samengevat. Afwijkingen in proto-oncogenen, tumorsuppres-
sor genen, mismatch repair genen en mitotische checkpoint genen resulteren in genomische 
instabiliteit. Gevonden afwijkingen in deze groepen genen in slokdarm adenocarcinomen 
werden beschreven. De conclusie luidde dat in het uitgebreide proces van slokdarm adeno-
carcinogenese nog geen unieke moleculaire marker is gevonden die kan voorspellen welke 
Barrett patiënt een hoog risico heeft op het krijgen van kanker en welke patiënt niet. In plaats 
daarvan zullen naar verwachting combinaties van moleculaire markers in de toekomst bij-
dragen aan risico predictie. 
Deel II betreft moleculair biologische studies in SMO adenocarcinomen. Het aandeel van de 
zogenaamde ‘Wnt pathway’ in SMO adenocarcinomen werd onderzocht in Hoofdstuk 3 en 
4. De Wnt pathway of, beter gezegd, afwijkingen in de Wnt pathway waardoor de pathway 
wordt geactiveerd, spelen een sleutelrol in dikke darm tumoren (colon en rectum). De aan-
wezigheid van ß-catenine in de kern van tumorcellen wordt in het algemeen beschouwd 
als uiting van een geactiveerde pathway en daarmee als tumorigeen. In Hoofdstuk 4 werd 
aangetoond dat kernexpressie van ß-catenine correleert met T-cell factor 4 (TCF-4) geme-
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dieerde transcriptie activatie en daardoor met een geactiveerde pathway. In verscheidene 
typen tumoren wordt TCF-4/ ß-catenine activatie veroorzaakt door mutaties in Adenoma-
tous Polyposis Coli (APC), ß-catenine exon 3, AXIN1, AXIN2 of ß-Transducin repeat-Contain-
ing Protein (ß-TrCP). In SMO adenocarcinomen zijn in de literatuur slechts enkele gevallen 
beschreven van APC en ß-catenine mutante tumoren en daarom lijken mutaties in APC en 
ß-catenine geen verklaring voor activatie van de Wnt pathway in SMO adenocarcinomen 
met nucleair ß-catenine. Zoals in Hoofdstuk 4 beschreven werden in een serie van 17 SMO 
adenocarcinomen met ß-catenine kernexpressie (en zonder ß-catenine exon 3 mutatie) geen 
AXIN1 mutaties gevonden. Het Wnt pathway mechanisme in SMO adenocarcinomen is dus 
nog altijd onduidelijk. In Hoofdstuk 3 werd een immunohistochemische studie verricht met 
de vraagstelling of componenten van de Wnt pathway een prognostische betekenis hebben 
in SMO adenocarcinomen. Expressie van verschillende eiwitten werd onderzocht in forma-
line gefixeerd paraffine materiaal van 164 SMO adenocarcinomen en 5 SMO tumor cellijnen. 
De onderzochte eiwitten waren: ß-catenine, phospho-ß-catenine Ser33/37/Thr41, phospho-
ß-catenine Thr41/Ser45, gedefosforyleerd ‘active’ ß-catenine, Lymphoid Enhancer-binding 
Factor 1 (LEF1), TCF4 en de Wnt target genen CD44V6 en Ephrin receptor B2 (EphB2). In 35% 
van de tumoren werd kernexpressie van ß-catenine aangetoond in de kern in >10% van de 
tumorcellen, erop duidend dat de Wnt pathway mogelijk een minder belangrijke rol speelt in 
SMO adenocarcinomen dan aanvankelijk gedacht. Desalniettemin correleerde afwezigheid 
van EphB2 in celmembraan of het cytoplasma met een slechtere tumor differentiatiegraad 
(p=0.05 en p=0.04) en slechtere survival (p=0.04 en p=0.04).
In de zoektocht naar genetische afwijkingen welke een rol spelen in SMO adenocarcinoge-
nese werd recent gevonden dat een gebied op de lange arm van chromosoom 14 frequent 
verloren was in SMO adenocarcinomen. Dit zou kunnen duiden op de lokalisatie van een 
tumorsuppressor gen in dat gebied. In Hoofdstuk 5 werd een gedetailleerde Loss of He-
terozygosity (LOH) analyse verricht in 34 SMO adenocarcinomen en 1 dysplastisch Barrett 
epitheel gelegen naast een SMO adenocarcinoom, met behulp van 37 polymorfe microsatel-
liet markers. In 14 van de 34 samples (41%) werd 14q LOH aangetoond. Tussen de markers 
D14S1000 en D14S256 werd een minimale regio van verlies gevonden van 7105440 base-
paren (14q31.1-32.11), een gebied waar zich 7 bekende genen bevinden. Identificatie van 
deze regio in combinatie met database informatie over de genen in de minimale verlies regio 
vergemakkelijken de zoektocht naar een kandidaat SMO adenocarcinoom tumorsuppressor 
gen/genen.
In Hoofdstuk 6 werd de prevalentie en eventueel prognostische betekenis van neuroen-
docriene cellen onderzocht in 208 SMO adenocarcinomen en 56 Barrett epithelia gelegen 
naast tumor. Hiertoe werd Chromogranine A (CGA) immunohistochemie verricht. CGA werd 
aangetoond in 49% (102/108) van de tumoren en in 68% (38/56) van de Barrett epithelia. In 
multivariate analyse bleek CGA in Barrett epitheel gelegen naast tumor een onafhankelijke 
prognostische factor voor betere overleving na chirurgie. Dat een kenmerk van een prema-
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ligne lesie, gelegen naast tumor, prognostische betekenis heeft, is niet eerder aangetoond. 
Een mogelijke verklaring voor deze bevinding hebben we vooralsnog niet gevonden. Toch 
zou deze uitkomst van prognostische betekenis kunnen zijn in patiënten met SMO adeno-
carcinomen.
In Deel III van dit proefschrift werden epidemiologische aspecten bediscussieerd. In de 
literatuur worden overeenkomsten in epidemiologische factoren en histomorfologische 
kenmerken beschreven tussen patiënten met adenocarcinomen van het onderste deel van 
de slokdarm en patiënten met adenocarcinomen van het bovenste gedeelte van de maag, 
de cardia. Ook wordt een vergelijkbare, parallel stijgende incidentie van deze tumoren 
beschreven. Dit vormde de aanname om in de studies beschreven in dit proefschrift de 
tumoren van onderste gedeelte van slokdarm en bovenste gedeelte van maag als één 
klinische entiteit te beschouwen en als zodanig te analyseren.
In Hoofdstuk 7 werd onderzocht of de aanwezigheid van comorbiditeit verschilde tussen 
patiënten met adenocarcinomen van het onderste deel van de slokdarm en patiënten met 
adenocarcinomen van de cardia. Gegevens over aanwezige comorbiditeit ten tijde van diag-
nose (eerdere maligniteit, Chronic Obstructive Pulmonary Disease (COPD), cardiovasculaire 
en cerebrovasculaire ziekten, hypertensie, ulcuslijden van het maagdarmstelsel, leverziekten 
en diabetes) werden verkregen uit een Nederlandse populatie database (Kankerregistratie 
Eindhoven/IKZ). Comorbiditeitsprofielen van 479 slokdarm plaveiselcelcarcinomen, 339 
slokdarm adenocaricnomen, 570 cardia adenocarcinomen en 1965 subcardia carcinomen 
werden met elkaar vergeleken. Patiënten met cardia adenocarcinomen waren qua comor-
biditeitspatroon vergelijkbaar met patiënten met onderste slokdarm adenocarcinomen, met 
eveneens vergelijkbare leeftijds- en geslachtsverdeling. 
Vervolgens werd de invloed van comorbiditeit op keuze van therapie (curatief (chirurgie) 
of palliatief ) onderzocht in 430 slokdarm plaveiselcelcarcinomen, 392 slokdarm adenocar-
cinomen, 494 cardia adenocarcinomen en 1708 subcardia carcinomen in een retrospectieve 
studie in Hoofdstuk 8. Multivariate analyse met correctie voor TNM stadium en therapie 
wees uit dat patiënten met slokdarm- of maagtumoren bij aanwezigheid van ≥2 comorbi-
diteiten een kleinere kans hadden op het krijgen van chirurgie. Tevens was er een slechtere 
overleving. De slechtere prognose van patiënten met ≥2 comorbiditeiten leek een direct 
effect te zijn van hun slechtere conditie. Dit legt de nadruk op het belang van zorgvuldige 
perioperatieve zorg. 
In Deel IV van het proefschrift werden aspecten van chirurgie belicht. Chirurgische resectie 
van SMO tumoren is geassocieerd met substantiële morbiditeit en mortaliteit. Mogelijk zou 
dit met een minder invasieve behandeling bij patiënten met vroege tumoren bespaard kun-
nen blijven. Vroege tumoren zijn hooggradige dysplasie en intramucosale en submucosale 
tumoren (T1 tumoren). Lokale endoscopische technieken lijken een veilig alternatief voor 
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chirurgie in deze patiënten. In Hoofdstuk 9 werd een retrospectieve studie beschreven 
waarin de uitkomsten na chirurgie werden geanalyseerd in 120 patiënten met vroege SMO 
tumoren (13 hooggradige dysplasiëen en 107 intramucosale of submucosale tumoren). 
Deze groep werd onderverdeeld in 6 verschillende niveaus van invasie (‘T1-mucosaal’ m1-
m3 en ‘T1-submucosaal’ sm1-sm3). T1m1-m3/sm1 SMO tumoren hadden een laag risico op 
lymfkliermetastasering en lijken daardoor veilig toegankelijk voor locale endoscopische 
therapie. Daarentegen bijna de helft van de patiënten met T1sm2-sm3 tumoren ontwikkelde 
tumorrecidief binnen 5 jaar en deze tumoren lijken agressief te moeten worden behandeld 
om overleving te verbeteren.
Met <25% 5-jaars overleving na chirurgie moeten de risico’s van chirurgie op korte termijn en 
de daardoor potentieel verminderde kwaliteit van leven worden afgewogen tegen de baten 
op lange termijn. De risico’s van chirurgie worden beïnvloed door patiënt kenmerken zoals 
leeftijd en comorbiditeit. In Hoofdstuk 10 werden 3592 patiënten uit 4 verschillende co-
horten na chirurgie geanalyseerd en werd een risico score model ontwikkeld en gevalideerd 
waarmee 30-dagen mortaliteit na chirurgie kon worden voorspeld. De score combineert 
gegevens van leeftijd, comorbiditeit (cardiaal, pulmonaal, renaal, leverziekten en diabetes), 
preoperatieve radiotherapie of gecombineerde chemoradiotherapie en ziekenhuisvolume.
In Deel V van het proefschrift werd geprobeerd moleculaire biologie te gebruiken voor het 
identificeren van Barrett patiënten met een hoog risico op het krijgen van kanker. Met het 
identificeren van genetische afwijkingen, geassocieerd met een verhoogde kans op het 
ontstaan van kanker in Barrett epitheel, zou surveillance kunnen worden verbeterd als ook 
behandeling en informatievoorziening van Barrett patiënten. In Hoofdstuk 11 werd het 
CHEK2 gen onderzocht als mogelijk kandidaatgen voor deze toepassing in een cohort van 
adenocarcinomen, (dysplastische) Barrett epithelia en slokdarm plaveiselcelcarcinomen. 
CHEK2*1100delC is een truncerende kiembaanmutatie die kinase activiteit blokkeert. 
Deze mutatie is geassocieerd met een hogere kans op borstkanker (lage penetrantie). 
CHEK2*1100delC was aanwezig in 1.5% van 196 adenocarcinomen, 3.0% van 99 Barrett’s 
metaplasieën, 1.5% van 66 dysplastische Barrett epithelia en 0.5% van 190 plaveiselcelcarci-
nomen. Aangezien deze CHEK2*1100delC mutatiefrequenties niet significant verschilden met 
de mutatiefrequentie in een cohort gezonde vrijwilligers luidde de conclusie van Hoofdstuk 
11 dat CHEK2*1100delC geen grote bijdrage levert aan het ontstaan van slokdarmkanker. 
CHEK2*1100delC is daarom geen geschikte kandidaat voor het identificeren van hoog risico 
patiënten. In de recente literatuur komt naar voren dat Single Nucleotide Polymorfismen 
(SNPs) geassocieerd zijn met het risico op het ontwikkelen van verschillende tumoren. Een 
genpolymorphisme is een variante sequentie van kiembaan DNA die frequent voorkomt in de 
populatie. In hoofdstuk 12 werd de frequentie van verschillende SNPs onderzocht in patiën-
ten met adenocarcinoom en plaveiselcelcarcinoom van de slokdarm. De frequentie van SNPs 
werd vergeleken met de frequentie in controles (gezonde bloeddonoren) om zodoende vast 
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te stellen of een of meerdere van de onderzochte SNPs geassocieerd waren met het krijgen 
van slokdarmcarcinoom. De onderzochte genen betroffen de tumorsuppressorgenen of pro-
to-oncogenen p53, p16, Cycline D1, p73, Transforming Growth Factor β (TGF β) receptor 1, 
TGF β, E-cadherine, Peroxisome Proliferator-Activator Receptor-γ (PPAR-γ), Serine/Threonine 
proteïne Kinase 15 (STK15) en Her-2/neu. In Hoofdstuk 13 werd de waarde van verscheidene 
kandidaat moleculaire markers onderzocht als voorspellers van neoplastische progressie 
in Barrett epitheel. Eventuele toepasbaarheid van moleculaire markers in de toekomst zou 
aangemoedigd worden als er een monoclonaal groeipatroon van Barrett metaplasie richting 
tumor zou bestaan. Dit betekent dat de voorlopercellen waaruit kanker ontstaat dezelfde 
genetische afwijkingen hebben als de uiteindelijke tumor. Een monoclonaal groeipatroon 
zou de betrouwbaarheid van moleculaire markers verhogen omdat de genetisch afwijkende 
cel welke een mogelijk ontwikkelende tumor representeert dan geoogst zou kunnen worden 
uit Barrett epitheel. Om dit te onderzoeken werden van 14 SMO adenocarcinomen per tumor 
meerdere biopten verzameld waarna DNA werd geïsoleerd na Laser Capture Microdissec-
tion (LCM). Met de LCM techniek werden selectief de cellen van interesse verkregen voor het 
isoleren van DNA zonder bijmenging van normale cellen. Vervolgens werd LOH analyse ver-
richt van verscheidende chromosoom loci (17p (p53), 9p (p16), 5q (APC, Mutated in Colorec-
tal Cancer (MCC)), 13q (Retinoblastoma (Rb)) en 18q (Deleted in Colorectal Cancer (DCC), 
Deleted in Pancreatic Cancer (DPC4/SMAD4)), werd mutatie analyse van p53 (exon 5 tot en 
met 8) verricht en werd mutatie analyse verricht van mitochondriaal DNA (mtDNA, D310). In 
9 van de 14 tumoren liet p53 mutatie analyse complete intratumor homogeniteit zien, dat wil 
zeggen alle biopten van dezelfde tumor hadden dezelfde, identieke, p53 mutatie waarmee 
een bewijs werd geleverd voor het monoclonaal ontstaan van SMO adenocarcinomen. Ver-
volgens werden de LOH en mutatie analyses verricht in 31 verschillende combinaties van de 
‘metaplasie-laaggradige dyplasie-hooggradige dysplasie-carcinoom sequentie’. Een deel van 
de genetische afwijkingen aanwezig in de SMO adenocarcinomen was ook aanwezig in de, 
naast de tumor gelegen, voorloperstadia en zou daarmee geschikt zijn voor het voorspellen 
van adenocarcinoomvorming in Barrett patiënten. Een combinatie van de onderzochte 
moleculaire markers, met name p53 mutaties, 17p LOH, 9p LOH, 13q LOH, en 18q LOH zou in 
de toekomst deel uit kunnen maken van een set van moleculaire markers in Barrett patiënten 
in combinatie met histopathologie. 
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Adenocarcinomas of the GEJ are often diagnosed at an advanced disease state and associated 
with a poor prognosis. These carcinomas are thought to arise within the ‘Barrett’s metapla-
sia-low grade dysplasia-high grade dysplasia-carcinoma sequence’. Therefore the detection 
of preneoplastic lesions is important to ensure early and appropriate treatment. Presently, 
the histological detection of dysplasia is the best available marker for cancer risk. Intensive 
endoscopic surveillance, including tissue biopsies, is aiming at early detection of high-grade 
dysplasia and early adenocarcinoma. Probably, molecular genetic analysis could be of help to 
identify high risk patients. This assumption formed the aim of this thesis. Genetic and clinical 
studies were performed and, as described in part V of the thesis, combined in order to build 
a bridge from Laboratory to Clinic. 
MOLECULAR BIOLOGY
The formation of adenocarcinoma in Barrett’s esophagus is complex from a molecular point 
of view and in this thesis it was aimed to further unravel the complex molecular alterations 
present in GEJ adenocarcinomas and its precursor lesions. Moreover it was aimed to correlate 
these molecular changes to clinicopathologic characteristics. 
Many questions still exist and could not be answered in this thesis. Wnt signaling, having 
importance in a number of developmental processes, is able to contribute to tumorigenesis 
by altering the state and activity of β-catenin, and as such plays an important role in colorec-
tal adenocarcinoma formation, amongst others. In the absence of Wnt signals β-catenin is 
located at the plasma membrane, linked to E-cadherin, and functions in cell-cell adhesion. 
Excess cytoplasmic β-catenin is sequestered, phosphorylated and eventually targeted to 
degradation in a protein complex comprised of adenomatous polyposis coli (APC), glyco-
gen synthase kinase 3β (GSK-3β) and AXIN1 or AXIN2. Activated Wnt signaling inhibits the 
phosphorylation and therefore degradation of β-catenin, which translocates to the nucleus 
where it activates genes containing T-cell factor (TCF)-binding sites, a family of transcription 
factors. In addition to work from others, who did not find mutations in β-catenin nor in APC 
to be responsible for Wnt signaling in GEJ adenocarcinomas 1-4, neither AXIN1 mutations nor 
AXIN1 LOH were shown to be responsible for Wnt signaling. Therefore, the mechanism of Wnt 
activation remains obscure in these tumors. We did show however that loss of expression of 
the recently identified Wnt target gene EphB2 was shown to be significantly correlated with 
worse survival and poor tumor differentiation grade. 
We identified the commonly deleted region of allelic loss of chromosome 14q31-32.1, occur-
ring in more than 40% of all GEJ adenocarcinomas, and determined an overlapping region of 
LOH with a size of about 7.1 Mb. This suggests that this region contains one or more tumor 
suppressor genes involved in GEJ tumorigenesis. 
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The presence of neuroendocrine cells, as shown by chromogranin immunohistochemistry, 
in Barrett’s epithelium adjacent to tumor was an independent prognostic factor for bet-
ter survival after surgery. Using mouse models and transfection of chromogranin cDNA a 
slower progression of tumor growth was demonstrated in the literature, probably being an 
explanation for the findings in this thesis 5. Future experiments focusing on transfection of 
chromogranin cDNA in Barrett’s metaplasia cell lines could possibly gain more insight in the 
role of CGA in GEJ adenocarcinoma development. It also needs to be established which kind 
of hormone(s) is/are being secreted by the neuroendocrine cells in Barrett and GEJ adeno-
carcinomas to unravel their function. A large panel of candidate hormones has being tested 
already at the Department of Pathology of the Erasmus MC but none of these has provided 
a firm conclusion yet.
EPIDEMIOLOGY
Concerning the epidemiology of esophageal cancer, remarkable changes have taken place 
over the past decades. About 50 years ago, the incidence of esophageal adenocarcinoma was 
lower than the incidence of squamous cell carcinoma 6. To date, adenocarcinoma is the most 
common esophageal carcinoma and moreover, carcinomas from the gastric cardia show a 
parallel increasing incidence. Both esophageal and cardia adenocarcinomas occur mainly 
in Caucasian men. The risk of both esophageal and cardia adenocarcinomas is increased in 
people with Gastro-Esophageal Reflux Disease. Although studies concerning molecular bio-
logy produced conflicting results, many have demonstrated the similarity of these tumors 
7-11. In this thesis it was investigated whether distribution of comorbidity (previous cancers, 
Chronic Obstructive Pulmonary Diseases (COPD), cardiovascular and cerebrovascular di-
seases, hypertension, ulcerative digestive tract diseases, liver diseases and diabetes) differed 
between esophageal squamous cell carcinoma, distal esophageal adenocarcinoma, cardia 
adenocarcinoma and subcardia carcinoma patients within a large population based database 
(Eindhoven Cancer Registry). Cardia adenocarcinoma patients resembled distal esophageal 
adenocarcinoma patients considerably more than subcardia carcinoma patients concerning 
comorbidity, with likewise equal age and gender distribution and therefore again it seems 
justified to evaluate these tumors similarly.
Importantly, there is evidence that the likelihood and pattern of lymph node metastases as 
well as overall survival are similar in esophageal and cardia adenocarcinoma patients 12-14. 
Therefore treatment should also be similar. In a retrospective study it was shown that the 
presence of comorbidity influenced the choice of treatment in patients with esophageal and 
gastric carcinoma. 
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TREATMENT
Surgery
Esophageal resection with extensive lymph node dissection is still considered the standard 
therapy for early GEJ lesions, i.e. high grade dysplasia or T1 adenocarcinoma, at many institu-
tions. We showed lymph node metastases in only one out of 79 T1 tumors (1%) with location 
in the mucosa or superficial submucosa as compared to 18 out of 41 T1 tumors (44%) with 
location in the deep submucosa. Moreover, recurrence free period differed significantly be-
tween these two groups (p log rank < 0.0001, with 5-year recurrence free percentages of 97% 
and 57% respectively). Less invasive and more limited surgical procedures and endoscopic 
procedures might therefore be appropriate alternatives for high grade dysplasia and T1 tu-
mors (intramucosal or superficial submucosa). Hence, an individualized treatment strategy 
should be employed based on depth of tumor penetration into the mucosa or submucosa, 
presence of lymph node metastases, endoscopic appearance concerning multicentricity of 
tumor growth and length of the underlying Barrett’s mucosa and comorbidity of the affected 
patient. Esophageal resection is associated with substantial morbidity and compromised 
postoperative quality of life. Moreover, the average reported mortality nowadays varies from 
4% in specialized centres to more than 10% in low volume hospitals 15,16. We attempted to 
develop a simple and robust prediction model for surgical mortality in esophageal cancer 
patients. Mortality after esophagectomy was found to be related to patient characteristics 
(age and comorbidity (pulmonary, diabetes)), neoadjuvant therapy and hospital volume. 
Interestingly, neoadjuvant treatment with radiotherapy was associated with a substantially 
higher surgical mortality risk, as was neoadjuvant chemoradiotherapy. 
Neoadjuvant therapy
In the literature, irradical resections are reported to occur frequently after esophageal resec-
tion, varying from 25-41% 17-19. Adequate loco-regional control is an important issue and might 
be improved by neoadjuvant therapy. Concerning neoadjuvant chemotherapy, available 
randomised phase III studies and reviews show that the possible benefit, if any, is considered 
to be small and it is uncertain whether such a potential survival benefit outweighs the morbi-
dity caused by such a treatment 17,19-26. From several studies on neoadjuvant radiotherapy it 
was learned that concurrent chemoradiotherapy is recommended compared to radiotherapy 
alone since chemotherapy and radiotherapy can interact in several ways. 27-33. To date several 
randomized controlled trials have been reported in which neoadjuvant chemoradiotherapy 
was applied 24,34-39. Only one trial could show a survival benefit for the chemoradiotherapy-
followed-by-surgery-arm and the reliability of the results in this study have been debated 
6,39. Complete pathologic response rate seems to be crucial for a beneficial effect of neoadju-
vant chemoradiotherapy. A phase II study has recently been performed at the Erasmus MC, 
studying neoadjuvant paclitaxel and carboplatin in combination with radiotherapy prior to 
Linetta BW.indd   270 08-05-2006   18:01:34
Summay, Conclusions and Epilogue 271
surgery within 50 patients having resectable adenocarcinomas or squamous cell carcinomas 
of the esophagus. All patients received 100% of the planned dose of chemotherapy and 
radiotherapy with mild adverse effects. All but one patient had a radical surgical resection 
(R0-resection). Approximately 25% of patients had a complete pathological response. All but 
one had negative lymphnodes. The concept that this regimen of preoperative chemoradio-
therapy improves the overall survival has, however, to be proven in a randomized phase III 
prospective trial, which is currently being performed in a multicenter setting. 
Evidence is mounting that patients who do not respond to chemoradiotherapy may have 
worse survival due to delay of surgery. Molecular genetic analysis might be helpful in the 
identification of patients who are most likely to achieve a complete response before initia-
tion of neoadjuvant chemoradiotherapy. Currently, GEJ adenocarcinoma cell lines as well as 
esophageal squamous cell carcinoma cell lines are being treated with chemoradiotherapy 
at the Department of Pathology to reveal genetic alterations that can predict therapy resis-
tance/response. 
SUSCEPTIBILITY
The identification of genes that confer susceptibility for adenocarcinoma formation in Bar-
rett’s esophagus would imply improved manageability of patients with Barrett’s esophagus. 
However, familial cases of esophageal cancer are rare, and susceptibility genes are thus un-
likely to be found by linkage analysis. Consequently, screening of candidate susceptibility 
genes may be a more feasible approach. A study of a large and unselected series of Barrett’s 
metaplasias and dysplasias, esophageal adenocarcinomas and squamous cell carcinomas 
was performed in which the candidate susceptibility germline CHEK2*1100delC mutation 
was screened. This mutation had no major contribution in esophageal carcinogenesis. Ge-
netic polymorphisms may play a significant role in person-to-person variability in cancer 
susceptibility. In this thesis the distribution of numerous Single Nucleotide Polymorphisms 
(SNPs) was screened in GEJ adenocarcinomas and squamous cell carcinomas and compared 
to a cohort of healthy blood donors. Interestingly, data confirm that SNPs influence risk for 
esophageal squamous cell carcinoma (p16 exon 2 C540G, Cyclin D1 exon 4 A870G and p73 
exon 2 G4C14-A4T14) and for GEJ adenocarcinoma (p73 exon 2 G4C14-A4T14). SNPs might 
be used in the setting of surveillance of patients with Barrett’s esophagus. Currently a large 
cohort of Barrett’s esophagus patients, who did not develop cancer yet, is being analysed for 
p73 exon 2 G4C14-A4T14 genotype frequencies as well as for the other SNPs described in this 
study to reveal whether SNPs could be helpful to stratify surveillance. 
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FROM BARRETT’S ESOPHAGUS TOWARDS ADENOCARCINOMA: FROM 
LABORATORY TO CLINIC
At the Erasmus MC, patients with Barrett’s metaplasia undergo surveillance endoscopy with 
tissue biopsies once in two years and patients with low grade dysplasia once a year. Impor-
tantly, high grade dysplasia harbors areas of invasive carcinoma in 30-60% already, which is a 
reason for surgical resection in many institutions. An alternative option for patients with high 
grade dysplasia forms intensive endoscopic follow-up (once in 3 months) until invasion is 
observed. Patients with high grade dysplasia or early adenocarcinoma have a survival rate of 
80% after surgical resection as compared to 20% after surgery for invasive adenocarcinoma. 
This stresses the importance of early detection. 
Interestingly, new endoscopic ablative techniques have emerged over the past two decades. 
These techniques have been developed primarily to treat dysplasia and early carcinoma. New 
techniques include endoscopic mucosal resection, photodynamic therapy, laser therapy, 
multipolar electrocoagulation, argon plasma coagulation, radiofrequency ablation and cryo-
therapy 40. It has yet to be determined whether the risks associated with ablation therapy 
are less than the risk of Barrett’s esophagus progressing to cancer. Whether ablation therapy 
eliminates or significantly reduces the risk of cancer is subject of currently performed com-
parative trials. 
Endoscopic recognition of preneoplastic lesions might be difficult. The same holds for the 
histological classification of dyplasia. Significant intra- and interobserver variation exists in 
classifying dysplasia whereas the decision to treat or to follow-up largely depends on this 
diagnosis. New developments in both endoscopy technique and tissue sampling aim to im-
prove diagnosis of high grade dysplasia and early cancer 41. 
To date it is not possible to predict which patients with Barrett’s esophagus will progress 
to invasive carcinoma. Stratification of patients with Barrett’s esophagus who are at risk 
of esophageal adenocarcinoma and those who are not, is therefore urgently needed. This 
would allow more aggressive or preventative treatment of the people at risk, but also release 
the vast majority of people that are not at risk from years of unnecessary endoscopic surveil-
lance.
Molecular genetic analysis might be helpful for two reasons: 
1. The histological classification of dysplasia could be supplemented by the screening for 
genetic alterations to ensure accurate diagnosis. In this thesis areas of Barrett’s metaplasia, 
low and high grade dysplasia and carcinoma were selected in H&E stained slides by a spe-
cialised GE pathologist. However, a major obstacle to apply molecular biologic techniques 
effectively to the genetic analysis of (pre)neoplastic tissue is the presence of abundant non-
neoplastic elements in the analyzed specimen. These nonneoplastic elements, including 
reactive fibrous cells, vascular cells, and a variety of infiltrating white blood cells, may mask 
Linetta BW.indd   272 08-05-2006   18:01:35
Summay, Conclusions and Epilogue 273
genetic alterations that otherwise would be easily detectable if the (pre)neoplastic cells were 
procured selectively. In chapter 13 DNA from (pre)neoplastic areas was obtained after Laser 
Capture Microdissection technique. This technique allows to selectively procure and geneti-
cally analyze small populations of (pre)neoplastic cells from the glass slides. We compared the 
mean number of investigated molecular aberrations (i.e. LOH at p53 (17p), p16 (9p), Adeno-
matous Polyposis Coli (APC, 5q), Mutated in Colorectal Cancer (MCC, 5q), Retinoblastoma (Rb, 
13q), Deleted in Colorectal Cancer (DCC, 18q), Deleted in Pancreatic Cancer (DPC4/SMAD4, 
18q), mutation of the p53 gene, and mutation of mitochondrial DNA). The mean number 
was significantly lower in the combined group metaplasia/low grade dysplasia (3.0 ± 1.74) 
as compared to the combined group high grade dysplasia/carcinoma (5.0 ± 1.71, p<0.001). 
Screening for molecular aberrations might therefore indeed be valuable and add to histology 
within patients with difficulty to diagnose grade of dysplasia.
2. Endoscopic biopsy samples of Barrett’s esophagus that histologically appear as low risk 
for neoplastic progression might in fact harbor genetic alterations that are indicative for a 
high risk profile (Figure 15.1). Therefore genetic alterations should perhaps also be investi-
gated within evident metaplastic or low grade dysplastic lesions. A more intense surveillance 
should perhaps be offered to the patients harboring genetic alterations in their histologically 
unsuspected metaplasia or low grade dysplasia. It has been estimated that at least 1% of the 
Caucasian population may have Barrett’s metaplasia and that from the patients with Barrett’s 
esophagus 0.5-1% will develop adenocarcinoma 42. It would be of great importance to be 
able to discriminate at an early stage which metaplasia- or low grade dysplasia patients will 
develop invasive disease and which will not. 
Numerous genetic aberrations are known to frequently occur in esophageal adenocarcinoma. 
However, knowledge of the timing of these genetic events during esophageal adenocarcino-
genesis is limited. In particular, few studies have analysed genetic aberrations in Barrett’s 
epithelia that did not progress to esophageal adenocarcinoma. At the Erasmus MC, there is 
access to longitudinal esophageal biopsies from a cohort of at least 550 patients with Barrett’s 
esophagus who underwent annual endoscopic surveillance since 1973. The cohort includes 
patients that have developed esophageal adenocarcinoma as well as patients that are still 
disease-free for more than 5 years. This collection of biopsies provides an unique opportunity 
to compare genetic aberrations in lesions from patients with Barrett’s esophagus that are 
at risk of esophageal adenocarcinoma and those that are not at risk. Within a present study 
performed at the Departments of Pathology, Gastroenterology, Surgery and Epidemiology it 
is aimed to identify genetic markers that distinguish Barrett’s epithelia that will progress to 
esophageal adenocarcinoma from those that will not progress to malignancy.
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FUTURE PERSPECTIVES
Targeted therapy
The sequence of the human genome has enabled systematic approaches to identify cancer 
genome alterations including point mutations, copy number increases and decreases, loss of 
allelic heterozygosity and chromosome translocations 43. Molecular targets for therapy are be-
coming more widely known and include epidermal growth factors, tyrosine kinases, vascular 
endothelial growth factor and intracellular signaling pathways. With further development of 
targeted cancer therapies and improvement in genome analysis technology, genome-wide 
surveys of cancer will likely become tools for diagnosis as well as discovery 43-45. Microarray 
analysis to study gene expression is able to rapidly identify genes which can function as a 
guide for tailored (neoadjuvant chemoradiation) therapy 46,47. Examples of cancer-targeted 
therapy are the drugs Herceptin, used to treat c-erbB2 overexpressing breast cancer, Gleevec, 
used to treat a type of leukemia and certain rare cancers, and Gefitinib (Iressa), used to treat 
Figure 15.1 Metaplasia-Dysplasia-Carcinoma sequence. Index case is histologically at low risk for 
neoplastic progression, however genetic alterations are indicative for high risk profile. 
Figure 15.1 Metaplasia-Dysplasia-Carcinoma sequence. Index case is histologically at low risk for neoplastic progression, however genetic 
alterations are indicative for high risk profile. Also see color figures page 291.
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lung cancers with EGFR mutations and probably other epithelial cancers with similar muta-
tions in the near future. Intervention trials are underway in which neoadjuvant chemoradio-
therapy is combined with EGFR-inhibitor Iressa prior to surgery for resectable esophageal 
cancer 48. The concept of a cancer stem cell population as described in the literature gives 
hope that the isolation of these cells, coupled with the knowledge of the mutations causing 
cancer, will result in ways to eliminate cancer cells while sparing normal tissues 49. In search for 
the Achilles’ heel for cancer, future targeted cancer therapies will become available, although 
the pace at which molecular developments have been translated in clinical applications have 
been slow to date. 
Molecular markers
Concerning Barrett’s metaplasia and its malignant potential there is still need for improved 
understanding of the molecular biology in order to develop a more scientific approach to 
cancer prevention in these patients. Biopsy samples from patients with Barrett’s esophagus 
might histologically appear as low risk for neoplastic progression whereas genetic alterations 
might be indicative for a high risk profile (Figure 15.1). Since the annual incidence rate for 
developing esophageal adenocarcinoma in Barrett’s esophagus is as low as 0.5-1%, a cancer 
preventive strategy needs to be cost effective and acceptable to a large number of patients 
at relatively low risk 50. It has been propagated that endoscopic cancer surveillance should 
therefore be limited to patients with increased cancer risk (for example Caucasian men, 55-70 
years age, people with GERD) 51. Perhaps it may someday be possible to identify a molecu-
lar marker that identifies GERD patients at high risk for Barrett’s esophagus who might be-
nefit from endoscopic surveillance 52. Despite ongoing efforts to characterize the molecular 
changes leading to esophageal adenocarcinoma, no clinically applicable molecular markers 
for prediction of prognosis and/or response to therapy came forward to date. Several stud-
ies performed and described in this thesis intended to identify genetic alterations in GEJ 
adenocarcinogenesis and to develop molecular markers applicable in Barrett’s patients. Un-
fortunately many patients with GEJ adenocarcinoma present with advanced stage of disease 
since they were not known to harbor Barrett’s esophagus. Having realized this, one of the 
other main concerns in the finding of molecular markers forms the suspected existence of in-
tralesional heterogeneity of genetic alterations in Barrett’s epithelium. In the literature, FISH 
analysis, LOH and gene amplification analysis showed intratumoral heterogeneity in Barrett’s 
adenocarcinomas 53,54. This highlights one of the main problems associated with surveillance 
of Barrett’s patients namely sampling error. From other studies it seemed likely that the ac-
quisition of 9p LOH and 17p LOH predisposes to the evolution of aneuploid cell populations 
and other genetic abnormalities that culminate in the development of cancer 55-57. Tumors 
may be monoclonal in origin and share, common, early genetic abnormalities predisposing 
to the evolution of clones with accumulated, different, late genetic abnormalities 58,59. Several 
studies on GEJ adenocarcinomas with or without metaplastic areas and studies on high 
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grade dysplasia without carcinoma indeed show evidence for a monoclonal origin of these 
lesions by use of comparative genomic hybridisation (CGH), LOH analysis, mutation analysis, 
X-chromosome inactivation analysis as well as methylation analysis 54,56,60-65. 
This issue of clonality of genetic alterations was investigated in this thesis. We presented 
molecular evidence that GEJ adenocarcinomas are monoclonal in orgin concerning early 
genetic alterations, i.e. especially p53 mutations, 17p LOH, 9p LOH, 13q LOH and 18q LOH. 
Mitochondrial DNA mutations have been suggested to be indicators of clonal expansion 
66,67 and were also analyzed but they seemed to have limited value as clonality marker in 
GEJ adenocarcinomas. Most likely, a monoclonal tumor concerning early genetic alterations 
harbors clonal diversity concerning later genetic alterations. Such early genetic events in the 
neoplastic progression of Barrett’s metaplasia concern loss of p16 and p53 but also loss of 
APC, Rb and DCC with aneuploidy as a probable driving force; additional genetic alterations 
superpose. Since this thesis provided evidence for monoclonality concerning early genetic 
alterations, molecular markers potentially can be applied in conjunction with histopathology 
to identify Barrett’s patients at risk for neoplastic progression. 
Most probably no single ‘universal’ genetic marker is sufficient to enable prediction of which 
patient will and which patient will not develop cancer in the setting of Barrett’s esophagus. 
Thus a ‘multimarker’ approach seems more promising than a ‘single marker’ approach. A com-
bination of the investigated markers, especially p53 mutations, 17p LOH, 9p LOH, 13q LOH 
and 18q LOH might be part of a future panel of markers, in conjunction with histopathologi-
cal diagnosis. Early genetic alterations should be given highest priority in the ongoing search 
for molecular markers both for diagnostic and prognostic use. This will hopefully lead to a 
further differentiation in the prediction of neoplastic risk in Barrett’s esophagus patients with 
early intervention and individualized treatment as ultimate goal. 
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Barrett’s metaplasia 
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Figure 1.1 Endoscopy images
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Figure 1.2 Histology of ‘metaplasia-low grade dysplasia-high grade dysplasia-carcinoma sequence’ 
Adenocarcinoma
Normal squamous epithelium
Barrett’s metaplasia
Low grade dysplasia
High grade dysplasia
Figure 1.2 Histology of ‘metaplasia-low grade dysplasia-high grade dysplasia-carcinoma sequence’
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Figure 1.6 Schematic overview of surgical resection of GEJ adenocarcinoma. Photographs below the scheme 
show upper abdominal incision (A.), creation of the gastric tube (A. B. C.) to restore continuation of 
gastrointestinal tract after transhiatal en-bloc removal of esophagus and gastric cardia including tumor and 
adjacent lymph nodes (D.). Esophagogastrostomy will be performed in the neck (smaller incision left side of 
picture D.) 
A
C
B
D
Figure 1.6 Schematic overview of surgical resection of GEJ adenocarcinoma. Photographs below the scheme show upper abdominal incision 
(A.), and creation of the gastric tube (A. B. C.) to restore continuation of the gastrointestinal tract after transhiatal en-bloc removal of esophagus 
and gastric cardia including tumor and adjacent lymph nodes (D.). Esophagogastrostomy will be performed in the neck (smaller incision left side 
of picture D.)
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Figure 1.7 Schematic overview of Loss of Heterozygosity (LOH) analysis. Amplified fragments of maternal and 
paternal DNA of chromosome 9 are compared between normal and tumor DNA of a patient. Length of CA 
repeats within the fragments differs in the normal DNA, i.e. there is heterozygosity (maternal contains 20 CA 
repeats and paternal contains 15 CA repeats). In patients tumor DNA part of the short arm of paternal 
chromosome 9, containing the 15 CA repeat, is lost and therefore the heterozygosity is lost. This is visualized on 
a gel after radioactive labeling. Only the maternal 20 CA repeat is visualized in the tumor as compared to the 
normal DNA in which both fragments are shown and therefore this tumor shows LOH. Within LOH analysis, a 
separation of fragments takes place through difference in length, whereas Single Strand Conformation 
Polymorphism (SSCP) analysis separates fragments by a different conformation between normal and mutated 
DNA. 
Figure 1.7 Schematic overview of Loss of Heterozygosity (LOH) analysis. Amplified fragments of maternal and paternal DNA of chromosome 9 
are compared between normal and tumor DNA of a patient. Length of CA repeats within the fragments differs in the normal DNA, i.e. there is 
heterozygosity (maternal contains 20 CA repeats and paternal contains 15 CA repeats). In patients tumor DNA part of the short arm of paternal 
chromosome 9, containing the 15 CA repeat, is lost and therefore the heterozygosity is lost. This is visualized on a gel after radioactive labeling. 
Only the maternal 20 CA repeat is visualized in the tumor as compared to the normal DNA in which both fragments are shown and therefore this 
tumor shows LOH. Within LOH analysis, a separation of fragments takes place through difference in length, whereas Single Strand Conformation 
Polymorphism (SSCP) analysis separates fragments by a different conformation between normal and mutated DNA.
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Figure 3.1 
Figure 3.1. Immunohistochemistry of β-catenin in GEJ adenocarcinomas (Magnification x 200 (A., B., C., G.) and magnification x 400 (D., E., 
F., H.). A. Nuclear and cytoplasmic expression of β-catenin in the tumor cells. B. Nuclear active β-catenin staining in same GEJ tumor tissue as 
mentioned in A. C. Strong nuclear active β-catenin. D. Active β-catenin in membrane and cytoplasm of GEJ adenocarcinoma. E. EphB2 staining 
in cytoplasm of the tumor cells. F. Membranous EphB2 staining. G. Nuclear phospho β-catenin (Thr41/Ser45) with strong staining patterns in 
mitotic cells (insert H.).
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Figure 4.1 Immunohistochemistry of �-catenin in GEJ adenocarcinomas and cell lines. (�-catenin antibody, 
DAB and haematoxylin counterstain, magnification x 400). A. GEJ adenocarcinoma. Strong nuclear expression 
of �-catenin in the tumor cells. B. GEJ adenocarcinoma. Prominent membranous expression of �-catenin. C. Cell 
line JROECL19. Strong nuclear expression of �-catenin. D. Cell line TE-7. Membranous expression of �-
catenin.
Figure 4.1 Immunohistochemistry of β-catenin in GEJ adenocarcinomas and cell lines. (β-catenin antibody, DAB and haematoxylin counterstain, 
magnification x 400). A. GEJ adenocarcinoma. Strong nuclear expression of β-catenin in the tumor cells. B. GEJ adenocarcinoma. Prominent 
membranous expression of β-catenin. C. Cell line JROECL19. Strong nuclear expression of β-catenin. D. Cell line TE-7. Membranous expression 
of β-catenin.
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Figure 4.3 PCR-SSCP and sequencing analyses of the SNPs in tumors (T) and corresponding normal DNA (N), 
compared with DNA from individuals without SNPs (N1). Shown are informative cases with LOH. Black arrows 
point to allelic patterns. Red arrow heads point to deleted alleles in the tumor DNA. The sequencing 
chromatograms below each autoradiograph show the alterations (note the substituted nucleotide marked by an 
asterisk), which all represent SNPs. SNPs A94C and G1396A are annotated in the reverse complementary 
direction, whereas the SNPs C874, intron 4+17 G�A, T1942C and G2063A are annotated in forward direction. 
Figure 4.3 PCR-SSCP and sequencing analyses of the SNPs in tumors (T) and corresponding normal DNA (N), compared with DNA from individuals 
without SNPs (N1). Shown are informative cases with LOH. Black arrows point to allelic patterns. Red arrow heads point to deleted alleles in the 
tumor DNA. The sequencing chromatograms below each autoradiograph show the alterations (note the substituted nucleotide marked by an 
asterisk), which all represent SNPs. SNPs A94C and G1396A are annotated in the reverse complementary direction, whereas the SNPs C874, intron 
4+17 G→A, T1942C and G2063A are annotated in forward direction.
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Figure 4.5 Immunohistochemistry of AXIN1 in GEJ adenocarcinomas. (AXIN1 antibody, DAB and 
haematoxylin counterstain, magnification x 200). A. and B. GEJ adenocarcinomas with nuclear �-catenin 
expression without (A.) and with (B.) AXIN1 locus LOH. C. and D. GEJ adenocarcinomas with membranous �-
catenin expression without (C.) and with (D.) AXIN1 locus LOH. Note the strong cytoplasmic AXIN1 expression 
in the tumor cells in all 4 cases. 
Figure 4.5 Immunohistochemistry of AXIN1 in GEJ adenocarcinomas. (AXIN1 antibody, DAB and haematoxylin counterstain, magnification x 200). 
A. and B. GEJ adenocarcinomas with nuclear β-catenin expression without (A.) and with (B.) AXIN1 locus LOH. C. and D. GEJ adenocarcinomas 
with membranous β-catenin expression without (C.) and with (D.) AXIN1 locus LOH. Note the strong cytoplasmic AXIN1 expression in the tumor 
cells in all 4 cases.
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Fig. 6.1 CGA immunoreactivity in normal gastric epithelium (A), CGA negative adenocarcinoma (B). Scatters 
of individual tumor cells show CGA staining (1+) within a well-differentiated adenocarcinoma (C).
Adenocarcinoma shows apparent cytoplasmic CGA staining in >20% (2+) of tumor cells (D). CGA negative 
Barrett’s epithelium adjacent to adenocarcinoma (E), CGA positive cells in Barrett’s epithelium most 
prominently located in the basal layer of the epithelium (F).
Fig. 6.1 CGA immunoreactivity in normal gastric epithelium (A), CGA negative adenocarcinoma (B). Scatters of individual tumor cells show CGA 
staining (1+) within a well-differentiated adenocarcinoma (C). Adenocarcinoma shows apparent cytoplasmic CGA staining in >20% (2+) of 
tumor cells (D). CGA negative Barrett’s epithelium adjacent to adenocarcinoma (E), CGA positive cells in Barrett’s epithelium most prominently 
located in the basal layer of the epithelium (F). 
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Figure 13.4 PCR-SSCP and sequencing analyses of three p53 mutations in High grade dysplasia (H), 
Carcinoma (C) and corresponding normal DNA (N). Black arrows point to allelic patterns. Red arrow 
heads point to mutated alleles. The sequencing chromatograms below each autoradiograph show the 
alterations (note the substituted nucleotide marked by an asterisk), which all represent p53 mutations.  
Figure 13.4 PCR-SSCP and sequencing analyses of three p53 mutations in High grade dysplasia (H), Carcinoma (C) and corresponding normal DNA 
(N). Black arrows point to allelic patterns. Red arrow heads point to mutated alleles. The sequencing chromatograms below each autoradiograph 
show the alterations (note the substituted nucleotide marked by an asterisk), which all represent p53 mutations. 
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Figure 15.1 Metaplasia-Dysplasia-Carcinoma sequence. Index case is histologically at low risk for 
neoplastic progression, however genetic alterations are indicative for high risk profile. 
Figure 15.1 Metaplasia-Dysplasia-Carcinoma sequence. Index case is histologically at low risk for neoplastic progression, however genetic 
alterations are indicative for high risk profile.
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